

COMBINATION THERAPY FOR TREATMENT OF CANCER**CROSS-REFERENCE**

[001] This application claims the benefit of U.S. Provisional Application No. 63/043,342, filed June 24, 2020; and U.S. Provisional Application No. 63/162,184, filed March 17, 2021, which are incorporated herein by reference.

BACKGROUND

[002] Cancer, an uncontrolled proliferation of cells, is a multifactorial disease characterized by tumor formation, growth, and in some instances, metastasis. Cells carrying an activated oncogene, damaged genome, or other cancer-promoting alterations can be prevented from replicating through an elaborate tumor suppression network. A central component of this tumor suppression network is p53, one of the most potent tumor suppressors in the cell. Both the wild type and mutant conformations of p53 are implicated in the progression of cancer.

INCORPORATION BY REFERENCE

[003] Each patent, publication, and non-patent literature cited in the application is hereby incorporated by reference in its entirety as if each was incorporated by reference individually.

SUMMARY OF THE INVENTION

[004] Provided herein is a method of treating cancer in a subject in need thereof, the method comprising: (i) administering to the subject a therapeutically-effective amount of a compound, wherein the compound binds to a mutant p53 protein and reconfirms the mutant p53 protein to a conformation of p53 that exhibits anti-cancer activity; and (ii) administering to the subject a therapeutically-effective amount of an anti-cancer agent that functions through a pathway other than p53-induced apoptosis.

[005] Also provided herein is a method of treating cancer in a subject in need thereof, the method comprising: (i) administering to the subject a therapeutically-effective amount of a compound that increases anti-cancer activity of a mutant p53 protein in the subject; and (ii) administering to the subject a therapeutically-effective amount of an anti-cancer agent that functions through a pathway other than p53-induced apoptosis.

[006] Further provided herein is a method of treating cancer, the method comprising: (i) administering to a subject in need thereof a therapeutically-effective amount of a compound that binds to a mutant p53 protein and reconfirms the mutant p53 protein to a conformation of p53 that exhibits anti-cancer activity; and (ii) administering to the subject a therapeutically-effective amount of an additional anti-cancer agent that functions through a pathway other than p53-induced apoptosis, wherein if in a controlled study of treatment of the cancer in a first patient population and a second patient population: (a) a first median survival time of the first patient population is determined, wherein the first patient population is treated with the therapeutically-effective amount of the compound that binds to a mutant p53 protein and reconfirms the mutant p53 protein to a conformation of p53 that exhibits anti-cancer activity; and (b) a second median survival time of the

second patient population is determined, wherein the second patient population is treated with the therapeutically-effective amount of the compound that binds to a mutant p53 protein and reconfirms the mutant p53 protein to a conformation of p53 that exhibits anti-cancer activity and the therapeutically-effective amount of the additional therapeutic agent; then the second median survival time is at least about 50% greater than is the first median survival time.

BRIEF DESCRIPTION OF THE FIGURES

[007] **FIG. 1** shows changes in tumor volume (mm^3) in a mouse syngeneic model of sarcoma (MT373) over 27 days upon receiving treatment with vehicle (2Q7Dx4); anti-PD-1 200 μg (Q3Dx35); Compound 1, 75 mg/kg (2Q7Dx6); Compound 1, 150 mg/kg (2Q7Dx15); Compound 1, 75 mg/kg (2Q7Dx15) + anti-PD-1 (Q3Dx35); or Compound 1, 150 mg/kg (2Q7Dx15) + anti-PD-1 (Q3Dx35).

[008] **FIG. 2** shows changes in tumor volume (mm^3) in a mouse syngeneic model of sarcoma (MT373) over 185 days upon receiving treatment with vehicle (2Q7Dx4); anti-PD-1 200 μg (Q3Dx35); Compound 1, 75 mg/kg (2Q7Dx6); Compound 1, 150 mg/kg (2Q7Dx15); Compound 1, 75 mg/kg (2Q7Dx15) + anti-PD-1 (Q3Dx35); or Compound 1, 150 mg/kg (2Q7Dx15) + anti-PD-1 (Q3Dx35).

[009] **FIG. 3** shows changes in tumor volume (mm^3) in individual C57B1/6 mice implanted with MT373 mouse syngeneic sarcoma tumors upon receiving treatment with vehicle; anti-PD-1 200 μg ; Compound 1, 75 mg/kg; Compound 1, 150 mg/kg; Compound 1, 75 mg/kg + anti-PD-1; or Compound 1, 150 mg/kg + anti-PD-1.

[010] **FIG. 4** shows changes in percentage survival of mice upon receiving treatment with vehicle; anti-PD-1; Compound 1, 75 mg/kg; Compound 1, 150 mg/kg; Compound 1, 75 mg/kg + anti-PD-1; or Compound 1, 150 mg/kg + anti-PD-1.

[011] **FIG. 5** shows the changes in percent body weight change in female C57B1/6 mice implanted with MT373 mouse syngeneic sarcoma tumors upon receiving treatment with vehicle (2Q7Dx4); anti-PD-1 200 μg (Q3Dx35); Compound 1, 75 mg/kg (2Q7Dx6); Compound 1, 150 mg/kg (2Q7Dx15); Compound 1, 75 mg/kg (2Q7Dx15) + anti-PD-1 (Q3Dx35); or Compound 1, 150 mg/kg (2Q7Dx15) + anti-PD-1 (Q3Dx35).

[012] **FIG. 6** shows changes in tumor volume (mm^3) in female C57B1/6 mice implanted with MT245 mouse syngeneic sarcoma tumors over 20 days upon receiving treatment with vehicle (Q7Dx3); anti-PD-1 200 μg (Q3Dx19); Compound 1, 150 mg/kg (Q7Dx5); Compound 1, 300 mg/kg (Q7Dx9); Compound 1, 600 mg/kg (Q7Dx9); Compound 1, 150 mg/kg (Q7Dx9) + anti-PD-1 200 μg (Q3Dx19); or Compound 1, 300 mg/kg (Q7Dx9) + anti-PD-1 200 μg (Q3Dx19).

[013] **FIG. 7** shows changes in tumor volume (mm^3) in female C57B1/6 mice implanted with MT245 mouse syngeneic sarcoma tumors over 157 days upon receiving treatment with vehicle (Q7Dx3); anti-PD-1 200 μg (Q3Dx19); Compound 1, 150 mg/kg (Q7Dx5); Compound 1, 300 mg/kg (Q7Dx9); Compound 1, 600 mg/kg (Q7Dx9); Compound 1, 150 mg/kg (Q7Dx9) + anti-PD-1 200 μg

(Q3Dx19); or Compound 1, 300 mg/kg (Q7Dx9) + anti-PD-1 200 µg (Q3Dx19).

[014] **FIG. 8** shows changes in tumor volume (mm³) in individual C57B1/6 mice implanted with MT245 mouse syngeneic sarcoma tumors upon receiving treatment with vehicle (Q7Dx3); anti-PD-1 200 µg (Q3Dx19); Compound 1, 150 mg/kg (Q7Dx5); Compound 1, 300 mg/kg (Q7Dx9); Compound 1, 600 mg/kg (Q7Dx9); Compound 1, 150 mg/kg (Q7Dx9) + anti-PD-1 200 µg (Q3Dx19); or Compound 1, 300 mg/kg (Q7Dx9) + anti-PD-1 200 µg (Q3Dx19).

[015] **FIG. 9** provides a Kaplan-Meier survival curve of C57B1/6 mice implanted with MT245 mouse syngeneic sarcoma tumors upon receiving treatment with vehicle (Q7Dx3); anti-PD-1 200 µg (Q3Dx19); Compound 1, 150 mg/kg (Q7Dx5); Compound 1, 300 mg/kg (Q7Dx9); Compound 1, 600 mg/kg (Q7Dx9); Compound 1, 150 mg/kg (Q7Dx9) + anti-PD-1 200 µg (Q3Dx19); or Compound 1, 300 mg/kg (Q7Dx9) + anti-PD-1 200 µg (Q3Dx19).

[016] **FIG. 10** shows changes in percent body weight C57B1/6 mice implanted with MT245 mouse syngeneic sarcoma tumors upon receiving treatment with vehicle (Q7Dx3); anti-PD-1 200 µg (Q3Dx19); Compound 1, 150 mg/kg (Q7Dx5); Compound 1, 300 mg/kg (Q7Dx9); Compound 1, 600 mg/kg (Q7Dx9); Compound 1, 150 mg/kg (Q7Dx9) + anti-PD-1 200 µg (Q3Dx19); or Compound 1, 300 mg/kg (Q7Dx9) + anti-PD-1 200 µg (Q3Dx19).

[017] **FIG. 11** shows changes in tumor volume (mm³) of C57B1/6 mice implanted with MT245 mouse syngeneic sarcoma tumors upon receiving treatment with Vehicle; Compound 1, 150 mg/kg (Q7Dx2); Compound 1, 300 mg/kg (Q7Dx2); or Compound 1, 600 mg/kg (Q7Dx2).

[018] **FIG. 12** shows changes in tumor volume (mm³) for C57B1/6 mice implanted with MT373 mouse sarcoma tumors over 20 days upon receiving treatment with vehicle (2Q7Dx4); anti-PD-1 200 µg (Q3Dx7); Compound 2, 50 mg/kg (QDx44); Compound 2, 100 mg/kg (QDx71); Compound 2, 150 mg/kg (2Q7Dx10); Compound 2, 300 mg/kg (2Q7Dx11); Compound 2 50 mg/kg (QDx71) + anti-PD-1 200 µg (Q3Dx24); or Compound 2, 150 mg/kg (2Q7Dx11) + anti-PD-1 200 µg (Q3Dx24).

[019] **FIG. 13** shows changes in tumor volume (mm³) for C57B1/6 mice implanted with MT373 mouse sarcoma tumors over 182 days upon receiving treatment with vehicle (2Q7Dx4); anti-PD-1 200 µg (Q3Dx7); Compound 2, 50 mg/kg (QDx44); Compound 2, 100 mg/kg (QDx71); Compound 2, 150 mg/kg (2Q7Dx10); Compound 2, 300 mg/kg (2Q7Dx11); Compound 2 50 mg/kg (QDx71) + anti-PD-1 200 µg (Q3Dx24); or Compound 2, 150 mg/kg (2Q7Dx11) + anti-PD-1 200 µg (Q3Dx24).

[020] **FIG. 14** shows changes in tumor volume (mm³) of individual C57B1/6 mice implanted with MT373 mouse sarcoma tumors upon receiving treatment with vehicle (2Q7Dx4); anti-PD-1 200 µg (Q3Dx7); Compound 2, 50 mg/kg (QDx44); Compound 2, 100 mg/kg (QDx71); Compound 2, 150 mg/kg (2Q7Dx10); Compound 2, 300 mg/kg (2Q7Dx11); Compound 2 50 mg/kg (QDx71) + anti-PD-1 200 µg (Q3Dx24); or Compound 2, 150 mg/kg (2Q7Dx11) + anti-PD-1 200 µg (Q3Dx24).

[021] **FIG. 15** shows changes in percent survival of C57B1/6 mice implanted with MT373 mouse sarcoma tumors upon receiving treatment with vehicle (2Q7Dx4); anti-PD-1 200 µg (Q3Dx7); Compound 2, 50 mg/kg (QDx44); Compound 2, 100 mg/kg (QDx71); Compound 2, 150 mg/kg

(2Q7Dx10); Compound 2, 300 mg/kg (2Q7Dx11); Compound 2 50 mg/kg (QDx71) + anti-PD-1 200 µg (Q3Dx24); or Compound 2, 150 mg/kg (2Q7Dx11) + anti-PD-1 200 µg (Q3Dx24).

[022] FIG. 16 shows changes in percent survival of C57B1/6 mice implanted with MT373 mouse sarcoma tumors upon receiving treatment with vehicle; anti-PD-1; Compound 2, 50 mg/kg (QD); Compound 2, 100 mg/kg (QD); or Compound 2, 50 mg/kg (QD) + anti-PD-1.

[023] FIG. 17 shows changes in percentage body weight of C57B1/6 mice implanted with MT373 mouse sarcoma tumors upon receiving treatment with vehicle (2Q7Dx4); anti-PD-1 200 µg (Q3Dx7); Compound 2, 50 mg/kg (QDx44); Compound 2, 100 mg/kg (QDx71); Compound 2, 150 mg/kg (2Q7Dx10); Compound 2, 300 mg/kg (2Q7Dx11); Compound 2 50 mg/kg (QDx71) + anti-PD-1 200 µg (Q3Dx24); or Compound 2, 150 mg/kg (2Q7Dx11) + anti-PD-1 200 µg (Q3Dx24).

DETAILED DESCRIPTION

[024] The present invention provides compounds and methods for restoring wild-type function to mutant p53. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA. The restoration of activity of the p53 mutant can allow for the activation of downstream effectors of p53 leading to inhibition of cancer progression. The invention further provides methods of treatment of a cancerous lesion or a tumor harboring a p53 mutation.

[025] Cancer is a collection of related diseases characterized by uncontrolled proliferation of cells with the potential to metastasize throughout the body. Cancer can be classified into five broad categories including, for example: carcinomas, which can arise from cells that cover internal and external parts of the body such as the lung, breast, and colon; sarcomas, which can arise from cells that are located in bone, cartilage, fat, connective tissue, muscle, and other supportive tissues; lymphomas, which can arise in the lymph nodes and immune system tissues; leukemia, which can arise in the bone marrow and accumulate in the bloodstream; and adenomas, which can arise in the thyroid, the pituitary gland, the adrenal gland, and other glandular tissues.

[026] Although different cancers can develop in virtually any of the body's tissues, and contain unique features, the basic processes that cause cancer can be similar in all forms of the disease. Cancer begins when a cell breaks free from the normal restraints on cell division and begins to grow and divide out of control. Genetic mutations in the cell can preclude the ability of the cell to repair damaged DNA or initiate apoptosis, and can result in uncontrolled growth and division of cells.

[027] The ability of tumor cell populations to multiply is determined not only by the rate of cell proliferation but also by the rate of cell attrition. Programmed cell death, or apoptosis, represents a major mechanism of cellular attrition. Cancer cells can evade apoptosis through a variety of strategies, for example, through the suppression of p53 function, thereby suppressing expression of pro-apoptotic proteins.

[028] Oncogenes and tumor suppressor genes can regulate the proliferation of cells. Genetic mutations can affect oncogenes and tumor suppressors, potentially activating or suppressing activity abnormally, further facilitating uncontrolled cell division. Whereas oncogenes assist in cellular

growth, tumor suppressor genes slow cell division by repairing damaged DNA and activating apoptosis. Cellular oncogenes that can be mutated in cancer include, for example, Cdk1, Cdk2, Cdk3, Cdk4, Cdk6, EGFR, PDGFR, VEGF, HER2, Raf kinase, K-Ras, and myc. Tumor suppressor genes that can be mutated in cancer include, for example, BRCA1, BRCA2, cyclin-dependent kinase inhibitor 1C, Retinoblastoma protein (pRb), PTEN, p16, p27, p53, and p73.

Tumor suppressor p53.

[029] The tumor suppressor protein p53 is a 393 amino acid transcription factor that can regulate cell growth in response to cellular stresses including, for example, UV radiation, hypoxia, oncogene activation, and DNA damage. p53 has various mechanisms for inhibiting the progression of cancer including, for example, initiation of apoptosis, maintenance of genomic stability, cell cycle arrest, induction of senescence, and inhibition of angiogenesis. Due to the critical role of p53 in tumor suppression, p53 is inactivated in almost all cancers either by direct mutation or through perturbation of associated signaling pathways involved in tumor suppression. Homozygous loss of the p53 gene occurs in almost all types of cancer, including carcinomas of the breast, colon, and lung. The presence of certain p53 mutations in several types of human cancer can correlate with less favorable patient prognosis.

[030] In the absence of stress signals, p53 levels are maintained at low levels via the interaction of p53 with Mdm2, an E3 ubiquitin ligase. In an unstressed cell, Mdm2 can target p53 for degradation by the proteasome. Under stress conditions, the interaction between Mdm2 and p53 is disrupted, and p53 accumulates. The critical event leading to the activation of p53 is phosphorylation of the N-terminal domain of p53 by protein kinases, thereby transducing upstream stress signals. The phosphorylation of p53 leads to a conformational change, which can promote DNA binding by p53 and allow transcription of downstream effectors. The activation of p53 can induce, for example, the intrinsic apoptotic pathway, the extrinsic apoptotic pathway, cell cycle arrest, senescence, and DNA repair. p53 can activate proteins involved in the above pathways including, for example, Fas/Apo1, KILLER/DR5, Bax, Puma, Noxa, Bid, caspase-3, caspase-6, caspase-7, caspase-8, caspase-9, and p21 (WAF1). Additionally, p53 can repress the transcription of a variety of genes including, for example, c-MYC, Cyclin B, VEGF, RAD51, and hTERT.

[031] Each chain of the p53 tetramer is composed of several functional domains including the transactivation domain (amino acids 1-100), the DNA-binding domain (amino acids 101-306), and the tetramerization domain (amino acids 307-355), which are highly mobile and largely unstructured. Most p53 cancer mutations are located in the DNA-binding core domain of the protein, which contains a central β -sandwich of anti-parallel β -sheets that serves as a basic scaffold for the DNA-binding surface. The DNA-binding surface is composed of two β -turn loops, L2 and L3, which are stabilized by a zinc ion, for example, at Arg175 and Arg248, and a loop-sheet-helix motif. Altogether, these structural elements form an extended DNA-binding surface that is rich in positively-charged amino acids, and makes specific contact with various p53 response elements.

[032] Due to the prevalence of p53 mutations in virtually every type of cancer, the reactivation of wild type p53 function in a cancerous cell can be an effective therapy. Mutations in p53 located in the DNA-binding domain of the protein or periphery of the DNA-binding surface result in aberrant protein folding required for DNA recognition and binding. Mutations in p53 can occur, for example, at amino acids Val143, His168, Arg175, Tyr220, Gly245, Arg248, Arg249, Phe270, Arg273, and Arg282. p53 mutations that can abrogate the activity of p53 include, for example, R175H, Y220C, G245S, R248Q, R248W, R273H, and R282H. These p53 mutations can either distort the structure of the DNA-binding site or thermodynamically destabilize the folded protein at body temperature. Wild-type function of p53 mutants can be recovered by binding of the p53 mutant to a compound that can shift the folding-unfolding equilibrium towards the folded state, thereby reducing the rate of unfolding and destabilization.

[033] Non-limiting examples of amino acids include: alanine (A, Ala); arginine (R, Arg); asparagine (N, Asn); aspartic acid (D, Asp); cysteine (C, Cys); glutamic acid (E, Glu); glutamine (Q, Gln); glycine (G, Gly); histidine (H, His); isoleucine (I, Ile); leucine (L, Leu); lysine (K, Lys); methionine (M, Met); phenylalanine (F, Phe); proline (P, Pro); serine (S, Ser); threonine (T, Thr); tryptophan (W, Trp); tyrosine (Y, Tyr); and valine (V, Val).

Mechanism of compounds of the invention.

[034] The compounds of the present invention can selectively bind to a p53 mutant and can recover wild-type activity of the p53 mutant including, for example, DNA binding function and activation of downstream targets involved in tumor suppression. In some embodiments, a compound of the invention selectively binds to the p53 Y220C mutant. The Y220C mutant is a temperature sensitive mutant, which binds to DNA at lower temperature and is denatured at body temperature. A compound of the invention can stabilize the Y220C mutant to reduce the likelihood of denaturation of the protein at body temperature.

[035] In some embodiments, the compounds of the disclosure stabilize a mutant p53 and allows the mutant p53 to bind to DNA, thereby shifting the equilibrium of wild type and mutant p53 proteins to wild type p53. In some embodiments, the compounds of the disclosure reactivate the mutant p53 protein to provide wild type p53 activity. In some embodiments, the compounds of the disclosure reactivate the mutant p53 protein to provide pro-apoptotic p53 activity. In some embodiments, the compounds of the disclosure reactivate the mutant p53 protein to block angiogenesis. In some embodiments, the compounds of the disclosure reactivate the mutant p53 protein to induce cellular senescence. In some embodiments, the compounds of the disclosure reactivate the mutant p53 protein to induce cell cycle arrest.

[036] In some embodiments, the compounds of the disclosure can reconfirm mutant p53 to a conformation of p53 that exhibits anti-cancer activity. In some embodiments, the mutant p53 is reconfirmed to a wild type conformation p53. In some embodiments, the mutant p53 is reconfirmed to a pro-apoptotic conformation of p53. In some embodiments, the mutant p53 is reconfirmed to a

conformation of p53 that blocks angiogenesis. In some embodiments, the mutant p53 is reconformed to a conformation of p53 that induces cellular senescence. In some embodiments, the mutant p53 is reconformed to a conformation of p53 that induces cell-cycle arrest.

[037] Located in the periphery of the p53 β -sandwich connecting β -strands S7 and S8, the aromatic ring of Y220 is an integral part of the hydrophobic core of the β -sandwich. The Y220C mutation can be highly destabilizing, due to the formation of an internal surface cavity. A compound of the invention can bind to and occupy this surface crevice to stabilize the β -sandwich, thereby restoring wild-type p53 DNA-binding activity.

[038] To determine the ability of a compound of the invention to bind and stabilize mutant p53, assays can be employed to detect, for example, a conformational change in the p53 mutant or activation of wild-type p53 targets. Conformational changes in p53 can be measured by, for example, differential scanning fluorimetry (DSF), isothermal titration calorimetry (ITC), nuclear magnetic resonance spectrometry (NMR), or X-ray crystallography. Additionally, antibodies specific for the wild type of mutant conformation of p53 can be used to detect a conformational change via, for example, immunoprecipitation (IP), immunofluorescence (IF), or immunoblotting.

[039] Methods used to detect the ability of the p53 mutant to bind DNA can include, for example, DNA affinity immunoblotting, modified enzyme-linked immunosorbent assay (ELISA), electrophoretic mobility shift assay (EMSA), fluorescence resonance energy transfer (FRET), homogeneous time-resolved fluorescence (HTRF), and a chromatin immunoprecipitation (ChIP) assay.

[040] To determine whether a compound described herein is able to reactivate the transcriptional activity of p53, the activation of downstream targets in the p53 signaling cascade can be measured. Activation of p53 effector proteins can be detected by, for example, immunohistochemistry (IHC-P), reverse transcription polymerase chain reaction (RT-PCR), and western blotting. The activation of p53 can also be measured by the induction of apoptosis via the caspase cascade and using methods including, for example, Annexin V staining, TUNEL assays, pro-caspase and caspase levels, and cytochrome c levels. Another consequence of p53 activation is senescence, which can be measured using methods such as β -galactosidase staining.

[041] A p53 mutant that can be used to determine the effectiveness of a compound of the invention to increase the DNA binding ability of a p53 mutant is a p53 truncation mutant, which contains only amino acids 94-312, encompassing the DNA-binding domain of p53. For example, the sequence of the p53 Y220C mutant used for testing compound efficacy can be:

SSSVPSQ KTYQGSYGFR LGFLHSGTAK SVTCTYSPAL NKMFCQLAKT
CPVQLWVDST PPPGTRVRAM AIYKQSQHMT EVVRRCPHHE
RCSDSGLAP PQHLIRVEGN LRVEYLDDRN TFRHSVVVPC
EPPEVGSDCT TIHYNMCNS SCMGGMNRRP ILTIITLED SGNLLGRNSF
EVHVCACPGR DRRTEENLR KKGEPPHELP PGSTKRALSNT (SEQ ID

NO. 1)

[042] A compound of the invention can increase the ability of a p53 mutant to bind DNA by at least or up to about 0.1%, at least or up to about 0.2%, at least or up to about 0.3%, at least or up to about 0.4%, at least or up to about 0.5%, at least or up to about 0.6%, at least or up to about 0.7%, at least or up to about 0.8%, at least or up to about 0.9%, at least or up to about 1%, at least or up to about 2%, at least or up to about 3%, at least or up to about 4%, at least or up to about 5%, at least or up to about 6%, at least or up to about 7%, at least or up to about 8%, at least or up to about 9%, at least or up to about 10%, at least or up to about 11%, at least or up to about 12%, at least or up to about 13%, at least or up to about 14%, at least or up to about 15%, at least or up to about 16%, at least or up to about 17%, at least or up to about 18%, at least or up to about 19%, at least or up to about 20%, at least or up to about 21%, at least or up to about 22%, at least or up to about 23%, at least or up to about 24%, at least or up to about 25%, at least or up to about 26%, at least or up to about 27%, at least or up to about 28%, at least or up to about 29%, at least or up to about 30%, at least or up to about 31%, at least or up to about 32%, at least or up to about 33%, at least or up to about 34%, at least or up to about 35%, at least or up to about 36%, at least or up to about 37%, at least or up to about 38%, at least or up to about 39%, at least or up to about 40%, at least or up to about 41%, at least or up to about 42%, at least or up to about 43%, at least or up to about 44%, at least or up to about 45%, at least or up to about 46%, at least or up to about 47%, at least or up to about 48%, at least or up to about 49%, at least or up to about 50%, at least or up to about 51%, at least or up to about 52%, at least or up to about 53%, at least or up to about 54%, at least or up to about 55%, at least or up to about 56%, at least or up to about 57%, at least or up to about 58%, at least or up to about 59%, at least or up to about 60%, at least or up to about 61%, at least or up to about 62%, at least or up to about 63%, at least or up to about 64%, at least or up to about 65%, at least or up to about 66%, at least or up to about 67%, at least or up to about 68%, at least or up to about 69%, at least or up to about 70%, at least or up to about 71%, at least or up to about 72%, at least or up to about 73%, at least or up to about 74%, at least or up to about 75%, at least or up to about 76%, at least or up to about 77%, at least or up to about 78%, at least or up to about 79%, at least or up to about 80%, at least or up to about 81%, at least or up to about 82%, at least or up to about 83%, at least or up to about 84%, at least or up to about 85%, at least or up to about 86%, at least or up to about 87%, at least or up to about 88%, at least or up to about 89%, at least or up to about 90%, at least or up to about 91%, at least or up to about 92%, at least or up to about 93%, at least or up to about 94%, at least or up to about 95%, at least or up to about 96%, at least or up to about 97%, at least or up to about 98%, at least or up to about 99%, at least or up to about 100%, at least or up to about 125%, at least or up to about 150%, at least or up to about 175%, at least or up to about 200%, at least or up to about 225%, or at least or up to about 250% as compared to the ability of the p53 mutant to bind DNA in the absence of a compound of the invention.

[043] A compound described herein can increase the activity of the p53 mutant that is, for example,

at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 11-fold, at least or up to about 12-fold, at least or up to about 13-fold, at least or up to about 14-fold, at least or up to about 15-fold, at least or up to about 16-fold, at least or up to about 17-fold, at least or up to about 18-fold, at least or up to about 19-fold, at least or up to about 20-fold, at least or up to about 25-fold, at least or up to about 30-fold, at least or up to about 35-fold, at least or up to about 40-fold, at least or up to about 45-fold, at least or up to about 50-fold, at least or up to about 55-fold, at least or up to about 60-fold, at least or up to about 65-fold, at least or up to about 70-fold, at least or up to about 75-fold, at least or up to about 80-fold, at least or up to about 85-fold, at least or up to about 90-fold, at least or up to about 95-fold, at least or up to about 100-fold, at least or up to about 110-fold, at least or up to about 120-fold, at least or up to about 130-fold, at least or up to about 140-fold, at least or up to about 150-fold, at least or up to about 160-fold, at least or up to about 170-fold, at least or up to about 180-fold, at least or up to about 190-fold, at least or up to about 200-fold, at least or up to about 250-fold, at least or up to about 300-fold, at least or up to about 350-fold, at least or up to about 400-fold, at least or up to about 450-fold, at least or up to about 500-fold, at least or up to about 550-fold, at least or up to about 600-fold, at least or up to about 650-fold, at least or up to about 700-fold, at least or up to about 750-fold, at least or up to about 800-fold, at least or up to about 850-fold, at least or up to about 900-fold, at least or up to about 950-fold, at least or up to about 1,000-fold, at least or up to about 1,500-fold, at least or up to about 2,000-fold, at least or up to about 3,000-fold, at least or up to about 4,000-fold, at least or up to about 5,000-fold, at least or up to about 6,000-fold, at least or up to about 7,000-fold, at least or up to about 8,000-fold, at least or up to about 9,000-fold, or at least or up to about 10,000-fold greater than the activity of the p53 mutant in the absence of the compound.

[044] A compound of the invention can be used, for example, to induce apoptosis, cell cycle arrest, or senescence in a cell. In some embodiments, the cell is a cancer cell. In some embodiments, the cell carries a mutation in p53.


Compounds of the invention.


[045] In some embodiments, a compound of the disclosure comprises a substituted heterocyclyl group, wherein the compound binds a mutant p53 protein and increases wild-type p53 activity of the mutant protein. In some embodiments, a compound of the disclosure comprises a heterocyclyl group comprising a halo substituent, wherein the compound binds a mutant p53 protein and increases wild-type p53 activity of the mutant protein. In some embodiments, the compound further comprises an indole group. In some embodiments, the indole group has a 1,1,1,-trifluoroethyl substituent at a 1-position of the indole group.


[046] In some embodiments, the indole group has a propargyl substituent at a 2-position of the indole group. In some embodiments, the propargyl substituent is attached to the indole group via an


sp carbon atom of the propargyl substituent. In some embodiments, the propargyl substituent is attached to a nitrogen atom of an aniline group via a methylene group of the propargyl substituent. In some embodiments, the indole group comprises an amino substituent at a 4-position of the indole group. In some embodiments, the amino substituent is attached to the heterocyclyl group. In some embodiments, the heterocyclyl group is a piperidine group. In some embodiments, the halo substituent is a fluoro group. In some embodiments, the halo substituent is a chloro group. In some embodiments, the compound has oral bioavailability that is at least about 50% greater than that of an analogous compound that lacks the halo substituent on the heterocyclyl group.


[047] Non-limiting examples of compounds of the invention include compounds of any of the following formulae:












[048] In some embodiments, the compound is of the formula:



wherein:

- each ----- is independently a single bond or a double bond;
- X^1 is CR^5 , CR^5R^6 , N, NR^5 , O, S, C=O, C=S, or a carbon atom connected to Q^1 ;
- X^2 is CR^7 , CR^7R^8 , N, NR^7 , O, S, C=O, C=S, or a carbon atom connected to Q^1 ;
- X^3 is CR^9 , CR^9R^{10} , N, NR^9 , O, S, C=O, C=S, or a carbon atom connected to Q^1 ;
- X^4 is CR^{11} , $CR^{11}R^{12}$, N, NR^{11} , O, S, C=O, C=S, or a carbon atom connected to Q^1 ;
- X^5 is CR^{13} , N, or NR^{13} ;

wherein at least one of X^1 , X^2 , X^3 , and X^4 is a carbon atom connected to Q^1 ;

- A is a linking group;
- Q^1 is C=O, C=S, C=CR¹⁴R¹⁵, C=NR¹⁴, alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond;
- m is 1, 2, 3, or 4;
- Y is N, O, or absent;
- R^1 is -C(O)R¹⁶, -C(O)OR¹⁶, -C(O)NR¹⁶R¹⁷, -OR¹⁶, -SR¹⁶, -NR¹⁶R¹⁷, -NR¹⁶C(O)R¹⁶, -OC(O)R¹⁶, -SiR¹⁶R¹⁷R¹⁸, alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, heterocyclyl, or halo, each of which is independently substituted or unsubstituted, or hydrogen;
- each R^3 and R^4 is independently -C(O)R¹⁹, -C(O)OR¹⁹, -C(O)NR¹⁹R²⁰, -SOR¹⁹, -SO₂R¹⁹, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen, or R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a ring, wherein the ring is substituted or unsubstituted, or R^3 is absent;
- each R^2 , R^5 , R^6 , R^7 , R^8 , R^9 , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , and R^{18} is independently -C(O)R²¹, -C(O)OR²¹, -C(O)NR²¹R²², -OR²¹, -SR²¹, -NR²¹R²², -NR²¹C(O)R²², -OC(O)R²¹, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R^{19} and R^{20} is independently -C(O)R²³, -C(O)OR²³, -C(O)NR²³R²⁴, -OR²³, -SR²³, -NR²³R²⁴, -NR²³C(O)R²⁴, -OC(O)R²³, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or

heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;

- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,


or a pharmaceutically-acceptable salt thereof.

[049] In some embodiments, A is alkylene, alkenylene, or alkynylene, each of which is substituted or unsubstituted. In some embodiments, A is alkylene. In some embodiments, A is alkenylene. In some embodiments, A is alkynylene.

[050] In some embodiments, A is aryl, heteroaryl, or heterocyclyl, each of which is substituted or unsubstituted. In some embodiments, A is substituted aryl. In some embodiments, A is substituted heteroaryl. In some embodiments, A is substituted heterocyclyl.

[051] In some embodiments, R^1 is alkyl, alkenyl, $-C(O)R^{16}$, $-C(O)OR^{16}$, or $-C(O)NR^{16}R^{17}$, each of which is unsubstituted or substituted. In some embodiments, R^1 is substituted alkyl. In some embodiments, R^1 is alkyl substituted with $NR^{16}R^{17}$.

[052] In some embodiments, the compound of the formula is:



wherein:

- each ----- is independently a single bond or a double bond;
- X^1 is CR^5 , CR^5R^6 , N, NR^5 , O, S, C=O, C=S, or a carbon atom connected to Q^1 ;
- X^2 is CR^7 , CR^7R^8 , N, NR^7 , O, S, C=O, C=S, or a carbon atom connected to Q^1 ;
- X^3 is CR^9 , CR^9R^{10} , N, NR^9 , O, S, C=O, C=S, or a carbon atom connected to Q^1 ;
- X^4 is CR^{11} , $CR^{11}R^{12}$, N, NR^{11} , O, S, C=O, C=S, or a carbon atom connected to Q^1 ;
- X^5 is CR^{13} , N, or NR^{13} ;


wherein at least one of X^1 , X^2 , X^3 , and X^4 is a carbon atom connected to Q^1 ;

- Q^1 is C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond;
- m is 1, 2, 3, or 4;
- Y is N, O, or absent;
- ring A is a cyclic group;

- R^1 is $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, $C=O$, $C=S$, $-CN$, $-SiR^{16}R^{17}R^{18}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen;
- R^3 is $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, alkyl, alkylene, alkenyl, alkenylene, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen, or R^3 and A together with the nitrogen atom to which R^3 and A are bound form a ring, wherein the ring is substituted or unsubstituted, or R^3 is absent,
- each R^2 , R^5 , R^6 , R^7 , R^8 , R^9 , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , and R^{18} is independently $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R^{19} and R^{20} is $C(O)R^{23}$, $-C(O)OR^{23}$, $-C(O)NR^{23}R^{24}$, $-OR^{23}$, $-SR^{23}$, $-NR^{23}R^{24}$, $-NR^{23}C(O)R^{24}$, $-OC(O)R^{23}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,

or a pharmaceutically-acceptable salt thereof.

[053] In some embodiments, a compound of the invention is a compound of the formula



wherein:


- each ----- is independently a single bond or a double bond;
- X^1 is CR^5 , CR^5R^6 , N , NR^5 , O , S , $C=O$, $C=S$, or a carbon atom connected to Q^1 ;
- X^2 is CR^7 , CR^7R^8 , N , NR^7 , O , S , $C=O$, $C=S$, or a carbon atom connected to Q^1 ;
- X^3 is CR^9 , CR^9R^{10} , N , NR^9 , O , S , $C=O$, $C=S$, or a carbon atom connected to Q^1 ;
- X^4 is CR^{11} , $CR^{11}R^{12}$, N , NR^{11} , O , S , $C=O$, $C=S$, or a carbon atom connected to Q^1 ;
- X^5 is CR^{13} , N , or NR^{13} ;

wherein at least one of X^1 , X^2 , X^3 , and X^4 is a carbon atom connected to Q^1 ;

- Q^1 is $C=O$, $C=S$, $C=CR^{14}R^{15}$, $C=NR^{14}$, alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond;
- m is 1, 2, 3, or 4;
- Y is N , O , or absent;

- R^1 is $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, $C=O$, $C=S$, $-CN$, $-SiR^{16}R^{17}R^{18}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen;
 - each R^3 and R^4 is independently, $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, alkyl, alkylene, alkenyl, alkenylene, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen, or R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a ring, wherein the ring is substituted or unsubstituted, or R^3 is absent,
 - each R^2 , R^5 , R^6 , R^7 , R^8 , R^9 , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , and R^{18} is independently $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
 - each R^{19} and R^{20} is $C(O)R^{23}$, $-C(O)OR^{23}$, $-C(O)NR^{23}R^{24}$, $-OR^{23}$, $-SR^{23}$, $-NR^{23}R^{24}$, $-NR^{23}C(O)R^{24}$, $-OC(O)R^{23}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
 - each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
 - each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,
- or a pharmaceutically-acceptable salt thereof.

[054] In some embodiments, the compound is of the formula:



wherein:

- each ----- is independently a single bond or a double bond;
- X^1 is CR^5 , CR^5R^6 , N , NR^5 , O , S , $C=O$, $C=S$, or a carbon atom connected to Q^1 ;
- X^2 is CR^7 , CR^7R^8 , N , NR^7 , O , S , $C=O$, $C=S$, or a carbon atom connected to Q^1 ;
- X^3 is CR^9 , CR^9R^{10} , N , NR^9 , O , S , $C=O$, $C=S$, or a carbon atom connected to Q^1 ;
- X^4 is CR^{11} , $CR^{11}R^{12}$, N , NR^{11} , O , S , $C=O$, $C=S$, or a carbon atom connected to Q^1 ;
- X^5 is CR^{13} , N , or NR^{13} ;

wherein at least one of X^1 , X^2 , X^3 , and X^4 is a carbon atom connected to Q^1 ;

- Q^1 is $C=O$, $C=S$, $C=CR^{14}R^{15}$, $C=NR^{14}$, alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond;

- m is 1, 2, 3, or 4;
- Y is N, O, or absent;
- ring A is a cyclic group;
- R¹ is -C(O)R¹⁶, -C(O)OR¹⁶, -C(O)NR¹⁶R¹⁷, -OR¹⁶, -SR¹⁶, -NR¹⁶R¹⁷, -NR¹⁶C(O)R¹⁶, -OC(O)R¹⁶, C=O, C=S, -CN, -SiR¹⁶R¹⁷R¹⁸, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen;
- R³ is -C(O)R¹⁹, -C(O)OR¹⁹, -C(O)NR¹⁹R²⁰, -SOR¹⁹, -SO₂R¹⁹, alkyl, alkylene, alkenyl, alkenylene, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen, or R³ and A together with the nitrogen atom to which R³ and A are bound form a ring, wherein the ring is substituted or unsubstituted, or R³ is absent,
- each R², R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, and R¹⁸ is independently -C(O)R²¹, -C(O)OR²¹, -C(O)NR²¹R²², -OR²¹, -SR²¹, -NR²¹R²², -NR²¹C(O)R²², -OC(O)R²¹, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R¹⁹ and R²⁰ is C(O)R²³, -C(O)OR²³, -C(O)NR²³R²⁴, -OR²³, -SR²³, -NR²³R²⁴, -NR²³C(O)R²⁴, -OC(O)R²³, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R²¹ and R²² is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R²³ and R²⁴ is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,

or a pharmaceutically-acceptable salt thereof.

[055] In some embodiments, the pattern of dashed bonds is chosen to provide an aromatic system, for example, an indole, an indolene, a pyrrolopyridine, a pyrrolopyrimidine, or a pyrrolopyrazine.

[056] In some embodiments, X¹ is CR⁵, CR⁵R⁶, or a carbon atom connected to Q¹. In some embodiments, X² is CR⁷, CR⁷R⁸, or a carbon atom connected to Q¹. In some embodiments, X³ is CR⁹, CR⁹R¹⁰, or a carbon atom connected to Q¹. In some embodiments, X⁴ is CR¹¹, CR¹¹R¹², or a carbon atom connected to Q¹. In some embodiments, X⁵ is CR¹³, N, or NR¹³. In some embodiments, X¹ is a carbon atom connected to Q¹. In some embodiments, X² is a carbon atom connected to Q¹. In some embodiments, X³ is a carbon atom connected to Q¹. In some embodiments, X⁴ is a carbon atom connected to Q¹. In some embodiments, X⁵ is N.

[057] In some embodiments, Q¹ is a bond. In some embodiments, Q¹ is C₁-alkylene. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, m is 4.


[058] In some embodiments, R^1 is alkyl, alkenyl, $-C(O)R^{16}$, $-C(O)OR^{16}$, or $-C(O)NR^{16}R^{17}$, each of which is unsubstituted or substituted. In some embodiments, R^1 is substituted alkyl. In some embodiments, R^1 is alkyl substituted with $NR^{16}R^{17}$.


[059] In some embodiments, ring A is aryl, heteroaryl, or heterocyclyl, each of which is substituted or unsubstituted. In some embodiments, ring A is substituted aryl. In some embodiments, ring A is aryl substituted with fluoro-. In some embodiments, ring A is aryl substituted with chloro-. In some embodiments, ring A is substituted heteroaryl. In some embodiments, ring A is heteroaryl substituted with fluoro-. In some embodiments, ring A is heteroaryl substituted with chloro-. In some embodiments, ring A is substituted heterocyclyl. In some embodiments, ring A is heterocyclyl substituted with fluoro-. In some embodiments, A is heterocyclyl substituted with chloro-.

[060] In some embodiments, ring A is piperidiny, piperaziny, tetrahydropyrany, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted. In some embodiments, ring A is piperidiny, piperaziny, tetrahydropyrany, morpholinyl, or pyrrolidinyl, each of which is independently substituted with at least halo-. In some embodiments, ring A is piperidiny substituted with halo-. In some embodiments, ring A is methylpiperidiny substituted with halo-. In some embodiments, ring A is 3-fluoro-1-methylpiperidiny. In some embodiments, ring A is 3-fluoro-1-(2-hydroxy-3-methoxypropyl)piperidiny. In some embodiments, ring A is tetrahydropyrany substituted with at least halo-.

[061] In some embodiments, each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^{16} is hydrogen or alkyl. In some embodiments, R^{17} is aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted. In some embodiments, R^{17} is substituted aryl. In some embodiments, R^{17} is substituted phenyl. In some embodiments, R^{17} is phenyl substituted with a sulfoxide group, carboxyl group, amide group, amino group, alkyl, alkoxy, hydroxy, halo, cyano, or heterocyclyl, each of which is independently substituted or unsubstituted. In some embodiments, R^{17} is phenyl substituted with methoxy. In some embodiments, R^{17} is phenyl substituted with a substituted sulfoxide group. In some embodiments, R^{17} is phenyl substituted with a carboxyl group. In some embodiments, R^{17} is phenyl substituted with a substituted amide group.

[062] In some embodiments, the compound is of the formula:





[063] In some embodiments, Q¹ is C=O, C=S, C=CR¹⁴R¹⁵, C=NR¹⁴, alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond. In some embodiments, Q¹ is alkylene, alkenylene, or alkynylene. In some embodiments, Q¹ is C₁-alkylene or a bond. In some embodiments, Q¹ is C₁-alkylene. In some embodiments, Q¹ is a bond.


[064] In some embodiments, Y is N. In some embodiments, Y is O. In some embodiments, Y is absent.

[065] In some embodiments, R² is hydrogen or alkyl. In some embodiments, R² is alkyl. In some embodiments, R² is substituted C₁-C₅-alkyl. In some embodiments, R² is trifluoroethyl. In some embodiments, R² is cycloalkyl. In some embodiments, R² is cyclopropyl.


[066] In some embodiments, R¹³ is alkyl, alkenyl, hydrogen, or halogen. In some embodiments, R¹³ is hydrogen.

[067] In some embodiments, R² is C₁-C₅-alkyl, and R¹³ is C₁-C₅-alkyl. In some embodiments, R² is C₁-C₅-alkyl, and R¹³ is hydrogen. In some embodiments, R² is substituted C₁-C₅-alkylene. In some embodiments, R² is methyl, ethyl, propyl, iso-propyl, butyl, or tert-butyl, each of which is substituted or unsubstituted. In some embodiments, R¹³ is methyl, ethyl, propyl, iso-propyl, butyl or tert-butyl. In some embodiments, R² is hydrogen, and R¹³ is hydrogen. In some embodiments, R² is trifluoroethyl, and R¹³ is hydrogen.

[068] In some embodiments, the compound is of the formula:




[069] In some embodiments, the compound is of the formula:




[070] In some embodiments, R³ is H, and R⁴ is -C(O)R¹⁹, -C(O)OR¹⁹, -C(O)NR¹⁹R²⁰, -SOR¹⁹, -SO₂R¹⁹, alkyl, alkylene, alkenyl, alkenylene, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which

is independently substituted or unsubstituted. In some embodiments, each R^3 and R^4 is independently substituted or unsubstituted C_1 - C_6 -alkylene. In some embodiments, R^3 is H, and R^4 is substituted or unsubstituted C_1 - C_4 alkylene. In some embodiments, R^3 is H, and R^4 is substituted or unsubstituted heterocyclyl. In some embodiments, R^3 is H, and R^4 is substituted or unsubstituted piperidinyl. In some embodiments, R^3 is H, and R^4 is substituted or unsubstituted cycloalkyl. In some embodiments, R^3 is H, and R^4 is cycloalkyl substituted with an amino group. In some embodiments, R^3 is H, and R^4 is substituted or unsubstituted cyclobutyl. In some embodiments, R^3 is H, and R^4 is cyclobutyl substituted with an amino group. In some embodiments, R^3 is H, and R^4 is substituted or unsubstituted cyclohexyl. In some embodiments, R^3 is H, and R^4 is cyclohexyl substituted with an amino group.

[071] In some embodiments, the compound is of the formula:



[072] In some embodiments, the compound is of the formula:



[073] R^1 can be a group substituted with one or more substituents selected from a hydroxyl group, sulfhydryl group, halogens, amino group, nitro group, nitroso group, cyano group, azido group, sulfoxide group, sulfone group, sulfonamide group, carboxyl group, carboxaldehyde group, imine group, alkyl group, halo-alkyl group, cyclic alkyl group, alkenyl group, halo-alkenyl group, alkynyl group, halo-alkynyl group, alkoxy group, aryl group, aryloxy group, aralkyl group, arylalkoxy group, heterocyclyl group, acyl group, acyloxy group, carbamate group, amide group, urethane group, and ester group. In some embodiments, R^1 is alkyl, alkenyl, $-C(O)R^{16}$, $-C(O)OR^{16}$, or $-C(O)NR^{16}R^{17}$.

[074] In some embodiments, R^1 is substituted or unsubstituted C_1 - C_3 alkyl. In some embodiments, R^1 is C_1 - C_3 -alkyl substituted with an amine group. In some embodiments, R^1 is C_1 -alkyl substituted with $NR^{16}R^{17}$. In some embodiments, each R^{16} and R^{17} is independently aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^{16} is H, and R^{17} is substituted aryl. In some embodiments, R^{16} is H, and R^{17} is

substituted phenyl. In some embodiments, R^{16} is H, and R^{17} is phenyl substituted with alkyl, alkoxy, halo, sulfonamide, a sulfone, or a carboxy group. In some embodiments, R^{16} is H, and R^{17} is substituted heteroaryl. In some embodiments, R^{16} is H, and R^{17} is substituted heterocyclyl.

[075] In some embodiments, Q^1 is C=O, C=S, C=CR¹⁴R¹⁵, C=NR¹⁴, alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond. In some embodiments, Q^1 is alkylene, alkenylene, or alkynylene. In some embodiments, Q^1 is C₁-alkylene. In some embodiments, each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, or hydrogen. In some embodiments, Q^1 is C₁-alkylene, R^{16} is aryl, and R^{17} is alkyl. In some embodiments, Q^1 is C₁-alkylene, R^{16} is aryl, and R^{17} is hydrogen. In some embodiments, Q^1 is C₁-alkylene, R^{16} is heteroaryl, and R^{17} is alkyl. In some embodiments, Q^1 is C₁-alkylene, R^{16} is heteroaryl, and R^{17} is hydrogen. In some embodiments, Q^1 is C₁-alkylene, R^{16} is substituted heteroaryl, and R^{17} is hydrogen. In some embodiments, Q^1 is C₁-alkylene, R^{16} is substituted alkyl, and R^{17} is hydrogen. In some embodiments, R^{17} is aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted with halogen, alkyl, or hydroxyl. In some embodiments, R^{16} is hydrogen, and R^{17} is aryl or heteroaryl, substituted or unsubstituted with halogen or alkyl. In some embodiments, R^{16} is alkyl, and R^{17} is heteroaryl substituted with halogen or alkyl. In some embodiments, R^{17} is aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted with alkyl. In some embodiments, R^{17} is aryl or heteroaryl, each of which is independently substituted with alkyl, wherein the alkyl is optionally substituted with fluorine, chlorine, bromine, iodine, or cyano.

[076] In some embodiments, R^2 is alkyl, and R^{13} is alkyl, each of which is substituted or substituted. In some embodiments, R^2 is hydrogen, and R^{13} is unsubstituted or substituted alkyl. In some embodiments, R^2 is methyl, ethyl, propyl, iso-propyl, butyl, or tert-butyl, each of which is substituted or unsubstituted. In some embodiments, R^{13} is methyl, ethyl, propyl, iso-propyl, butyl or tert-butyl. In some embodiments, R^2 is hydrogen, and R^{13} is hydrogen. In some embodiments, R^2 is hydrogen, and R^{13} is alkyl. In some embodiments, R^2 is trifluoroethyl, and R^{13} is hydrogen.

[077] In some embodiments, R^3 is -C(O)R¹⁹, -C(O)OR¹⁹, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen, and R^4 is -C(O)R¹⁹, -C(O)OR¹⁹, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^3 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^3 is substituted alkyl. In some embodiments, R^3 is H.

[078] In some embodiments, R^3 is H, and R^4 is unsubstituted or substituted alkyl. In some embodiments, R^3 is H, and R^4 is unsubstituted or substituted cycloalkyl. In some embodiments, R^3 is H, and R^4 is substituted cyclohexyl. In some embodiments, R^3 is H, and R^4 is substituted cyclobutyl.

[079] In some embodiments, at least one of R^3 and R^4 is alkyl, alkylene, alkenyl, alkenylene, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is substituted at least with halo-. In some

embodiments, R³ is hydrogen and R⁴ is a ring A. In some embodiments, R⁴ or ring A is cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted. In some embodiments, R⁴ or ring A is substituted or unsubstituted aryl. In some embodiments, R⁴ or ring A is substituted or unsubstituted phenyl. In some embodiments, R⁴ or ring A is substituted or unsubstituted cycloalkyl. In some embodiments, R⁴ or ring A is substituted or unsubstituted cyclopropyl. In some embodiments, R⁴ or ring A is substituted cyclopropyl. In some embodiments, R⁴ or ring A is substituted cyclohexyl. In some embodiments, R⁴ or ring A is cyclohexyl substituted with an amino group.


[080] In some embodiments, R³ is H, and R⁴ or ring A is unsubstituted or substituted heterocyclyl. In some embodiments, R⁴ or ring A is heterocyclyl. In some embodiments, R⁴ or ring A is piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted. In some embodiments, R³ is H, and R⁴ or ring A is substituted piperidinyl. In some embodiments, R³ is H, and R⁴ or ring A is piperidine substituted with alkyl, carboxy, heterocyclyl, or an amide group. In some embodiments, R³ is H, and R⁴ or ring A is unsubstituted or substituted methyl piperidinyl. In some embodiments, R³ is H, and R⁴ or ring A is 3-fluoro-1-methylpiperidinyl. In some embodiments, R³ is H, and R⁴ or ring A is piperidinyl substituted with methoxypropanol. In some embodiments, R³ is H, and R⁴ or ring A is 3-fluoro-1-(2-hydroxy-3-methoxypropyl)piperidinyl. In some embodiments, R³ is H, and R⁴ or ring A is unsubstituted or substituted tetrahydropyranyl. In some embodiments, R³ is H, and R⁴ or ring A is unsubstituted tetrahydropyranyl. In some embodiments, R³ is H, and R⁴ or ring A is tetrahydropyranyl substituted with alkyl. In some embodiments, R³ is H, and R⁴ or ring A is tetrahydrothiopyran-1,1-dioxide.

[081] In some embodiments, R⁴ or ring A is cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which is substituted at least with halo-. In some embodiments, R⁴ or ring A is C₄-C₆-cycloalkyl substituted with at least halo-. In some embodiments, R⁴ or ring A is cyclohexyl substituted with at least halo-. In some embodiments, R⁴ or ring A is aryl substituted with at least halo-. In some embodiments, R⁴ or ring A is phenyl substituted with at least halo-. In some embodiments, R⁴ or ring A is aryl substituted with fluoro-. In some embodiments, R⁴ or ring A is phenyl substituted with fluoro-. In some embodiments, R⁴ or ring A is aryl substituted with chloro-. In some embodiments, R⁴ or ring A is phenyl substituted with chloro-. In some embodiments, R⁴ or ring A is heteroaryl substituted with at least halo-. In some embodiments, R⁴ or ring A is heteroaryl substituted with fluoro-. In some embodiments, R⁴ or ring A is heteroaryl substituted with chloro-. In some embodiments, R⁴ or ring A is C₄-C₆-heterocyclyl substituted with at least halo-. In some embodiments, R⁴ or ring A is heterocyclyl substituted with fluoro-. In some embodiments, R⁴ or ring A is heterocyclyl substituted with chloro-.


[082] In some embodiments, R⁴ or ring A is piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted with at least halo-. In some embodiments, R⁴ or ring A is piperidinyl substituted with halo-. In some embodiments, R⁴ or ring A


is methylpiperidinyl substituted with halo-. In some embodiments, R^4 or ring A is 3-fluoro-1-methylpiperidinyl. In some embodiments, R^4 or ring A is 3-fluoro-1-(2-hydroxy-3-methoxypropyl)piperidinyl. In some embodiments, R^4 or ring A is tetrahydropyranyl substituted with at least halo-.


[083] In some embodiments, R^4 or Ring A is a ring that is:




wherein the ring is substituted or unsubstituted. In some embodiments, the ring is substituted with halo-. In some embodiments, the ring is substituted with fluoro. In some embodiments, R^3 is H, and

R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, the ring is substituted with halo-. In some embodiments, the ring is substituted with

fluoro. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, R^a is alkylene. In some embodiments, R^a is methyl. In some embodiments, the ring is substituted with halo. In some embodiments, the ring is

substituted with fluoro. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, the ring is substituted with halo. In some embodiments, the ring is substituted with fluoro. In some embodiments, R^3 is H, and R^4 is a

ring that is , wherein the ring is substituted or unsubstituted.


[084] In some embodiments, the R^4 or ring A is substituted with one or more substituents selected from a hydroxyl group, sulfhydryl group, halogens, amino group, nitro group, nitroso group, cyano group, azido group, sulfoxide group, sulfone group, sulfonamide group, carboxyl group, carboxaldehyde group, imine group, alkyl group, halo-alkyl group, cyclic alkyl group, alkenyl group, halo-alkenyl group, alkynyl group, halo-alkynyl group, alkoxy group, aryl group, aryloxy group, aralkyl group, arylalkoxy group, heterocyclyl group, acyl group, acyloxy group, carbamate group, amide group, urethane group, and ester group.

[085] In some embodiments, R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a ring, wherein the ring is substituted or unsubstituted. In some embodiments, R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a substituted heterocycle. In some embodiments, R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a


heterocycle substituted with a hydroxyl group, halogen, amino group, or alkyl group. In some embodiments, R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a heterocycle, wherein the heterocycle is substituted by a substituted or unsubstituted heterocycle.

[086] In some embodiments, R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are

bound form a ring of a following formula:



[087] In some embodiments, the compound is of the formula:



wherein:

- R^1 is $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, $C=O$, $C=S$, $-CN$, $-SiR^{16}R^{17}R^{18}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen;
- each R^Q is independently $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- y is 0, 1, 2, 3, or 4;
- each R^{16} , R^{17} , and R^{18} is independently $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R^{19} and R^{20} is $C(O)R^{23}$, $-C(O)OR^{23}$, $-C(O)NR^{23}R^{24}$, $-OR^{23}$, $-SR^{23}$, $-NR^{23}R^{24}$, $-NR^{23}C(O)R^{24}$, $-OC(O)R^{23}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;

- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,


or a pharmaceutically-acceptable salt thereof.


[088] In some embodiments, R^1 is $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, $-SiR^{16}R^{17}R^{18}$, alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^1 is alkyl, alkylene, alkoxy, $-NR^{21}R^{22}$, or aryl, each of which is independently substituted or unsubstituted; halo or hydrogen.

[089] In some embodiments, R^1 is substituted C_1 - C_3 -alkyl. In some embodiments, R^1 is C_1 - C_3 -alkyl substituted with $NR^{16}R^{17}$. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein each R^{16} and R^{17} is independently alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkoxy, carboxyl group, amino group, acyl group, acyloxy group, or an amide group, any of which is unsubstituted or substituted, or hydrogen. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} is a substituted carboxyl group. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} is substituted aryl. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} is substituted phenyl. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} is phenyl substituted with a sulfoxide group, carboxyl group, amide group, amino group, alkyl, alkoxy, hydroxy, halo, cyano, or heterocyclyl, each of which is independently substituted or unsubstituted. In some embodiments, R^{17} is phenyl substituted with methoxy. In some embodiments, R^{17} is phenyl substituted with a substituted sulfoxide group. In some embodiments, R^{17} is phenyl substituted with a carboxyl group. In some embodiments, R^{17} is a substituted amide group. In some embodiments, R^{17} is substituted with methoxy and sulfonamide.

[090] In some embodiments, R^2 is hydrogen or alkyl. In some embodiments, R^2 is substituted C_1 - C_5 -alkylene. In some embodiments, R^2 is trifluoroethyl. In some embodiments, R^{13} is alkyl, alkenyl, hydrogen, or halogen. In some embodiments, R^2 is alkyl, and R^{13} is alkyl. In some embodiments, R^2 is hydrogen, and R^{13} is alkyl. In some embodiments, R^2 is methyl, ethyl, propyl, iso-propyl, butyl, or tert-butyl. In some embodiments, R^{13} is methyl, ethyl, propyl, iso-propyl, butyl or tert-butyl. In some embodiments, R^2 is hydrogen, and R^{13} is hydrogen.

[091] In some embodiments, the compound is of the formula:





or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.

[092] In some embodiments, each R^Q is independently $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen. In some embodiments, each R^Q is


[093] In some embodiments, y is 1. In some embodiments, y is 2. In some embodiments, y is 3. In some embodiments, y is 4.

[094] In some embodiments, R^1 is $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, $-SiR^{16}R^{17}R^{18}$, alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^1 is alkyl, alkylene, alkoxy, $-NR^{21}R^{22}$, or aryl, each of which is independently substituted or unsubstituted; halo or hydrogen.


[095] In some embodiments, R^1 is substituted alkyl. In some embodiments, R^1 is substituted C_1 - C_3 -alkyl. In some embodiments, R^1 is alkyl substituted with $NR^{16}R^{17}$. In some embodiments, R^1 is C_1 - C_3 -alkyl substituted with $NR^{16}R^{17}$. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein each R^{16} and R^{17} is independently alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkoxy, carboxyl group, amino group, acyl group, acyloxy group, or an amide group, any of which is unsubstituted or substituted, or hydrogen. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} is a substituted carboxyl group.

[096] In some embodiments, R^{16} is alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, or hydrogen, and R^{17} is aryl, heteroaryl, or heterocyclyl. In some embodiments, R^{16} is hydrogen, and R^{17} is phenyl, indolyl, piperidinyl, imidazolyl, thiazolyl, morpholinyl, pyrrolyl, or pyridinyl, each of which is substituted or unsubstituted.


[097] In some embodiments, the compound is of the formula:



[098] In some embodiments, the compound is of the formula:



[099] In some embodiments, the compound is of the formula:




[0100] In some embodiments, each R¹⁶ and R¹⁷ is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, or hydrogen. In some embodiments, R¹⁶ is aryl, and R¹⁷ is alkyl. In some embodiments, R¹⁶ is aryl, and R¹⁷ is hydrogen. In some embodiments, R¹⁶ is heteroaryl, and R¹⁷ is alkyl. In some embodiments, R¹⁶ is heteroaryl, and R¹⁷ is hydrogen. In some embodiments, R¹⁶ is substituted heteroaryl, and R¹⁷ is hydrogen. In some embodiments, R¹⁶ is substituted alkyl, and R¹⁷ is hydrogen. In some embodiments, R¹⁷ is aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted with halogen, alkyl, or hydroxyl. In some embodiments, R¹⁶ is hydrogen, and R¹⁷ is aryl or heteroaryl, substituted or unsubstituted with halogen or alkyl. In some embodiments, R¹⁶ is alkyl, and R¹⁷ is heteroaryl substituted with halogen or alkyl. In some embodiments, R¹⁶ is hydrogen. In some embodiments, R¹⁷ is aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted with alkyl. In some embodiments, R¹⁷ is aryl or heteroaryl, each of which is independently substituted with alkyl, wherein the alkyl is optionally substituted with fluorine, chlorine, bromine, iodine, or cyano. In some embodiments, R¹⁶ is alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, or hydrogen, and R¹⁷ is aryl, heteroaryl, or heterocyclyl. In some embodiments, R¹⁶ is hydrogen, and R¹⁷ is phenyl, indolyl, piperidinyl, imidazolyl, thiazolyl, morpholinyl, pyrrolyl, or pyridinyl, each of which is substituted or unsubstituted. In some embodiments, R¹⁶ is hydrogen, and R¹⁷ is substituted phenyl. In some embodiments, R¹⁶ is hydrogen, and R¹⁷ is phenyl substituted with a sulfoxide group, carboxyl group, amide group, amino group, alkyl, alkoxy, hydroxy, halo, cyano, or heterocyclyl, each of which is independently substituted or

unsubstituted. In some embodiments, R^{17} is phenyl substituted with methoxy. In some embodiments, R^{17} is phenyl substituted with a substituted sulfoxide group. In some embodiments, R^{17} is phenyl substituted with a carboxyl group. In some embodiments, R^{17} is a substituted amide group. In some embodiments, R^{17} is substituted with methoxy and sulfonamide.

[0101] In some embodiments, each R^3 and R^4 is independently unsubstituted or substituted alkyl. In some embodiments, R^3 is hydrogen and R^4 is $-C(O)R^{19}$, $-C(O)OR^{19}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted. In some embodiments, R^3 is hydrogen, and R^4 is alkyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is substituted heterocyclyl. In some embodiments, R^3 is H, and R^4 is substituted or unsubstituted C_4 - C_6 -heterocyclyl. In some embodiments, R^3 is H, and R^4 is substituted alkyl. In some embodiments, R^3 is H, and R^4 is substituted C_1 - C_6 -alkyl. In some embodiments, R^3 is H, and R^4 is substituted or unsubstituted cycloalkyl. In some embodiments, R^3 is H, and R^4 is substituted or unsubstituted C_4 - C_6 -cycloalkyl. In some embodiments, R^3 is H, and R^4 is C_4 - C_6 -cycloalkyl substituted with an amino group.

[0102] In some embodiments, the compound is of the formula:



wherein:

- Q^1 is $C=O$, $C=S$, $C=CR^{14}R^{15}$, $C=NR^{14}$, alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond;
- R^1 is $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, $C=O$, $C=S$, $-CN$, $-SiR^{16}R^{17}R^{18}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen;
- each R^3 and R^4 is independently, $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, alkyl, alkylene, alkenyl, alkenylene, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen, or R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a ring, wherein the ring is substituted or unsubstituted, or R^3 is absent;
- each Z^1 and Z^2 is independently CR^{28} , CR^{29} , or N;
- each R^2 , R^5 , R^6 , R^7 , R^8 , R^9 , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , and R^{18} is independently $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;


- each R^{19} and R^{20} is $C(O)R^{23}$, $-C(O)OR^{23}$, $-C(O)NR^{23}R^{24}$, $-OR^{23}$, $-SR^{23}$, $-NR^{23}R^{24}$, $-NR^{23}C(O)R^{24}$, $-OC(O)R^{23}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen;
- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R^{25} , R^{26} , R^{27} , R^{28} , and R^{29} is independently hydrogen or a substituent selected from a hydroxyl group, sulfhydryl group, halogen, amino group, nitro group, nitroso group, cyano group, azido group, sulfoxide group, sulfone group, sulfonamide group, carboxyl group, carboxaldehyde group, imine group, alkyl group, halo-alkyl group, alkenyl group, halo-alkenyl group, alkynyl group, halo-alkynyl group, alkoxy group, aryl group, aryloxy group, aralkyl group, arylalkoxy group, heterocyclyl group, acyl group, acyloxy group, carbamate group, amide group, ureido group, epoxy group, and ester group.


or a pharmaceutically-acceptable salt thereof.

[0103] In some embodiments, Z^1 is N. In some embodiments, Z^1 and Z^2 are N. In some

embodiments, each R^{25} and R^{26} is independently a halogen. In some embodiments, R^{25} is . In some embodiments, R^{25} is a substituted sulfone group. In some embodiments, R^{25} is a sulfone group substituted with alkyl. In some embodiments, R^{25} is a methanesulfonyl group. In some embodiments, R^{25} is a sulfone group substituted with an amino group. In some embodiments, R^{25} is a sulfonamide. In some embodiments, R^{25} is a carboxy group. In some embodiments, R^{25} is a methoxycarbonyl group.

[0104] In some embodiments, the compound is of the formula:







wherein:

- R^2 is $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R^Q is independently $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted;
- y is 0, 1, 2, 3, or 4;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R^{25} , R^{26} , R^{27} , R^{28} , and R^{29} is independently hydrogen or a substituent selected from a hydroxyl group, sulfhydryl group, halogen, amino group, nitro group, nitroso group, cyano group, azido group, sulfoxide group, sulfone group, sulfonamide group, carboxyl group, carboxaldehyde group, imine group, alkyl group, halo-alkyl group, alkenyl group, halo-alkenyl group, alkynyl group, halo-alkynyl group, alkoxy group, aryl group, aryloxy group, aralkyl group, arylalkoxy group, heterocyclyl group, acyl group, acyloxy group, carbamate group, amide group, ureido group, epoxy group, and ester group.

or a pharmaceutically-acceptable salt thereof.


[0105] In some embodiments, the compound is of the formula:






[0106] In some embodiments, R^{25} is a substituted sulfone group. In some embodiments, R^{25} is a sulfone group substituted with alkyl. In some embodiments, R^{25} is a methanesulfonyl group. In some embodiments, R^{25} is a sulfone group substituted with an amino group. In some embodiments, R^{25} is a sulfonamide. In some embodiments, R^{25} is a carboxy group. In some embodiments, R^{25} is a methoxycarbonyl group.

[0107] In some embodiments, the compound is of the formula:






wherein:

- each R^Q is independently $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted;
- y is 0, 1, 2, 3, or 4;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen;
- each R^{26} , R^{27} , R^{28} , and R^{29} is independently hydrogen or a substituent selected from a hydroxyl group, sulfhydryl group, halogen, amino group, nitro group, nitroso group, cyano group, azido group, sulfoxide group, sulfone group, sulfonamide group, carboxyl group, carboxaldehyde group, imine group, alkyl group, halo-alkyl group, alkenyl group, halo-alkenyl group, alkynyl group, halo-alkynyl group, alkoxy group, aryl group, aryloxy group, aralkyl group, arylalkoxy group, heterocyclyl group, acyl group, acyloxy group, carbamate group, amide group, ureido group, epoxy group, and ester group; and
- R^{30} is alkyl or an amino group, each of which is substituted or unsubstituted,

or a pharmaceutically-acceptable salt thereof.


[0108] In some embodiments, R^{30} is methyl. In some embodiments, R^{30} is NH_2 . In some embodiments, R^{30} is $NHMe$. In some embodiments, R^{30} is NMe_2 .


[0109] In some embodiments, the compound is of the formula:



wherein R^{30} is alkyl or an amino group, each of which is unsubstituted or substituted. In some embodiments, R^{30} is methyl.


[0110] Non-limiting examples of compounds of the current disclosure include the following:






or a pharmaceutically-acceptable salt thereof.

[0111] Non-limiting examples of compounds of the current disclosure include the following:




or a pharmaceutically-acceptable salt thereof.

[0112] Non-limiting examples of compounds of the current disclosure include the following:




or a pharmaceutically-acceptable salt thereof.


[0113] Non-limiting examples of compounds of the current disclosure include the following:



or a pharmaceutically-acceptable salt thereof.


[0114] Non-limiting examples of compounds of the current disclosure include the following:






or a pharmaceutically-acceptable salt thereof.

[0115] Non-limiting examples of compounds of the current disclosure include the following:



or a pharmaceutically-acceptable salt thereof.


[0116] Non-limiting examples of compounds of the current disclosure include the following:






or a pharmaceutically-acceptable salt thereof.


[0117] Non-limiting examples of compounds of the current disclosure include the following:



















- 42 -









[0120] Non-limiting examples of compounds of the current disclosure include the following:



or a pharmaceutically-acceptable salt thereof.


[0121] Non-limiting examples of compounds of the current disclosure include the following:






or a pharmaceutically-acceptable salt thereof.


[0122] Non-limiting examples of compounds of the current disclosure include the following:



or a pharmaceutically-acceptable salt thereof.


[0123] Non-limiting examples of compounds of the current disclosure include the following:






or a pharmaceutically-acceptable salt thereof.

[0124] Non-limiting examples of compounds of the current disclosure include the following:




or a pharmaceutically-acceptable salt thereof.

[0125] Non-limiting examples of compounds of the current disclosure include the following:



or a pharmaceutically-acceptable salt thereof.

[0126] Non-limiting examples of compounds of the current disclosure include the following:



or a pharmaceutically-acceptable salt thereof.

[0127] In some embodiments, the disclosure provides a compound comprising: an indole group, wherein the indole group comprises: a) a haloalkyl group at a 1-position of the indole group; b) a first substituent at a 2-position of the indole group, wherein the first substituent is a cyclic group; and c) a second substituent, wherein the second substituent is substituted with at least halo-; or a pharmaceutically-acceptable salt thereof.

[0128] In some embodiments, the cyclic group is aryl, heteroaryl, or heterocyclyl, each of which is substituted or unsubstituted. In some embodiments, the cyclic group is unsubstituted aryl. In some embodiments, the cyclic group is substituted aryl. In some embodiments, the cyclic group is substituted phenyl. In some embodiments, the cyclic group is substituted or unsubstituted heteroaryl.

In some embodiments, the heteroaryl is an aromatic 5-membered or 6-membered monocyclic ring. In some embodiments, the heteroaryl is thiazolyl, thiadiazolyl, pyrazolyl, thiophenyl, or oxadiazolyl. In some embodiments, the heteroaryl is pyridinyl or pyrimidinyl.

[0129] In some embodiments, the second substituent is at a 4-position of the indole group. In some embodiments, the second substituent is a second cyclic group that is substituted or unsubstituted. In some embodiments, the second cyclic group is heterocyclyl. In some embodiments, the heterocyclyl is piperidinyl. In some embodiments, the heterocyclyl is tetrahydropyranyl. In some embodiments, the heterocyclyl is substituted with fluoro-. In some embodiments, the heterocyclyl is substituted with chloro-. In some embodiments, the haloalkyl group is trifluoroethyl.


[0130] In some embodiments, the disclosure provides a compound, the compound comprising an indole group, wherein the indole group comprises: a) a substituted or unsubstituted non-cyclic group at a 3-position of the indole group; and b) a substituted or unsubstituted cyclic group at a 2-position of the indole group, wherein the compound increases a stability of a biologically-active conformation of a p53 mutant relative to a stability of a biologically-active conformation of the p53 mutant in an absence of the compound, or a pharmaceutically-acceptable salt thereof.


[0131] In some embodiments, the non-cyclic group is hydrogen. In some embodiments, the non-cyclic group is halo-. In some embodiments, the cyclic group is aryl, heteroaryl, heterocyclyl, or cycloalkylene, each of which is substituted or unsubstituted. In some embodiments, the cyclic group is aryl or heteroaryl, each of which is substituted or unsubstituted. In some embodiments, the cyclic group is substituted aryl. In some embodiments, the cyclic group is substituted phenyl. In some embodiments, the cyclic group is phenyl substituted with alkyl, cycloalkyl, alkoxy, an amine group, a carboxyl group, a carboxylic acid group, a carbamide group, or an amide group, each of which is substituted or unsubstituted; cyano, halo-, or hydrogen.

[0132] In some embodiments, the cyclic group is substituted heteroaryl. In some embodiments, the cyclic group is an aromatic 5-membered, 6-membered, 7-membered, or 8-membered monocyclic ring system comprising 1, 2, or 3 heteroatoms as ring members, wherein each heteroatom is independently selected from O, N, or S. In some embodiments, the cyclic group is pyridinyl, pyrimidinyl, thiadiazolyl, thiazolyl, pyrazolyl, thiophenyl, or oxadiazolyl. In some embodiments, the cyclic group is 1,3,5-thiadiazol-2-yl. In some embodiments, the cyclic group is 1,3,4-oxadiazol-2-yl or 1,2,4-oxadiazol-2-yl. In some embodiments, the cyclic group is pyridinyl.

[0133] In some embodiments, the indole group further comprises a substituent at a 4-position of the indole group. In some embodiments, the substituent is an amino group that is substituted or unsubstituted. In some embodiments, the amino group is substituted with a second cyclic group. In some embodiments, the second cyclic group is a heterocyclyl group substituted with at least halo-. In some embodiments, the heterocyclyl group is substituted with at least fluoro-. In some embodiments, the heterocyclyl group is substituted with at least chloro-. In some embodiments, the heterocyclyl group is piperidinyl. In some embodiments, the heterocyclyl group is tetrahydropyranyl.


[0134] Non-limiting examples of compounds of the disclosure include compounds of any of the following formulae:





or a pharmaceutically-acceptable salt thereof.

[0135] In some embodiments, the disclosure provides a compound of the formula:



wherein:

- each ----- is independently a single bond or a double bond;
- X^1 is CR^5 , CR^5R^6 , N, NR^5 , O, S, C=O, C=S, or a carbon atom connected to Q^1 ;
- X^2 is CR^7 , CR^7R^8 , N, NR^7 , O, S, C=O, C=S, or a carbon atom connected to Q^1 ;
- X^3 is CR^9 , CR^9R^{10} , N, NR^9 , O, S, C=O, C=S, or a carbon atom connected to Q^1 ;
- X^4 is CR^{11} , $CR^{11}R^{12}$, N, NR^{11} , O, S, C=O, C=S, or a carbon atom connected to Q^1 ;
- X^5 is CR^{13} , N, or NR^{13} ;

wherein at least one of X^1 , X^2 , X^3 , and X^4 is a carbon atom connected to Q^1 ;

- A is a substituted or unsubstituted ring;
- Q^1 is C=O, C=S, C=CR¹⁴R¹⁵, C=NR¹⁴, alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond;
- m is 1, 2, 3, or 4;

- Y is N, O, or absent;
- R^1 is $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, $-SiR^{16}R^{17}R^{18}$, alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, heterocyclyl, or halo, each of which is independently substituted or unsubstituted, or hydrogen;
- each R^3 and R^4 is independently $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen, or R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a ring, wherein the ring is substituted or unsubstituted, or R^3 is absent;
- each R^2 , R^5 , R^6 , R^7 , R^8 , R^9 , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , and R^{18} is independently $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R^{19} and R^{20} is $-C(O)R^{23}$, $-C(O)OR^{23}$, $-C(O)NR^{23}R^{24}$, $-OR^{23}$, $-SR^{23}$, $-NR^{23}R^{24}$, $-NR^{23}C(O)R^{24}$, $-OC(O)R^{23}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,

or a pharmaceutically-acceptable salt thereof.

[0136] In some embodiments, A is substituted or unsubstituted aryl, heteroaryl, heterocyclyl, cycloalkylene. In some embodiments, A is a 6-carbon monocyclic or 10-carbon bicyclic aromatic ring system wherein 0, 1, 2, 3, or 4 atoms of each ring are optionally substituted. In some embodiments, A is naphthyl. In some embodiments, A is indazolyl.

[0137] In some embodiments, A is substituted aryl. In some embodiments, A is substituted phenyl. In some embodiments, A is phenyl substituted with alkyl, cycloalkyl, alkoxy, an amine group, a carboxyl group, a carboxylic acid group, a carbamide group, or an amide group, each of which is substituted or unsubstituted; cyano, halogen, or hydrogen. In some embodiments, A is phenyl substituted with alkyl, wherein alkyl is substituted. In some embodiments, A is phenyl substituted with alkyl, wherein alkyl is substituted with an amino group that is substituted or unsubstituted. In some embodiments, A is phenyl substituted with an amine group that is substituted or unsubstituted. In some embodiments, A is phenyl substituted with a carboxyl group that is substituted or unsubstituted. In some embodiments, A is phenyl substituted with cyano. In some embodiments, A is

phenyl substituted with halo-.

[0138] In some embodiments, A is substituted or unsubstituted heterocyclyl. In some embodiments, A is substituted heterocyclyl.

[0139] In some embodiments, A is an aromatic 5-membered, 6-membered, 7-membered, or 8-membered monocyclic ring system comprising 1, 2, or 3 heteroatoms as ring members, wherein each heteroatom is independently selected from O, N, or S. In some embodiments, A is an aromatic 8-membered, 9-membered, 10-membered, 11-membered, or 12-membered bicyclic ring system comprising 1, 2, 3, 4, 5, or 6 heteroatoms, wherein each heteroatom is independently selected from O, N, or S. In some embodiments, A is an aromatic 5-membered, 6-membered, 7-membered, or 8-membered monocyclic ring system comprising 1, 2, or 3 heteroatoms, and the aromatic 5-membered, 6-membered, 7-membered, or 8-membered monocyclic ring system is substituted. In some embodiments, A is an 8-membered, 9-membered, 10-membered, 11-membered, or 12-membered bicyclic ring system having 1, 2, 3, 4, 5, or 6 heteroatoms, and the 8-membered, 9-membered, 10-membered, 11-membered, or 12-membered bicyclic ring system is substituted.

[0140] In some embodiments, A is pyridinyl, pyrimidinyl, thiadiazolyl, thiazolyl, pyrazolyl, thiophenyl, or oxadiazolyl, each of which is independently substituted or unsubstituted. In some embodiments, A is 1,3,5-thiadiazol-2-yl. In some embodiments, A is 1,3,4-oxadiazol-2-yl or 1,2,4-oxadiazol-2-yl. In some embodiments, A is 1,3,4-oxadiazol-2-yl.

[0141] In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, Q¹ is alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond. In some embodiments, Q¹ is a bond. In some embodiments, Y is N.


[0142] In some embodiments, R² is hydrogen. In some embodiments, R² is substituted or unsubstituted alkyl. In some embodiments, R² is trifluoroethyl. In some embodiments, R² is cycloalkyl.

[0143] In some embodiments, R¹ is -C(O)R¹⁶, -C(O)OR¹⁶, -C(O)NR¹⁶R¹⁷, -OR¹⁶, -NR¹⁶R¹⁷, -NR¹⁶C(O)R¹⁶, -OC(O)R¹⁶, alkyl, alkoxy, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; cyano, halo, or halogen. In some embodiments, R¹ is -NR¹⁶R¹⁷. In some embodiments, R¹ is substituted alkyl.

[0144] In some embodiments, each R³ and R⁴ is independently aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; or hydrogen. In some embodiments, R³ is hydrogen, and R⁴ is heterocyclyl substituted at least with halo-. In some embodiments, R⁴ is heterocyclyl substituted with fluoro. In some embodiments, R⁴ is heterocyclyl substituted with chloro.


[0145] In some embodiments, R¹³ is alkyl, alkenyl, hydrogen, or halogen. In some embodiments, R¹³ is hydrogen.

[0146] In some embodiments, the compound has the formula:




or a pharmaceutically-acceptable salt thereof, wherein the variable are as defined above.

[0147] In some embodiments, the compound has the formula:




or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.

[0148] In some embodiments, the compound has the formula:




or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.

[0149] In some embodiments, the compound has the formula:



or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.

[0150] In some embodiments, the disclosure provides a compound of the formula:




or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.

[0151] In some embodiments, Q¹ is C=O, C=S, C=CR¹⁴R¹⁵, C=NR¹⁴, alkylene, alkenylene, or

alkynylene, each of which is independently substituted or unsubstituted, or a bond. In some embodiments, Q^1 is alkylene, alkenylene, or alkynylene. In some embodiments, Q^1 is C_1 -alkylene. In some embodiments, each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, or hydrogen. In some embodiments, Q^1 is a bond.


[0152] In some embodiments, R^3 is H, and R^4 is $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; or hydrogen. In some embodiments, R^3 is H, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^4 is heterocyclyl. In some embodiments, R^4 is piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted.

[0153] In some embodiments, R^4 is a ring that is:




, wherein the ring is substituted or unsubstituted. In some

embodiments, R^3 is H, and R^4 is a ring that is




, wherein the ring is substituted or

unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is




, wherein the ring is substituted or unsubstituted. In some embodiments, R^a is alkylene. In some embodiments, R^a is

methyl. In some embodiments, R^3 is H, and R^4 is a ring that is



, wherein the ring is


substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is



, wherein the ring is substituted or unsubstituted.


[0154] In some embodiments, each R^{16} and R^{17} is independently alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkoxy, carboxyl group, amino group, acyl group, acyloxy group, or an amide group, any of which is unsubstituted or substituted, or hydrogen. In some embodiments, R^{16} is hydrogen, and R^{17} is a substituted carboxyl group.

[0155] In some embodiments, the compound is of the formula:



wherein R^{25} is $-C(O)R^{16}$, $-C(O)NR^{16}R^{17}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^{25} is aryl that is substituted or unsubstituted. In some embodiments, R^{25} is substituted phenyl. In some embodiments, R^{25} is $-C(O)R^{16}$, wherein R^{16} is alkyl, aryl, heteroaryl, or heterocyclyl. In some embodiments, R^{25} is $-C(O)R^{16}$, wherein R^{16} is substituted phenyl.

[0156] In some embodiments, the disclosure provides a compound of the formula:



wherein:

- each ----- is independently a single bond or a double bond;
- X^1 is CR^5 , CR^5R^6 , N, NR^5 , O, S, C=O, C=S, or a carbon atom connected to Q^1 ;
- X^2 is CR^7 , CR^7R^8 , N, NR^7 , O, S, C=O, C=S, or a carbon atom connected to Q^1 ;
- X^3 is CR^9 , CR^9R^{10} , N, NR^9 , O, S, C=O, C=S, or a carbon atom connected to Q^1 ;
- X^4 is CR^{11} , $CR^{11}R^{12}$, N, NR^{11} , O, S, C=O, C=S, or a carbon atom connected to Q^1 ;
- X^5 is CR^{13} , N, or NR^{13} ;

wherein at least one of X^1 , X^2 , X^3 , and X^4 is a carbon atom connected to Q^1 ;

- Ar is unsubstituted or substituted aryl;
- Q^1 is C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond;
- m is 1, 2, 3, or 4;
- n is 0, 1, 2, 3, or 4;
- Y is N, O, or absent;
- each R^x and R^1 is independently $C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, $-SiR^{16}R^{17}R^{18}$, alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; cyano, halo, or hydrogen; or R^1 and R^x together with Ar form a fused ring;
- each R^3 and R^4 is independently $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen, or R^3 and R^4 together with

the nitrogen atom to which R^3 and R^4 are bound form a ring, wherein the ring is substituted or unsubstituted, or R^3 is absent;

- each R^2 , R^5 , R^6 , R^7 , R^8 , R^9 , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , and R^{18} is independently $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocycl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R^{19} and R^{20} is $-C(O)R^{23}$, $-C(O)OR^{23}$, $-C(O)NR^{23}R^{24}$, $-OR^{23}$, $-SR^{23}$, $-NR^{23}R^{24}$, $-NR^{23}C(O)R^{24}$, $-OC(O)R^{23}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocycl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocycl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocycl, each of which is independently substituted or unsubstituted, or hydrogen,

or a pharmaceutically-acceptable salt thereof.

[0157] The pattern of dashed bonds can be chosen to provide an aromatic system, for example, an indole, an indolene, a pyrrolopyridine, a pyrrolopyrimidine, or a pyrrolopyrazine. In some embodiments, X^1 is CR^5 , CR^5R^6 , or a carbon atom connected to Q^1 . In some embodiments, X^2 is CR^7 , CR^7R^8 , or a carbon atom connected to Q^1 . In some embodiments, X^3 is CR^9 , CR^9R^{10} , or a carbon atom connected to Q^1 . In some embodiments, X^4 is CR^{11} , $CR^{11}R^{12}$, or a carbon atom connected to Q^1 . In some embodiments, X^5 is CR^{13} , N, or NR^{13} . In some embodiments, X^1 is a carbon atom connected to Q^1 . In some embodiments, X^2 is a carbon atom connected to Q^1 . In some embodiments, X^3 is a carbon atom connected to Q^1 . In some embodiments, X^4 is a carbon atom connected to Q^1 . In some embodiments, X^5 is N.

[0158] In some embodiments, Ar is a 6-carbon monocyclic or 10-carbon bicyclic aromatic ring system wherein 0, 1, 2, 3, or 4 atoms of each ring are optionally substituted. In some embodiments, Ar is phenyl. In some embodiments, Ar is naphthyl. In some embodiments, Ar is indazolyl.

[0159] R^1 can be $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, $-SiR^{16}R^{17}R^{18}$, alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, or heterocycl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^1 is alkyl, alkylene, alkoxy, $-NR^{21}R^{22}$, or aryl, each of which is independently substituted or unsubstituted; halo or hydrogen. In some embodiments, R^1 is methyl, cyclohexyl, methylene, methoxy, or benzyl. In some embodiments, R^1 is fluoro or chloro. In some embodiments, R^1 is phenyl. In some embodiments, R^1 is hydrogen.

[0160] In some embodiments, R^1 is a substituted alkyl. R^1 can be substituted by one or more substituents selected from a hydroxyl group, sulfhydryl group, halogen, amino group, nitro group,

nitroso group, cyano group, azido group, sulfoxide group, sulfone group, sulfonamide group, carboxyl group, carboxaldehyde group, imine group, alkyl group, halo-alkyl group, cyclic alkyl group, alkenyl group, halo-alkenyl group, alkynyl group, halo-alkynyl group, alkoxy group, aryl group, aryloxy group, aralkyl group, arylalkoxy group, heterocyclyl group, acyl group, acyloxy group, carbamate group, amide group, urethane group, and ester group.

[0161] In some embodiments, R^1 is alkyl substituted with an amine group. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$. In some embodiments, R^1 is alkyl substituted with $-C(O)NR^{16}R^{17}$. In some embodiments, R^1 is methyl substituted with $-C(O)NR^{16}R^{17}$. In some embodiments, R^1 is alkyl substituted with $-C(O)OR^{16}$. In some embodiments, R^1 is methyl substituted with $COOH$.


[0162] In some embodiments, m is 1, 2, 3, or 4. In some embodiments, m is 1. In some embodiments, X^3 is carbon atom connected to Q^1 , and m is 1. In some embodiments, n is 1, 2, or 3. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 0.

[0163] In some embodiments, Q^1 is $C=O$, $C=S$, $C=CR^{14}R^{15}$, $C=NR^{14}$, alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond. In some embodiments, Q^1 is alkylene, alkenylene, or alkynylene. In some embodiments, Q^1 is a bond. In some embodiments, Q^1 is C_1 -alkylene.


[0164] In some embodiments, R^2 is hydrogen or alkyl. In some embodiments, R^{13} is alkyl, alkenyl, hydrogen, or halogen. In some embodiments, R^2 is alkyl, and R^{13} is alkyl. In some embodiments, R^2 is hydrogen, and R^{13} is alkyl. In some embodiments, R^2 is methyl, ethyl, propyl, iso-propyl, butyl, or tert-butyl. In some embodiments, R^{13} is methyl, ethyl, propyl, iso-propyl, butyl or tert-butyl. In some embodiments, R^2 is hydrogen, and R^{13} is hydrogen. In some embodiments, R^2 is trifluoroethyl, and R^{13} is hydrogen.


[0165] In some embodiments, R^3 is $-C(O)R^{19}$, $-C(O)OR^{19}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen, and R^4 is $-C(O)R^{19}$, $-C(O)OR^{19}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen.


[0166] In some embodiments, R^3 is H, and R^4 is $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; or hydrogen. In some embodiments, R^3 is H, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^4 is heterocyclyl. In some embodiments, R^4 is piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted.





[0167] In some embodiments, R^4 is a ring that is:




unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is
 
, wherein the ring


is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is
 
,
 wherein the ring is substituted or unsubstituted. In some embodiments, R^a is alkylene. In some

embodiments, R^a is methyl. In some embodiments, R^3 is H, and R^4 is a ring that is
 
,
 wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is


, wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4


is a ring that is
 
.

[0168] In some embodiments, the disclosure provides a compound of the formula:



wherein the variables are as defined above.

[0169] In some embodiments, the disclosure provides a compound of the formula:




wherein:

- X^1 is CR^5 , CR^3R^6 , N, NR^5 , O, S, C=O, C=S, or a carbon atom connected to Q^1 ;
- X^2 is CR^7 , CR^7R^8 , N, NR^7 , O, S, C=O, C=S, or a carbon atom connected to Q^1 ;
- X^3 is CR^9 , CR^9R^{10} , N, NR^9 , O, S, C=O, C=S, or a carbon atom connected to Q^1 ;
- X^4 is CR^{11} , $CR^{11}R^{12}$, N, NR^{11} , O, S, C=O, C=S, or a carbon atom connected to Q^1 ;

- Ar is unsubstituted or substituted aryl;
- Q^1 is C=O, C=S, C=CR¹⁴R¹⁵, C=NR¹⁴, alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond;
- n is 0, 1, 2, 3, or 4;
- each R^x and R¹ is independently C(O)R¹⁶, -C(O)OR¹⁶, -C(O)NR¹⁶R¹⁷, -OR¹⁶, -SR¹⁶, -NR¹⁶R¹⁷, -NR¹⁶C(O)R¹⁶, -OC(O)R¹⁶, -SiR¹⁶R¹⁷R¹⁸, alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; cyano, halo, or hydrogen; or R¹ and R^x together with Ar form a fused ring;
- each R³ and R⁴ is independently -C(O)R¹⁹, -C(O)OR¹⁹, -C(O)NR¹⁹R²⁰, -SOR¹⁹, -SO₂R¹⁹, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen, or R³ and R⁴ together with the nitrogen atom to which R³ and R⁴ are bound form a ring, wherein the ring is substituted or unsubstituted, or R³ is absent;
- each R², R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, and R¹⁸ is independently -C(O)R²¹, -C(O)OR²¹, -C(O)NR²¹R²², -OR²¹, -SR²¹, -NR²¹R²², -NR²¹C(O)R²², -OC(O)R²¹, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R¹⁹ and R²⁰ is -C(O)R²³, -C(O)OR²³, -C(O)NR²³R²⁴, -OR²³, -SR²³, -NR²³R²⁴, -NR²³C(O)R²⁴, -OC(O)R²³, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R²¹ and R²² is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R²³ and R²⁴ is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,

or a pharmaceutically-acceptable salt thereof.

[0170] In some embodiments, the compound is of the formula:



wherein the variables are as defined above.

[0171] In some embodiments, Ar is a 6-carbon monocyclic or 10-carbon bicyclic aromatic ring system wherein 0, 1, 2, 3, or 4 atoms of each ring are optionally substituted. In some embodiments, Ar is phenyl. In some embodiments, Ar is naphthyl. In some embodiments, Ar is indazolyl.

[0172] In some embodiments, R^1 is a substituted alkyl. R^1 can be substituted by one or more substituents selected from a hydroxyl group, sulfhydryl group, halogen, amino group, nitro group, nitroso group, cyano group, azido group, sulfoxide group, sulfone group, sulfonamide group, carboxyl group, carboxaldehyde group, imine group, alkyl group, halo-alkyl group, cyclic alkyl group, alkenyl group, halo-alkenyl group, alkynyl group, halo-alkynyl group, alkoxy group, aryl group, aryloxy group, aralkyl group, arylalkoxy group, heterocyclyl group, acyl group, acyloxy group, carbamate group, amide group, urethane group, and ester group.

[0173] In some embodiments, R^1 is alkyl substituted with an amine group. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$. In some embodiments, R^1 is alkyl substituted with $-C(O)NR^{16}R^{17}$. In some embodiments, R^1 is methyl substituted with $-C(O)NR^{16}R^{17}$. In some embodiments, R^1 is alkyl substituted with $-C(O)OR^{16}$. In some embodiments, R^1 is methyl substituted with $COOH$.


[0174] In some embodiments, Q^1 is $C=O$, $C=S$, $C=CR^{14}R^{15}$, $C=NR^{14}$, alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond. In some embodiments, Q^1 is alkylene, alkenylene, or alkynylene. In some embodiments, Q^1 is a bond. In some embodiments, Q^1 is C_1 -alkylene.


[0175] In some embodiments, R^2 is hydrogen or alkyl. In some embodiments, R^{13} is alkyl, alkenyl, hydrogen, or halogen. In some embodiments, R^2 is alkyl, and R^{13} is alkyl. In some embodiments, R^2 is hydrogen, and R^{13} is alkyl. In some embodiments, R^2 is methyl, ethyl, propyl, iso-propyl, butyl, or tert-butyl. In some embodiments, R^{13} is methyl, ethyl, propyl, iso-propyl, butyl or tert-butyl. In some embodiments, R^2 is hydrogen, and R^{13} is hydrogen. In some embodiments, R^2 is trifluoroethyl, and R^{13} is hydrogen.


[0176] In some embodiments, R^3 is $-C(O)R^{19}$, $-C(O)OR^{19}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen, and R^4 is $-C(O)R^{19}$, $-C(O)OR^{19}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen.


[0177] In some embodiments, R^3 is H, and R^4 is $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; or hydrogen. In some embodiments, R^3 is H, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^4 is heterocyclyl. In some embodiments, R^4 is piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted.


[0178] In some embodiments, R^4 is a ring that is:







unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is
 
, wherein the ring


is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is
 
,
 wherein the ring is substituted or unsubstituted. In some embodiments, R^a is alkylene. In some

embodiments, R^a is methyl. In some embodiments, R^3 is H, and R^4 is a ring that is
 
,
 wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is


, wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4


is a ring that is
 
.

[0179] In some embodiments, the disclosure provides a compound of the formula:



or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.

[0180] In some embodiments, the disclosure provides a compound of the formula:



wherein:

- Q^1 is C=O, C=S, C=CR¹⁴R¹⁵, C=NR¹⁴, alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond;
- each R^1 , R^x , R^{x1} , R^{x2} , R^{x3} , and R^{x4} is independently -C(O)R¹⁶, -C(O)OR¹⁶, -C(O)NR¹⁶R¹⁷, -OR¹⁶, -SR¹⁶, -NR¹⁶R¹⁷, -NR¹⁶C(O)R¹⁶, -OC(O)R¹⁶, -SiR¹⁶R¹⁷R¹⁸, alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; cyano, halo, or hydrogen; or R^1 and R^x together with Ar form a fused ring;
- each R^3 and R^4 is independently -C(O)R¹⁹, -C(O)OR¹⁹, -C(O)NR¹⁹R²⁰, -SOR¹⁹, -SO₂R¹⁹, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen, or R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a ring, wherein the ring is substituted or unsubstituted, or R^3 is absent;
- n is 0, 1, 2, 3, or 4;
each R^2 , R^{14} , R^{15} , R^{16} , R^{17} , and R^{18} is independently -C(O)R²¹, -C(O)OR²¹, -C(O)NR²¹R²², -OR²¹, -SR²¹, -NR²¹R²², -NR²¹C(O)R²², -OC(O)R²¹, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R^{19} and R^{20} is -C(O)R²³, -C(O)OR²³, -C(O)NR²³R²⁴, -OR²³, -SR²³, -NR²³R²⁴, -NR²³C(O)R²⁴, -OC(O)R²³, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or

heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and

- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,

or a pharmaceutically-acceptable salt thereof.

[0181] In some embodiments, R^1 is a substituted alkyl. R^1 can be substituted by one or more substituents selected from a hydroxyl group, sulfhydryl group, halogen, amino group, nitro group, nitroso group, cyano group, azido group, sulfoxide group, sulfone group, sulfonamide group, carboxyl group, carboxaldehyde group, imine group, alkyl group, halo-alkyl group, cyclic alkyl group, alkenyl group, halo-alkenyl group, alkynyl group, halo-alkynyl group, alkoxy group, aryl group, aryloxy group, aralkyl group, arylalkoxy group, heterocyclyl group, acyl group, acyloxy group, carbamate group, amide group, urethane group, and ester group.

[0182] In some embodiments, R^1 is alkyl substituted with an amine group. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} is alkyl, aryl, heteroaryl, an amino group, a carboxyl group, or an ester group, any of which is substituted or unsubstituted. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} is substituted or unsubstituted alkyl, aryl, or heteroaryl. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} is substituted or unsubstituted phenyl. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} is substituted or unsubstituted pyridinyl.

[0183] In some embodiments, R^1 is $-C(O)NR^{16}R^{17}$. In some embodiments, R^1 is $-C(O)NR^{16}R^{17}$, wherein R^{16} and R^{17} are hydrogen. In some embodiments, R^1 is $-C(O)NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} alkyl. In some embodiments, R^1 is $-C(O)NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} methyl. In some embodiments, R^1 is $-C(O)OR^{16}$. In some embodiments, R^1 is $-C(O)OH$. In some embodiments, R^1 is methyl. In some embodiments, R^1 is halogen. In some embodiments, R^1 is chloro or fluoro.

[0184] In some embodiments, n is 0, 1, 2, or 3. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 0.

[0185] In some embodiments, Q^1 is $C=O$, $C=S$, $C=CR^{14}R^{15}$, $C=NR^{14}$, alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond. In some embodiments, Q^1 is alkylene, alkenylene, or alkynylene. In some embodiments, Q^1 is a bond. In some embodiments, Q^1 is C_1 -alkylene.


[0186] In some embodiments, R^2 is hydrogen or alkyl. In some embodiments, R^{13} is alkyl, alkenyl, hydrogen, or halogen. In some embodiments, R^2 is alkyl, and R^{13} is alkyl. In some embodiments, R^2 is hydrogen, and R^{13} is alkyl. In some embodiments, R^2 is methyl, ethyl, propyl, iso-propyl, butyl, or tert-butyl. In some embodiments, R^{13} is methyl, ethyl, propyl, iso-propyl, butyl or tert-butyl. In some

embodiments, R^2 is hydrogen, and R^{13} is hydrogen. In some embodiments, R^2 is trifluoroethyl, and R^{13} is hydrogen.

[0187] In some embodiments, R^3 is $-C(O)R^{19}$, $-C(O)OR^{19}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen, and R^4 is $-C(O)R^{19}$, $-C(O)OR^{19}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen.


[0188] In some embodiments, R^3 is H, and R^4 is $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; or hydrogen. In some embodiments, R^3 is H, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^4 is heterocyclyl. In some embodiments, R^4 is piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted.

[0189] In some embodiments, R^4 is a ring that is:




, wherein the ring is substituted or

unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is




, wherein the ring

is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is




, wherein the ring is substituted or unsubstituted. In some embodiments, R^a is alkylene. In some


embodiments, R^a is methyl. In some embodiments, R^3 is H, and R^4 is a ring that is




, wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is


, wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4

is a ring that is



[0190] In some embodiments, the disclosure provides a compound of the formula:



or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.

[0191] In some embodiments, R^1 is a substituted alkyl. R^1 can be substituted by one or more substituents selected from a hydroxyl group, sulfhydryl group, halogen, amino group, nitro group, nitroso group, cyano group, azido group, sulfoxide group, sulfone group, sulfonamide group, carboxyl group, carboxaldehyde group, imine group, alkyl group, halo-alkyl group, cyclic alkyl group, alkenyl group, halo-alkenyl group, alkynyl group, halo-alkynyl group, alkoxy group, aryl group, aryloxy group, aralkyl group, arylalkoxy group, heterocyclyl group, acyl group, acyloxy group, carbamate group, amide group, urethane group, and ester group.

[0192] In some embodiments, R^1 is alkyl substituted with an amine group. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} is alkyl, aryl, heteroaryl, an amino group, a carboxyl group, or an ester group, any of which is substituted or unsubstituted. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} is substituted or unsubstituted alkyl, aryl, or heteroaryl. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} is substituted or unsubstituted phenyl. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} is substituted or unsubstituted pyridinyl.


[0193] In some embodiments, R^1 is $-C(O)NR^{16}R^{17}$. In some embodiments, R^1 is $-C(O)NR^{16}R^{17}$, wherein R^{16} and R^{17} are hydrogen. In some embodiments, R^1 is $-C(O)NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} alkyl. In some embodiments, R^1 is $-C(O)NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} methyl. In some embodiments, R^1 is $-C(O)OR^{16}$. In some embodiments, R^1 is $-C(O)OH$. In some embodiments, R^1 is methyl. In some embodiments, R^1 is halogen. In some embodiments, R^1 is chloro or fluoro.

[0194] In some embodiments, n is 1, 2, or 3. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 0.


[0195] In some embodiments, R^3 is $-C(O)R^{19}$, $-C(O)OR^{19}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen, and R^4 is $-C(O)R^{19}$, $-C(O)OR^{19}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen.

[0196] In some embodiments, R^3 is H, and R^4 is $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; or hydrogen. In some embodiments, R^3 is H, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted,


or hydrogen. In some embodiments, R^4 is heterocyclyl. In some embodiments, R^4 is piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted.




[0197] In some embodiments, R^3 is H, and R^4 is a ring that is:




. In some embodiments, R^3 is H, and R^4 is




a ring that is . In some embodiments, R^3 is H, and R^4 is a ring that is



[0198] Non-limiting examples of compounds of the disclosure include compounds of any of the following formulae:






or

or a pharmaceutically-acceptable salt thereof.

[0199] In some embodiments, the disclosure provides a compound of the formula:



wherein:

- each ----- is independently a single bond or a double bond;
- X^1 is CR^5 , CR^5R^6 , N, NR^5 , O, S, C=O, C=S, or a carbon atom connected to Q^1 ;
- X^2 is CR^7 , CR^7R^8 , N, NR^7 , O, S, C=O, C=S, or a carbon atom connected to Q^1 ;

- X^3 is CR^9 , CR^9R^{10} , N, NR^9 , O, S, C=O, C=S, or a carbon atom connected to Q^1 ;
- X^4 is CR^{11} , $CR^{11}R^{12}$, N, NR^{11} , O, S, C=O, C=S, or a carbon atom connected to Q^1 ;
- X^5 is CR^{13} , N, or NR^{13} ;

wherein at least one of X^1 , X^2 , X^3 , and X^4 is a carbon atom connected to Q^1 ;

- Het is substituted or unsubstituted heteroaryl;
- Q^1 is C=O, C=S, C=CR¹⁴R¹⁵, C=NR¹⁴, alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond;
- m is 1, 2, 3, or 4;
- Y is N, O, or absent;
- R^1 is -C(O)R¹⁶, -C(O)OR¹⁶, -C(O)NR¹⁶R¹⁷, -OR¹⁶, -SR¹⁶, -NR¹⁶R¹⁷, -NR¹⁶C(O)R¹⁶, -OC(O)R¹⁶, -SiR¹⁶R¹⁷R¹⁸, alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, heterocyclyl, or halo, each of which is independently substituted or unsubstituted, or hydrogen;
- each R^3 and R^4 is independently -C(O)R¹⁹, -C(O)OR¹⁹, -C(O)NR¹⁹R²⁰, -SOR¹⁹, -SO₂R¹⁹, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen, or R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a ring, wherein the ring is substituted or unsubstituted, or R^3 is absent;
- each R^2 , R^5 , R^6 , R^7 , R^8 , R^9 , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , and R^{18} is independently -C(O)R²¹, -C(O)OR²¹, -C(O)NR²¹R²², -OR²¹, -SR²¹, -NR²¹R²², -NR²¹C(O)R²², -OC(O)R²¹, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R^{19} and R^{20} is -C(O)R²³, -C(O)OR²³, -C(O)NR²³R²⁴, -OR²³, -SR²³, -NR²³R²⁴, -NR²³C(O)R²⁴, -OC(O)R²³, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen;

or a pharmaceutically-acceptable salt thereof.

[0200] The pattern of dashed bonds can be chosen to provide an aromatic system, for example, an indole, an indolene, a pyrrolopyridine, a pyrrolopyrimidine, or a pyrrolopyrazine. In some embodiments, X^1 is CR^5 , CR^5R^6 , or a carbon atom connected to Q^1 . In some embodiments, X^2 is CR^7 , CR^7R^8 , or a carbon atom connected to Q^1 . In some embodiments, X^3 is CR^9 , CR^9R^{10} , or a carbon atom connected to Q^1 . In some embodiments, X^4 is CR^{11} , $CR^{11}R^{12}$, or a carbon atom connected to Q^1 .

In some embodiments, X^5 is CR^{13} , N, or NR^{13} . In some embodiments, X^1 is a carbon atom connected to Q^1 . In some embodiments, X^2 is a carbon atom connected to Q^1 . In some embodiments, X^3 is a carbon atom connected to Q^1 . In some embodiments, X^4 is a carbon atom connected to Q^1 . In some embodiments, X^5 is N.

[0201] In some embodiments, Het is an aromatic 5-membered, 6-membered, 7-membered, or 8-membered monocyclic ring system comprising 1, 2, or 3 heteroatoms as ring members, wherein each heteroatom is independently selected from O, N, or S. In some embodiments, Het is an aromatic 8-membered, 9-membered, 10-membered, 11-membered, or 12-membered bicyclic ring system comprising 1, 2, 3, 4, 5, or 6 heteroatoms, wherein each heteroatom is independently selected from O, N, or S. In some embodiments, Het is an aromatic 5-membered, 6-membered, 7-membered, or 8-membered monocyclic ring system comprising 1, 2, or 3 heteroatoms, and the aromatic 5-membered, 6-membered, 7-membered, or 8-membered monocyclic ring system is substituted. In some embodiments, Het is an 8-membered, 9-membered, 10-membered, 11-membered, or 12-membered bicyclic ring system having 1, 2, 3, 4, 5, or 6 heteroatoms, and the 8-membered, 9-membered, 10-membered, 11-membered, or 12-membered bicyclic ring system is substituted.

[0202] In some embodiments, Het is pyridinyl, pyrimidinyl, thiadiazolyl, thiazolyl, pyrazolyl, thiophenyl, or oxadiazolyl, each of which is independently substituted or unsubstituted. In some embodiments, Het is 1,3,5-thiadiazol-2-yl. In some embodiments, Het is 1,3,4-oxadiazol-2-yl or 1,2,4-oxadiazol-2-yl. In some embodiments, Het is 1,3,4-oxadiazol-2-yl.

[0203] In some embodiments, R^1 is $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, $-SiR^{16}R^{17}R^{18}$, alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^1 is alkyl, alkylene, alkoxy, $-NR^{21}R^{22}$, or aryl, each of which is independently substituted or unsubstituted; halo or hydrogen. In some embodiments, R^1 is methyl, cyclohexyl, methylene, methoxy, or benzyl. In some embodiments, R^1 is fluoro or chloro. In some embodiments, R^1 is phenyl. In some embodiments, R^1 is hydrogen.

[0204] In some embodiments, R^1 is a substituted alkyl or alkylene. R^1 can be substituted by one or more substituents selected from a hydroxyl group, sulfhydryl group, halogen, amino group, nitro group, nitroso group, cyano group, azido group, sulfoxide group, sulfone group, sulfonamide group, carboxyl group, carboxaldehyde group, imine group, alkyl group, halo-alkyl group, cyclic alkyl group, alkenyl group, halo-alkenyl group, alkynyl group, halo-alkynyl group, alkoxy group, aryl group, aryloxy group, aralkyl group, arylalkoxy group, heterocyclyl group, acyl group, acyloxy group, carbamate group, amide group, urethane group, and ester group.

[0205] In some embodiments, R^1 is substituted alkyl. In some embodiments, R^1 is alkyl substituted with $NR^{16}R^{17}$. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein each R^{16} and R^{17} is independently alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkoxy, carboxyl group, amino group, acyl group, acyloxy group, or an amide group, any of which is unsubstituted or substituted, or

hydrogen. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} is a substituted carboxyl group.

[0206] In some embodiments, m is 1, 2, 3, or 4. In some embodiments, m is 1. In some embodiments, X^1 is carbon atom connected to Q^1 , and m is 1. In some embodiments, X^2 is carbon atom connected to Q^1 , and m is 1.

[0207] In some embodiments, Q^1 is $C=O$, $C=S$, $C=CR^{14}R^{15}$, $C=NR^{14}$, alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond. In some embodiments, Q^1 is alkylene, alkenylene, or alkynylene. In some embodiments, Q^1 is C_1 -alkylene. In some embodiments, each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, or hydrogen. In some embodiments, Q^1 is a bond.




[0208] In some embodiments, Q^1 is C_1 -alkylene, R^{16} is aryl, and R^{17} is alkyl. In some embodiments, Q^1 is C_1 -alkylene, R^{16} is aryl, and R^{17} is hydrogen. In some embodiments, Q^1 is C_1 -alkylene, R^{16} is heteroaryl, and R^{17} is alkyl. In some embodiments, Q^1 is C_1 -alkylene, R^{16} is substituted heteroaryl, and R^{17} is hydrogen. In some embodiments, Q^1 is C_1 -alkylene, R^{16} is substituted alkyl, and R^{17} is hydrogen. In some embodiments, R^{17} is aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted with halogen, alkyl, or hydroxyl. In some embodiments, R^{16} is hydrogen, and R^{17} is aryl or heteroaryl, substituted or unsubstituted with halogen or alkyl. In some embodiments, R^{16} is alkyl, and R^{17} is heteroaryl substituted with halogen or alkyl. In some embodiments, R^{17} is aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted with alkyl. In some embodiments, R^{17} is aryl or heteroaryl, each of which is independently substituted with alkyl, wherein the alkyl is optionally substituted with fluorine, chlorine, bromine, iodine, or cyano.


[0209] In some embodiments, R^2 is hydrogen or alkyl. In some embodiments, R^2 is substituted alkyl. In some embodiments, R^2 is trifluoroethyl. In some embodiments, R^{13} is alkyl, alkenyl, hydrogen, or halogen. In some embodiments, R^{13} is methyl, ethyl, propyl, iso-propyl, butyl or tert-butyl. In some embodiments, R^2 is trifluoroethyl, and R^{13} is hydrogen.


[0210] In some embodiments, R^3 is $-C(O)R^{19}$, $-C(O)OR^{19}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and R^4 is $-C(O)R^{19}$, $-C(O)OR^{19}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen.


[0211] In some embodiments, R^3 is H, and R^4 is $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; or hydrogen. In some embodiments, R^3 is H, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^4 is heterocyclyl. In some embodiments, R^4 is piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently


substituted or unsubstituted.

[0212] In some embodiments, R^4 is a ring that is: , , or , wherein the ring is substituted or unsubstituted. In some

embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or


unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, R^a is alkylene. In some embodiments, R^a is

methyl. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is

substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted.


[0213] In some embodiments, R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a ring, wherein the ring is substituted or unsubstituted. In some embodiments, R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a substituted heterocycle. In some embodiments, R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a heterocycle substituted with a hydroxyl group, halogen, amino group, or alkyl group. In some embodiments, R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a heterocycle, wherein the heterocycle is substituted by a substituted or unsubstituted heterocycle.

[0214] In some embodiments, the disclosure provides a compound of the formula:




or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.

[0215] In some embodiments, the disclosure provides a compound of the formula:




or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.

[0216] In some embodiments, the compound is of the formula:



or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.

[0217] In some embodiments, the disclosure provides a compound of the formula:



or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.

[0218] In some embodiments, R^1 is $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, $-SiR^{16}R^{17}R^{18}$, alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^1 is alkyl, alkylene, alkoxy, $-NR^{21}R^{22}$, or aryl, each of which is independently substituted or unsubstituted; halo or hydrogen.



[0219] In some embodiments, R^1 is substituted alkyl. In some embodiments, R^1 is alkyl substituted with $NR^{16}R^{17}$. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein each R^{16} and R^{17} is independently alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkoxy, carboxyl group, amino group, acyl group, acyloxy group, or an amide group, any of which is unsubstituted or substituted, or hydrogen. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} is a substituted carboxyl group.


[0220] In some embodiments, R^2 is hydrogen or alkyl. In some embodiments, R^2 is substituted alkyl. In some embodiments, R^2 is trifluoroethyl.


[0221] In some embodiments, Q^1 is $C=O$, $C=S$, $C=CR^{14}R^{15}$, $C=NR^{14}$, alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond. In some


embodiments, Q^1 is alkylene, alkenylene, or alkynylene. In some embodiments, Q^1 is C_1 -alkylene. In some embodiments, each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, or hydrogen. In some embodiments, Q^1 is a bond.


[0222] In some embodiments, R^3 is H, and R^4 is $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; or hydrogen. In some embodiments, R^3 is H, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^4 is heterocyclyl. In some embodiments, R^4 is piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted.

[0223] In some embodiments, R^4 is a ring that is: , , wherein the ring is substituted or unsubstituted. In some


embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or

unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, R^a is alkylene. In some embodiments, R^a is

methyl. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is

substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted.

[0224] In some embodiments, the disclosure provides a compound of the formula:






or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.


[0225] In some embodiments, Q^1 is $C=O$, $C=S$, $C=CR^{14}R^{15}$, $C=NR^{14}$, alkylene, alkenylene, or


alkynylene, each of which is independently substituted or unsubstituted, or a bond. In some embodiments, Q^1 is alkylene, alkenylene, or alkynylene. In some embodiments, Q^1 is C_1 -alkylene. In some embodiments, each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, or hydrogen. In some embodiments, Q^1 is a bond.


[0226] In some embodiments, R^3 is H, and R^4 is $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; or hydrogen. In some embodiments, R^3 is H, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^4 is heterocyclyl. In some embodiments, R^4 is piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted.

[0227] In some embodiments, R^4 is a ring that is: , , wherein the ring is substituted or unsubstituted. In some

embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or


unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, R^a is alkylene. In some embodiments, R^a is

methyl. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is

substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted.


[0228] In some embodiments, each R^{16} and R^{17} is independently alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkoxy, carboxyl group, amino group, acyl group, acyloxy group, or an amide group, any of which is unsubstituted or substituted, or hydrogen. In some embodiments, R^{16} is hydrogen, and R^{17} is a substituted carboxyl group.

[0229] In some embodiments, the compound is of the formula:



wherein R^{25} is $-C(O)R^{16}$, $-C(O)NR^{16}R^{17}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^{25} is aryl that is substituted or unsubstituted. In some embodiments, R^{25} is substituted phenyl. In some embodiments, R^{25} is $-C(O)R^{16}$, wherein R^{16} is alkyl, aryl, heteroaryl, or heterocyclyl. In some embodiments, R^{25} is $-C(O)R^{16}$, wherein R^{16} is substituted phenyl; or a pharmaceutically-acceptable salt thereof,

[0230] In some embodiments, the compound is of the formula:



wherein:


- Q^1 is $C=O$, $C=S$, $C=CR^{14}R^{15}$, $C=NR^{14}$, alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond;
- R^1 is $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, $-SiR^{16}R^{17}R^{18}$, alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, heterocyclyl, or halo, each of which is independently substituted or unsubstituted, or hydrogen;
- each R^3 and R^4 is independently $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen, or R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a ring, wherein the ring is substituted or unsubstituted, or R^3 is absent;
- each R^2 , R^{14} , R^{15} , R^{16} , R^{17} , and R^{18} is independently $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R^{19} and R^{20} is $-C(O)R^{23}$, $-C(O)OR^{23}$, $-C(O)NR^{23}R^{24}$, $-OR^{23}$, $-SR^{23}$, $-NR^{23}R^{24}$, $-NR^{23}C(O)R^{24}$, $-OC(O)R^{23}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and

- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,

or a pharmaceutically-acceptable salt thereof.

the variables are as defined above, and wherein o is 1, 2, 3, or 4.

[0231] In some embodiments, the compound is of the formula:



wherein:

- Q^1 is $C=O$, $C=S$, $C=CR^{14}R^{15}$, $C=NR^{14}$, alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond;
- each R^1 , R^{1a} , and R^{1b} is independently $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, $-SiR^{16}R^{17}R^{18}$, alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, heterocyclyl, or halo, each of which is independently substituted or unsubstituted, or hydrogen;
- each R^3 and R^4 is independently $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen, or R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a ring, wherein the ring is substituted or unsubstituted, or R^3 is absent;
- o is 0, 1, 2, 3, or 4;
- each R^2 , R^{14} , R^{15} , R^{16} , R^{17} , and R^{18} is independently $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R^{19} and R^{20} is $-C(O)R^{23}$, $-C(O)OR^{23}$, $-C(O)NR^{23}R^{24}$, $-OR^{23}$, $-SR^{23}$, $-NR^{23}R^{24}$, $-NR^{23}C(O)R^{24}$, $-OC(O)R^{23}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or


heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and

- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,

or a pharmaceutically-acceptable salt thereof.

[0232] In some embodiments, each R^{1a} and R^{1b} is independently alkyl, alkoxy, aryl, heteroaryl, heterocyclyl, or $NR^{16}R^{17}$. In some embodiments, R^{1a} is unsubstituted phenyl, and R^{1b} is amino.

[0233] In some embodiments, the compound is of the formula:







or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.


[0234] In some embodiments, R^1 is $-C(O)NR^{16}R^{17}$, alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, heterocyclyl, or halo, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^1 is alkyl, alkoxy, aryl, or halo. In some embodiments, R^1 is methoxy, methyl, or phenyl. In some embodiments, each R^{1a} and R^{1b} is independently alkyl, alkoxy, aryl, heteroaryl, heterocyclyl, or $NR^{16}R^{17}$. In some embodiments, R^{1a} is unsubstituted phenyl, and R^{1b} is amino.


[0235] In some embodiments, Q^1 is $C=O$, $C=S$, $C=CR^{14}R^{15}$, $C=NR^{14}$, alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond. In some embodiments, Q^1 is alkylene, alkenylene, or alkynylene. In some embodiments, Q^1 is C_1 -alkylene. In some embodiments, each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, or hydrogen. In some embodiments, Q^1 is a bond.


[0236] In some embodiments, R^3 is H, and R^4 is $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; or hydrogen. In some embodiments, R^3 is H, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^4 is heterocyclyl. In some embodiments, R^4 is piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted.

[0237] In some embodiments, R^4 is a ring that is: , , or , wherein the ring is substituted or unsubstituted. In some

embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or

unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, R^a is alkylene. In some embodiments, R^a is


methyl. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is

substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted.

[0238] In some embodiments, each R^{16} and R^{17} is independently alkyl, cycloalkyl, aryl, heteroaryl,

heterocyclyl, alkoxy, carboxyl group, amino group, acyl group, acyloxy group, or an amide group, any of which is unsubstituted or substituted, or hydrogen. In some embodiments, R^{16} is hydrogen, and R^{17} is a substituted carboxyl group.

[0239] In some embodiments, the compound is of the formula:




wherein:

- Q^1 is $C=O$, $C=S$, $C=CR^{14}R^{15}$, $C=NR^{14}$, alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond;
- each R^{1c} and R^{1d} is independently $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, $-SiR^{16}R^{17}R^{18}$, alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, heterocyclyl, or halo, each of which is independently substituted or unsubstituted, or hydrogen;
- each R^3 and R^4 is independently $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen, or R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a ring, wherein the ring is substituted or unsubstituted, or R^3 is absent;
- each R^2 , R^{14} , R^{15} , R^{16} , R^{17} , and R^{18} is independently $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R^{19} and R^{20} is $-C(O)R^{23}$, $-C(O)OR^{23}$, $-C(O)NR^{23}R^{24}$, $-OR^{23}$, $-SR^{23}$, $-NR^{23}R^{24}$, $-NR^{23}C(O)R^{24}$, $-OC(O)R^{23}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,

or a pharmaceutically-acceptable salt thereof.

[0240] In some embodiments, each R^{1c} and R^{1d} is independently $-OR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen.

[0241] In some embodiments, the compound is of the formula:




or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.

[0242] In some embodiments, each R^{1c} and R^{1d} is independently

$C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, $-SiR^{16}R^{17}R^{18}$, alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, heterocyclyl, or halo, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^{1c} is amino, and R^{1d} is phenyl. In some embodiments, R^{1c} is amino, and R^{1d} is cycloalkenyl.

[0243] In some embodiments, the compound is of the formula:



wherein:


- Q^1 is $C=O$, $C=S$, $C=CR^{14}R^{15}$, $C=NR^{14}$, alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond;
- each R^{1e} and R^{1f} is independently $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, $-SiR^{16}R^{17}R^{18}$, alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, heterocyclyl, or halo, each of which is independently substituted or unsubstituted, or hydrogen;
- each R^3 and R^4 is independently $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen, or R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a ring, wherein the ring is substituted or unsubstituted, or R^3 is absent;
- each R^2 , R^{14} , R^{15} , R^{16} , R^{17} , and R^{18} is independently $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R^{19} and R^{20} is $-C(O)R^{23}$, $-C(O)OR^{23}$, $-C(O)NR^{23}R^{24}$, $-OR^{23}$, $-SR^{23}$, $-NR^{23}R^{24}$, $-NR^{23}C(O)R^{24}$, $-OC(O)R^{23}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or

heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and

- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,


or a pharmaceutically-acceptable salt thereof.

[0244] In some embodiments, the compound is of the formula:



or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.




[0245] In some embodiments, the compound is of the formula:





or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.


[0246] In some embodiments, Q^1 is $C=O$, $C=S$, $C=CR^{14}R^{15}$, $C=NR^{14}$, alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond. In some embodiments, Q^1 is alkylene, alkenylene, or alkynylene. In some embodiments, Q^1 is C_1 -alkylene. In some embodiments, each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, or hydrogen. In some embodiments, Q^1 is a bond.


[0247] In some embodiments, R^3 is H, and R^4 is $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; or hydrogen. In some embodiments, R^3 is H, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^4 is heterocyclyl. In some embodiments, R^4 is piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted.

[0248] In some embodiments, R^4 is a ring that is: , , or , wherein the ring is substituted or unsubstituted. In some

embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or


unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, R^a is alkylene. In some embodiments, R^a is

methyl. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is

substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted.

[0249] In some embodiments, each R^{1e} and R^{1f} is independently alkyl, $NR^{16}R^{17}$, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^{1e} is substituted alkyl, and R^{1f} is hydrogen. In some embodiments, R^{1e} is hydrogen, and R^{1f} is $NR^{16}R^{17}$, wherein each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^{1e} is hydrogen, and R^{1f} is $NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} is alkyl. In some embodiments, R^{1e} is hydrogen, and R^{1f} is $NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} is phenyl. In some embodiments, R^{1e} is hydrogen, and R^{1f} is amino.

[0250] In some embodiments, the compound is of the formula:




wherein:

- Q^1 is $C=O$, $C=S$, $C=CR^{14}R^{15}$, $C=NR^{14}$, alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond;
- each R^1 , R^{1g} , and R^{1h} is independently $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, $-SiR^{16}R^{17}R^{18}$, alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, heterocyclyl, or halo, each of which is independently

- substituted or unsubstituted, or hydrogen;
- each R^3 and R^4 is independently $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen, or R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a ring, wherein the ring is substituted or unsubstituted, or R^3 is absent;
 - each R^2 , R^{14} , R^{15} , R^{16} , R^{17} , and R^{18} is independently $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
 - each R^{19} and R^{20} is $-C(O)R^{23}$, $-C(O)OR^{23}$, $-C(O)NR^{23}R^{24}$, $-OR^{23}$, $-SR^{23}$, $-NR^{23}R^{24}$, $-NR^{23}C(O)R^{24}$, $-OC(O)R^{23}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
 - each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
 - each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,


or a pharmaceutically-acceptable salt thereof.

[0251] In some embodiments, the compound is of the formula:



or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.

[0252] In some embodiments, the compound is of the formula:



or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.

[0253] In some embodiments, Q^1 is $C=O$, $C=S$, $C=CR^{14}R^{15}$, $C=NR^{14}$, alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond. In some embodiments, Q^1 is alkylene, alkenylene, or alkynylene. In some embodiments, Q^1 is C_1 -alkylene. In some embodiments, each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, or hydrogen. In some embodiments, Q^1 is a bond.

[0254] In some embodiments, R^3 is H, and R^4 is $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; or hydrogen. In some embodiments, R^3 is H, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^4 is heterocyclyl. In some embodiments, R^4 is piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted.

[0255] In some embodiments, R^4 is a ring that is:

, wherein the ring is substituted or unsubstituted. In some

embodiments, R^3 is H, and R^4 is a ring that is

, wherein the ring is substituted or

unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is

, wherein the ring is substituted or unsubstituted. In some embodiments, R^a is alkylene. In some embodiments, R^a is

methyl. In some embodiments, R^3 is H, and R^4 is a ring that is


, wherein the ring is

substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is

, wherein the ring is substituted or unsubstituted.

[0256] In some embodiments, R^1 is $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, $-SiR^{16}R^{17}R^{18}$, alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, heterocyclyl, or halo, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^1 is substituted alkyl. In some embodiments, R^1 is alkyl substituted with $NR^{16}R^{17}$, wherein each R^{16} and R^{17} is independently alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkoxy, carboxyl group, amino group, acyl group, acyloxy group, or an amide group, any of which is unsubstituted or substituted, or hydrogen. In some embodiments, R^{16} is hydrogen, and R^{17} is a substituted carboxyl group. In some embodiments, R^{16} is hydrogen, and R^{17} is carboxyl substituted with alkyl or aryl. In some embodiments, R^{16} is hydrogen, and R^{17} is carboxyl substituted with cycloalkyl or phenyl. In some embodiments, R^{16} and R^{17} are hydrogen.


[0257] In some embodiments, the compound is of the formula:



or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.

[0258] In some embodiments, R^1 is $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, $-SiR^{16}R^{17}R^{18}$, alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, heterocyclyl, or halo, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^1 is substituted alkyl. In some embodiments, R^1 is alkyl substituted with $NR^{16}R^{17}$, wherein each R^{16} and R^{17} is independently alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkoxy, carboxyl group, amino group, acyl group, acyloxy group, or an amide group, any of which is unsubstituted or substituted, or hydrogen. In some embodiments, R^{16} is hydrogen, and R^{17} is a substituted carboxyl group. In some embodiments, R^{16} is hydrogen, and R^{17} is carboxyl substituted with alkyl or aryl. In some embodiments, R^{16} is hydrogen, and R^{17} is carboxyl substituted with cycloalkyl or phenyl. In some embodiments, R^{16} and R^{17} are hydrogen.

[0259] In some embodiments, the compounds if of the formula:






or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.


[0260] In some embodiments, Q^1 is $C=O$, $C=S$, $C=CR^{14}R^{15}$, $C=NR^{14}$, alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond. In some


embodiments, Q^1 is alkylene, alkenylene, or alkynylene. In some embodiments, Q^1 is C_1 -alkylene. In some embodiments, each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, or hydrogen. In some embodiments, Q^1 is a bond.


[0261] In some embodiments, R^3 is H, and R^4 is $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; or hydrogen. In some embodiments, R^3 is H, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^4 is heterocyclyl. In some embodiments, R^4 is piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted.

[0262] In some embodiments, R^4 is a ring that is: , , wherein the ring is substituted or unsubstituted. In some

embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or

unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, R^a is alkylene. In some embodiments, R^a is


methyl. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is

substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted.

[0263] In some embodiments, R^1 is $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, $-SiR^{16}R^{17}R^{18}$, alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, heterocyclyl, or halo, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments R^1 is substituted alkyl. In some embodiments, R^1 is alkyl substituted with $NR^{16}R^{17}$, wherein each R^{16} and R^{17} is independently alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkoxy, carboxyl group, amino group, acyl group, acyloxy group, or an amide group, any of which is unsubstituted or substituted, or hydrogen. In some embodiments, R^{16} is hydrogen, and R^{17} is aryl, heteroaryl, carboxyl, or hydrogen. In some embodiments, R^{16} is hydrogen, and R^{17} is carboxyl

substituted with aryl, heteroaryl, cycloalkyl, or alkyl. In some embodiments, R^{16} and R^{17} are hydrogen.

[0264] In some embodiments, the compound is of the formula:




wherein:

- Q^1 is $C=O$, $C=S$, $C=CR^{14}R^{15}$, $C=NR^{14}$, alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond;
- R^1 is $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, $-SiR^{16}R^{17}R^{18}$, alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, heterocyclyl, or halo, each of which is independently substituted or unsubstituted, or hydrogen;
- each R^3 and R^4 is independently $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen, or R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a ring, wherein the ring is substituted or unsubstituted, or R^3 is absent;
- each R^2 , R^{14} , R^{15} , R^{16} , R^{17} , and R^{18} is independently $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R^{19} and R^{20} is $-C(O)R^{23}$, $-C(O)OR^{23}$, $-C(O)NR^{23}R^{24}$, $-OR^{23}$, $-SR^{23}$, $-NR^{23}R^{24}$, $-NR^{23}C(O)R^{24}$, $-OC(O)R^{23}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,


or a pharmaceutically-acceptable salt thereof.

[0265] In some embodiments, the compound is of the formula:




or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.

[0266] In some embodiments, the compound is of the formula:



or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.

[0267] In some embodiments, the compound is of the formula:



wherein:


- Q¹ is C=O, C=S, C=CR¹⁴R¹⁵, C=NR¹⁴, alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond;
- each R^{1c} and R^{1d} is independently -C(O)R¹⁶, -C(O)OR¹⁶, -C(O)NR¹⁶R¹⁷, -OR¹⁶, -SR¹⁶, -NR¹⁶R¹⁷, -NR¹⁶C(O)R¹⁶, -OC(O)R¹⁶, -SiR¹⁶R¹⁷R¹⁸, alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, heterocyclyl, or halo, each of which is independently substituted or unsubstituted, or hydrogen;
- each R³ and R⁴ is independently -C(O)R¹⁹, -C(O)OR¹⁹, -C(O)NR¹⁹R²⁰, -SOR¹⁹, -SO₂R¹⁹, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen, or R³ and R⁴ together with the nitrogen atom to which R³ and R⁴ are bound form a ring, wherein the ring is substituted or unsubstituted, or R³ is absent;


- each R^{14} , R^{15} , R^{16} , R^{17} , and R^{18} is independently $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R^{19} and R^{20} is $-C(O)R^{23}$, $-C(O)OR^{23}$, $-C(O)NR^{23}R^{24}$, $-OR^{23}$, $-SR^{23}$, $-NR^{23}R^{24}$, $-NR^{23}C(O)R^{24}$, $-OC(O)R^{23}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,
- R^{25} is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen;

or a pharmaceutically-acceptable salt thereof.


[0268] In some embodiments, R^{25} is heterocyclyl, cycloalkyl, aryl, each of which is substituted or unsubstituted. In some embodiments, R^{25} is phenyl or cyclopropyl, each of which is substituted or unsubstituted. In some embodiments, R^{25} is substituted cyclopropyl. In some embodiments, R^{25} is heteroaryl or heterocyclyl, each of which is substituted or unsubstituted. In some embodiments, R^{25} is thiophenyl, indolenyl, or pyrrolyl, each of which is substituted or unsubstituted.

[0269] Non-limiting examples of compounds of the disclosure include compounds of any of the following formulae:













or a pharmaceutically-acceptable salt thereof.

[0270] Non-limiting examples of compounds of the disclosure include compounds of any of the following formulae:









or a pharmaceutically-acceptable salt thereof.

[0271] Compounds herein can include all stereoisomers, enantiomers, diastereomers, mixtures, racemates, atropisomers, and tautomers thereof.

[0272] Non-limiting examples of optional substituents include hydroxyl groups, sulfhydryl groups, halogens, amino groups, nitro groups, nitroso groups, cyano groups, azido groups, sulfoxide groups, sulfone groups, sulfonamide groups, carboxyl groups, carboxaldehyde groups, imine groups, alkyl groups, halo-alkyl groups, alkenyl groups, halo-alkenyl groups, alkynyl groups, halo-alkynyl groups, alkoxy groups, aryl groups, aryloxy groups, aralkyl groups, arylalkoxy groups, heterocyclyl groups, acyl groups, acyloxy groups, carbamate groups, amide groups, ureido groups, epoxy groups, and ester groups.

[0273] Non-limiting examples of alkyl and alkylene groups include straight, branched, and cyclic alkyl and alkylene groups. An alkyl or alkylene group can be, for example, a C₁, C₂, C₃, C₄, C₅, C₆, C₇, C₈, C₉, C₁₀, C₁₁, C₁₂, C₁₃, C₁₄, C₁₅, C₁₆, C₁₇, C₁₈, C₁₉, C₂₀, C₂₁, C₂₂, C₂₃, C₂₄, C₂₅, C₂₆, C₂₇, C₂₈, C₂₉, C₃₀, C₃₁, C₃₂, C₃₃, C₃₄, C₃₅, C₃₆, C₃₇, C₃₈, C₃₉, C₄₀, C₄₁, C₄₂, C₄₃, C₄₄, C₄₅, C₄₆, C₄₇, C₄₈, C₄₉, or C₅₀

group that is substituted or unsubstituted.

[0274] Non-limiting examples of straight alkyl groups include methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, and decyl.

[0275] Branched alkyl groups include any straight alkyl group substituted with any number of alkyl groups. Non-limiting examples of branched alkyl groups include isopropyl, isobutyl, sec-butyl, and t-butyl.

[0276] Non-limiting examples of substituted alkyl groups includes hydroxymethyl, chloromethyl, trifluoromethyl, aminomethyl, 1-chloroethyl, 2-hydroxyethyl, 1,2-difluoroethyl, and 3-carboxypropyl.

[0277] Non-limiting examples of cyclic alkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups. Cyclic alkyl groups also include fused-, bridged-, and spiro-bicycles and higher fused-, bridged-, and spiro-systems. A cyclic alkyl group can be substituted with any number of straight, branched, or cyclic alkyl groups. Non-limiting examples of cyclic alkyl groups include cyclopropyl, 2-methyl-cycloprop-1-yl, cycloprop-2-en-1-yl, cyclobutyl, 2,3-dihydroxycyclobut-1-yl, cyclobut-2-en-1-yl, cyclopentyl, cyclopent-2-en-1-yl, cyclopenta-2,4-dien-1-yl, cyclohexyl, cyclohex-2-en-1-yl, cycloheptyl, cyclooctanyl, 2,5-dimethylcyclopent-1-yl, 3,5-dichlorocyclohex-1-yl, 4-hydroxycyclohex-1-yl, 3,3,5-trimethylcyclohex-1-yl, octahydropentalenyl, octahydro-1*H*-indenyl, 3a,4,5,6,7,7a-hexahydro-3*H*-inden-4-yl, decahydroazulenyl, bicyclo-[2.1.1]hexanyl, bicyclo[2.2.1]heptanyl, bicyclo[3.1.1]heptanyl, 1,3-dimethyl[2.2.1]heptan-2-yl, bicyclo[2.2.2]octanyl, and bicyclo[3.3.3]undecanyl.

[0278] Non-limiting examples of alkenyl and alkenylene groups include straight, branched, and cyclic alkenyl groups. The olefin or olefins of an alkenyl group can be, for example, *E*, *Z*, *cis*, *trans*, terminal, or *exo*-methylene. An alkenyl or alkenylene group can be, for example, a C₂, C₃, C₄, C₅, C₆, C₇, C₈, C₉, C₁₀, C₁₁, C₁₂, C₁₃, C₁₄, C₁₅, C₁₆, C₁₇, C₁₈, C₁₉, C₂₀, C₂₁, C₂₂, C₂₃, C₂₄, C₂₅, C₂₆, C₂₇, C₂₈, C₂₉, C₃₀, C₃₁, C₃₂, C₃₃, C₃₄, C₃₅, C₃₆, C₃₇, C₃₈, C₃₉, C₄₀, C₄₁, C₄₂, C₄₃, C₄₄, C₄₅, C₄₆, C₄₇, C₄₈, C₄₉, or C₅₀ group that is substituted or unsubstituted. Non-limiting examples of alkenyl and alkenylene groups include ethenyl, prop-1-en-1-yl, isopropenyl, but-1-en-4-yl; 2-chloroethenyl, 4-hydroxybuten-1-yl, 7-hydroxy-7-methyloct-4-en-2-yl, and 7-hydroxy-7-methyloct-3,5-dien-2-yl.

[0279] Non-limiting examples of alkynyl or alkynylene groups include straight, branched, and cyclic alkynyl groups. The triple bond of an alkynyl or alkynylene group can be internal or terminal. An alkynyl or alkynylene group can be, for example, a C₂, C₃, C₄, C₅, C₆, C₇, C₈, C₉, C₁₀, C₁₁, C₁₂, C₁₃, C₁₄, C₁₅, C₁₆, C₁₇, C₁₈, C₁₉, C₂₀, C₂₁, C₂₂, C₂₃, C₂₄, C₂₅, C₂₆, C₂₇, C₂₈, C₂₉, C₃₀, C₃₁, C₃₂, C₃₃, C₃₄, C₃₅, C₃₆, C₃₇, C₃₈, C₃₉, C₄₀, C₄₁, C₄₂, C₄₃, C₄₄, C₄₅, C₄₆, C₄₇, C₄₈, C₄₉, or C₅₀ group that is substituted or unsubstituted. Non-limiting examples of alkynyl or alkynylene groups include ethynyl, prop-2-yn-1-yl, prop-1-yn-1-yl, and 2-methyl-hex-4-yn-1-yl; 5-hydroxy-5-methylhex-3-yn-1-yl, 6-hydroxy-6-methylhept-3-yn-2-yl, and 5-hydroxy-5-ethylhept-3-yn-1-yl.

[0280] A halo-alkyl group can be any alkyl group substituted with any number of halogen atoms, for

example, fluorine, chlorine, bromine, and iodine atoms. A halo-alkenyl group can be any alkenyl group substituted with any number of halogen atoms. A halo-alkynyl group can be any alkynyl group substituted with any number of halogen atoms.

[0281] An alkoxy group can be, for example, an oxygen atom substituted with any alkyl, alkenyl, or alkynyl group. An ether or an ether group comprises an alkoxy group. Non-limiting examples of alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, and isobutoxy.

[0282] An aryl group can be heterocyclic or non-heterocyclic. An aryl group can be monocyclic or polycyclic. An aryl group can be substituted with any number of substituents described herein, for example, hydrocarbyl groups, alkyl groups, alkoxy groups, and halogen atoms. Non-limiting examples of aryl groups include phenyl, toluyl, naphthyl, pyrrolyl, pyridyl, imidazolyl, thiophenyl, and furyl. Non-limiting examples of substituted aryl groups include 3,4-dimethylphenyl, 4-*tert*-butylphenyl, 4-cyclopropylphenyl, 4-diethylaminophenyl, 4-(trifluoromethyl)phenyl, 4-(difluoromethoxy)-phenyl, 4-(trifluoromethoxy)phenyl, 3-chlorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 2-fluorophenyl, 2-chlorophenyl, 2-iodophenyl, 3-iodophenyl, 4-iodophenyl, 2-methylphenyl, 3-fluorophenyl, 3-methylphenyl, 3-methoxyphenyl, 4-fluorophenyl, 4-methylphenyl, 4-methoxyphenyl, 2,3-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,3-dichlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2,3-dimethoxyphenyl, 3,4-dimethoxyphenyl, 3,5-dimethoxyphenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2,6-difluorophenyl, 2,3,4-trifluorophenyl, 2,3,5-trifluorophenyl, 2,3,6-trifluorophenyl, 2,4,5-trifluorophenyl, 2,4,6-trifluorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 2,6-dichlorophenyl, 3,4-dichlorophenyl, 2,3,4-trichlorophenyl, 2,3,5-trichlorophenyl, 2,3,6-trichlorophenyl, 2,4,5-trichlorophenyl, 3,4,5-trichlorophenyl, 2,4,6-trichlorophenyl, 2,3-dimethylphenyl, 2,4-dimethylphenyl, 2,5-dimethylphenyl, 2,6-dimethylphenyl, 2,3,4-trimethylphenyl, 2,3,5-trimethylphenyl, 2,3,6-trimethylphenyl, 2,4,5-trimethylphenyl, 2,4,6-trimethylphenyl, 2-ethylphenyl, 3-ethylphenyl, 4-ethylphenyl, 2,3-diethylphenyl, 2,4-diethylphenyl, 2,5-diethylphenyl, 2,6-diethylphenyl, 3,4-diethylphenyl, 2,3,4-triethylphenyl, 2,3,5-triethylphenyl, 2,3,6-triethylphenyl, 2,4,5-triethylphenyl, 2,4,6-triethylphenyl, 2-isopropylphenyl, 3-isopropylphenyl, and 4-isopropylphenyl.

[0283] Non-limiting examples of substituted aryl groups include 2-aminophenyl, 2-(*N*-methylamino)phenyl, 2-(*N,N*-dimethylamino)phenyl, 2-(*N*-ethylamino)phenyl, 2-(*N,N*-diethylamino)phenyl, 3-aminophenyl, 3-(*N*-methylamino)phenyl, 3-(*N,N*-dimethylamino)phenyl, 3-(*N*-ethylamino)phenyl, 3-(*N,N*-diethylamino)phenyl, 4-aminophenyl, 4-(*N*-methylamino)phenyl, 4-(*N,N*-dimethylamino)phenyl, 4-(*N*-ethylamino)phenyl, and 4-(*N,N*-diethylamino)phenyl.

[0284] A heterocycle can be any ring containing a ring atom that is not carbon, for example, N, O, S, P, Si, B, or any other heteroatom. A heterocycle can be substituted with any number of substituents, for example, alkyl groups and halogen atoms. A heterocycle can be aromatic (heteroaryl) or non-aromatic. Non-limiting examples of heterocycles include pyrrole, pyrrolidine, pyridine, piperidine,

succinamide, maleimide, morpholine, imidazole, thiophene, furan, tetrahydrofuran, pyran, and tetrahydropyran.

[0285] Non-limiting examples of heterocycles include: heterocyclic units having a single ring containing one or more heteroatoms, non-limiting examples of which include, diazirinyl, aziridinyl, azetidiny, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolinyl, thiazolidinyl, isothiazolinyl, oxathiazolidinonyl, oxazolidinonyl, hydantoinyl, tetrahydrofuranyl, pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl, dihydropyranyl, tetrahydropyranyl, piperidin-2-onyl, 2,3,4,5-tetrahydro-1*H*-azepinyl, 2,3-dihydro-1*H*-indole, and 1,2,3,4-tetrahydroquinoline; and ii) heterocyclic units having 2 or more rings one of which is a heterocyclic ring, non-limiting examples of which include hexahydro-1*H*-pyrrolizinyl, 3a,4,5,6,7,7a-hexahydro-1*H*-benzo[d]imidazolyl, 3a,4,5,6,7,7a-hexahydro-1*H*-indolyl, 1,2,3,4-tetrahydroquinolinyl, and decahydro-1*H*-cycloocta[b]pyrrolyl.

[0286] Non-limiting examples of heteroaryl include: i) heteroaryl rings containing a single ring, non-limiting examples of which include, 1,2,3,4-tetrazolyl, [1,2,3]triazolyl, [1,2,4]triazolyl, triazinyl, thiazolyl, 1*H*-imidazolyl, oxazolyl, isoxazolyl, isothiazolyl, furanyl, thiophenyl, pyrimidinyl, 2-phenylpyrimidinyl, pyridinyl, 3-methylpyridinyl, and 4-dimethylaminopyridinyl; and ii) heteroaryl rings containing 2 or more fused rings one of which is a heteroaryl ring, non-limiting examples of which include: 7*H*-purinyl, 9*H*-purinyl, 6-amino-9*H*-purinyl, 5*H*-pyrrolo[3,2-*d*]pyrimidinyl, 7*H*-pyrrolo[2,3-*d*]pyrimidinyl, pyrido[2,3-*d*]pyrimidinyl, 4,5,6,7-tetrahydro-1-*H*-indolyl, quinoxalinyl, quinazolinyl, quinolinyl, 8-hydroxy-quinolinyl, and isoquinolinyl.

[0287] Any compound herein can be purified. A compound herein can be least 1% pure, at least 2% pure, at least 3% pure, at least 4% pure, at least 5% pure, at least 6% pure, at least 7% pure, at least 8% pure, at least 9% pure, at least 10% pure, at least 11% pure, at least 12% pure, at least 13% pure, at least 14% pure, at least 15% pure, at least 16% pure, at least 17% pure, at least 18% pure, at least 19% pure, at least 20% pure, at least 21% pure, at least 22% pure, at least 23% pure, at least 24% pure, at least 25% pure, at least 26% pure, at least 27% pure, at least 28% pure, at least 29% pure, at least 30% pure, at least 31% pure, at least 32% pure, at least 33% pure, at least 34% pure, at least 35% pure, at least 36% pure, at least 37% pure, at least 38% pure, at least 39% pure, at least 40% pure, at least 41% pure, at least 42% pure, at least 43% pure, at least 44% pure, at least 45% pure, at least 46% pure, at least 47% pure, at least 48% pure, at least 49% pure, at least 50% pure, at least 51% pure, at least 52% pure, at least 53% pure, at least 54% pure, at least 55% pure, at least 56% pure, at least 57% pure, at least 58% pure, at least 59% pure, at least 60% pure, at least 61% pure, at least 62% pure, at least 63% pure, at least 64% pure, at least 65% pure, at least 66% pure, at least 67% pure, at least 68% pure, at least 69% pure, at least 70% pure, at least 71% pure, at least 72% pure, at least 73% pure, at least 74% pure, at least 75% pure, at least 76% pure, at least 77% pure, at least 78% pure, at least 79% pure, at least 80% pure, at least 81% pure, at least 82% pure, at least 83% pure, at least 84% pure, at least 85% pure, at least 86% pure, at least 87% pure, at least 88% pure, at least 89% pure, at least 90% pure, at least 91% pure, at least 92% pure, at least 93% pure, at

least 94% pure, at least 95% pure, at least 96% pure, at least 97% pure, at least 98% pure, at least 99% pure, at least 99.1% pure, at least 99.2% pure, at least 99.3% pure, at least 99.4% pure, at least 99.5% pure, at least 99.6% pure, at least 99.7% pure, at least 99.8% pure, or at least 99.9% pure.

[0288] In some embodiments, compounds of the invention can be used to treat cancer in a subject. A compound of the invention can, for example, slow the proliferation of cancer cell lines, or kill cancer cells. Non-limiting examples of cancer that can be treated by a compound of the invention include: acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, AIDS-related cancers, AIDS-related lymphoma, anal cancer, appendix cancer, astrocytomas, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancers, brain tumors, such as cerebellar astrocytoma, cerebral astrocytoma/malignant glioma, ependymoma, medulloblastoma, supratentorial primitive neuroectodermal tumors, visual pathway and hypothalamic glioma, breast cancer, bronchial adenomas, Burkitt lymphoma, carcinoma of unknown primary origin, central nervous system lymphoma, cerebellar astrocytoma, cervical cancer, childhood cancers, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myeloproliferative disorders, colon cancer, cutaneous T-cell lymphoma, desmoplastic small round cell tumor, endometrial cancer, ependymoma, esophageal cancer, Ewing's sarcoma, germ cell tumors, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor, gliomas, hairy cell leukemia, head and neck cancer, heart cancer, hepatocellular (liver) cancer, Hodgkin lymphoma, Hypopharyngeal cancer, intraocular melanoma, islet cell carcinoma, Kaposi sarcoma, kidney cancer, laryngeal cancer, lip and oral cavity cancer, liposarcoma, liver cancer, lung cancers, such as non-small cell and small cell lung cancer, lymphomas, leukemias, macroglobulinemia, malignant fibrous histiocytoma of bone/osteosarcoma, medulloblastoma, melanomas, mesothelioma, metastatic squamous neck cancer with occult primary, mouth cancer, multiple endocrine neoplasia syndrome, myelodysplastic syndromes, myeloid leukemia, nasal cavity and paranasal sinus cancer, nasopharyngeal carcinoma, neuroblastoma, non-Hodgkin lymphoma, non-small cell lung cancer, oral cancer, oropharyngeal cancer, osteosarcoma/malignant fibrous histiocytoma of bone, ovarian cancer, ovarian epithelial cancer, ovarian germ cell tumor, pancreatic cancer, pancreatic cancer islet cell, paranasal sinus and nasal cavity cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, pineal astrocytoma, pineal germinoma, pituitary adenoma, pleuropulmonary blastoma, plasma cell neoplasia, primary central nervous system lymphoma, prostate cancer, rectal cancer, renal cell carcinoma, renal pelvis and ureter transitional cell cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcomas, skin cancers, skin carcinoma merkel cell, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, stomach cancer, T-cell lymphoma, throat cancer, thymoma, thymic carcinoma, thyroid cancer, trophoblastic tumor (gestational), cancers of unknown primary site, urethral cancer, uterine sarcoma, vaginal cancer, vulvar cancer, Waldenström macroglobulinemia, and Wilms tumor.

[0289] In some embodiments, the compounds of the invention show non-lethal toxicity.

Pharmaceutically-acceptable salts.

[0290] The invention provides the use of pharmaceutically-acceptable salts of any therapeutic compound described herein. Pharmaceutically-acceptable salts include, for example, acid-addition salts and base-addition salts. The acid that is added to the compound to form an acid-addition salt can be an organic acid or an inorganic acid. A base that is added to the compound to form a base-addition salt can be an organic base or an inorganic base. In some embodiments, a pharmaceutically-acceptable salt is a metal salt. In some embodiments, a pharmaceutically-acceptable salt is an ammonium salt.

[0291] Metal salts can arise from the addition of an inorganic base to a compound of the invention. The inorganic base consists of a metal cation paired with a basic counterion, such as, for example, hydroxide, carbonate, bicarbonate, or phosphate. The metal can be an alkali metal, alkaline earth metal, transition metal, or main group metal. In some embodiments, the metal is lithium, sodium, potassium, cesium, cerium, magnesium, manganese, iron, calcium, strontium, cobalt, titanium, aluminum, copper, cadmium, or zinc.

[0292] In some embodiments, a metal salt is a lithium salt, a sodium salt, a potassium salt, a cesium salt, a cerium salt, a magnesium salt, a manganese salt, an iron salt, a calcium salt, a strontium salt, a cobalt salt, a titanium salt, an aluminum salt, a copper salt, a cadmium salt, or a zinc salt.

[0293] Ammonium salts can arise from the addition of ammonia or an organic amine to a compound of the invention. In some embodiments, the organic amine is triethyl amine, diisopropyl amine, ethanol amine, diethanol amine, triethanol amine, morpholine, N-methylmorpholine, piperidine, N-methylpiperidine, N-ethylpiperidine, dibenzylamine, piperazine, pyridine, pyrazole, pipyrazole, imidazole, pyrazine, or pipyrazine.

[0294] In some embodiments, an ammonium salt is a triethyl amine salt, a diisopropyl amine salt, an ethanol amine salt, a diethanol amine salt, a triethanol amine salt, a morpholine salt, an N-methylmorpholine salt, a piperidine salt, an N-methylpiperidine salt, an N-ethylpiperidine salt, a dibenzylamine salt, a piperazine salt, a pyridine salt, a pyrazole salt, a pipyrazole salt, an imidazole salt, a pyrazine salt, or a pipyrazine salt.

[0295] Acid addition salts can arise from the addition of an acid to a compound of the invention. In some embodiments, the acid is organic. In some embodiments, the acid is inorganic. In some embodiments, the acid is hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, nitrous acid, sulfuric acid, sulfurous acid, a phosphoric acid, isonicotinic acid, lactic acid, salicylic acid, tartaric acid, ascorbic acid, gentisinic acid, gluconic acid, glucaronic acid, saccharic acid, formic acid, benzoic acid, glutamic acid, pantothenic acid, acetic acid, propionic acid, butyric acid, fumaric acid, succinic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, oxalic acid, or maleic acid.

[0296] In some embodiments, the salt is a hydrochloride salt, a hydrobromide salt, a hydroiodide salt, a nitrate salt, a nitrite salt, a sulfate salt, a sulfite salt, a phosphate salt, isonicotinate salt, a lactate

salt, a salicylate salt, a tartrate salt, an ascorbate salt, a gentisinate salt, a gluconate salt, a glucaronate salt, a saccharate salt, a formate salt, a benzoate salt, a glutamate salt, a pantothenate salt, an acetate salt, a propionate salt, a butyrate salt, a fumarate salt, a succinate salt, a methanesulfonate (mesylate) salt, an ethanesulfonate salt, a benzenesulfonate salt, a p-toluenesulfonate salt, a citrate salt, an oxalate salt, or a maleate salt.

Pharmaceutical Compositions of the invention.

[0297] A pharmaceutical composition of the invention can be used, for example, before, during, or after treatment of a subject with, for example, another pharmaceutical agent.

[0298] Subjects can be, for example, elderly adults, adults, adolescents, pre-adolescents, children, toddlers, infants, neonates, and non-human animals. In some embodiments, a subject is a patient.

[0299] A pharmaceutical composition of the invention can be a combination of any pharmaceutical compounds described herein with other chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and/or excipients. The pharmaceutical composition facilitates administration of the compound to an organism. Pharmaceutical compositions can be administered in therapeutically-effective amounts as pharmaceutical compositions by various forms and routes including, for example, intravenous, subcutaneous, intramuscular, oral, parenteral, ophthalmic, subcutaneous, transdermal, nasal, vaginal, and topical administration.

[0300] A pharmaceutical composition can be administered in a local manner, for example, via injection of the compound directly into an organ, optionally in a depot or sustained release formulation or implant. Pharmaceutical compositions can be provided in the form of a rapid release formulation, in the form of an extended release formulation, or in the form of an intermediate release formulation. A rapid release form can provide an immediate release. An extended release formulation can provide a controlled release or a sustained delayed release.

[0301] For oral administration, pharmaceutical compositions can be formulated by combining the active compounds with pharmaceutically-acceptable carriers or excipients. Such carriers can be used to formulate liquids, gels, syrups, elixirs, slurries, or suspensions, for oral ingestion by a subject. Non-limiting examples of solvents used in an oral dissolvable formulation can include water, ethanol, isopropanol, saline, physiological saline, DMSO, dimethylformamide, potassium phosphate buffer, phosphate buffer saline (PBS), sodium phosphate buffer, 4-2-hydroxyethyl-1-piperazineethanesulfonic acid buffer (HEPES), 3-(N-morpholino)propanesulfonic acid buffer (MOPS), piperazine-N,N'-bis(2-ethanesulfonic acid) buffer (PIPES), and saline sodium citrate buffer (SSC). Non-limiting examples of co-solvents used in an oral dissolvable formulation can include sucrose, urea, cremaphor, DMSO, and potassium phosphate buffer.

[0302] Pharmaceutical preparations can be formulated for intravenous administration. The pharmaceutical compositions can be in a form suitable for parenteral injection as a sterile suspension, solution or emulsion in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Pharmaceutical formulations for parenteral

administration include aqueous solutions of the active compounds in water-soluble form. Suspensions of the active compounds can be prepared as oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. The suspension can also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. Alternatively, the active ingredient can be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

[0303] The active compounds can be administered topically and can be formulated into a variety of topically administrable compositions, such as solutions, suspensions, lotions, gels, pastes, medicated sticks, balms, creams, and ointments. Such pharmaceutical compositions can contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.

[0304] The compounds of the invention can be applied topically to the skin, or a body cavity, for example, oral, vaginal, bladder, cranial, spinal, thoracic, or pelvic cavity of a subject. The compounds of the invention can be applied to an accessible body cavity.

[0305] The compounds can also be formulated in rectal compositions such as enemas, rectal gels, rectal foams, rectal aerosols, suppositories, jelly suppositories, or retention enemas, containing conventional suppository bases such as cocoa butter or other glycerides, as well as synthetic polymers such as polyvinylpyrrolidone, and PEG. In suppository forms of the compositions, a low-melting wax such as a mixture of fatty acid glycerides, optionally in combination with cocoa butter, can be melted.

[0306] In practicing the methods of treatment or use provided herein, therapeutically-effective amounts of the compounds described herein are administered in pharmaceutical compositions to a subject having a disease or condition to be treated. In some embodiments, the subject is a mammal such as a human. A therapeutically-effective amount can vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compounds used, and other factors. The compounds can be used singly or in combination with one or more therapeutic agents as components of mixtures.

[0307] Pharmaceutical compositions can be formulated using one or more physiologically-acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active compounds into preparations that can be used pharmaceutically. Formulations can be modified depending upon the route of administration chosen. Pharmaceutical compositions comprising a compound described herein can be manufactured, for example, by mixing, dissolving, emulsifying, encapsulating, entrapping, or compression processes.

[0308] The pharmaceutical compositions can include at least one pharmaceutically-acceptable carrier, diluent, or excipient and compounds described herein as free-base or pharmaceutically-acceptable salt form. Pharmaceutical compositions can contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.

[0309] Methods for the preparation of compositions comprising the compounds described herein

include formulating the compounds with one or more inert, pharmaceutically-acceptable excipients or carriers to form a solid, semi-solid, or liquid composition. Solid compositions include, for example, powders, tablets, dispersible granules, capsules, and cachets. Liquid compositions include, for example, solutions in which a compound is dissolved, emulsions comprising a compound, or a solution containing liposomes, micelles, or nanoparticles comprising a compound as disclosed herein. Semi-solid compositions include, for example, gels, suspensions and creams. The compositions can be in liquid solutions or suspensions, solid forms suitable for solution or suspension in a liquid prior to use, or as emulsions. These compositions can also contain minor amounts of nontoxic, auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, and other pharmaceutically-acceptable additives.

[0310] Non-limiting examples of dosage forms suitable for use in the invention include liquid, powder, gel, nanosuspension, nanoparticle, microgel, aqueous or oily suspensions, emulsion, and any combination thereof.

[0311] Non-limiting examples of pharmaceutically-acceptable excipients suitable for use in the invention include binding agents, disintegrating agents, anti-adherents, anti-static agents, surfactants, anti-oxidants, coating agents, coloring agents, plasticizers, preservatives, suspending agents, emulsifying agents, anti-microbial agents, spheronization agents, and any combination thereof.

[0312] A composition of the invention can be, for example, an immediate release form or a controlled release formulation. An immediate release formulation can be formulated to allow the compounds to act rapidly. Non-limiting examples of immediate release formulations include readily dissolvable formulations. A controlled release formulation can be a pharmaceutical formulation that has been adapted such that release rates and release profiles of the active agent can be matched to physiological and chronotherapeutic requirements or, alternatively, has been formulated to effect release of an active agent at a programmed rate. Non-limiting examples of controlled release formulations include granules, delayed release granules, hydrogels (e.g., of synthetic or natural origin), other gelling agents (e.g., gel-forming dietary fibers), matrix-based formulations (e.g., formulations comprising a polymeric material having at least one active ingredient dispersed through), granules within a matrix, polymeric mixtures, and granular masses.

[0313] In some, a controlled release formulation is a delayed release form. A delayed release form can be formulated to delay a compound's action for an extended period of time. A delayed release form can be formulated to delay the release of an effective dose of one or more compounds, for example, for about 4, about 8, about 12, about 16, or about 24 hours.

[0314] A controlled release formulation can be a sustained release form. A sustained release form can be formulated to sustain, for example, the compound's action over an extended period of time. A sustained release form can be formulated to provide an effective dose of any compound described herein (e.g., provide a physiologically-effective blood profile) over about 4, about 8, about 12, about 16 or about 24 hours.

[0315] Non-limiting examples of pharmaceutically-acceptable excipients can be found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, H.A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkins 1999), each of which is incorporated by reference in its entirety.

[0316] Multiple therapeutic agents can be administered in any order or simultaneously. In some embodiments, a compound of the invention is administered in combination with, before, or after treatment with another therapeutic agent. If simultaneously, the multiple therapeutic agents can be provided in a single, unified form, or in multiple forms, for example, as multiple separate pills. The agents can be packed together or separately, in a single package or in a plurality of packages. One or all of the therapeutic agents can be given in multiple doses. If not simultaneous, the timing between the multiple doses can vary to as much as about a month.

[0317] Therapeutic agents described herein can be administered before, during, or after the occurrence of a disease or condition, and the timing of administering the composition containing a therapeutic agent can vary. For example, the compositions can be used as a prophylactic and can be administered continuously to subjects with a propensity to conditions or diseases in order to lessen a likelihood of the occurrence of the disease or condition. The compositions can be administered to a subject during or as soon as possible after the onset of the symptoms. The administration of the therapeutic agents can be initiated within the first 48 hours of the onset of the symptoms, within the first 24 hours of the onset of the symptoms, within the first 6 hours of the onset of the symptoms, or within 3 hours of the onset of the symptoms. The initial administration can be via any route practical, such as by any route described herein using any formulation described herein.

[0318] A compound can be administered as soon as is practical after the onset of a disease or condition is detected or suspected, and for a length of time necessary for the treatment of the disease, such as, for example, from about 1 month to about 3 months. In some embodiments, the length of time a compound can be administered can be about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 1 month, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 3 months, about 13 weeks, about 14 weeks, about 15 weeks, about 16 weeks, about 4 months, about 17 weeks, about 18 weeks, about 19 weeks, about 20 weeks, about 5 months, about 21 weeks, about 22 weeks, about 23 weeks, about 24 weeks, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 13 months, about 14 months, about 15 months, about 16 months, about 17 months, about 18 months, about 19 months, about 20 months, about 21 months, about 22 months, about 23 months, about 2 years, about 2.5 years, about 3 years, about 3.5 years, about 4 years, about

4.5 years, about 5 years, about 6 years, about 7 years, about 8 years, about 9 years, or about 10 years. The length of treatment can vary for each subject.

[0319] Pharmaceutical compositions described herein can be in unit dosage forms suitable for single administration of precise dosages. In unit dosage form, the formulation is divided into unit doses containing appropriate quantities of one or more compounds. The unit dosage can be in the form of a package containing discrete quantities of the formulation. Non-limiting examples are packaged injectables, vials, or ampoules. Aqueous suspension compositions can be packaged in single-dose non-reclosable containers. Multiple-dose reclosable containers can be used, for example, in combination with or without a preservative. Formulations for injection can be presented in unit dosage form, for example, in ampoules, or in multi-dose containers with a preservative.

[0320] Pharmaceutical compositions provided herein, can be administered in conjunction with other therapies, for example, chemotherapy, radiation, surgery, anti-inflammatory agents, and selected vitamins. The other agents can be administered prior to, after, or concomitantly with the pharmaceutical compositions.

[0321] Depending on the intended mode of administration, the pharmaceutical compositions can be in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, suppositories, pills, capsules, powders, liquids, suspensions, lotions, creams, or gels, for example, in unit dosage form suitable for single administration of a precise dosage.

[0322] For solid compositions, nontoxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, glucose, sucrose, and magnesium carbonate.

[0323] Non-limiting examples of pharmaceutically active agents suitable for combination with compositions of the disclosure include anti-infectives, i.e., aminoglycosides, antiviral agents, antimicrobials, anticholinergics/antispasmodics, antidiabetic agents, antihypertensive agents, antineoplastics, cardiovascular agents, central nervous system agents, coagulation modifiers, hormones, immunologic agents, immunosuppressive agents, and ophthalmic preparations.

[0324] Compounds can be delivered via liposomal technology. The use of liposomes as drug carriers can increase the therapeutic index of the compounds. Liposomes are composed of natural phospholipids, and can contain mixed lipid chains with surfactant properties (e.g., egg phosphatidylethanolamine). A liposome design can employ surface ligands for attaching to unhealthy tissue. Non-limiting examples of liposomes include the multilamellar vesicle (MLV), the small unilamellar vesicle (SUV), and the large unilamellar vesicle (LUV). Liposomal physicochemical properties can be modulated to optimize penetration through biological barriers and retention at the site of administration, and to reduce a likelihood of developing premature degradation and toxicity to non-target tissues. Optimal liposomal properties depend on the administration route: large-sized liposomes show good retention upon local injection, small-sized liposomes are better suited to achieve passive targeting. PEGylation reduces the uptake of the liposomes by the liver and spleen,

and increases the circulation time, resulting in increased localization at the inflamed site due to the enhanced permeability and retention (EPR) effect. Additionally, liposomal surfaces can be modified to achieve selective delivery of the encapsulated drug to specific target cells. Non-limiting examples of targeting ligands include monoclonal antibodies, vitamins, peptides, and polysaccharides specific for receptors concentrated on the surface of cells associated with the disease.

[0325] Non-limiting examples of dosage forms suitable for use in the disclosure include liquid, elixir, nanosuspension, aqueous or oily suspensions, drops, syrups, and any combination thereof. Non-limiting examples of pharmaceutically-acceptable excipients suitable for use in the disclosure include granulating agents, binding agents, lubricating agents, disintegrating agents, sweetening agents, glidants, anti-adherents, anti-static agents, surfactants, anti-oxidants, gums, coating agents, coloring agents, flavoring agents, coating agents, plasticizers, preservatives, suspending agents, emulsifying agents, plant cellulosic material and spheronization agents, and any combination thereof.

[0326] Compositions of the invention can be packaged as a kit. In some embodiments, a kit includes written instructions on the administration/use of the composition. The written material can be, for example, a label. The written material can suggest conditions methods of administration. The instructions provide the subject and the supervising physician with the best guidance for achieving the optimal clinical outcome from the administration of the therapy. The written material can be a label. In some embodiments, the label can be approved by a regulatory agency, for example the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other regulatory agencies.

Dosing.

[0327] Pharmaceutical compositions described herein can be in unit dosage forms suitable for single administration of precise dosages. In unit dosage form, the formulation is divided into unit doses containing appropriate quantities of one or more compounds. The unit dosage can be in the form of a package containing discrete quantities of the formulation. Non-limiting examples are liquids in vials or ampoules. Aqueous suspension compositions can be packaged in single-dose non-reclosable containers. Multiple-dose reclosable containers can be used, for example, in combination with a preservative. Formulations for parenteral injection can be presented in unit dosage form, for example, in ampoules, or in multi-dose containers with a preservative.

[0328] A compound described herein can be present in a composition in a range of from about 1 mg to about 2000 mg; from about 100 mg to about 2000 mg; from about 10 mg to about 2000 mg; from about 5 mg to about 1000 mg, from about 10 mg to about 500 mg, from about 50 mg to about 250 mg, from about 100 mg to about 200 mg, from about 1 mg to about 50 mg, from about 50 mg to about 100 mg, from about 100 mg to about 150 mg, from about 150 mg to about 200 mg, from about 200 mg to about 250 mg, from about 250 mg to about 300 mg, from about 300 mg to about 350 mg, from about 350 mg to about 400 mg, from about 400 mg to about 450 mg, from about 450 mg to about 500 mg, from about 500 mg to about 550 mg, from about 550 mg to about 600 mg, from about

600 mg to about 650 mg, from about 650 mg to about 700 mg, from about 700 mg to about 750 mg, from about 750 mg to about 800 mg, from about 800 mg to about 850 mg, from about 850 mg to about 900 mg, from about 900 mg to about 950 mg, or from about 950 mg to about 1000 mg.

[0329] A compound described herein can be present in a composition in an amount of about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 550 mg, about 600 mg, about 650 mg, about 700 mg, about 750 mg, about 800 mg, about 850 mg, about 900 mg, about 950 mg, about 1000 mg, about 1050 mg, about 1100 mg, about 1150 mg, about 1200 mg, about 1250 mg, about 1300 mg, about 1350 mg, about 1400 mg, about 1450 mg, about 1500 mg, about 1550 mg, about 1600 mg, about 1650 mg, about 1700 mg, about 1750 mg, about 1800 mg, about 1850 mg, about 1900 mg, about 1950 mg, or about 2000 mg.

[0330] In some embodiments, a dose can be expressed in terms of an amount of the drug divided by the mass of the subject, for example, milligrams of drug per kilograms of subject body mass. In some embodiments, a compound is administered in an amount ranging from about 5 mg/kg to about 50 mg/kg, 250 mg/kg to about 2000 mg/kg, about 10 mg/kg to about 800 mg/kg, about 50 mg/kg to about 400 mg/kg, about 100 mg/kg to about 300 mg/kg, or about 150 mg/kg to about 200 mg/kg.

Combination Treatment

[0331] Combination therapy with a compound of the disclosure and at least one additional therapeutic agent, for example, any additional therapeutic agent described herein, can be used to treat a condition. In some embodiments, the combination therapy can produce a significantly better therapeutic result than the additive effects achieved by each individual constituent when administered alone at a therapeutic dose. In some embodiments, the dosage of the compound or additional therapeutic agent, for example, any additional therapeutic agent described herein, in combination therapy can be reduced as compared to monotherapy with each agent, while still achieving an overall therapeutic effect. In some embodiments, a compound and an additional therapeutic agent, for example, any additional therapeutic agent described herein, can exhibit a synergistic effect. In some embodiments, the synergistic effect of a compound and additional therapeutic agent, for example, any additional therapeutic agent described herein, can be used to reduce the total amount drugs administered to a subject, which decrease side effects experienced by the subject.

[0332] The compounds of the disclosure can be used in combination with at least one additional pharmaceutically-active agent, for example, any additional therapeutic agent described herein. In some embodiments, the at least one additional pharmaceutically-active agent, for example, any additional therapeutic agent described herein, can modulate the same or a different target as the compounds of the disclosure. In some embodiments, the at least one additional pharmaceutically-

active agent, for example, any additional therapeutic agent described herein, can modulate the same target as the compounds of the disclosure, or other components of the same pathway, or overlapping sets of target enzymes. In some embodiments, the at least one additional pharmaceutically-active agent, for example, any additional therapeutic agent described herein, can modulate a different target from the compounds of the disclosure.

[0333] Accordingly, in one aspect, the present disclosure provides a method for treating cancer, the method comprising administering to a subject in need thereof (a) an effective amount of a compound of the disclosure and (b) an effective amount of at least one additional pharmaceutically active agent, for example, any additional therapeutic agent described herein, to provide a combination therapy. In some embodiments, the combination therapy may have an enhanced therapeutic effect compared to the effect of the compound and the at least one additional pharmaceutically active agent each administered alone. According to certain exemplary embodiments, the combination therapy has a synergistic therapeutic effect. According to this embodiment, the combination therapy produces a significantly better therapeutic result (*e.g.*, anti-cancer, cell growth arrest, apoptosis, induction of differentiation, cell death, etc.) than the additive effects achieved by each individual constituent when administered alone at a therapeutic dose.

[0334] Combination therapy includes but is not limited to the combination of compounds of the disclosure with chemotherapeutic agents, therapeutic antibodies, or radiation treatment, to provide a synergistic therapeutic effect. In some embodiments, the compounds of the disclosure are used in combination with one or more anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Suitable chemotherapeutic agents for use in the combinations of the present disclosure include, but are not limited to, alkylating agents, antibiotic agents, antimetabolic agents, hormonal agents, plant-derived agents, anti-angiogenic agents, differentiation inducing agents, cell growth arrest inducing agents, apoptosis inducing agents, cytotoxic agents, agents affecting cell bioenergetics, biologic agents, *e.g.*, monoclonal antibodies, kinase inhibitors and inhibitors of growth factors and their receptors, gene therapy agents, cell therapy, or any combination thereof.

a. Combination treatment with estrogen receptor antagonists

[0335] In some embodiments, a compound of the disclosure is used in combination with an estrogen receptor antagonist. In some embodiments, a compound of the disclosure is used in combination with toremifene (Fareston®), fulvestrant (Faslodex®), or tamoxifen citrate (Soltamox®).

[0336] Fulvestrant is a selective estrogen receptor degrader (SERD) and is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. Fulvestrant is a complete estrogen receptor antagonist with little to no agonist effects and accelerates the proteasomal degradation of the estrogen receptor. Fulvestrant has poor oral bioavailability and is administered via intramuscular injection. Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes estrogen receptor-positive

breast cancer cells to heregulin beta1. In some embodiments, a compound of the disclosure is used in combination with fulvestrant.

b. Combination treatment with aromatase inhibitors

[0337] In some embodiments, a compound of the disclosure is used in combination with an aromatase inhibitor. Aromatase inhibitors are used in the treatment of breast cancer in post-menopausal women and gynecomastia in men. Aromatase inhibitors can be used off-label to reduce estrogen conversion when using external testosterone. Aromatase inhibitors can also be used for chemoprevention in high-risk women.

[0338] In some embodiments, a compound of the disclosure is used in combination with a non-selective aromatase inhibitor. In some embodiments, a compound of the disclosure is used in combination with a non-selective aromatase inhibitor, such as aminoglutethimide or testolactone (Teslac®). In some embodiments, a compound of the disclosure is used in combination with a selective aromatase inhibitor. In some embodiments, a compound of the disclosure is used in combination with a selective aromatase inhibitor, such as anastrozole (Arimidex®), letrozole (Femara®), exemestane (Aromasin®), vorozole (Rivizor®), formestane (Lentaron®), or fadrozole (Afema®). In some embodiments, a compound of the disclosure is used in combination with exemestane. In some embodiments, a compound of the disclosure is used in combination with an aromatase inhibitor such as 1,4,6-androstatrien-3,17-dione (ATD) or 4-androstene-3,6,17-trione.

c. Combination treatment with mTOR inhibitors

[0339] In some embodiments, a compound of the disclosure is used in combination with an mTOR inhibitor. mTOR inhibitors are drugs that inhibit the mechanistic target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that belongs to the family of phosphatidylinositol-3 kinase (PI3K)-related kinases (PIKKs). mTOR regulates cellular metabolism, growth, and proliferation by forming and signaling through the protein complexes mTORC1 and mTORC2.

[0340] In some embodiments, a compound of the disclosure is used in combination with an mTOR inhibitor, such as rapamycin, temsirolimus (CCI-779), everolimus (RAD001), ridaforolimus (AP-23573). In some embodiments, a compound of the disclosure is used in combination with everolimus (Afinitor®). Everolimus affects the mTORC1 protein complex and can lead to hyper-activation of the kinase AKT, which can lead to longer survival in some cell types. Everolimus binds to FKBP12, a protein receptor which directly interacts with mTORC1 and inhibits downstream signaling. mRNAs that codify proteins implicated in the cell cycle and in the glycolysis process are impaired or altered as a result, inhibiting tumor growth and proliferation.

[0341] In some embodiments, a compound of the disclosure is used in combination with a mTOR inhibitor and an aromatase inhibitor. For example, a compound of the disclosure is used in combination with everolimus and exemestane.

d. Combination treatment with antimetabolites

[0342] Antimetabolites are chemotherapy treatments that are similar to normal substances within the cell. When cells incorporate the antimetabolites into the cellular metabolism, the cells are unable to divide. Antimetabolites are cell-cycle specific and attack cells at specific phases in the cell cycle.

[0343] In some examples, a compound of the disclosure is used in combination with one or more antimetabolites, such as a folic acid antagonist, pyrimidine antagonist, purine antagonist, or an adenosine deaminase inhibitor. In some embodiments, a compound of the disclosure is used in combination with an antimetabolite, such as methotrexate, 5-fluorouracil, floxuridine, cytarabine, capecitabine, gemcitabine, 6-mercaptopurine, 6-thioguanine, cladribine, fludarabine, nelarabine, or pentostatin. In some embodiments, a compound of the disclosure is used in combination with capecitabine (Xeloda®), gemcitabine (Gemzar®), or cytarabine (Cytosar-U®).

e. Combination treatment with plant alkaloids

[0344] In some embodiments, a compound of the disclosure is used in combination with a plant alkaloid. In some embodiments, a compound of the disclosure is used in combination with a plant alkaloid, such as vinca alkaloids, taxanes, podophyllotoxins, or camptothecin analogues. In some embodiments, a compound of the disclosure is used in combination with plant alkaloids, such as vincristine, vinblastine, vinorelbine, paclitaxel, docetaxel, etoposide, teniposide, irinotecan, or topotecan.

[0345] In some embodiments, a compound of the disclosure is used in combination with a taxane, such as paclitaxel (Abraxane® or Taxol®) and docetaxel (Taxotere®). In some embodiments, a compound of the disclosure is used in combination with paclitaxel. In some embodiments, a compound of the disclosure is used in combination with docetaxel.

f. Combination treatment with therapeutic antibodies

[0346] In some embodiments, a compound of the disclosure is used in combination with therapeutic antibodies. In some embodiments, a compound of the disclosure is used in combination with naked monoclonal antibodies, such as alemtuzumab (Campath®) or trastuzumab (Herceptin®). In some embodiments, a compound of the disclosure is used in combination with conjugated monoclonal antibodies, such as radiolabeled antibodies or chemolabeled antibodies. In some embodiments, a compound of the disclosure is used in combination with conjugated monoclonal antibodies, such as ibritumomab tiuxetan (Zevalin®), brentuximab vedotin (Adcetris®), ado-trastuzumab emtansine (Kadcyla®), or denileukin diftitox (Ontak®). In some embodiments, a compound of the disclosure is used in combination with bispecific monoclonal antibodies, such as blinatumomab (Blincyto®).

[0347] In some embodiments, a compound of the disclosure is used in combination with an anti-CD20 antibody, such as rituximab (Mabthera®/ Rituxan®), obinutuzumab (Gazyva®), ibritumomab tiuxetan, tositumomab, ofatumumab (Genmab®), ocaratuzumab, ocrelizumab, TRU-015, or velutuzumab. Other antibodies that can be used in combination with a compound of the disclosure include antibodies against the programmed cell death (PD-1) receptor, for example pembrolizumab (Keytruda®) or nivolumab (Opdivo®).

g. Combination treatment with PD-L1 and/or PD-1 antagonists

[0348] The PD-1 pathway comprises the immune cell co-receptor Programmed Death-1 (PD-1) and the PD-1 ligands PD-L1 and PD-L2. The PD-1 pathway mediates local immunosuppression in the tumor microenvironment. PD-1 and PD-L1 antagonists suppress the immune system. In some embodiments, a PD-1 or PD-L1 antagonist is a monoclonal antibody or antigen binding fragment thereof that specifically binds to, blocks, or downregulates PD-1 or PD-L1, respectively. In some embodiments, a PD-1 or PD-L1 antagonist is a compound or biological molecule that specifically binds to, blocks, or downregulates PD-1 or PD-L1, respectively.

[0349] In some embodiments, the compounds of the disclosure are used in combination with a PD-1 or PD-L1 antagonist. In some embodiments, the compounds of the disclosure are used in combination with a PD-1/PD-L1 antagonist, for example, MK-3475, nivolumab (Opdivo®), pembrolizumab (Keytruda®), humanized antibodies (i.e., h409A11, h409A16 and h409A17), AMP-514, BMS-936559, MEDI0680, MEDI4736, MPDL3280A, MSB0010718C, MDX-1105, MDX-1106, or pidilizumab. In some embodiments, the compounds of the disclosure are used in combination with a PD-1/PD-L1 antagonist that is an immunoadhesion molecule, such as AMP-224. In some embodiments, the compounds of the disclosure are used in combination with a PD-1/PD-L1 antagonist to treat cancer cells or a tumor that overexpresses PD-1 or PD-L1. In some embodiments, the compounds of the disclosure are used in combination with a PD-1/PD-L1 antagonist to treat cancer cells or a tumor that overexpresses miR-34.

h. Combination treatment with anti-hormone therapy

[0350] Anti-hormone therapy uses an agent to suppress selected hormones or the effects. Anti-hormone therapy is achieved by antagonizing the function of hormones with a hormone antagonist and/or by preventing the production of hormones. In some embodiments, the suppression of hormones can be beneficial to subjects with certain cancers that grow in response to the presence of specific hormones. In some embodiments, a compound of the disclosure is used in combination with a hormone antagonist.

[0351] In some embodiments, a compound of the disclosure is used in combination with anti-androgens, anti-estrogens, aromatase inhibitors, or luteinizing hormone-releasing hormone (LHRH) agonists. In some embodiments, a compound of the disclosure is used in combination with anti-androgens, such as bicalutamide (Casodex®), cyproterone (Androcur®), flutamide (Euflex®), or nilutamide (Anandron®). In some embodiments, a compound of the disclosure is used in combination with anti-estrogens, such as fulvestrant (Faslodex®), raloxifene (Evista®), or tamoxifen (Novaladex®, Tamofen®). In some embodiments, a compound of the disclosure is used in combination with LHRH agonists, such as buserelin (Suprefact®), goserelin (Zoladex®), or leuprolide (Lupron®, Lupron Depot®, Eligard®).

i. Combination treatment with hypomethylating (demethylating) agents

[0352] Hypomethylating (demethylating) agents inhibit DNA methylation, which affects cellular function through successive generations of cells without changing the underlying DNA sequence. Hypomethylating agents can block the activity of DNA methyltransferase. In some embodiments, a compound of the disclosure is used in combination with hypomethylating agents, such as azacitidine (Vidaza®, Azadine®) or decitabine (Dacogen®).

j. Combination treatment with anti-inflammatory agents

[0353] In some embodiments, a compound of the disclosure is used in combination with nonsteroidal anti-inflammatory drugs (NSAIDs), specific COX-2 inhibitors, or corticosteroids. In some embodiments, a compound of the disclosure is used in combination with NSAIDs, such as aspirin, ibuprofen, naproxen, celecoxib, ketorolac, or diclofenac. In some embodiments, a compound of the disclosure is used in combination with specific COX-2 inhibitors, such as celecoxib (Celebrex®), rofecoxib, or etoricoxib. In some embodiments, a compound of the disclosure is used in combination with corticosteroids, such as dexamethasone or glucocorticoids (e.g., hydrocortisone and prednisone).

k. Combination treatment with HDAC inhibitors

[0354] Histone deacetylase (HDAC) inhibitors are chemical compounds that inhibit histone deacetylase. HDAC inhibitors can induce p21 expression, a regulator of p53 activity. In some embodiments, a compound of the disclosure is used in combination with an HDAC inhibitor. In some embodiments, a compound of the disclosure is used in combination with an HDAC inhibitor, such as vorinostat, romidepsin (Istodax®), chidamide, panobinostat (Farydak®), belinostat (PDX101), panobinostat (LBH589), valproic acid, mocetinostat (MGCD0103), abexinostat (PCI-24781), entinostat (MS-275), SB939, resminostat (4SC-201), givinostat (ITF2357), quisinostat (JNJ-26481585), HBI-8000, kevetrin, CUDC-101, AR-42, CHR-2845, CHR-3996, 4SC-202, CG200745, ACY-1215, ME-344, sulforaphane, or trichostatin A.

l. Combination treatment with platinum-based antineoplastic drugs

[0355] Platinum-based antineoplastic drugs are coordinated complex of platinum. In some embodiments, a compound of the disclosure is used in combination with a platinum-based antineoplastic drug, such as cisplatin, oxaliplatin, carboplatin, nedaplatin, triplatin tetranitrate, phenanthriplatin, picoplatin, or satraplatin. In some embodiments, a compound of the disclosure is used in combination with cisplatin or carboplatin. In some embodiments, a compound of the disclosure is used in combination with cisplatin, platamin, neoplatin, cismaplat, cis-diamminedichloroplatinum(II), or CDDP; Platinol®) and carboplatin (also known as cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II); tradenames Paraplatin® and Paraplatin-AQ®).

m. Combination treatment with kinase inhibitors

[0356] Abnormal activation of protein phosphorylation is frequently either a driver of direct consequence of cancer. Kinase signaling pathways are involved in the phenotypes of tumor biology, including proliferation, survival, motility, metabolism, angiogenesis, and evasion of antitumor immune responses.

[0357] **MEK inhibitors:** MEK inhibitors are drugs that inhibit the mitogen-activated protein kinase enzymes MEK1 and/or MEK2. In some embodiments, a compound of the disclosure is used in combination with a MEK1 inhibitor. In some embodiments, a compound of the disclosure is used in combination with a MEK2 inhibitor. In some embodiments, a compound of the disclosure is used in combination with an agent that can inhibit MEK1 and MEK2. In some embodiments, a compound of the disclosure is used in combination with a MEK1/MEK2 inhibitor, such as trametinib (Mekinist®), cobimetinib, binimetinib, selumetinib (AZD6244), pimasertibe (AS-703026), PD-325901, CI-1040, PD035901, or TAK-733. In some embodiments, a compound of the disclosure is used in combination with trametinib. In some embodiments, a compound of the disclosure is used in combination with cobimetinib.

[0358] **BRAF inhibitors:** BRAF inhibitors are drugs that inhibit the serine/threonine-protein kinase B-raf (BRAF) protein. In some embodiments, a compound of the disclosure is used in combination with a BRAF inhibitor. In some embodiments, a compound of the disclosure is used in combination with a BRAF inhibitor that can inhibit wild type BRAF. In some embodiments, a compound of the disclosure is used in combination with a BRAF inhibitor that can inhibit mutated BRAF. In some embodiments, a compound of the disclosure is used in combination with a BRAF inhibitor that can inhibit V600E mutated BRAF. In some embodiments, a compound of the disclosure is used in combination with a BRAF inhibitor, such as vemurafenib (Zelboraf®), dabrafenib (Tafinlar®), C-1, NVP-LGX818, or sorafenib (Nexavar®).

[0359] **KRAS inhibitors:** KRAS is a gene that acts as an on/off switch in cell signaling. In some embodiments, a compound of the disclosure is used in combination with a KRAS inhibitor. In some embodiments, a compound of the disclosure is used in combination with a wild type KRAS inhibitor. In some embodiments, a compound of the disclosure is used in combination with a mutated KRAS inhibitor.

[0360] **BTK inhibitors:** Bruton's tyrosine kinase (BTK) is a non-receptor tyrosine kinase of the Tec kinase family that is involved in B-cell receptor signaling. In some embodiments, a compound of the disclosure is used in combination with a BTK inhibitor. In some embodiments, a compound of the disclosure is used in combination with a BTK inhibitor, such as ibrutinib or acalabrutinib.

[0361] **CDK inhibitors:** CDK4 and CDK6 are cyclin-dependent kinases that control the transition between the G1 and S phases of the cell cycle. CDK4/CDK6 activity is deregulated and overactive in cancer cells. Selective CDK4/CDK6 inhibitors can block cell-cycle progression in the mid-G1 phase of the cell cycle, causing arrest and preventing the proliferation of cancer cells. In some embodiments, a compound of the disclosure is used in combination with a CDK4/CDK6 inhibitor. In some embodiments, a compound of the disclosure is used in combination with a CDK4/CDK6 inhibitor, such as palbociclib (Ibrance®), ribociclib, trilaciclib, seliciclib, dinaciclib, milciclib, roniciclib, atuvaciclib, briciclib, riviciclib, voruciclib, or abemaciclib. In some embodiments, a compound of the disclosure is used in combination with palbociclib. In some embodiments, a

compound of the disclosure is used in combination with ribociclib. In some embodiments, a compound of the disclosure is used in combination with abemaciclib.

[0362] In some examples, a compound of the disclosure is used in combination with an inhibitor of CDK4 and/or CDK6 and with an agent that reinforces the cytostatic activity of CDK4/6 inhibitors and/or with an agent that converts reversible cytostasis into irreversible growth arrest or cell death. Examples of cancer subtypes include NSCLC, melanoma, neuroblastoma, glioblastoma, liposarcoma, and mantle cell lymphoma. In some examples, a compound of the disclosure is used in combination with at least one additional pharmaceutically active agent that alleviates CDKN2A (cyclin-dependent kinase inhibitor 2A) deletion. In some examples, a compound of the disclosure is used in combination with at least one additional pharmaceutically active agent that alleviates CDK9 (cyclin-dependent kinase 9) abnormality.

[0363] In some embodiments, a compound of the disclosure is used in combination with a CDK2, CDK7, and/or CDK9 inhibitor. In some embodiments, a compound of the disclosure is used in combination with a CDK2, CDK7, or CDK9 inhibitor, such as seliciclib, voruciclib, or milciclib. In some embodiments, a compound of the disclosure is used in combination with a CDK inhibitor, such as dinaciclib, roniciclib (Kisqali®), or briciclib. In some examples, a compound of the disclosure is used in combination with at least one additional pharmaceutically-active agent that alleviates CDKN2A (cyclin-dependent kinase inhibitor 2A) deletion.

[0364] **ATM regulators:** A compound of the disclosure can be used in combination with one or more pharmaceutically-active agent that regulates the ATM (upregulate or downregulate). In some embodiments the compounds described herein can synergize with one or more ATM regulators. In some embodiments one or more of the compounds described herein can synergize with all ATM regulators.

[0365] **AKT inhibitors:** In some embodiments, a compound of the disclosure is used in combination with one or more pharmaceutically-active agent that inhibits the AKT (protein kinase B (PKB)). In some embodiments the compounds described herein can synergize with one or more AKT inhibitors.

n. Combination treatment with other pharmaceutically-active agents

[0366] In some examples, a compound of the disclosure is used in combination with at least one additional pharmaceutically-active agent that alleviates PTEN (phosphatase and tensin homolog) deletion. In some examples, a compound of the disclosure is used in combination with at least one additional pharmaceutically-active agent that alleviates Wip-1 Alpha over expression. In some examples, a compound of the disclosure is used in combination with at least one additional pharmaceutically-active agent that is a Nucleoside metabolic inhibitor. Examples of nucleoside metabolic inhibitors include capecitabine, gemcitabine and cytarabine (Arac).

[0367] The table below lists suitable additional pharmaceutically-active agents for use with the methods described herein.

Cancer Type	Drug name	Brand name
ALL	ABT-199	none
ALL	clofarabine	Clofarex
ALL	cyclophosphamide	Clafen, Cytosan, Neosar
ALL	cytarabine	Cytosar-U, Tarabine PFS
ALL	doxorubicin	Adriamycin
ALL	imatinib mesylate	Gleevec
ALL	methotrexate	Abitrexate, Mexate, Folex
ALL	prednisone	Deltasone, Medicorten
ALL	romidepsin	Istodax
ALL	vincristine	Vincasar
AML	ABT-199	none
AML	azacitadine	Vidaza
AML	cyclophosphamide	Clafen, Cytosan, Neosar
AML	cytarabine	Cytosar-U, Tarabine PFS
AML	decitabine	Dacogen
AML	doxorubicin	Adriamycin
AML	etoposide	Etopophos, Vepesid
AML	vincristine	Vincasar
bone	doxorubicin	Adriamycin
bone	methotrexate	Abitrexate, Mexate, Folex
breast	capecitabine	Xeloda
breast	cyclophosphamide	Clafen, Cytosan, Neosar
breast	docetaxel	Taxotere
breast	doxorubicin	Adriamycin
breast	eribulin mesylate	Haliben
breast	everolimus	Afinitor
breast	exemestane	Aromasin
breast	fluorouracil	Adrucil, Efudex
breast	fulvestrant	Faslofex
breast	gemcitabine	Gemzar
breast	goserelin acetate	Zoladex
breast	letrozole	Femara
breast	megestrol acetate	Megace
breast	methotrexate	Abitrexate, Mexate, Folex

Cancer Type	Drug name	Brand name
breast	paclitaxel	Abraxane®, Taxol
breast	palbociclib	Ibrance
breast	pertuzumab	Perjeta
breast	tamoxifen citrate	Nolvadex
breast	trastuzumab	Herceptin, Kadcyla
colon	capecitabine	Xeloda
colon	cetuximab	Erbix
colon	fluorouracil	Adrucil, Efudex
colon	irinotecan	camptosar
colon	ramucirumab	Cyramza
endometrial	carboplatin	Paraplatin, Paraplat
endometrial	cisplatin	Platinol
endometrial	doxorubicin	Adriamycin
endometrial	megestrol acetate	Megace
endometrial	paclitaxel	Abraxane®, Taxol
gastric	docetaxel	Taxotere
gastric	doxorubicin	Adriamycin
gastric	fluorouracil	Adrucil, Efudex
gastric	ramucirumab	Cyramza
gastric	trastuzumab	Herceptin
kidney	axitinib	Inlyta
kidney	everolimus	Afinitor
kidney	pazopanib	Votrient
kidney	sorafenib tosylate	Nexavar
liver	sorafenib tosylate	Nexavar
melanoma	dacarbazine	DTIC, DTIC-Dome
melanoma	paclitaxel	Abraxane®, Taxol
melanoma	trametinib	Mekinist
melanoma	vemurafenib	Zelboraf
melanoma	dabrafenib	Tafinlar
mesothelioma	cisplatin	Platinol
mesothelioma	pemetrexed	Alimta
NHL	ABT-199	none
NHL	bendamustine	Treanda

Cancer Type	Drug name	Brand name
NHL	bortezomib	Velcade
NHL	brentuximab vedotin	Adcetris
NHL	chlorambucil	Ambochlorin, Leukeran, Linfovizin
NHL	cyclophosphamide	Clafen, Cytosan, Neosar
NHL	dexamethasone	Decadron, Dexasone
NHL	doxorubicin	Adriamycin
NHL	Ibrutinib	Imbruvica
NHL	lenalidomide	Revlimid
NHL	methotrexate	Abitrexate, Mexate, Folex
NHL	obinutuzumab	Gazyva
NHL	prednisone	Deltasone, Medicorten
NHL	romidepsin	Istodax
NHL	rituximab	Rituxan
NHL	vincristine	Vincasar
NSCLC	afatinib Dimaleate	Gilotrif
NSCLC	carboplatin	Paraplatin, Paraplat
NSCLC	cisplatin	Platinol
NSCLC	crizotinib	Xalkori
NSCLC	docetaxel	Taxotere
NSCLC	erlotinib	Tarceva
NSCLC	gemcitabine	Gemzar
NSCLC	methotrexate	Abitrexate, Mexate, Folex
NSCLC	paclitaxel	Abraxane®, Taxol
NSCLC	palbociclib	Ibrance
NSCLC	pemetrexed	Alimta
NSCLC	ramucirumab	Cyramza
ovarian	carboplatin	Paraplatin, Paraplat
ovarian	cisplatin	Platinol
ovarian	cyclophosphamide	Clafen, Cytosan, Neosar
ovarian	gemcitabine	Gemzar
ovarian	olaparib	Lynparza
ovarian	paclitaxel	Abraxane®, Taxol
ovarian	topotecan	Hycamtin
prostate	abiraterone	Zytiga

Cancer Type	Drug name	Brand name
prostate	cabazitaxel	Jevtana
prostate	docetaxel	Taxotere
prostate	enzalutamide	Xtandi
prostate	goserelin acetate	Zoladex
prostate	prednisone	Deltasone, Medicorten
soft tissue sarcoma	doxorubicin	Adriamycin
soft tissue sarcoma	imatinib mesylate	Gleevec
soft tissue sarcoma	pazopanib	Votrient
T-cell lymphoma	romidepsin	Istodax

Administration of Combination Treatment

[0368] A compound of the disclosure or a pharmaceutical composition comprising a compound of the disclosure and at least one additional pharmaceutically-active agent or a pharmaceutical composition comprising at least one additional pharmaceutically-active agent can be administered simultaneously (i.e., simultaneous administration) or sequentially (i.e., sequential administration).

[0369] In some embodiments, a compound of the disclosure and the at least one additional pharmaceutically-active agent, for example, any additional therapeutic agent described herein, are administered simultaneously, either in the same composition or in separate compositions. When the drugs are administered simultaneously, the compound and the at least one additional pharmaceutically-active agent, for example, any additional therapeutic agent described herein, may be contained in the same composition (*e.g.*, a composition comprising both the compound and the at least additional pharmaceutically-active agent) or in separate compositions (*e.g.*, the compound is contained in one composition and the at least additional pharmaceutically-active agent is contained in another composition).

[0370] In some embodiments, the compound and the at least one additional pharmaceutically-active agent, for example, any additional therapeutic agent described herein, are administered sequentially, *i.e.*, the compound is administered either prior to or after the administration of the additional pharmaceutically-active agent. In some embodiments, the compound is administered before the additional pharmaceutically-active agent, for example, any additional therapeutic agent described herein. In some embodiments, the pharmaceutically-active agent, for example, any additional therapeutic agent described herein, is administered before the compound. The compound and the additional pharmaceutically-active agent, for example, any additional therapeutic agent described herein, are contained in separate compositions, which may be contained in the same or different packages.

[0371] In some embodiments, the administration of the compounds and the additional pharmaceutically-active agent, for example, any additional therapeutic agent described herein, are concurrent, *i.e.*, the administration period of the compounds and that of the agent overlap with each other. In some embodiments, the administration of the compounds and the additional pharmaceutically-active agent, for example, any additional therapeutic agent described herein, are non-concurrent. For example, in some embodiments, the administration of the compound is terminated before the additional pharmaceutically-active agent, for example, any additional therapeutic agent described herein, is administered. In some embodiments, the administration of the additional pharmaceutically-active agent, for example, any additional therapeutic agent described herein, is terminated before the compound is administered. The time period between these two non-concurrent administrations can range from being days apart to being weeks apart.

[0372] The dosing frequency of the compound and the at least one additional pharmaceutically-active agent, for example, any additional therapeutic agent described herein, may be adjusted over the course of the treatment, based on the judgment of the administering physician. When administered separately, the compound and the at least one additional pharmaceutically-active agent, for example, any additional therapeutic agent described herein, can be administered at different dosing frequency or intervals. For example, the compound can be administered weekly, while the at least one additional pharmaceutically-active agent, for example, any additional therapeutic agent described herein, can be administered more or less frequently. Or, the compound can be administered twice weekly, while the at least one additional pharmaceutically-active agent, for example, any additional therapeutic agent described herein, can be administered more or less frequently. In addition, the compound and the at least one additional pharmaceutically-active agent, for example, any additional therapeutic agent described herein, can be administered using the same route of administration or using different routes of administration.

[0373] A therapeutically-effective amount of a compound and/or the additional pharmaceutically-active agent, for example, any additional therapeutic agent described herein, for use in therapy can vary with the nature of the condition being treated, the length of treatment time desired, the age and the condition of the patient, and can be determined by the attending physician.

[0374] In some embodiments, when a compound of the disclosure is administered in combination with at least one additional pharmaceutically-active agent, for example, any additional therapeutic agent described herein, the dosage of the compound can be given a lower dosage than when the compound is administered alone. In some embodiments, the dosage of a compound of the disclosure in combination therapy can be from about 5 mg/kg to about 1000 mg/kg; from about 50 mg/kg to about 600 mg/kg; from about 150 mg/kg to about 600 mg/kg; or from about 300 mg/kg to about 600 mg/kg. In some embodiments, the dosage of a compound of the disclosure in combination therapy can be from about 5 mg/kg to about 25 mg/kg; from about 25 mg/kg to about 50 mg/kg; from about 50 mg/kg to about 75 mg/kg; from about 75 mg/kg to about 100 mg/kg; from about 100 mg/kg to

about 125 mg/kg; from about 125 mg/kg to about 150 mg/kg; from about 150 mg/kg to about 200 mg/kg; from about 200 mg/kg to about 250 mg/kg; from about 250 mg/kg to about 300 mg/kg; from about 300 mg/kg to about 350 mg/kg; from about 350 mg/kg to about 400 mg/kg; from about 400 mg/kg to about 450 mg/kg; from about 450 mg/kg to about 500 mg/kg; from about 500 mg/kg to about 550 mg/kg; from about 550 mg/kg to about 600 mg/kg; from about 600 mg/kg to about 700 mg/kg; from about 700 mg/kg to about 800 mg/kg; from about 800 mg/kg to about 900 mg/kg; or from about 900 mg/kg to about 1000 mg/kg. In some embodiments, the dosage of a compound of the disclosure in combination therapy can be from about 50 mg/kg to about 75 mg/kg. In some embodiments, the dosage of a compound of the disclosure in combination therapy can be from about 75 mg/kg to about 150 mg/kg. In some embodiments, the dosage of a compound of the disclosure in combination therapy can be from about 150 mg/kg to about 300 mg/kg. In some embodiments, the dosage of a compound of the disclosure in combination therapy can be from about 300 mg/kg to about 600 mg/kg.

[0375] In some embodiments, the dosage of a compound of the disclosure in combination therapy can be in an amount of about 5 mg/kg; about 25 mg/kg; about 50 mg/kg; about 75 mg/kg; about 100 mg/kg; about 125 mg/kg; about 150 mg/kg; about 175 mg/kg; about 200 mg/kg; about 250 mg/kg; about 300 mg/kg; about 350 mg/kg; about 400 mg/kg; about 450 mg/kg; about 500 mg/kg; about 550 mg/kg; about 600 mg/kg; about 700 mg/kg; about 800 mg/kg; about 900 mg/kg; or about 1000 mg/kg. In some embodiments, the dosage of a compound of the disclosure in combination therapy can be in an amount of about 50 mg/kg. In some embodiments, the dosage of a compound of the disclosure in combination therapy can be in an amount of about 75 mg/kg. In some embodiments, the dosage of a compound of the disclosure in combination therapy can be in an amount of about 150 mg/kg. In some embodiments, the dosage of a compound of the disclosure in combination therapy can be in an amount of about 300 mg/kg. In some embodiments, the dosage of a compound of the disclosure in combination therapy can be in an amount of about 600 mg/kg.

[0376] In some embodiments, when a compound of the disclosure is administered in combination with at least one additional pharmaceutically-active agent, for example, any additional therapeutic agent described herein, the dosage of the at least one additional pharmaceutically-active agent can be given a lower dosage than when the compound is administered alone. In some embodiments, the dosage of the at least one additional pharmaceutically-active agent in combination therapy can be from about 50 µg to about 100 µg; from about 100 µg to about 150 µg; from about 150 µg to about 200 µg; from about 200 µg to about 250 µg; from about 250 µg to about 300 µg; from about 300 µg to about 350 µg; from about 350 µg to about 400 µg; from about 400 µg to about 450 µg; from about 450 µg to about 500 µg; from about 500 µg to about 600 µg; from about 600 µg to about 700 µg; from about 700 µg to about 800 µg; from about 800 µg to about 900 µg; or from about 900 µg to about 1000 µg. In some embodiments, the dosage of the at least one additional pharmaceutically-active agent in combination therapy can be from about 100 µg to about 150 µg. In some

embodiments, the dosage of the at least one additional pharmaceutically-active agent in combination therapy can be from about 150 µg to about 200 µg. In some embodiments, the dosage of the at least one additional pharmaceutically-active agent in combination therapy can be from about 200 µg to about 250 µg.

[0377] In some embodiments, the dosage of the at least one additional pharmaceutically-active agent in combination therapy can be in an amount of about 50 µg; about 100 µg; about 150 µg; about 200 µg; about 250 µg; about 300 µg; about 350 µg; about 400 µg; about 450 µg; or about 500 µg. In some embodiments, the dosage of the at least one additional pharmaceutically-active agent in combination therapy can be in an amount of about 200 µg.

[0378] In some embodiments, the dosage of the at least one additional pharmaceutically-active agent in combination therapy can be from about 1 mg/kg to about 5 mg/kg; from about 5 mg/kg to about 25 mg/kg; from about 25 mg/kg to about 50 mg/kg; from about 50 mg/kg to about 75 mg/kg; from about 75 mg/kg to about 100 mg/kg; from about 100 mg/kg to about 150 mg/kg; from about 150 mg/kg to about 200 mg/kg; from about 200 mg/kg to about 250 mg/kg; from about 250 mg/kg to about 300 mg/kg; from about 300 mg/kg to about 350 mg/kg; from about 350 mg/kg to about 400 mg/kg; from about 400 mg/kg to about 450 mg/kg; from about 450 mg/kg to about 500 mg/kg; from about 500 mg/kg to about 600 mg/kg; from about 600 mg/kg to about 700 mg/kg; from about 700 mg/kg to about 800 mg/kg; from about 800 mg/kg to about 900 mg/kg; or from about 900 mg/kg to about 1000 mg/kg. In some embodiments, the dosage of the at least one additional pharmaceutically-active agent in combination therapy can be from about 1 mg/kg to about 5 mg/kg. In some embodiments, the dosage of the at least one additional pharmaceutically-active agent in combination therapy can be from about 100 mg/kg to about 150 mg/kg. In some embodiments, the dosage of the at least one additional pharmaceutically-active agent in combination therapy can be from about 200 mg/kg to about 250 mg/kg.

[0379] In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be from about 50 mg/kg to about 600 mg/kg; and the dosage of the at least one additional pharmaceutically-active agent in combination therapy can be from about 1 mg/kg to about 500 mg/kg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be from about 50 mg/kg to about 150 mg/kg; and the dosage of the at least one additional pharmaceutically-active agent in combination therapy can be from about 1 mg/kg to about 250 mg/kg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be from about 150 mg/kg to about 600 mg/kg; and the dosage of the at least one additional pharmaceutically-active agent in combination therapy can be from about 1 mg/kg to about 500 mg/kg.

[0380] In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be about 50 mg/kg; and the dosage of the at least one additional pharmaceutically-active agent in combination therapy can about 5 mg/kg. In some embodiments, the

dosage of the compound of the disclosure administered in combination therapy can be about 75 mg/kg; and the dosage of the at least one additional pharmaceutically-active agent in combination therapy can about 5 mg/kg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be about 150 mg/kg; and the dosage of the at least one additional pharmaceutically-active agent in combination therapy can about 5 mg/kg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be about 300 mg/kg; and the dosage of the at least one additional pharmaceutically-active agent in combination therapy can about 5 mg/kg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be about 600 mg/kg; and the dosage of the at least one additional pharmaceutically-active agent in combination therapy can about 5 mg/kg.

[0381] In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be from about 50 mg/kg to about 600 mg/kg; and the dosage of the at least one additional pharmaceutically-active agent in combination therapy can be from about 100 µg to about 500 µg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be from about 50 mg/kg to about 150 mg/kg; and the dosage of the at least one additional pharmaceutically-active agent in combination therapy can be from about 100 µg to about 500 µg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be from about 150 mg/kg to about 300 mg/kg; and the dosage of the at least one additional pharmaceutically-active agent in combination therapy can be from about 100 µg to about 500 µg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be from about 300 mg/kg to about 600 mg/kg; and the dosage of the at least one additional pharmaceutically-active agent in combination therapy can be from about 100 µg to about 500 µg.

[0382] In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be about 50 mg/kg; and the dosage of the at least one additional pharmaceutically-active agent in combination therapy is about 200 µg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy is be about 75 mg/kg; and the dosage of the at least one additional pharmaceutically-active agent in combination therapy is about 200 µg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy is be about 150 mg/kg; and the dosage of the at least one additional pharmaceutically-active agent in combination therapy is about 200 µg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy is be about 300 mg/kg; and the dosage of the at least one additional pharmaceutically-active agent in combination therapy is about 200 µg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy is be about 600 mg/kg; and the dosage of the at least one additional pharmaceutically-active agent in combination therapy is about 200 µg.

[0383] In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be from about 50 mg/kg to about 600 mg/kg; and the dosage of anti-PD-1 as an additional pharmaceutically-active agent in combination therapy is about 200 µg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be from about 50 mg/kg to about 150 mg/kg; and the dosage of anti-PD-1 as an additional pharmaceutically-active agent in combination therapy is about 200 µg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be from about 150 mg/kg to about 300 mg/kg; and the dosage of anti-PD-1 as an additional pharmaceutically-active agent in combination therapy is about 200 µg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be from about 300 mg/kg to about 600 mg/kg; and the dosage of anti-PD-1 as an additional pharmaceutically-active agent in combination therapy is about 200 µg.

[0384] In some embodiments, the dosage of the compound of the disclosure administered in combination therapy is about 50 mg/kg; and the dosage of anti-PD-1 as an additional pharmaceutically-active agent in combination therapy is about 200 µg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy is about 75 mg/kg; and the dosage of anti-PD-1 as an additional pharmaceutically-active agent in combination therapy is about 200 µg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy is about 150 mg/kg; and the dosage of anti-PD-1 as an additional pharmaceutically-active agent in combination therapy is about 200 µg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy is about 300 mg/kg; and the dosage of anti-PD-1 as an additional pharmaceutically-active agent in combination therapy is about 200 µg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy is about 600 mg/kg; and the dosage of anti-PD-1 as an additional pharmaceutically-active agent in combination therapy is about 200 µg.

[0385] In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject 1, 2, 3, 4, or 5 times a day. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject once a day. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject twice a day. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject three times a day.

[0386] In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject 1, 2, 3, 4, or 5 times a day once every 1, 2, 3, 4, 5, 6, or 7 days. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject once a day once every 3 days. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a

subject twice a day once every 3 days. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject 1, 2, 3, 4, or 5 times a day once every 7 days. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject once a day once every 7 days. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject twice a day once every 7 days.

[0387] In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject 1, 2, 3, 4, or 5 times a day once every 1, 2, 3, 4, 5, 6, or 7 days for 1 to 50 doses. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject 1, 2, 3, 4, or 5 times a day once every 1, 2, 3, 4, 5, 6, or 7 days for about 5 doses. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject 1, 2, 3, 4, or 5 times a day once every 1, 2, 3, 4, 5, 6, or 7 days for about 10 doses. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject 1, 2, 3, 4, or 5 times a day once every 1, 2, 3, 4, 5, 6, or 7 days for about 15 doses. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject 1, 2, 3, 4, or 5 times a day once every 1, 2, 3, 4, 5, 6, or 7 days for about 20 doses. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject 1, 2, 3, 4, or 5 times a day once every 1, 2, 3, 4, 5, 6, or 7 days for about 25 doses. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject 1, 2, 3, 4, or 5 times a day once every 1, 2, 3, 4, 5, 6, or 7 days for about 30 doses. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject 1, 2, 3, 4, or 5 times a day once every 1, 2, 3, 4, 5, 6, or 7 days for about 35 doses.

[0388] In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject once a day every 7 days for about 5 doses. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject once a day every 7 days for about 10 doses. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject twice a day every 7 days for about 15 doses. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject once a day every 3 days for about 20 doses. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject once a day every 3 days for about 35 doses.

[0389] In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject twice a day every 7 days for about 5 doses. In some

embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject twice a day every 7 days for about 15 doses.

Pharmaceutical compositions for combination treatment

[0390] According to certain embodiments, the compounds and the additional pharmaceutically-active agent, for example, any additional therapeutic agent described herein, are administered within a single pharmaceutical composition. In some embodiments, the compounds of the disclosure and the additional pharmaceutically-active agent, for example, any additional therapeutic agent described herein, can be provided in a single unit dosage form for being taken together. According to some embodiments, the pharmaceutical composition further comprises pharmaceutically-acceptable diluents or carrier. According to certain embodiments, the compounds of the disclosure and the additional pharmaceutically-active agent, for example, any additional therapeutic agent described herein, are administered within different pharmaceutical composition. In some embodiments, the compounds of the disclosure and the additional pharmaceutically-active agent, for example, any additional therapeutic agent described herein, can be provided in a single unit dosage as separate entities (e.g., in separate containers) to be administered simultaneously or with a certain time difference.

[0391] In some embodiments, the compounds of the disclosure and the additional pharmaceutically-active agent, for example, any additional therapeutic agent described herein, can be administered via the same route of administration. In some embodiments, the compounds of the disclosure and the additional pharmaceutically-active agent, for example, any additional therapeutic agent described herein, can be administered via the different route of administration. In some embodiments, a compound of the disclosure and the additional pharmaceutically-active agent are administered orally. In some embodiments, a compound of the disclosure is administered orally, and the additional pharmaceutically-acceptable agent is not administered orally. In some embodiments, a compound of the disclosure is not administered orally, and the additional pharmaceutically-acceptable agent is administered orally.

[0392] Treatment of a condition by administering a compound of the disclosure in combination with an additional anti-cancer agent can increase a median survival time of a subject compared to subjects who do not receive combination therapy with a compound of the disclosure and the additional anti-cancer agent. In some embodiments, a median survival time of a first patient population receiving combination therapy with a compound of the disclosure and an additional anti-cancer agent can be greater than a median survival time of a second patient population that does not receive any cancer therapy. In some embodiments, a median survival time of a first patient population receiving combination therapy with a compound of the disclosure and an additional anti-cancer agent can be greater than a median survival time of a second patient population that receives therapy with a compound of the disclosure alone. In some embodiments, a median survival time of a first patient population receiving combination therapy with a compound of the disclosure and an additional anti-

cancer agent can be greater than a median survival time of a second patient population that receives therapy with the additional anti-cancer agent alone.

[0393] In some embodiments, a median survival time of a first patient population receiving combination therapy with a compound of the disclosure and an additional anti-cancer agent can be greater than a median survival time of a second patient population not receiving combination therapy by at least about 50%, about 60%, about 70%, about 80%, about 90%, about 100%, about 110%, about 120%, about 130%, about 140%, about 150%, about 160%, about 170%, about 180%, about 190%, about 200%, about 210%, about 220%, about 230%, about 240%, about 250%, about 260%, about 270%, about 280%, about 290%, about 300%, about 310%, about 320%, about 330%, about 340%, about 350%, about 360%, about 370%, about 380%, about 390%, about 400%, about 410%, about 420%, about 430%, about 440%, about 450%, about 460%, about 470%, about 480%, about 490%, or about 500%. In some embodiments, a median survival time of a first patient population receiving combination therapy with a compound of the disclosure and an additional anti-cancer agent can be greater than a median survival time of a second patient population not receiving combination therapy by at least about 50%. In some embodiments, a median survival time of a first patient population receiving combination therapy with a compound of the disclosure and an additional anti-cancer agent can be greater than a median survival time of a second patient population not receiving combination therapy by at least about 100%. In some embodiments, a median survival time of a first patient population receiving combination therapy with a compound of the disclosure and an additional anti-cancer agent can be greater than a median survival time of a second patient population not receiving combination therapy by at least about 150%. In some embodiments, a median survival time of a first patient population receiving combination therapy with a compound of the disclosure and an additional anti-cancer agent can be greater than a median survival time of a second patient population not receiving combination therapy by at least about 200%.

Methods of treatment

[0394] Provided herein is a method of treating cancer in a subject in need thereof, the method comprising: (i) administering to the subject a therapeutically-effective amount of a compound, wherein the compound binds to a mutant p53 protein and reconfirms the mutant p53 protein to a conformation of p53 that exhibits anti-cancer activity; and (ii) administering to the subject a therapeutically-effective amount of an anti-cancer agent that functions through a pathway other than p53-induced apoptosis.

[0395] Also provided herein is a method of treating cancer in a subject in need thereof, the method comprising: (i) administering to the subject a therapeutically-effective amount of a compound that increases anti-cancer activity of a mutant p53 protein in the subject; and (ii) administering to the subject a therapeutically-effective amount of an anti-cancer agent that functions through a pathway other than p53-induced apoptosis.

[0396] In some embodiments, the compound binds to the mutant p53 protein and reconfirms the

mutant p53 protein to a conformation of p53 that exhibits anti-cancer activity.

[0397] Further provided herein is a method of treating cancer, the method comprising: (i) administering to a subject in need thereof a therapeutically-effective amount of a compound that binds to a mutant p53 protein and reconfirms the mutant p53 protein to a conformation of p53 that exhibits anti-cancer activity; and (ii) administering to the subject a therapeutically-effective amount of an additional anti-cancer agent that functions through a pathway other than p53-induced apoptosis, wherein if in a controlled study of treatment of the cancer in a first patient population and a second patient population: (a) a first median survival time of the first patient population is determined, wherein the first patient population is treated with the therapeutically-effective amount of the compound that binds to a mutant p53 protein and reconfirms the mutant p53 protein to a conformation of p53 that exhibits anti-cancer activity; and (b) a second median survival time of the second patient population is determined, wherein the second patient population is treated with the therapeutically-effective amount of the compound that binds to a mutant p53 protein and reconfirms the mutant p53 protein to a conformation of p53 that exhibits anti-cancer activity and the therapeutically-effective amount of the additional therapeutic agent; then the second median survival time is at least about 50% greater than is the first median survival time.

[0398] In some embodiments, the second median survival time is at least about 100% greater than the first median survival time. In some embodiments, the second median survival time is at least about 200% greater than the first median survival time.

[0399] In some embodiments, the compound increases a stability of the mutant p53 protein. In some embodiments, the cancer expresses a mutant p53 protein. In some embodiments, the mutant p53 protein has a mutation at amino acid 220. In some embodiments, the mutant p53 protein is p53 Y220C. In some embodiments, the compound selectively binds the mutant p53 protein as compared to a wild type p53. In some embodiments, the cancer is ovarian cancer. In some embodiments, the cancer is breast cancer. In some embodiments, the cancer is lung cancer. In some embodiments, the subject is human.

[0400] In some embodiments, the administering of the compound is oral. In some embodiments, the administering of the compound is subcutaneous. In some embodiments, the administering of the compound is topical. In some embodiments, the therapeutically-effective amount of the compound is from about 1 mg/kg to about 500 mg/kg. In some embodiments, the therapeutically-effective amount of the compound is from about 100 mg to about 5000 mg. In some embodiments, the therapeutically-effective amount of the compound is from about 500 mg to about 2000 mg. In some embodiments, the therapeutically-effective amount of the compound is about 250 mg, about 500 mg, about 750 mg, about 1000 mg, about 1250 mg, about 1500 mg, about 1750 mg, about 2000 mg, about 2250 mg, or about 2500 mg. In some embodiments, the therapeutically-effective amount of the compound is about 150 mg. In some embodiments, the therapeutically-effective amount of the compound is about 300 mg. In some embodiments, the therapeutically-effective amount of the compound is about 500 mg. In

some embodiments, the therapeutically-effective amount of the compound is about 600 mg. In some embodiments, the therapeutically-effective amount of the compound is about 1200 mg. In some embodiments, the therapeutically-effective amount of the compound is about 1500 mg. In some embodiments, the therapeutically-effective amount of the compound is about 2000 mg.

[0401] In some embodiments, the anti-cancer agent is a small molecule. In some embodiments, the anti-cancer agent is an antibody. In some embodiments, the anti-cancer agent is an immune checkpoint inhibitor. In some embodiments, the immune checkpoint inhibitor is an anti-PD-1 agent. In some embodiments, the anti-PD-1 agent is nivolumab. In some embodiments, the anti-PD-1 agent is pembrolizumab. In some embodiments, the anti-PD-1 agent is cemiplimab. In some embodiments, the immune checkpoint inhibitor is an anti-PD-L1 agent. In some embodiments, the anti-PD-L1 agent is atezolizumab. In some embodiments, the anti-PD-L1 agent is avelumab. In some embodiments, the anti-PD-L1 agent is durvalumab. In some embodiments, the administering of the anti-cancer agent is oral. In some embodiments, the administering of the anti-cancer agent is subcutaneous. In some embodiments, the administering of the anti-cancer agent is topical. In some embodiments, the therapeutically-effective amount of the anti-cancer agent is from about 5 mg/kg to about 500 mg/kg. In some embodiments, the therapeutically-effective amount of the anti-cancer agent is from about 10 µg to about 500 µg. In some embodiments, the therapeutically-effective amount of the anti-cancer agent is about 200 µg.

[0402] Pharmacokinetic and pharmacodynamic data can be obtained by various experimental techniques. Appropriate pharmacokinetic and pharmacodynamic profile components describing a particular composition can vary due to variations in drug metabolism in human subjects. Pharmacokinetic and pharmacodynamic profiles can be based on the determination of the mean parameters of a group of subjects. The group of subjects includes any reasonable number of subjects suitable for determining a representative mean, for example, 5 subjects, 10 subjects, 15 subjects, 20 subjects, 25 subjects, 30 subjects, 35 subjects, or more. The mean is determined, for example, by calculating the average of all subject's measurements for each parameter measured. A dose can be modulated to achieve a desired pharmacokinetic or pharmacodynamics profile, such as a desired or effective blood profile, as described herein.

[0403] The pharmacodynamic parameters can be any parameters suitable for describing compositions of the invention. For example, the pharmacodynamic profile can be obtained at a time after dosing of, for example, about zero minutes, about 1 minute, about 2 minutes, about 3 minutes, about 4 minutes, about 5 minutes, about 6 minutes, about 7 minutes, about 8 minutes, about 9 minutes, about 10 minutes, about 11 minutes, about 12 minutes, about 13 minutes, about 14 minutes, about 15 minutes, about 16 minutes, about 17 minutes, about 18 minutes, about 19 minutes, about 20 minutes, about 21 minutes, about 22 minutes, about 23 minutes, about 24 minutes, about 25 minutes, about 26 minutes, about 27 minutes, about 28 minutes, about 29 minutes, about 30 minutes, about 31 minutes, about 32 minutes, about 33 minutes, about 34 minutes, about 35 minutes, about 36 minutes,

about 37 minutes, about 38 minutes, about 39 minutes, about 40 minutes, about 41 minutes, about 42 minutes, about 43 minutes, about 44 minutes, about 45 minutes, about 46 minutes, about 47 minutes, about 48 minutes, about 49 minutes, about 50 minutes, about 51 minutes, about 52 minutes, about 53 minutes, about 54 minutes, about 55 minutes, about 56 minutes, about 57 minutes, about 58 minutes, about 59 minutes, about 60 minutes, about zero hours, about 0.5 hours, about 1 hour, about 1.5 hours, about 2 hours, about 2.5 hours, about 3 hours, about 3.5 hours, about 4 hours, about 4.5 hours, about 5 hours, about 5.5 hours, about 6 hours, about 6.5 hours, about 7 hours, about 7.5 hours, about 8 hours, about 8.5 hours, about 9 hours, about 9.5 hours, about 10 hours, about 10.5 hours, about 11 hours, about 11.5 hours, about 12 hours, about 12.5 hours, about 13 hours, about 13.5 hours, about 14 hours, about 14.5 hours, about 15 hours, about 15.5 hours, about 16 hours, about 16.5 hours, about 17 hours, about 17.5 hours, about 18 hours, about 18.5 hours, about 19 hours, about 19.5 hours, about 20 hours, about 20.5 hours, about 21 hours, about 21.5 hours, about 22 hours, about 22.5 hours, about 23 hours, about 23.5 hours, or about 24 hours.

[0404] The pharmacokinetic parameters can be any parameters suitable for describing a compound. The $C_{\max}$ can be, for example, not less than about 1 ng/mL; not less than about 5 ng/mL; not less than about 10 ng/mL; not less than about 15 ng/mL; not less than about 20 ng/mL; not less than about 25 ng/mL; not less than about 50 ng/mL; not less than about 75 ng/mL; not less than about 100 ng/mL; not less than about 200 ng/mL; not less than about 300 ng/mL; not less than about 400 ng/mL; not less than about 500 ng/mL; not less than about 600 ng/mL; not less than about 700 ng/mL; not less than about 800 ng/mL; not less than about 900 ng/mL; not less than about 1000 ng/mL; not less than about 1250 ng/mL; not less than about 1500 ng/mL; not less than about 1750 ng/mL; not less than about 2000 ng/mL; or any other $C_{\max}$ appropriate for describing a pharmacokinetic profile of a compound described herein. The $C_{\max}$ can be, for example, about 1 ng/mL to about 5,000 ng/mL; about 1 ng/mL to about 4,500 ng/mL; about 1 ng/mL to about 4,000 ng/mL; about 1 ng/mL to about 3,500 ng/mL; about 1 ng/mL to about 3,000 ng/mL; about 1 ng/mL to about 2,500 ng/mL; about 1 ng/mL to about 2,000 ng/mL; about 1 ng/mL to about 1,500 ng/mL; about 1 ng/mL to about 1,000 ng/mL; about 1 ng/mL to about 900 ng/mL; about 1 ng/mL to about 800 ng/mL; about 1 ng/mL to about 700 ng/mL; about 1 ng/mL to about 600 ng/mL; about 1 ng/mL to about 500 ng/mL; about 1 ng/mL to about 450 ng/mL; about 1 ng/mL to about 400 ng/mL; about 1 ng/mL to about 350 ng/mL; about 1 ng/mL to about 300 ng/mL; about 1 ng/mL to about 250 ng/mL; about 1 ng/mL to about 200 ng/mL; about 1 ng/mL to about 150 ng/mL; about 1 ng/mL to about 125 ng/mL; about 1 ng/mL to about 100 ng/mL; about 1 ng/mL to about 90 ng/mL; about 1 ng/mL to about 80 ng/mL; about 1 ng/mL to about 70 ng/mL; about 1 ng/mL to about 60 ng/mL; about 1 ng/mL to about 50 ng/mL; about 1 ng/mL to about 40 ng/mL; about 1 ng/mL to about 30 ng/mL; about 1 ng/mL to about 20 ng/mL; about 1 ng/mL to about 10 ng/mL; about 1 ng/mL to about 5 ng/mL; about 10 ng/mL to about 4,000 ng/mL; about 10 ng/mL to about 3,000 ng/mL; about 10 ng/mL to about 2,000 ng/mL; about 10 ng/mL to about 1,500 ng/mL; about 10 ng/mL to about 1,000 ng/mL; about 10 ng/mL to about

900 ng/mL; about 10 ng/mL to about 800 ng/mL; about 10 ng/mL to about 700 ng/mL; about 10 ng/mL to about 600 ng/mL; about 10 ng/mL to about 500 ng/mL; about 10 ng/mL to about 400 ng/mL; about 10 ng/mL to about 300 ng/mL; about 10 ng/mL to about 200 ng/mL; about 10 ng/mL to about 100 ng/mL; about 10 ng/mL to about 50 ng/mL; about 25 ng/mL to about 500 ng/mL; about 25 ng/mL to about 100 ng/mL; about 50 ng/mL to about 500 ng/mL; about 50 ng/mL to about 100 ng/mL; about 100 ng/mL to about 500 ng/mL; about 100 ng/mL to about 400 ng/mL; about 100 ng/mL to about 300 ng/mL; or about 100 ng/mL to about 200 ng/mL.

[0405] The $T_{\max}$ of a compound described herein can be, for example, not greater than about 0.5 hours, not greater than about 1 hours, not greater than about 1.5 hours, not greater than about 2 hours, not greater than about 2.5 hours, not greater than about 3 hours, not greater than about 3.5 hours, not greater than about 4 hours, not greater than about 4.5 hours, not greater than about 5 hours, or any other $T_{\max}$ appropriate for describing a pharmacokinetic profile of a compound described herein. The $T_{\max}$ can be, for example, about 0.1 hours to about 24 hours; about 0.1 hours to about 0.5 hours; about 0.5 hours to about 1 hour; about 1 hour to about 1.5 hours; about 1.5 hours to about 2 hour; about 2 hours to about 2.5 hours; about 2.5 hours to about 3 hours; about 3 hours to about 3.5 hours; about 3.5 hours to about 4 hours; about 4 hours to about 4.5 hours; about 4.5 hours to about 5 hours; about 5 hours to about 5.5 hours; about 5.5 hours to about 6 hours; about 6 hours to about 6.5 hours; about 6.5 hours to about 7 hours; about 7 hours to about 7.5 hours; about 7.5 hours to about 8 hours; about 8 hours to about 8.5 hours; about 8.5 hours to about 9 hours; about 9 hours to about 9.5 hours; about 9.5 hours to about 10 hours; about 10 hours to about 10.5 hours; about 10.5 hours to about 11 hours; about 11 hours to about 11.5 hours; about 11.5 hours to about 12 hours; about 12 hours to about 12.5 hours; about 12.5 hours to about 13 hours; about 13 hours to about 13.5 hours; about 13.5 hours to about 14 hours; about 14 hours to about 14.5 hours; about 14.5 hours to about 15 hours; about 15 hours to about 15.5 hours; about 15.5 hours to about 16 hours; about 16 hours to about 16.5 hours; about 16.5 hours to about 17 hours; about 17 hours to about 17.5 hours; about 17.5 hours to about 18 hours; about 18 hours to about 18.5 hours; about 18.5 hours to about 19 hours; about 19 hours to about 19.5 hours; about 19.5 hours to about 20 hours; about 20 hours to about 20.5 hours; about 20.5 hours to about 21 hours; about 21 hours to about 21.5 hours; about 21.5 hours to about 22 hours; about 22 hours to about 22.5 hours; about 22.5 hours to about 23 hours; about 23 hours to about 23.5 hours; or about 23.5 hours to about 24 hours. In some embodiments, the $T_{\max}$ of a compound of the disclosure is about 2 hours. In some embodiments, the $T_{\max}$ of a compound of the disclosure is about 4 hours. In some embodiments, the $T_{\max}$ of a compound of the disclosure is about 6 hours. In some embodiments, the $T_{\max}$ of a compound of the disclosure is about 8 hours.

[0406] The $AUC_{(0-\infty)}$ or $AUC_{(last)}$ of a compound described herein can be, for example, not less than about 1 ng•hr/mL, not less than about 5 ng•hr/mL, not less than about 10 ng•hr/mL, not less than about 20 ng•hr/mL, not less than about 30 ng•hr/mL, not less than about 40 ng•hr/mL, not less than about 50 ng•hr/mL, not less than about 100 ng•hr/mL, not less than about 150 ng•hr/mL, not less than

about 200 ng•hr/mL, not less than about 250 ng•hr/mL, not less than about 300 ng•hr/mL, not less than about 350 ng•hr/mL, not less than about 400 ng•hr/mL, not less than about 450 ng•hr/mL, not less than about 500 ng•hr/mL, not less than about 600 ng•hr/mL, not less than about 700 ng•hr/mL, not less than about 800 ng•hr/mL, not less than about 900 ng•hr/mL, not less than about 1000 ng•hr/mL, not less than about 1250 ng•hr/mL, not less than about 1500 ng•hr/mL, not less than about 1750 ng•hr/mL, not less than about 2000 ng•hr/mL, not less than about 2500 ng•hr/mL, not less than about 3000 ng•hr/mL, not less than about 3500 ng•hr/mL, not less than about 4000 ng•hr/mL, not less than about 5000 ng•hr/mL, not less than about 6000 ng•hr/mL, not less than about 7000 ng•hr/mL, not less than about 8000 ng•hr/mL, not less than about 9000 ng•hr/mL, not less than about 10,000 ng•hr/mL, or any other $AUC_{(0-inf)}$ or $AUC_{(last)}$ appropriate for describing a pharmacokinetic profile of a compound described herein. In some embodiments, the $AUC_{(0-inf)}$ or $AUC_{(last)}$ of a compound described herein can be, for example, not less than about 10,000 ng•hr/mL, not less than about 11,000 ng•hr/mL, not less than about 12,000 ng•hr/mL, not less than about 13,000 ng•hr/mL, not less than about 14,000 ng•hr/mL, not less than about 15,000 ng•hr/mL, not less than about 16,000 ng•hr/mL, not less than about 17,000 ng•hr/mL, not less than about 18,000 ng•hr/mL, not less than about 19,000 ng•hr/mL, not less than about 20,000 ng•hr/mL, not less than about 21,000 ng•hr/mL, not less than about 22,000 ng•hr/mL, not less than about 23,000 ng•hr/mL, not less than about 24,000 ng•hr/mL, or not less than about 25,000 ng•hr/mL.

[0407] The $AUC_{(0-inf)}$ or $AUC_{(last)}$ of a compound can be, for example, about 1 ng•hr/mL to about 10,000 ng•hr/mL; about 1 ng•hr/mL to about 10 ng•hr/mL; about 10 ng•hr/mL to about 25 ng•hr/mL; about 25 ng•hr/mL to about 50 ng•hr/mL; about 50 ng•hr/mL to about 100 ng•hr/mL; about 100 ng•hr/mL to about 200 ng•hr/mL; about 200 ng•hr/mL to about 300 ng•hr/mL; about 300 ng•hr/mL to about 400 ng•hr/mL; about 400 ng•hr/mL to about 500 ng•hr/mL; about 500 ng•hr/mL to about 600 ng•hr/mL; about 600 ng•hr/mL to about 700 ng•hr/mL; about 700 ng•hr/mL to about 800 ng•hr/mL; about 800 ng•hr/mL to about 900 ng•hr/mL; about 900 ng•hr/mL to about 1,000 ng•hr/mL; about 1,000 ng•hr/mL to about 1,250 ng•hr/mL; about 1,250 ng•hr/mL to about 1,500 ng•hr/mL; about 1,500 ng•hr/mL to about 1,750 ng•hr/mL; about 1,750 ng•hr/mL to about 2,000 ng•hr/mL; about 2,000 ng•hr/mL to about 2,500 ng•hr/mL; about 2,500 ng•hr/mL to about 3,000 ng•hr/mL; about 3,000 ng•hr/mL to about 3,500 ng•hr/mL; about 3,500 ng•hr/mL to about 4,000 ng•hr/mL; about 4,000 ng•hr/mL to about 4,500 ng•hr/mL; about 4,500 ng•hr/mL to about 5,000 ng•hr/mL; about 5,000 ng•hr/mL to about 5,500 ng•hr/mL; about 5,500 ng•hr/mL to about 6,000 ng•hr/mL; about 6,000 ng•hr/mL to about 6,500 ng•hr/mL; about 6,500 ng•hr/mL to about 7,000 ng•hr/mL; about 7,000 ng•hr/mL to about 7,500 ng•hr/mL; about 7,500 ng•hr/mL to about 8,000 ng•hr/mL; about 8,000 ng•hr/mL to about 8,500 ng•hr/mL; about 8,500 ng•hr/mL to about 9,000 ng•hr/mL; about 9,000 ng•hr/mL to about 9,500 ng•hr/mL; or about 9,500 ng•hr/mL to about 10,000 ng•hr/mL. In some embodiments, the $AUC_{(0-inf)}$ or $AUC_{(last)}$ of a compound described herein can be, for example, about 10,000 ng•hr/mL, about 11,000 ng•hr/mL, about 12,000 ng•hr/mL, about 13,000 ng•hr/mL,

about 14,000 ng•hr/mL, about 15,000 ng•hr/mL, about 16,000 ng•hr/mL, about 17,000 ng•hr/mL, about 18,000 ng•hr/mL, about 19,000 ng•hr/mL, about 20,000 ng•hr/mL, about 21,000 ng•hr/mL, about 22,000 ng•hr/mL, about 23,000 ng•hr/mL, about 24,000 ng•hr/mL, or about 25,000 ng•hr/mL.

[0408] The plasma concentration of a compound described herein can be, for example, not less than about 1 ng/mL, not less than about 5 ng/mL, not less than about 10 ng/mL, not less than about 15 ng/mL, not less than about 20 ng/mL, not less than about 25 ng/mL, not less than about 50 ng/mL, not less than about 75 ng/mL, not less than about 100 ng/mL, not less than about 150 ng/mL, not less than about 200 ng/mL, not less than about 300 ng/mL, not less than about 400 ng/mL, not less than about 500 ng/mL, not less than about 600 ng/mL, not less than about 700 ng/mL, not less than about 800 ng/mL, not less than about 900 ng/mL, not less than about 1000 ng/mL, not less than about 1200 ng/mL, or any other plasma concentration of a compound described herein. The plasma concentration can be, for example, about 1 ng/mL to about 2,000 ng/mL; about 1 ng/mL to about 5 ng/mL; about 5 ng/mL to about 10 ng/mL; about 10 ng/mL to about 25 ng/mL; about 25 ng/mL to about 50 ng/mL; about 50 ng/mL to about 75 ng/mL; about 75 ng/mL to about 100 ng/mL; about 100 ng/mL to about 150 ng/mL; about 150 ng/mL to about 200 ng/mL; about 200 ng/mL to about 250 ng/mL; about 250 ng/mL to about 300 ng/mL; about 300 ng/mL to about 350 ng/mL; about 350 ng/mL to about 400 ng/mL; about 400 ng/mL to about 450 ng/mL; about 450 ng/mL to about 500 ng/mL; about 500 ng/mL to about 600 ng/mL; about 600 ng/mL to about 700 ng/mL; about 700 ng/mL to about 800 ng/mL; about 800 ng/mL to about 900 ng/mL; about 900 ng/mL to about 1,000 ng/mL; about 1,000 ng/mL to about 1,100 ng/mL; about 1,100 ng/mL to about 1,200 ng/mL; about 1,200 ng/mL to about 1,300 ng/mL; about 1,300 ng/mL to about 1,400 ng/mL; about 1,400 ng/mL to about 1,500 ng/mL; about 1,500 ng/mL to about 1,600 ng/mL; about 1,600 ng/mL to about 1,700 ng/mL; about 1,700 ng/mL to about 1,800 ng/mL; about 1,800 ng/mL to about 1,900 ng/mL; or about 1,900 ng/mL to about 2,000 ng/mL.

[0409] In some embodiments, the plasma concentration can be about 2,500 ng/mL, about 3,000 ng/mL, about 3,500 ng/mL, about 4,000 ng/mL, about 4,500 ng/mL, about 5,000 ng/mL, about 5,500 ng/mL, about 6,000 ng/mL, about 6,500 ng/mL, about 7,000 ng/mL, about 7,500 ng/mL, about 8,000 ng/mL, about 8,500 ng/mL, about 9,000 ng/mL, about 9,500 ng/mL, or about 10,000 ng/mL. In some embodiments, the plasma concentration can be about 10,000 ng/mL, about 15,000 ng/mL, about 20,000 ng/mL, about 25,000 ng/mL, about 30,000 ng/mL, about 35,000 ng/mL, about 40,000 ng/mL, about 45,000 ng/mL, about 50,000 ng/mL, about 55,000 ng/mL, about 60,000 ng/mL, about 65,000 ng/mL, about 70,000 ng/mL, or about 75,000 ng/mL.

[0410] The pharmacodynamic parameters can be any parameters suitable for describing compositions of the disclosure. For example, the pharmacodynamic profile can exhibit decreases in viability phenotype for the tumor cells or tumor size reduction in tumor cell lines or xenograft studies, for example, about 24 hours, about 48 hours, about 72 hours, or 1 week.

EXAMPLES

EXAMPLE 1: *Compounds of the disclosure*

[0411] Indole compounds with alkynyl, aryl, and heteroaryl linkers were prepared. Alkynyl-linked indole compounds are shown in **TABLE 1**. Aryl-linked indole compounds are shown in **TABLE 2**. Heteroaryl-linked indole compounds are shown in **TABLE 3**.

TABLE 1. Alkynyl indole compounds of the disclosure.

Mol #	IUPAC name
1.	1-Anilino-3-{1-ethyl-5-[(1-methyl-4-piperidylamino)methyl]-1H-indol-2-yl}-2-propyne
2.	1-Anilino-3-{1-ethyl-5-[(methylamino)methyl]-1H-indol-2-yl}-2-propyne
3.	1-Anilino-3-{1-ethyl-5-[(tetrahydro-2H-pyran-4-ylamino)methyl]-1H-indol-2-yl}-2-propyne
4.	1-Anilino-3-[5-(benzylaminomethyl)-1-ethyl-1H-indol-2-yl]-2-propyne
5.	3-{1-Ethyl-5-[(methylamino)methyl]-1H-indol-2-yl}-1-(p-fluorophenylamino)-2-propyne
6.	3-{1-Ethyl-5-[(tetrahydro-2H-pyran-4-ylmino)methyl]-1H-indol-2-yl}-1-(p-fluorophenylamino)-2-propyne
7.	1-(p-Chlorophenylamino)-3-{1-ethyl-5-[(1-methyl-4-piperidylamino)methyl]-1H-indol-2-yl}-2-propyne
8.	3-{1-Ethyl-5-[(tetrahydro-2H-pyran-4-ylamino)methyl]-1H-indol-2-yl}-1-(6-methyl-3-pyridylamino)-2-propyne
9.	3-{1-Ethyl-5-[(methylamino)methyl]-1H-indol-2-yl}-1-(6-methyl-3-pyridylamino)-2-propyne
10.	3-{1-Ethyl-5-[(1-methyl-4-piperidylamino)methyl]-1H-indol-2-yl}-1-(2-methyl-4-pyridylamino)-2-propyne
11.	3-[5-(Benzylaminomethyl)-1-ethyl-1H-indol-2-yl]-1-(2-methyl-4-pyridylamino)-2-propyne
12.	N-(3-{5-[(Diethylamino)methyl]-1-ethyl-1H-indol-2-yl}prop-2-yn-1-yl)aniline
13.	4-Chloro-N-(3-{5-[(diethylamino)methyl]-1-ethyl-1H-indol-2-yl}prop-2-yn-1-yl)aniline
14.	N-({1-Ethyl-2-[3-(phenylamino)prop-1-yn-1-yl]-1H-indol-5-yl}methyl)oxetan-3-amine
15.	N-[3-(1-Ethyl-5-[(2-methylpropyl)amino]methyl)-1H-indol-2-yl]prop-2-yn-1-yl]aniline
16.	N-[3-(1-Ethyl-5-[(2-methoxyethyl)amino]methyl)-1H-indol-2-yl]prop-2-yn-1-yl]aniline
17.	N-({1-ethyl-2-[3-(phenylamino)prop-1-yn-1-yl]-1H-indol-5-yl}methyl)-1-methanesulfonylpiperidin-4-amine

Mol #	IUPAC name
18.	N-(3-{1-Ethyl-5-[(ethylamino)methyl]-1H-indol-2-yl}prop-2-yn-1-yl)aniline
19.	N-{3-[5-({2-(Dimethylamino)ethyl}amino)methyl]-1-ethyl-1H-indol-2-yl}prop-2-yn-1-yl}aniline
20.	6- <i>tert</i> -Butyl-N-[3-(1-ethyl-5-[(1-methylpiperidin-4-yl)amino]methyl)-1H-indol-2-yl]prop-2-yn-1-yl]pyridin-3-amine
21.	N-[(2-{3-[(4-Chlorophenyl)amino]prop-1-yn-1-yl}-1-ethyl-1H-indol-5-yl)methyl]oxan-4-amine
22.	6- <i>tert</i> -Butyl-N-(3-{1-ethyl-5-[(methylamino)methyl]-1H-indol-2-yl}prop-2-yn-1-yl)pyridin-3-amine
23.	4-[(3-{1-Ethyl-5-[(methylamino)methyl]-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzonitrile
24.	4- <i>tert</i> -Butyl-N-(3-{1-ethyl-5-[(methylamino)methyl]-1H-indol-2-yl}prop-2-yn-1-yl)benzamide
25.	4-Chloro-N-(3-{1-ethyl-5-[(methylamino)methyl]-1H-indol-2-yl}prop-2-yn-1-yl)-3-fluorobenzamide
26.	4-Cyano-N-({1-ethyl-2-[3-(phenylformamido)prop-1-yn-1-yl]-1H-indol-5-yl}methyl)-N-methylbenzamide
27.	3-(3-{1-Ethyl-5-[(methylamino)methyl]-1H-indol-2-yl}prop-2-yn-1-yl)-1-[4-(trifluoromethyl)phenyl]urea
28.	N-{[1-(2-Chloroethyl)-2-{3-[(4-chlorophenyl)amino]prop-1-yn-1-yl}-1H-indol-5-yl]methyl}oxan-4-amine
29.	2-(4-{[3-(1-Ethyl-5-[(1-methylpiperidin-4-yl)amino]methyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)phenyl)-2-methylpropanenitrile
30.	4-Cyano-N-(3-{1-ethyl-5-[(methylamino)methyl]-1H-indol-2-yl}prop-2-yn-1-yl)benzamide
31.	N-(3-{1-Ethyl-5-[(methylamino)methyl]-1H-indol-2-yl}prop-2-yn-1-yl)-6-methylpyridine-3-carboxamide
32.	3-[3-(1-Ethyl-5-[(1-methylpiperidin-4-yl)amino]methyl)-1H-indol-2-yl]prop-2-yn-1-yl]-1-phenylurea
33.	N-[(2-{3-[(4-Chloro-3-fluorophenyl)amino]prop-1-yn-1-yl}-1-ethyl-1H-indol-5-yl)methyl]-1-methylpiperidin-4-amine

Mol #	IUPAC name
34.	2-(5-{[3-(1-Ethyl-5-{[(1-methylpiperidin-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
35.	N-{[1-(2-Chloroethyl)-2-{3-[(4-chlorophenyl)amino]prop-1-yn-1-yl}-1H-indol-5-yl]methyl}-1-methylpiperidin-4-amine
36.	6- <i>tert</i> -Butyl-N-[3-(1-ethyl-5-{[(1-methanesulfonylpiperidin-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]pyridin-3-amine
37.	2-(4-{[3-(1-Ethyl-5-{[(1-methylpiperidin-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenyl)-2-methylpropanoic acid
38.	3-(1-Ethyl-5-{[(1-methylpiperidin-4-yl)amino]methyl}-1H-indol-2-yl)-N-methylprop-2-ynamide
39.	Ethyl 2-(4-{[3-(1-ethyl-5-{[(1-methylpiperidin-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenyl)-2-methylpropanoate
40.	2-(5-{[3-(1-Ethyl-5-{[(oxan-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
41.	N-[(1-Ethyl-2-{3-[(4-methylphenyl)amino]prop-1-yn-1-yl}-1H-indol-5-yl)methyl]-1-methylpiperidin-4-amine
42.	4-{[3-(1-Ethyl-5-{[(1-methylpiperidin-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzonitrile
43.	3-(1-Ethyl-5-{[(1-methylpiperidin-4-yl)amino]methyl}-1H-indol-2-yl)-N-phenylprop-2-ynamide
44.	N-[(2-{3-[(4-Chlorophenyl)amino]prop-1-yn-1-yl}-1-ethyl-1H-indol-5-yl)methyl]-1-methanesulfonylpiperidin-4-amine
45.	1-(4-{[(2-{3-[(4-Chlorophenyl)amino]prop-1-yn-1-yl}-1-ethyl-1H-indol-5-yl)methyl]amino}piperidin-1-yl)ethan-1-one
46.	6- <i>tert</i> -Butyl-N-[3-(1-ethyl-5-{[(1-methylpiperidin-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]pyridine-3-carboxamide
47.	N-(3-{1-Ethyl-5-[(methylamino)methyl]-1H-indol-2-yl}prop-2-yn-1-yl)-4-(trifluoromethyl)aniline
48.	N-[(1-Ethyl-2-{3-[(4-methylphenyl)amino]prop-1-yn-1-yl}-1H-indol-5-yl)methyl]oxan-4-amine
49.	N-(3-{1-ethyl-4-[(methylamino)methyl]-1H-indol-2-yl}prop-2-yn-1-yl)aniline

Mol #	IUPAC name
50.	N-[3-(1-ethyl-4-{[4-(pyrrolidin-1-yl)piperidin-1-yl]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]aniline
51.	N-({1-ethyl-2-[3-(phenylamino)prop-1-yn-1-yl]-1H-indol-4-yl} methyl)-1-methylpiperidin-4-amine
52.	1-[(2-{3-[(4-chlorophenyl)amino]prop-1-yn-1-yl}-1-ethyl-1H-indol-4-yl)methyl]piperidin-4-ol
53.	4-Chloro-N-[3-(1-ethyl-4-{[4-(pyrrolidin-1-yl)piperidin-1-yl]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]aniline
54.	1-[(2-{3-[(4-chlorophenyl)amino]prop-1-yn-1-yl}-1-ethyl-1H-indol-4-yl)methyl]-N,N-dimethylpiperidin-4-amine
55.	4-Chloro-N-(3-{1-ethyl-4-[(4-methylpiperazin-1-yl)methyl]-1H-indol-2-yl} prop-2-yn-1-yl)aniline
56.	1-{1-[(2-{3-[(4-Chlorophenyl)amino]prop-1-yn-1-yl}-1-ethyl-1H-indol-4-yl)methyl]piperidin-4-yl}piperidin-4-ol
57.	2-(5-{[3-(4-{[4-(4-Aminopiperidin-1-yl)piperidin-1-yl]methyl}-1-ethyl-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
58.	1-[(1-ethyl-2-{3-[(4-fluorophenyl)amino]prop-1-yn-1-yl}-1H-indol-5-yl)methyl]-N,N-dimethylpiperidin-4-amine
59.	4-N-({1-ethyl-2-[3-(phenylamino)prop-1-yn-1-yl]-1H-indol-5-yl} methyl)-1-N,1-N-dimethylcyclohexane-1,4-diamine
60.	4-chloro-N-(3-{1-ethyl-5-[(methylamino)methyl]-1H-indol-2-yl} prop-2-yn-1-yl)-3-fluoroaniline
61.	6- <i>tert</i> -butyl-N-(3-{1-ethyl-5-[(methylamino)methyl]-1H-indol-2-yl} prop-2-yn-1-yl)pyridine-3-carboxamide
62.	N-(3-{1-ethyl-5-[(methylamino)methyl]-1H-indol-2-yl} prop-2-yn-1-yl)benzamide
63.	3-(3-{1-ethyl-5-[(methylamino)methyl]-1H-indol-2-yl} prop-2-yn-1-yl)-1-(4-methylphenyl)urea
64.	4-chloro-N-(3-{1-ethyl-5-[(methylamino)methyl]-1H-indol-2-yl} prop-2-yn-1-yl)aniline
65.	4-{[3-(1-ethyl-5-{[(oxan-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzonitrile

Mol #	IUPAC name
66.	N-[(2-{3-[(4-chloro-3-fluorophenyl)amino]prop-1-yn-1-yl}-1-ethyl-1H-indol-5-yl)methyl]oxan-4-amine
67.	3-[3-(1-ethyl-5-[[oxan-4-yl)amino]methyl]-1H-indol-2-yl)prop-2-yn-1-yl]-1-phenylurea
68.	6- <i>tert</i> -butyl-N-[3-(1-ethyl-5-[[oxan-4-yl)amino]methyl]-1H-indol-2-yl)prop-2-yn-1-yl]pyridin-3-amine
69.	4-{[(2-{3-[(4-chlorophenyl)amino]prop-1-yn-1-yl}-1-ethyl-1H-indol-5-yl)methyl]amino}-1 λ ⁶ -thiane-1,1-dione
70.	N-[(2-{3-[(4-chlorophenyl)amino]prop-1-yn-1-yl}-1-ethyl-1H-indol-5-yl)methyl]-1-(2-methanesulfonyl)ethyl)piperidin-4-amine
71.	1-(4-{[(2-{3-[(4-chlorophenyl)amino]prop-1-yn-1-yl}-1-ethyl-1H-indol-5-yl)methyl]amino}piperidin-1-yl)-2-(dimethylamino)ethan-1-one
72.	2-(4-{[(2-{3-[(4-chlorophenyl)amino]prop-1-yn-1-yl}-1-ethyl-1H-indol-5-yl)methyl]amino}piperidin-1-yl)-N,N-dimethylacetamide
73.	2- <i>tert</i> -butyl-N-[3-(1-ethyl-5-[[1-methylpiperidin-4-yl)amino]methyl]-1H-indol-2-yl)prop-2-yn-1-yl]pyrimidin-5-amine
74.	2-methyl-2-(5-{[3-(5-[[oxan-4-yl)amino]methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
75.	2-[5-({3-[1-(2-fluoroethyl)-5-[[oxan-4-yl)amino]methyl]-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
76.	3-(1-ethyl-5-[[1-methylpiperidin-4-yl)amino]methyl)-1H-indol-2-yl)prop-2-yn-1-ol
77.	2-[5-({3-[1-(2-chloroethyl)-5-[[oxan-4-yl)amino]methyl]-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
78.	2-[5-({3-[1-(2,2-difluoroethyl)-5-[[oxan-4-yl)amino]methyl]-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
79.	6-chloro-N-[3-(1-ethyl-5-[[1-methylpiperidin-4-yl)amino]methyl]-1H-indol-2-yl)prop-2-yn-1-yl]pyridin-3-amine
80.	<i>tert</i> -butyl N-({3-ethyl-2-[3-(phenylamino)prop-1-yn-1-yl]-1H-indol-6-yl}methyl)-N-(oxan-4-yl)carbamate
81.	6-Chloro-N-[3-(1-ethyl-4-{[4-(pyrrolidin-1-yl)piperidin-1-yl]methyl]-1H-indol-2-yl)prop-2-yn-1-yl]pyridin-3-amine

Mol #	IUPAC name
82.	3-(1-ethyl-5-{[(1-methylpiperidin-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-yn-1-yl benzoate
83.	2-[5-(3-[1-(2-chloroethyl)-5-{[(1-methylpiperidin-4-yl)amino]methyl}-1H-indol-2-yl]prop-2-yn-1-yl)amino]pyridin-2-yl]-2-methylpropanenitrile
84.	N-(6-chloropyridin-3-yl)-3-(1-ethyl-5-{[(1-methylpiperidin-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-ynamide
85.	N-[6-(1-cyano-1-methylethyl)pyridin-3-yl]-3-(1-ethyl-5-{[(1-methylpiperidin-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-ynamide
86.	N-({3-ethyl-2-[3-(phenylamino)prop-1-yn-1-yl]-1H-indol-6-yl}methyl)oxan-4-amine
87.	2-[5-(3-[1-(2-chloroethyl)-4-{[4-(pyrrolidin-1-yl)piperidin-1-yl]methyl}-1H-indol-2-yl]prop-2-yn-1-yl)amino]pyridin-2-yl]-2-methylpropanenitrile
88.	2-(5-{[3-(5-{[(1-methanesulfonylpiperidin-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino}pyridin-2-yl)-2-methylpropanenitrile
89.	2-[5-(3-[5-(3-[1-(2-methanesulfonylethyl)piperidin-4-yl]amino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl)amino]pyridin-2-yl]-2-methylpropanenitrile
90.	2-(5-{[3-(5-{[(1-acetylpiperidin-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino}pyridin-2-yl)-2-methylpropanenitrile
91.	2-{5-[(3-{5-[(1-[2-(dimethylamino)acetyl]piperidin-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
92.	2-methyl-2-(5-{[3-(5-{[(1-methylpiperidin-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino}pyridin-2-yl)propanenitrile
93.	2-methyl-2-{5-[(3-{5-[(methylamino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
94.	6-Chloro-N-[3-(5-{[(1-methylpiperidin-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]pyridin-3-amine
95.	6-chloro-N-[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]pyridin-3-amine
96.	2-[5-(3-[1-(cyclopropylmethyl)-5-{[(oxan-4-yl)amino]methyl}-1H-indol-2-yl]prop-2-yn-1-yl)amino]pyridin-2-yl]-2-methylpropanenitrile

Mol #	IUPAC name
97.	2-(5-{[3-(4-{[4-(diethylamino)piperidin-1-yl]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
98.	2-methyl-2-{5-[(3-{4-[(4-methylpiperazin-1-yl)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
99.	2-(5-{[3-(1-ethyl-7-fluoro-4-{[4-(pyrrolidin-1-yl)piperidin-1-yl]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
100.	2-methyl-2-(5-{[3-(4-{[4-(pyrrolidin-1-yl)piperidin-1-yl]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
101.	2-(5-{[3-(4-{[4-(4-hydroxypiperidin-1-yl)piperidin-1-yl]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
102.	N-(6-cyanopyridin-3-yl)-3-(1-ethyl-5-{[(1-methylpiperidin-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-ynamide
103.	N-[6-(1-cyano-1-methylethyl)pyridin-3-yl]-3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-ynamide
104.	N-[6-(1-cyano-1-methylethyl)pyridin-3-yl]-3-(5-{[(1-methylpiperidin-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-ynamide
105.	2-methyl-2-(5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(oxiran-2-yl)methyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
106.	2-(5-{[3-(5-{[(2-methoxyethyl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
107.	2-methyl-2-[5-(3-{[5-{[2-(morpholin-4-yl)ethyl]amino}methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile
108.	2-methyl-2-(5-{[3-(4-{[(1-methylpiperidin-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
109.	2-methyl-2-(5-{[3-(4-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
110.	2-[5-(3-{[5-{[2-(dimethylamino)ethyl]amino}methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
111.	2-(5-{[3-(7-fluoro-4-{[4-(pyrrolidin-1-yl)piperidin-1-yl]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile

Mol #	IUPAC name
112.	2-methyl-2-[5-({3-[1-(2,2,2-trifluoroethyl)-5-{{(2,2,2-trifluoroethyl)amino}methyl}-1H-indol-2-yl}]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile
113.	2-[5-({3-[5-({1-(2-hydroxyethyl)piperidin-4-yl}amino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
114.	2-[5-({3-[5-({1-(2-methoxyethyl)piperidin-4-yl}amino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
115.	2-[5-({3-[5-({4-(dimethylamino)cyclohexyl}amino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
116.	2-methyl-2-[5-({3-({1-([2-(morpholin-4-yl)acetyl]piperidin-4-yl}amino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile
117.	2-(5-({3-(4-({(2-methoxyethyl)amino)methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}]prop-2-yn-1-yl}amino)pyridin-2-yl)-2-methylpropanenitrile
118.	2-methyl-2-[5-({3-({4-[(methylamino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile
119.	2-[5-({3-({4-[(4-acetyl)piperazin-1-yl]methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
120.	2-methyl-2-[5-({3-({4-(morpholin-4-yl)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile
121.	2-(5-({3-(4-({4-(dimethylamino)piperidin-1-yl}methyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}]prop-2-yn-1-yl}amino)pyridin-2-yl)-2-methylpropanenitrile
122.	2-[5-({3-({4-(hydroxymethyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
123.	2-methyl-2-[5-({3-({4-({4-[2-(morpholin-4-yl)-2-oxoethyl]piperazin-1-yl}methyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile
124.	2-(5-({3-(3-ethyl-7-({4-(pyrrolidin-1-yl)piperidin-1-yl}methyl)-1H-indol-2-yl}]prop-2-yn-1-yl}amino)pyridin-2-yl)-2-methylpropanenitrile
125.	methyl 5-[3-(5-({(oxan-4-yl)amino)methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}]prop-2-yn-1-yl]amino}pyridine-2-carboxylate
126.	N-methyl-5-[3-(5-({(oxan-4-yl)amino)methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}]prop-2-yn-1-yl]amino}pyridine-2-carboxamide

Mol #	IUPAC name
127.	N-(2-hydroxyethyl)-5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridine-2-carboxamide
128.	N-(2-methoxyethyl)-5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridine-2-carboxamide
129.	2-[(5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)formamido]acetic acid
130.	5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridine-2-carboxylic acid
131.	N-(2-methanesulfonyl-ethyl)-5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridine-2-carboxamide
132.	2-[5-(3-[1-(cyanomethyl)-5-{[(oxan-4-yl)amino]methyl}-1H-indol-2-yl]prop-2-yn-1-yl)amino]pyridin-2-yl]-2-methylpropanenitrile
133.	2-methyl-2-[5-(3-[1-(2-methylpropyl)-5-{[(oxan-4-yl)amino]methyl}-1H-indol-2-yl]prop-2-yn-1-yl)amino]pyridin-2-yl]propanenitrile
134.	2-methyl-2-[5-(3-[4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl)amino]pyridin-2-yl]propanenitrile
135.	5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridine-2-carbonitrile
136.	N,N-dimethyl-5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridine-2-carboxamide
137.	N-(oxan-4-yl)-5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridine-2-carboxamide
138.	2- <i>tert</i> -butyl-N-[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]pyrimidin-5-amine
139.	N-(1-methylpiperidin-4-yl)-5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridine-2-carboxamide
140.	N-[6-(1-cyano-1-methylethyl)pyridin-3-yl]-3-[1-(2-fluoroethyl)-5-{[(oxan-4-yl)amino]methyl}-1H-indol-2-yl]prop-2-ynamide
141.	2-(5-{[3-(7-chloro-4-{[4-(pyrrolidin-1-yl)piperidin-1-yl]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile

Mol #	IUPAC name
142.	2-(5-{[3-(6-fluoro-4-{[4-(pyrrolidin-1-yl)piperidin-1-yl]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
143.	2-(5-{[3-(1-ethyl-5-{[(oxan-4-yl)amino]methyl}-1H-pyrrolo[2,3-c]pyridin-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
144.	2-methyl-2-(5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
145.	2-(5-{[3-(5-{[4-(dimethylamino)piperidin-1-yl]methyl}-1-(2,2,2-trifluoroethyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
146.	2-(5-{[3-(7-chloro-4-{[4-(pyrrolidin-1-yl)piperidin-1-yl]methyl}-1-(2,2,2-trifluoroethyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
147.	2-(5-{[3-(4-{[4-(dimethylamino)-piperidin-1-yl]methyl}-6-fluoro-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
148.	2-(5-{[3-(4-{[4-(diethylamino)piperidin-1-yl]methyl}-6-fluoro-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
149.	2-(5-{[3-(6-fluoro-4-{[4-(4-hydroxypiperidin-1-yl)piperidin-1-yl]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
150.	2-(5-{[3-(6-fluoro-5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
151.	2-(5-{[3-(5-{[(1-acetylpiperidin-4-yl)amino]methyl}-6-fluoro-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
152.	2-(5-{[3-(6-chloro-4-{[4-(dimethylamino)piperidin-1-yl]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
153.	2-(5-{[3-(6-chloro-4-{[4-(diethylamino)piperidin-1-yl]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile

Mol #	IUPAC name
154.	2-(5-{[3-(6-chloro-4-{[4-(4-hydroxypiperidin-1-yl)piperidin-1-yl]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
155.	2-(5-{[3-(4-{[4-(2-methanesulfonyl-ethyl)piperazin-1-yl]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
156.	2-(4-{[2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]methyl}piperazin-1-yl)-N,N-dimethylacetamide
157.	2-methyl-2-[5-{(3-{4-{[3-(oxopiperazin-1-yl)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino}pyridin-2-yl}propanenitrile
158.	2-methyl-2-[5-{(3-{4-{[4-(2-(morpholin-4-yl)-2-oxoethyl]piperidin-1-yl)methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino}pyridin-2-yl]propanenitrile
159.	2-(4-{[2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]methyl}piperazin-1-yl)acetamide
160.	N-[6-(1-cyano-1-methylethyl)pyridin-3-yl]-3-(4-{[4-(pyrrolidin-1-yl)piperidin-1-yl]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-ynamide
161.	2-(1-{[2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]methyl}piperidin-4-yl)acetamide
162.	2-(5-{[3-(4-{[4-(2-aminoethyl)-piperazin-1-yl]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
163.	2-(1-{[2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]methyl}piperidin-4-yl)-N,N-dimethylacetamide
164.	2-methyl-2-(5-{[3-(4-{[4-(morpholin-4-yl)piperidin-1-yl]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
165.	2-(5-{[3-(4-{[4-(4-aminopiperidin-1-yl)piperidin-1-yl]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
166.	2-methyl-2-[5-{(3-[1-(oxiran-2-yl)methyl]-4-{[4-(pyrrolidin-1-yl)piperidin-1-yl]methyl}-1H-indol-2-yl]prop-2-yn-1-yl}amino}pyridin-2-yl]propanenitrile
167.	2-(5-{[3-(3-ethyl-6-{[(oxan-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile

Mol #	IUPAC name
168.	2-methyl-2-(5-{[3-(6-{[(oxan-4-yl)amino]methyl}-3-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
169.	2-(5-{[3-(1-acetyl-3-ethyl-6-{[(oxan-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
170.	2-(5-{[3-(3-ethyl-6-{[(1-methylpiperidin-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
171.	2-methyl-2-(5-{[3-(6-{[(1-methylpiperidin-4-yl)amino]methyl}-3-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
172.	2-{5-[(3-{6-chloro-4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
173.	2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-6-fluoro-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indole-4-carboxamide
174.	2-[5-({3-[6-fluoro-4-(4-methylpiperazine-1-carbonyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
175.	6-fluoro-2-{3-[(6-methanesulfonylpyridin-3-yl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
176.	2-{5-[(3-{6-fluoro-4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
177.	5-[(3-{6-fluoro-4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-N-(pyridin-3-yl)pyridine-2-carboxamide
178.	2-methyl-2-(5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
179.	2-methyl-2-{5-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
180.	2-(5-{[3-(7-chloro-1-ethyl-4-{[4-(pyrrolidin-1-yl)piperidin-1-yl]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
181.	2-(5-{[3-(7-chloro-5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
182.	2-(5-{[3-(7-chloro-5-{[(1-methylpiperidin-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile

Mol #	IUPAC name
183.	2-{5-[(3-{7-fluoro-4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
184.	2-(5-{[3-(7-fluoro-5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
185.	2-(5-{[3-(7-fluoro-5-{[(1-methylpiperidin-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
186.	2-methyl-2-(5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-1,3-benzodiazol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
187.	N-{[2-(2-phenylethynyl)-1-(2,2,2-trifluoroethyl)-1H-1,3-benzodiazol-5-yl]methyl}oxan-4-amine
188.	2-methyl-2-(5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-pyrrolo[3,2-b]pyridin-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
189.	2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-5-methyl-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
190.	4-[(2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-5-methyl-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ ⁶ -thiane-1,1-dione
191.	2-methyl-2-{5-[(3-{5-methyl-4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
192.	N-[1-(2-methanesulfonylphenyl)piperidin-4-yl]-2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-5-methyl-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
193.	4-[(3-{5-methyl-4-[(piperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
194.	2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-5-methyl-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
195.	2-{4-[(2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-5-methyl-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethan-1-ol
196.	2-[5-({3-[4-(methoxymethyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
197.	2-[5-({3-[4-(cyanomethyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile

Mol #	IUPAC name
198.	2-methyl-2-[5-({3-[5-(morpholine-4-carbonyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl} amino)pyridin-2-yl]propanenitrile
199.	2-methyl-2-[5-({3-[5-(4-methylpiperazine-1-carbonyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl} amino)pyridin-2-yl]propanenitrile
200.	2-{5-[(3-{5-[4-(dimethylamino)piperidine-1-carbonyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl} prop-2-yn-1-yl) amino]pyridin-2-yl}-2-methylpropanenitrile
201.	2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl] amino} prop-1-yn-1-yl)-N-{1-[2-(dimethylamino)acetyl]piperidin-4-yl}-1-(2,2,2-trifluoroethyl)-1H-indole-5-carboxamide
202.	2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl] amino} prop-1-yn-1-yl)-N-(oxan-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indole-5-carboxamide
203.	2-methyl-2-(5-{[3-(5-{1-[(oxan-4-yl) amino]ethyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl] amino} pyridin-2-yl)propanenitrile
204.	2-methyl-2-[5-[(3-{4-[(1-methylpiperidin-4-yl) amino]-1-(2,2,2-trifluoroethyl)-1H-pyrrolo[3,2-c]pyridin-2-yl} prop-2-yn-1-yl) amino]pyridin-2-yl]propanenitrile
205.	2-methyl-2-[5-({3-[5-(morpholin-4-ylmethyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl} amino)pyridin-2-yl]propanenitrile
206.	2-[5-({3-[5-({1-(2-cyanoethyl)-piperidin-4-yl] amino} methyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl} amino)pyridin-2-yl]-2-methylpropanenitrile
207.	2-methyl-2-(5-{[3-(5-{[(1-methylazetidin-3-yl) amino] methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl] amino} pyridin-2-yl)propanenitrile
208.	2-methyl-2-(5-{[3-(5-{[(oxetan-3-yl) amino] methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl] amino} pyridin-2-yl)propanenitrile
209.	2-(5-{[3-(5-{[4-(dimethylamino)-piperidin-1-yl] methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl] amino} pyridin-2-yl)-2-methylpropanenitrile
210.	2-methyl-2-[5-[(3-{5-[(1-[2-(4-methylpiperazin-1-yl)acetyl]piperidin-4-yl} amino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl} prop-2-yn-1-yl) amino]pyridin-2-yl]propanenitrile
211.	2-(5-{[3-(5-{[(1-methoxypropan-2-yl) amino] methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl] amino} pyridin-2-yl)-2-methylpropanenitrile
212.	2-methyl-2-(5-{[3-(5-{[(pyridin-4-yl)methyl] amino] methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl] amino} pyridin-2-yl)propanenitrile

Mol #	IUPAC name
213.	2-methyl-2-(5-{[3-(5-{[(pyridin-3-yl)methyl]amino}methyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl)propanenitrile
214.	2-[5-({3-[5-({1-(dimethylamino)-propan-2-yl}amino}methyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
215.	2-[4-({[2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-5-yl]methyl}amino)piperidin-1-yl]-N-(oxan-4-yl)acetamide
216.	2-[5-({3-[5-({1-(2-methoxyacetyl)-piperidin-4-yl}amino}methyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
217.	2-methyl-2-{5-[(3-{5-[(1-[2-(oxan-4-yl)acetyl]piperidin-4-yl}amino)-methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-pyridin-2-yl}propanenitrile
218.	2-methyl-2-{5-[(3-{5-[(1-[2-(pyridin-3-yl)acetyl]piperidin-4-yl}amino)-methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-pyridin-2-yl}propanenitrile
219.	2-methyl-2-(5-{[3-(5-{[(1-{2-[(oxan-4-yl)amino]acetyl}piperidin-4-yl)amino]methyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl)propanenitrile
220.	2-[4-({[2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-5-yl]methyl}amino)piperidin-1-yl]-N-methyl-N-(propan-2-yl)acetamide
221.	2-[4-({[2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-5-yl]methyl}amino)piperidin-1-yl]-N-(2-methoxyethyl)-N-methylacetamide
222.	6-methanesulfonyl-N-[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]pyridin-3-amine
223.	2-[4-({[2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-5-yl]methyl}amino)piperidin-1-yl]-N,N-dimethylacetamide
224.	2-methyl-2-{5-[(3-{5-[(1-[2-oxo-2-(pyrrolidin-1-yl)ethyl]piperidin-4-yl}amino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile

Mol #	IUPAC name
225.	4-({2-(3-{{6-(1-cyano-1-methylethyl)pyridin-3-yl}amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-5-yl)methyl}amino)-N,N-dimethylpiperidine-1-carboxamide
226.	2-{5-[(3-{5-[(1-[2-(azetidin-1-yl)-2-oxoethyl]piperidin-4-yl}amino)-methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
227.	2-methyl-2-{5-[(3-{5-[(1-[2-(pyrrolidin-1-yl)acetyl]piperidin-4-yl}amino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-propanenitrile
228.	2-(5-{[3-(5-{{1-[2-(4-(dimethylamino)piperidin-1-yl]acetyl}piperidin-4-yl)amino]-methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino}pyridin-2-yl)-2-methylpropanenitrile
229.	2-{5-[(3-{5-[(1-[2-(diethylamino)acetyl]piperidin-4-yl}amino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
230.	2-methyl-2-(5-{[3-(5-{{1-[2-(methyl(propan-2-yl)amino)acetyl]piperidin-4-yl}amino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino}pyridin-2-yl)propanenitrile
231.	2-methyl-2-{5-[(3-{5-[(1-[2-(pyridin-4-yl)acetyl]piperidin-4-yl}amino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
232.	2-[4-({2-(3-{{6-(1-cyano-1-methylethyl)pyridin-3-yl}amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-5-yl)methyl}amino)piperidin-1-yl]-N-(pyridin-4-yl)acetamide
233.	2-methyl-2-{5-[(3-{5-[(1-[2-(morpholin-4-yl)-2-oxoethyl]piperidin-4-yl}amino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
234.	2-methyl-2-{5-[(3-{5-[(1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]piperidin-4-yl}amino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
235.	2-[4-({2-(3-{{6-(1-cyano-1-methylethyl)pyridin-3-yl}amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-5-yl)methyl}amino)piperidin-1-yl]-N-(pyridin-3-yl)acetamide
236.	2-[4-({2-(3-{{6-(1-cyano-1-methylethyl)pyridin-3-yl}amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-5-yl)methyl}amino)piperidin-1-yl]-N-(1-methylpiperidin-4-yl)acetamide

Mol #	IUPAC name
237.	2-methyl-2-[5-(3-[5-({[4-(morpholin-4-yl)cyclohexyl]amino} methyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl) amino]pyridin-2-yl]propanenitrile
238.	2-{5-[(3-{5-[(1-[2-(4-hydroxypiperidin-1-yl)acetyl]piperidin-4-yl) amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl) amino]pyridin-2-yl}-2-methylpropanenitrile
239.	2-{5-[(3-{5-[(1-[2-(4-acetylpiperazin-1-yl)acetyl]piperidin-4-yl) amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl) amino]pyridin-2-yl}-2-methylpropanenitrile
240.	2-(5-{[3-(5-{[(1,1-dioxo-1 λ ⁶ -thian-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl] amino}pyridin-2-yl)-2-methylpropanenitrile
241.	2-{5-[(3-{5-[(1-[2-(1,1-dioxo-1 λ ⁶ ,4-thiomorpholin-4-yl)acetyl]piperidin-4-yl) amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl) amino]pyridin-2-yl}-2-methylpropanenitrile
242.	2-[5-(3-[5-({[1-(4-acetylpiperazine-1-carbonyl)piperidin-4-yl] amino} methyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl) amino]pyridin-2-yl]-2-methylpropanenitrile
243.	2-(5-{[3-(5-{[(1-{2-[bis(2-hydroxyethyl)amino]acetyl}piperidin-4-yl) amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl] amino}pyridin-2-yl)-2-methylpropanenitrile
244.	2-methyl-2-{5-[(3-{5-[(1-[2-(3-oxopiperazin-1-yl)acetyl]piperidin-4-yl) amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl) amino]pyridin-2-yl}propanenitrile
245.	2-methyl-2-[5-(3-[5-({[1-(morpholine-4-carbonyl)piperidin-4-yl] amino}-methyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl) amino]pyridin-2-yl]propanenitrile
246.	2-methyl-2-(5-{[3-(5-{[(1-methylpiperidin-3-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl] amino}pyridin-2-yl)propanenitrile
247.	N-[4-({[2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl] amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-5-yl]methyl} amino)-cyclohexyl]acetamide
248.	2-{5-[(3-{5-[(1-[2-(1H-imidazol-1-yl)acetyl]piperidin-4-yl) amino]-methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl) amino]pyridin-2-yl}-2-methylpropanenitrile

Mol #	IUPAC name
249.	2-(5-{[3-(5-{[(1-{2-[(2-methoxyethyl)(methyl)amino]acetyl}piperidin-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
250.	N-[4-({[2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-5-yl]methyl}amino)-cyclohexyl]methanesulfonamide
251.	2-methyl-2-(5-{[3-(5-{[(1-methyl-6-oxopiperidin-3-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
252.	2-[5-({3-[5-({[3-(dimethylamino)cyclohexyl]amino}methyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
253.	2-methyl-2-[5-({3-[5-({[1-(4-methylpiperazine-1-carbonyl)piperidin-4-yl]amino}methyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile
254.	2-{5-[(3-{5-[(1-[4-(dimethylamino)piperidine-1-carbonyl]piperidin-4-yl]amino)-methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
255.	2-{5-[(3-{5-[(1-[2-(3-hydroxypyrrolidin-1-yl)acetyl]-piperidin-4-yl]amino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
256.	2-{5-[(3-{5-[(1-[2-(3-methoxypyrrolidin-1-yl)acetyl]-piperidin-4-yl]amino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
257.	2-methyl-2-[5-({3-[5-({[1-(2-{2-oxa-8-azaspiro[4.5]decan-8-yl}acetyl)-piperidin-4-yl]amino}methyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile
258.	2-{5-[(3-{5-[(1-[2-(4-hydroxy-4-methylpiperidin-1-yl)acetyl]piperidin-4-yl]amino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
259.	2-(5-{[3-(5-{[(1-{2-[bis(2-methoxyethyl)amino]acetyl}piperidin-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile

Mol #	IUPAC name
260.	2-(5-{[3-(5-{[(1-{2-[methoxy(methyl)amino]acetyl}piperidin-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
261.	2-(5-{[3-(5-{[(1-{2-[(2,3-dihydroxypropyl)(methyl)amino]acetyl}piperidin-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
262.	2-methyl-2-(5-{[3-(5-{[(1-methyl-2-oxopiperidin-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
263.	2-methyl-2-(5-{[3-(5-{[(1-{2-[methyl(1-methylpiperidin-4-yl)amino]acetyl}piperidin-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
264.	2-methyl-2-[5-(5-{[3-(5-{[(1-(2-{9-methyl-3,9-diazaspiro[5.5]undecan-3-yl]acetyl}piperidin-4-yl)amino]methyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
265.	2-(5-{[3-(5-{[(1-{2-[3-(dimethyl-amino)pyrrolidin-1-yl]acetyl}piperidin-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
266.	N-[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]-6-(pyrrolidine-1-carbonyl)pyridin-3-amine
267.	6-(morpholine-4-carbonyl)-N-[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]pyridin-3-amine
268.	2-chloro-N-[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]pyrimidin-5-amine
269.	5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-phenylpyridine-2-carboxamide
270.	N-methyl-5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-(propan-2-yl)pyridine-2-carboxamide
271.	5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-(pyridin-4-yl)pyridine-2-carboxamide
272.	5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-(pyridin-3-yl)pyridine-2-carboxamide

Mol #	IUPAC name
273.	N-(1-methylazetidin-3-yl)-5-{{3-(5-{{(oxan-4-yl)amino}methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino}pyridine-2-carboxamide
274.	N,N-diethyl-5-{{3-(5-{{(oxan-4-yl)amino}methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino}pyridine-2-carboxamide
275.	5-{{3-(5-{{(oxan-4-yl)amino}methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino}-N-(oxetan-3-yl)pyridine-2-carboxamide
276.	1-(4-{{(2-{{3-[(2- <i>tert</i> -butylpyrimidin-5-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-5-yl)methyl}amino}piperidin-1-yl)-2-(dimethylamino)ethan-1-one
277.	1-(4-{{(2-{{3-[(6-chloropyridin-3-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-5-yl)methyl}amino}piperidin-1-yl)-2-(dimethylamino)ethan-1-one
278.	5-[(3-{{5-[(1-[2-(dimethylamino)-acetyl]piperidin-4-yl}amino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-N-(1-methylpiperidin-4-yl)pyridine-2-carboxamide
279.	1-(4-{{(2-{{3-[(4-chloro-3-fluorophenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-5-yl)methyl}amino}piperidin-1-yl)-2-(dimethylamino)ethan-1-one
280.	2-(dimethylamino)-1-(4-{{(2-{{3-[(6-methylpyridin-3-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-5-yl)methyl}amino}piperidin-1-yl)ethan-1-one
281.	1-(4-{{(2-{{3-[(6- <i>tert</i> -butylpyridin-3-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-5-yl)methyl}amino}piperidin-1-yl)-2-(dimethylamino)ethan-1-one
282.	N-[6-(1-cyano-1-methylethyl)pyridin-3-yl]-3-[1-(2-fluoroethyl)-5-{{(1-methylpiperidin-4-yl)amino}methyl}-1H-indol-2-yl]prop-2-ynamide
283.	2-{{5-[(3-{{5-[(1-[2-(dimethylamino)acetyl]piperidin-4-yl}amino)methyl]-1-ethyl-1H-indol-2-yl}prop-2-yn-1-yl)amino}pyridin-2-yl]-2-methylpropanenitrile
284.	2-{{5-[(3-{{1-(2,2-difluoroethyl)-5-[(1-[2-(dimethylamino)acetyl]piperidin-4-yl}amino)methyl]-1H-indol-2-yl}prop-2-yn-1-yl)amino}pyridin-2-yl]-2-methylpropanenitrile
285.	2-{{5-[(3-{{5-[(1-[2-(dimethylamino)acetyl]piperidin-4-yl}amino)methyl]-1-(2-fluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino}pyridin-2-yl]-2-methylpropanenitrile

Mol #	IUPAC name
286.	N-(6-chloropyridin-3-yl)-3-(5-{{(1-methylpiperidin-4-yl)amino}methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-ynamide
287.	2-(5-{{3-(5-{{(1-acetylpiperidin-4-yl)amino}methyl}-1-(oxiran-2-yl)methyl)-1H-indol-2-yl}prop-2-yn-1-yl}amino}pyridin-2-yl)-2-methylpropanenitrile
288.	2-methyl-2-{5-[(3-{5-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
289.	2-{5-[(3-{4-[(1-acetylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
290.	2-methyl-2-{5-[(3-{4-[(propan-2-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
291.	2-methyl-2-{5-[(3-{4-[(piperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
292.	2-(5-{{3-(4-{{1-(2-methoxyethyl)-piperidin-4-yl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl}amino}pyridin-2-yl)-2-methylpropanenitrile
293.	2-{5-[(3-{4-[(1,1-dioxo-1λ ⁶ -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
294.	3-[2-(3-{{6-(1-cyano-1-methylethyl)-pyridin-3-yl}amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-1-(oxan-4-yl)urea
295.	3-[2-(3-{{6-(1-cyano-1-methylethyl)-pyridin-3-yl}amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-1-(1-methylpiperidin-4-yl)urea
296.	2-(4-{{2-(3-{{6-(1-cyano-1-methylethyl)-pyridin-3-yl}amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl}amino}piperidin-1-yl)-N,N-dimethylacetamide
297.	2-methyl-2-(5-{{3-(4-{{1-(propan-2-yl)piperidin-4-yl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl}amino}pyridin-2-yl)propanenitrile
298.	2-methyl-2-(5-{{3-(4-{{1-(1-methylpiperidin-4-yl)piperidin-4-yl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl}amino}pyridin-2-yl)propanenitrile
299.	4-{2-(3-{{6-(1-cyano-1-methylethyl)-pyridin-3-yl}amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl}amino}-N,N-dimethylpiperidine-1-carboxamide
300.	N-[2-(3-{{6-(1-cyano-1-methylethyl)-pyridin-3-yl}amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-4-methylpiperazine-1-carboxamide

Mol #	IUPAC name
301.	1-[2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-3,3-dimethylurea
302.	N-[2-(3-{[6-(1-cyano-1-methylethyl)-pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]morpholine-4-carboxamide
303.	2-{5-[(3-{4-[(4-hydroxycyclohexyl)-amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
304.	2-methyl-2-[5-({3-[4-({1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile
305.	2-methyl-2-{5-[(3-{4-[(oxan-4-ylmethyl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
306.	2-{5-[(3-{4-[(1-ethylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
307.	2-(5-{[3-(4-{[1-(2-hydroxyethyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
308.	2-{5-[(3-{4-[(1-methanesulfonylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
309.	2-(5-{[3-(4-{[1-(2-methanesulfonyl-ethyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
310.	2-methyl-2-(5-{[3-(4-{[(1R,4R)-4-hydroxycyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
311.	2-methyl-2-(5-{[3-(4-{[(1S,4S)-4-hydroxycyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
312.	2-methyl-2-[5-({3-[4-({1-[2-(morpholin-4-yl)-2-oxoethyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile
313.	2-(4-{[2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)-N,N-bis(2-methoxyethyl)acetamide
314.	2-methyl-2-{5-[(3-{4-[(pyrrolidin-3-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile

Mol #	IUPAC name
315.	2-methyl-2-{5-[(3-{4-[(1-methylpyrrolidin-3-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
316.	2-(4-{[2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)acetamide
317.	methyl 2-(4-{[2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)acetate
318.	2-[5-(3-{4-[(1-[2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]piperidin-4-yl]amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
319.	2-methyl-2-{5-[(3-{4-[(2-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
320.	2-{5-[(3-{4-[(1,1-dioxo-1 λ ⁶ -thiolan-3-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
321.	2-methyl-2-[5-(3-{4-[(1-[2-oxo-2-(pyrrolidin-1-yl)ethyl]piperidin-4-yl]amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile
322.	2-{5-[(3-{4-[(1-{2-[4-(dimethylamino)piperidin-1-yl]-2-oxoethyl}piperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
323.	2-[5-(3-{4-[(1-[2-(dimethylamino)acetyl]piperidin-4-yl]amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
324.	2-(5-{[3-(4-{[1-(1,1-dioxo-1 λ ⁶ -thian-4-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino}pyridin-2-yl)-2-methylpropanenitrile
325.	2-(5-{[3-(4-{[1-(cyanomethyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino}pyridin-2-yl)-2-methylpropanenitrile
326.	2-methyl-2-[5-(3-{[1-(2,2,2-trifluoroethyl)-4-{[1-(2,2,2-trifluoroethyl)piperidin-4-yl]amino}-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile
327.	2-{5-[(3-{4-[(1-{2-[4-(2-methanesulfonyl)ethyl]piperazin-1-yl]-2-oxoethyl}piperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile

Mol #	IUPAC name
328.	2-[5-({3-[4-({1-[2-(1,1-dioxo-1λ ⁶ ,4-thiomorpholin-4-yl)-2-oxoethyl]piperidin-4-yl} amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl} amino)pyridin-2-yl]-2-methylpropanenitrile
329.	2-(5-({3-(4-({1-(1-methanesulfonylpiperidin-4-yl)piperidin-4-yl} amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl} amino)pyridin-2-yl)-2-methylpropanenitrile
330.	2-(4-({2-(3-({6-(1-cyano-1-methylethyl)pyridin-3-yl} amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl} amino)piperidin-1-yl)-N-(2,3-dihydroxypropyl)-N-methylacetamide
331.	2-(4-({2-(3-({6-(1-cyano-1-methylethyl)pyridin-3-yl} amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl} amino)piperidin-1-yl)-N-(2,3-dihydroxypropyl)acetamide
332.	2-[5-({3-[4-({1-[2-(4-methanesulfonylpiperazin-1-yl)-2-oxoethyl]piperidin-4-yl} amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl} amino)pyridin-2-yl]-2-methylpropanenitrile
333.	2-{5-[(3-{4-[(1-{2-[4-(2-hydroxyethyl)piperazin-1-yl]-2-oxoethyl]piperidin-4-yl} amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl} amino)pyridin-2-yl]-2-methylpropanenitrile
334.	2-methyl-2-(5-({3-(4-({1-(oxan-4-yl)piperidin-4-yl} amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl} amino)pyridin-2-yl)propanenitrile
335.	2-[5-({3-[4-({1-[1-(2-methanesulfonylethyl)piperidin-4-yl]piperidin-4-yl} amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl} amino)pyridin-2-yl]-2-methylpropanenitrile
336.	2-[5-({3-[4-({1-[1-(2-methoxyethyl)piperidin-4-yl]piperidin-4-yl} amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl} amino)pyridin-2-yl]-2-methylpropanenitrile
337.	2-[5-({3-[4-({1-[1-(2-hydroxyethyl)piperidin-4-yl]piperidin-4-yl} amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl} amino)pyridin-2-yl]-2-methylpropanenitrile
338.	2-[5-({3-[4-({1-[2-(dimethylamino)ethyl]piperidin-4-yl} amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl} amino)pyridin-2-yl]-2-methylpropanenitrile

Mol #	IUPAC name
339.	2-(5-{[3-(4-{[1-(1-acetylpiperidin-4-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
340.	2-methyl-2-[5-({3-[4-({1-[(1R,4R)-4-hydroxycyclohexyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile
341.	2-methyl-2-[5-({3-[4-({1-[(1S,4S)-4-hydroxycyclohexyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile
342.	N-(1-methylpiperidin-4-yl)-2-{3-[(6-methylpyridin-3-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
343.	2-methyl-2-{5-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
344.	5-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-N-(pyridin-3-yl)pyridine-2-carboxamide
345.	5-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridine-2-carbonitrile
346.	N-[6-(1-cyano-1-methylethyl)pyridin-3-yl]-3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-ynamide
347.	2-{3-[(2-fluorophenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
348.	2-{3-[(3-fluorophenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
349.	4-amino-N-(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)benzene-1-sulfonamide
350.	2-{3-[(6- <i>tert</i> -butylpyridin-3-yl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
351.	2-{3-[(4-fluorophenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
352.	N,N-dimethyl-5-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridine-2-carboxamide
353.	5-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-N-(propan-2-yl)pyridine-2-carboxamide

Mol #	IUPAC name
354.	N-(pyridin-3-yl)-5-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridine-2-carboxamide
355.	N-(pyridin-3-yl)-5-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridine-2-carboxamide
356.	2-{3-[(6-methanesulfonylpyridin-3-yl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
357.	6- <i>tert</i> -butyl-N-(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)pyridine-3-carboxamide
358.	2-{3-[(6-chloropyridin-3-yl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
359.	2-{4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]phenyl}propan-2-ol
360.	6-methyl-N-(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)pyridine-3-carboxamide
361.	N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-2-(3-{[6-(trifluoromethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1H-indol-4-amine
362.	3-(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)-1-phenylurea
363.	2-{3-[(4- <i>tert</i> -butyl-2-fluorophenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
364.	2-{3-fluoro-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]phenyl}-2-methylpropanenitrile
365.	4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
366.	2-{3-[(2,6-difluoro-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
367.	N-methyl-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
368.	2-{3-[(4-methanesulfonyl-3-methoxyphenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
369.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
370.	2-{3-[(5-methanesulfonylpyridin-2-yl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
371.	2-{3-[(4-methanesulfonyl-2-methylphenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
372.	methyl 3-methoxy-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzoate
373.	N-{3-methoxy-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]phenyl}methanesulfonamide
374.	3-methoxy-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzonitrile
375.	3-methoxy-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzoic acid
376.	2-{3-[(2,4-dimethoxyphenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
377.	2-{3-[(2-methoxypyridin-3-yl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
378.	2-{3-[(5-fluoro-2-methoxyphenyl)-amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
379.	2-{3-[(2-ethoxy-4-methane-sulfonylphenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
380.	2-{3-[(3-fluoro-2-methoxyphenyl)-amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
381.	3-methoxy-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
382.	2-{3-[(4-fluoro-2-methoxyphenyl)-amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
383.	3-methoxy-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-benzamide

Mol #	IUPAC name
384.	2-{3-[(2-fluoro-6-methoxyphenyl)-amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
385.	2-{3-[(4- <i>tert</i> -butyl-2-methoxyphenyl)-amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
386.	4-methoxy-3-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-benzonitrile
387.	2-{3-[(5- <i>tert</i> -butyl-2-methoxyphenyl)-amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
388.	N-(1-methylpiperidin-4-yl)-2-[3-(phenylamino)prop-1-yn-1-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
389.	5-methanesulfonyl-2-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzonitrile
390.	2-(3-{[2-(2-fluoroethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
391.	2-{3-[(3-methoxypyridin-4-yl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
392.	2-{3-[(2-chloro-4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
393.	2-{3-[(4-methoxyphenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
394.	2-(3-{[4-methanesulfonyl-2-(2-methoxyethoxy)phenyl]amino}prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
395.	5-[(3-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridine-2-carbonitrile
396.	4-{[2-(3-{[6-(morpholine-4-carbonyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1 λ^6 -thiane-1,1-dione
397.	4-{[2-(3-{[6-(4-methylpiperazine-1-carbonyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1 λ^6 -thiane-1,1-dione
398.	4-[(2-{3-[(quinolin-3-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ^6 -thiane-1,1-dione

Mol #	IUPAC name
399.	4-[(2-{3-[(quinoxalin-6-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ ⁶ -thiane-1,1-dione
400.	4-[(2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ ⁶ -thiane-1,1-dione
401.	5-[(3-{4-[(1,1-dioxo-1 λ ⁶ -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridine-2-carboxamide
402.	4-[(2-{3-[(6-methoxypyridin-3-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ ⁶ -thiane-1,1-dione
403.	4-{[2-(3-{[6-(4-hydroxypiperidine-1-carbonyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1 λ ⁶ -thiane-1,1-dione
404.	4-[(2-{3-[(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ ⁶ -thiane-1,1-dione
405.	4-[(2-{3-[(2-methoxypyridin-4-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ ⁶ -thiane-1,1-dione
406.	2-{4-[(3-{4-[(1,1-dioxo-1 λ ⁶ -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-fluorophenyl}-2-methylpropanenitrile
407.	5-[(3-{4-[(1,1-dioxo-1 λ ⁶ -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-N-(1-methylpiperidin-4-yl)pyridine-2-carboxamide
408.	4-[(2-{3-[(2-fluoro-4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ ⁶ -thiane-1,1-dione
409.	4-{[2-(3-{[4-(ethanesulfonyl)-phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1 λ ⁶ -thiane-1,1-dione
410.	4-[(2-{3-[(2- <i>tert</i> -butylpyrimidin-5-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ ⁶ -thiane-1,1-dione
411.	3-{4-[(1,1-dioxo-1 λ ⁶ -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-N-(4-methanesulfonyl-phenyl)-prop-2-ynamide
412.	5-[(3-{4-[(1,1-dioxo-1 λ ⁶ -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-N-(oxan-4-yl)pyridine-2-carboxamide
413.	5-[(3-{4-[(1,1-dioxo-1 λ ⁶ -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-N-(pyridin-3-yl)pyridine-2-carboxamide

Mol #	IUPAC name
414.	5-[(3-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-N-methylpyridine-2-carboxamide
415.	4-[(2-{3-[(3-chloro-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ^6 -thiane-1,1-dione
416.	N-(2,3-dihydroxypropyl)-5-[(3-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridine-2-carboxamide
417.	5-[(3-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-N-hydroxypyridine-2-carboxamide
418.	5-[(3-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-N-(2-hydroxyethyl)pyridine-2-carboxamide
419.	5-[(3-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-N-hydroxy-N-methylpyridine-2-carboxamide
420.	4-amino-N-(3-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)benzene-1-sulfonamide
421.	4-({2-[3-(pyrido[2,3-b]pyrazin-7-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)-1 λ^6 -thiane-1,1-dione
422.	4-[(3-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-benzamide
423.	4-{2-[3-{2-(methylsulfonyl)pyrimidin-5-yl}amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1 λ^6 -thiane-1,1-dione
424.	4-[(3-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
425.	4-{2-[3-{4-(2-methylpropane-2-sulfonyl)phenyl}amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1 λ^6 -thiane-1,1-dione
426.	4-[(3-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-N,N-dimethylbenzene-1-sulfonamide
427.	4-{1-(2,2,2-trifluoroethyl)-2-[2-(trimethylsilyl)ethynyl]-1H-indol-4-yl]amino}-1 λ^6 -thiane-1,1-dione
428.	4-[(2-{3-[(5-methanesulfonylpyridin-2-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ^6 -thiane-1,1-dione

Mol #	IUPAC name
429.	4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ ⁶ -thiane-1,1-dione
430.	4-[(3-{4-[(1,1-dioxo-1 λ ⁶ -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-N-methylbenzene-1-sulfonamide
431.	4-{[2-ethynyl-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1 λ ⁶ -thiane-1,1-dione
432.	N-{4-[(3-{4-[(1,1-dioxo-1 λ ⁶ -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxyphenyl}methanesulfonamide
433.	4-[(3-{4-[(1,1-dioxo-1 λ ⁶ -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxybenzoic acid
434.	4-[(3-{4-[(1,1-dioxo-1 λ ⁶ -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxybenzonitrile
435.	4-[(2-{3-[(5-fluoro-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ ⁶ -thiane-1,1-dione
436.	4-[(2-{3-[(2-methoxy-6-methylpyridin-3-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ ⁶ -thiane-1,1-dione
437.	4-[(2-{3-[(2-hydroxy-6-methylpyridin-3-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ ⁶ -thiane-1,1-dione
438.	4-[(3-{4-[(1,1-dioxo-1 λ ⁶ -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxybenzamide
439.	4-[(2-{3-[(2-methoxypyridin-3-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ ⁶ -thiane-1,1-dione
440.	4-[(2-{3-[(4-fluoro-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ ⁶ -thiane-1,1-dione
441.	4-[(2-{3-[(5- <i>tert</i> -butyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ ⁶ -thiane-1,1-dione
442.	4-[(2-{3-[(2-ethoxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ ⁶ -thiane-1,1-dione
443.	4-[(2-{3-[(3-fluoro-2-methoxyphenyl)-amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ ⁶ -thiane-1,1-dione
444.	4-[(2-{3-(methylamino)prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ ⁶ -thiane-1,1-dione

Mol #	IUPAC name
445.	4-[(3-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxybenzene-1-sulfonamide
446.	4-[(2-{3-[(2-fluoro-6-methoxyphenyl)-amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ^6 -thiane-1,1-dione
447.	3-[(3-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-4-methoxybenzonitrile
448.	4-[(2-{3-[(4- <i>tert</i> -butyl-2-methoxy-phenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ^6 -thiane-1,1-dione
449.	4-[(2-{3-(phenylamino)prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ^6 -thiane-1,1-dione
450.	4-[(2-{3-[(2-(2-fluoroethoxy)-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ^6 -thiane-1,1-dione
451.	2-[(3-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-5-methanesulfonylbenzonitrile
452.	4-[(2-{3-[(2-chloro-4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ^6 -thiane-1,1-dione
453.	4-[(2-{3-[(4-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ^6 -thiane-1,1-dione
454.	4-[(2-{3-[(4-methanesulfonyl-2-(2-methoxyethoxy)phenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ^6 -thiane-1,1-dione
455.	2-{4-[(2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-N,N-dimethylacetamide
456.	2-methyl-2-(5-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
457.	2-(5-((3-(4-(((1S,4S)-4-(dimethylamino)-cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)pyridin-2-yl)-2-methylpropanenitrile
458.	N-[1-(2-methanesulfonyl-ethyl)piperidin-4-yl]-2-{3-[(4-methanesulfonylphenyl)-amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
459.	5-({3-[4-({1-[(dimethylcarbamoyl)methyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridine-2-carboxamide

Mol #	IUPAC name
460.	5-{{3-(4-{{1-(2-methanesulfonyl)ethyl}piperidin-4-yl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}pyridine-2-carboxamide
461.	5-{{3-(4-{{(piperidin-4-yl)amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl}amino}pyridine-2-carboxamide
462.	5-{{3-(4-{{1-(carbamoylmethyl)piperidin-4-yl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}pyridine-2-carboxamide
463.	5-{{3-(4-{{1-(2-hydroxyethyl)piperidin-4-yl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}pyridine-2-carboxamide
464.	5-{{3-(4-{{1-(oxan-4-yl)piperidin-4-yl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}pyridine-2-carboxamide
465.	5-{{3-(4-{{(1R,4R)-4-(dimethylamino)-cyclohexyl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}pyridine-2-carboxamide
466.	4-{{3-(4-{{1-(2-methanesulfonyl)ethyl}piperidin-4-yl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}benzene-1-sulfonamide
467.	4-{{3-(4-{{1-(2-methoxyethyl)piperidin-4-yl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}benzene-1-sulfonamide
468.	5-{{3-(4-{{(1S,4S)-4-(dimethylamino)-cyclohexyl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}pyridine-2-carboxamide
469.	N,N-dimethyl-4-{{3-(4-{{1-(oxan-4-yl)piperidin-4-yl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}benzene-1-sulfonamide
470.	4-{{3-(4-{{1-(oxan-4-yl)piperidin-4-yl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}benzene-1-sulfonamide
471.	2-{{4-[(2-{{3-[(4-sulfamoylphenyl)-amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-piperidin-1-yl}acetamide
472.	4-{{3-(4-{{1-(2-methoxyethyl)piperidin-4-yl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}-N,N-dimethylbenzene-1-sulfonamide
473.	4-{{3-(4-{{(oxan-4-yl)amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl}amino}benzene-1-sulfonamide
474.	4-{{3-(4-{{1-(2-hydroxypropyl)piperidin-4-yl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}benzene-1-sulfonamide

Mol #	IUPAC name
475.	4-{[3-(4-{[1-(2,3-dihydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
476.	4-({3-[4-({1-[2-(morpholin-4-yl)-2-oxoethyl]piperidin-4-yl} amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl} amino)benzene-1-sulfonamide
477.	methyl 2-{4-[(2-{3-[(4-sulfamoylphenyl)-amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl} acetate
478.	4-{[3-(4-{[1-(2-hydroxyethyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
479.	4-({3-[4-({1-[2-(2-hydroxyethoxy)ethyl]piperidin-4-yl} amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl} amino)benzene-1-sulfonamide
480.	N,N-dimethyl-2-{4-[(2-{3-[(4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl} acetamide
481.	4-({3-[4-({1-[2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]piperidin-4-yl} amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl} amino)benzene-1-sulfonamide
482.	2-{4-[(2-{3-[(4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl} acetic acid
483.	4-({3-[4-({1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]piperidin-4-yl} amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl} amino)benzene-1-sulfonamide
484.	N-methyl-2-{4-[(2-{3-[(4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl} acetamide
485.	N-methyl-4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl} prop-2-yn-1-yl)amino]benzene-1-sulfonamide
486.	4-{[3-(4-{[1-(2-methoxyethyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-methylbenzene-1-sulfonamide
487.	N-methyl-4-{[3-(4-{[1-(oxan-4-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
488.	2-(dimethylamino)ethyl 2-{4-[(2-{3-[(4-methanesulfonylphenyl)-amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl} acetate
489.	2-methoxy-4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl} prop-2-yn-1-yl)amino]benzene-1-sulfonamide

Mol #	IUPAC name
490.	2-chloro-4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
491.	3-methoxy-4-{[3-(4-{[1-(oxan-4-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
492.	4-{[3-(4-{[1-(2,3-dihydroxypropyl)-piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
493.	3-methoxy-4-[(3-{4-[(piperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
494.	3-methoxy-4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
495.	3-methoxy-4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzamide
496.	3-methoxy-4-{[3-(4-{[1-(oxan-4-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
497.	4-{[3-(4-{[1-(2,3-dihydroxypropyl)-piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzamide
498.	2-[5-(3-[1-(cyanomethyl)-4-[(1-methylpiperidin-4-yl)amino]-1H-indol-2-yl]prop-2-yn-1-yl)amino]pyridin-2-yl]-2-methylpropanenitrile
499.	2-[5-(3-[1-(3-methoxypropyl)-4-[(1-methylpiperidin-4-yl)amino]-1H-indol-2-yl]prop-2-yn-1-yl)amino]pyridin-2-yl]-2-methylpropanenitrile
500.	2-[5-(3-[1-(2-chloroethyl)-4-[(1-methylpiperidin-4-yl)amino]-1H-indol-2-yl]prop-2-yn-1-yl)amino]pyridin-2-yl]-2-methylpropanenitrile
501.	2-methyl-2-{5-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(propan-2-yl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
502.	2-{5-[(3-{1-cyclopentyl-4-[(1-methylpiperidin-4-yl)amino]-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
503.	2-methyl-2-{5-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(3,3,3-trifluoropropyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
504.	1-(2-chloroethyl)-N-(1-methylpiperidin-4-yl)-2-{3-[(6-methylpyridin-3-yl)amino]prop-1-yn-1-yl}-1H-indol-4-amine

Mol #	IUPAC name
505.	1-(2-chloroethyl)-N-(1-methylpiperidin-4-yl)-2-{3-[(6-methylpyridin-3-yl)amino]-prop-1-yn-1-yl}-1H-indol-4-amine
506.	1-(2-chloroethyl)-2-{3-[(4-chlorophenyl)-amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1H-indol-4-amine
507.	2-[5-({3-[1-(1-cyanoethyl)-4-[(1-methylpiperidin-4-yl)amino]-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
508.	2-[5-({3-[1-(cyanomethyl)-4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
509.	4-[(2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(oxiran-2-ylmethyl)-1H-indol-4-yl)amino]-1 λ^6 -thiane-1,1-dione
510.	2-{3-[(4-methanesulfonylphenyl)-amino]prop-1-yn-1-yl}-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(oxiran-2-ylmethyl)-1H-indol-4-amine
511.	4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(oxiran-2-ylmethyl)-1H-indol-4-yl)amino]-1 λ^6 -thiane-1,1-dione
512.	2-{3-[(4-methanesulfonyl-2-methoxy-phenyl)amino]prop-1-yn-1-yl}-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(oxiran-2-ylmethyl)-1H-indol-4-amine
513.	1-[6-(1-cyano-1-methylethyl)pyridin-3-yl]-3-(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)urea
514.	1-(6-methanesulfonylpyridin-3-yl)-3-(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)urea
515.	1-[6-(1-cyano-1-methylethyl)pyridin-3-yl]-3-(3-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)urea
516.	3-(3-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)-1-(6-methanesulfonylpyridin-3-yl)urea
517.	1-(6-cyanopyridin-3-yl)-3-(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)urea
518.	1-(6-cyanopyridin-3-yl)-3-(3-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)urea
519.	3-(3-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)-1-(quinoxalin-6-yl)urea

Mol #	IUPAC name
520.	N-(3-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)-4-methylpiperazine-1-carboxamide
521.	N-(3-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)morpholine-4-carboxamide
522.	4-[(2-{3-[(6-methanesulfonylpyridin-3-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ^6 -thiane-1,1-dione
523.	2-{4-[(2-{3-[(6-methanesulfonylpyridin-3-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-N,N-dimethylacetamide
524.	N-(1-ethylpiperidin-4-yl)-2-{3-[(6-methanesulfonylpyridin-3-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
525.	N-[1-(2-methanesulfonyl-ethyl)piperidin-4-yl]-2-{3-[(6-methanesulfonylpyridin-3-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
526.	2-{3-[(6-methanesulfonylpyridin-3-yl)amino]prop-1-yn-1-yl}-N-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
527.	2-{4-[(2-{3-[(6-methanesulfonylpyridin-3-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethan-1-ol
528.	4-{4-[(2-{3-[(6-methanesulfonylpyridin-3-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-1 λ^6 -thiane-1,1-dione
529.	2-{4-[(2-{3-[(6-methanesulfonylpyridin-3-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-1-(4-methylpiperazin-1-yl)ethan-1-one
530.	2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-(oxan-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
531.	2-{4-[(2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethan-1-ol
532.	2-{4-[(2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-1-(4-methylpiperazin-1-yl)ethan-1-one
533.	2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
534.	N-(2,3-dihydroxypropyl)-2-{4-[(2-{3-[(4-methanesulfonylphenyl)-amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-N-methylacetamide

Mol #	IUPAC name
535.	4-N-(2-{3-[(4-methanesulfonylphenyl)-amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-1-N,1-N-dimethylcyclohexane-1,4-diamine
536.	(1S,4S)-4-N-(2-{3-[(4-methanesulfonylphenyl)-amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-1-N,1-N-dimethylcyclohexane-1,4-diamine
537.	2-{3-[(4-methanesulfonylphenyl)-amino]prop-1-yn-1-yl}-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
538.	2-{4-[(2-{3-[(4-methanesulfonylphenyl)-amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-1-(morpholin-4-yl)ethan-1-one
539.	1-(4-hydroxypiperidin-1-yl)-2-{4-[(2-{3-[(4-methanesulfonylphenyl)-amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethan-1-one
540.	2-{3-[(4-methanesulfonylphenyl)-amino]prop-1-yn-1-yl}-N-(piperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
541.	N-{1-[1-(2-methanesulfonyl)ethyl]piperidin-4-yl}piperidin-4-yl-2-{3-[(4-methanesulfonylphenyl)-amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
542.	2-{3-[(4-methanesulfonylphenyl)-amino]prop-1-yn-1-yl}-N-[1-(2-methoxyethyl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
543.	3-{4-[(2-{3-[(4-methanesulfonylphenyl)-amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propanenitrile
544.	2-{3-[(4-methanesulfonylphenyl)-amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
545.	2-{4-[(2-{3-[(4-methanesulfonylphenyl)-amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetamide
546.	4-{4-[(2-{3-[(4-methanesulfonylphenyl)-amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-1λ ⁶ -thiane-1,1-dione
547.	2-{4-[(2-{3-[(4-methanesulfonylphenyl)-amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-N-methylacetamide
548.	2-(3-{4-(ethanesulfonylphenyl)amino}prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
549.	2-{4-[(2-{3-[(2-fluoro-4-methanesulfonylphenyl)-amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethan-1-ol

Mol #	IUPAC name
550.	2-{3-[(2-fluoro-4-methanesulfonylphenyl)-amino]prop-1-yn-1-yl}-N-[1-(2-methanesulfonylethyl)-piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
551.	2-{4-[(2-{3-[(2-fluoro-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetamide
552.	2-{3-[(2-fluoro-4-methanesulfonylphenyl)-amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
553.	1-{4-[(2-{3-[(4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-2-methoxyethan-1-one
554.	2-{3-[(4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-N-(1-methylpyrrolidin-3-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
555.	N-hydroxy-2-{4-[(2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetamide
556.	3-{4-[(2-{3-[(4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propane-1,2-diol
557.	2-{3-[(2-fluoro-4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-N-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
558.	2-(3-{[4-(ethanesulfonyl)phenyl]amino}prop-1-yn-1-yl)-N-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
559.	2-{3-[(2-fluoro-4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-N-(oxan-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
560.	2-(4-{[2-(3-{[4-(ethanesulfonyl)-phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)ethan-1-ol
561.	1-{4-[(2-{3-[(4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propan-2-ol
562.	2-(3-{[4-(ethanesulfonyl)-phenyl]amino}prop-1-yn-1-yl)-N-[1-(2-methanesulfonylethyl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
563.	4-{[1-(2,2,2-trifluoroethyl)-2-{3-[(4-trifluoromethanesulfonylphenyl)amino]prop-1-yn-1-yl}-1H-indol-4-yl]amino}-1 λ ⁶ -thiane-1,1-dione
564.	2-(4-{[1-(2,2,2-trifluoroethyl)-2-{3-[(4-trifluoromethanesulfonylphenyl)amino]prop-1-yn-1-yl}-1H-indol-4-yl]amino}piperidin-1-yl)ethan-1-ol

Mol #	IUPAC name
565.	N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-2-{3-[(4-trifluoromethanesulfonylphenyl)amino]prop-1-yn-1-yl}-1H-indol-4-amine
566.	2-{3-[(4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-N-[1-(1-methylpyrrolidin-3-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
567.	2-{3-[(4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-N-[1-(3-methanesulfonylpropyl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
568.	2-(3-{[4-(ethanesulfonyl)-phenyl]amino} prop-1-yn-1-yl)-N-[1-(2-methoxyethyl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
569.	4-(4-{[2-(3-{[4-(ethanesulfonyl)-phenyl]amino} prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino} piperidin-1-yl)-1 λ ⁶ -thiane-1,1-dione
570.	2-(3-{[4-(ethanesulfonyl)-phenyl]amino} prop-1-yn-1-yl)-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
571.	N-[1-(2-methanesulfonyl-ethyl)-piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-2-{3-[(4-trifluoromethane-sulfonylphenyl)amino]prop-1-yn-1-yl}-1H-indol-4-amine
572.	N-[1-(oxan-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-2-{3-[(4-trifluoromethanesulfonylphenyl)amino]prop-1-yn-1-yl}-1H-indol-4-amine
573.	N-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-2-{3-[(4-trifluoromethanesulfonylphenyl)amino]prop-1-yn-1-yl}-1H-indol-4-amine
574.	2-{3-[(2-fluoro-4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
575.	2-{4-[(2-{3-[(4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl} acetonitrile
576.	2-{3-[(2-fluoro-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-[1-(2-methoxyethyl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
577.	2-{3-[(3-chloro-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
578.	2-{3-[(2,6-difluoro-4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
579.	2-{3-[(3-chloro-4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-N-[1-(2-methoxyethyl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
580.	2-{4-[(2-{3-[(3-chloro-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethan-1-ol
581.	(2S)-3-{4-[(2-{3-[(4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propane-1,2-diol
582.	N-(5-aminopentyl)-2-{4-[(2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetamide
583.	2-{3-[(2,6-difluoro-4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-N-[1-(2-methoxyethyl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
584.	2-(3-{[4-(ethanesulfonyl)phenyl]-amino}prop-1-yn-1-yl)-N-(oxan-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
585.	2-(4-{[2-(3-{[4-(ethanesulfonyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)acetonitrile
586.	2-(3-{[4-(2-methylpropane-2-sulfonyl)phenyl]amino}prop-1-yn-1-yl)-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
587.	2-(2-{4-[(2-{3-[(4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethoxy)ethan-1-ol
588.	1-{4-[(2-{3-[(2-fluoro-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propan-2-ol
589.	3-{4-[(2-{3-[(2-fluoro-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propane-1,2-diol
590.	(1S,4S)-4-N-(2-{3-[(2-fluoro-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-1-N,1-N-dimethylcyclohexane-1,4-diamine
591.	3-(4-{[2-(3-{[4-(ethanesulfonyl)-phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)propane-1,2-diol
592.	2-(3-{[4-(ethanesulfonyl)-phenyl]amino}prop-1-yn-1-yl)-N-[1-(3-methanesulfonylpropyl)-piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
593.	1-(4-{[2-(3-{[4-(ethanesulfonyl)-phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)propan-2-ol
594.	2-[2-(4-{[2-(3-{[4-(ethanesulfonyl)-phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)ethoxy]ethan-1-ol

Mol #	IUPAC name
595.	(1R,4R)-4-N-(2-{3-[(2-fluoro-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-1-N,1-N-dimethyl-cyclohexane-1,4-diamine
596.	2-{3-[(2,6-difluoro-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-[1-(2-methanesulfonylethyl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
597.	4-{4-[(2-{3-[(2,6-difluoro-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-1 λ ⁶ -thiane-1,1-dione
598.	2-{3-[(4-methanesulfonyl-3-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
599.	2-{3-[(4-methanesulfonyl-3-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[1-(2-methoxyethyl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
600.	4-N-(2-{3-[(2-fluoro-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-1-N,1-N-dimethylcyclohexane-1,4-diamine
601.	2-{4-[(2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetic acid
602.	2-hydroxyethyl 2-{4-[(2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetate
603.	2-{3-[(4-methanesulfonylphenyl)-amino]prop-1-yn-1-yl}-N-(2-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
604.	2-{4-[(2-{3-[(4-methanesulfonyl-3-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethan-1-ol
605.	(2S)-2-(2-{4-[(2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetamido)pentanedioic acid
606.	1,5-dimethyl (2S)-2-(2-{4-[(2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetamido)pentanedioate
607.	N-(4-carbamimidamidobutyl)-2-{4-[(2-{3-[(4-methanesulfonylphenyl)-amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetamide
608.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-(oxan-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
609.	2-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethan-1-ol

Mol #	IUPAC name
610.	2-{3-[(5-methanesulfonylpyridin-2-yl)amino]prop-1-yn-1-yl}-N-(oxan-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
611.	3-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propane-1,2-diol
612.	4-[(2-{3-[(2,4-dimethoxyphenyl)-amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ ⁶ -thiane-1,1-dione
613.	methyl 4-[(3-{4-[(1,1-dioxo-1 λ ⁶ -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxybenzoate
614.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[1-(2-methanesulfonylethyl)-piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
615.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[1-(2-methoxyethyl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
616.	(1S,4S)-4-N-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-1-N,1-N-dimethylcyclohexane-1,4-diamine
617.	(1R,4R)-4-N-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-1-N,1-N-dimethylcyclohexane-1,4-diamine
618.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
619.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propan-2-o
620.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[1-(1-methylpyrrolidin-3-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
621.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-(2-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
622.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-(piperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
623.	2-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-1-(4-methylpiperazin-1-yl)ethan-1-one
624.	2-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetamide

Mol #	IUPAC name
625.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
626.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexyl}piperidin-4-ol
627.	2-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-1-(morpholin-4-yl)ethan-1-one
628.	2-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-N,N-dimethylacetamide
629.	2-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetonitrile
630.	methyl 2-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetate
631.	1-(4-hydroxypiperidin-1-yl)-2-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethan-1-one
632.	2-(2-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethoxy)ethan-1-ol
633.	-[(1R,4R)-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexyl]piperidin-4-ol
634.	2-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetic acid
635.	(1R,4R)-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexan-1-ol
636.	(1S,4S)-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexan-1-ol
637.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
638.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexyl}-3-methylpyrrolidin-3-ol
639.	(3R,4R)-1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexyl}-pyrrolidine-3,4-diol

Mol #	IUPAC name
640.	4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidine-1-carboximidamide
641.	1-[(1S,4S)-4-[(2-{3-[(4-methane-sulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexyl]piperidin-4-ol
642.	4-[(2-{3-[(3-methoxypyridin-4-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ ⁶ -thiane-1,1-dione
643.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1S,4S)-4-(morpholin-4-yl)cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
644.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
645.	2-(3-{[2-(2-fluoroethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
646.	4-{2-(3-{[4-methanesulfonyl-2-(trifluoromethyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1 λ ⁶ -thiane-1,1-dione
647.	2-(3-{[4-methanesulfonyl-2-(trifluoromethyl)phenyl]amino}prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
648.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethan-1-one
649.	3-methoxy-4-{3-(4-{[1-(1-methylpiperidin-4-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
650.	3-methoxy-4-[(3-{4-[(piperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-benzamide
651.	3-methoxy-4-{3-(4-{[1-(1-methylpiperidin-4-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
652.	3-(4-{2-(3-{[2-(2-fluoroethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)propane-1,2-diol
653.	3-(4-{2-(3-{[4-methanesulfonyl-2-(2-methoxyethoxy)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)propane-1,2-diol
654.	2-(4-{2-(3-{[4-methanesulfonyl-2-(2-methoxyethoxy)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)acetamide

Mol #	IUPAC name
655.	2-(4-{[2-(3-{[2-(2-fluoroethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)-1-(4-methylpiperazin-1-yl)ethan-1-one
656.	2-(3-{[2-(2-fluoroethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-N-(oxan-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
657.	2-(3-{[2-(2-fluoroethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-N-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
658.	4-[(2-{3-[(4-methoxypyridin-3-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ ⁶ -thiane-1,1-dione
659.	S-{4-[(3-{4-[(1,1-dioxo-1 λ ⁶ -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxyphenyl}-2-hydroxyethane-1-sulfonamido
660.	2-hydroxy-S-{3-methoxy-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]phenyl}ethane-1-sulfonamido
661.	2-methyl-2-[5-({3-[4-(morpholin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile
662.	-{4-[(2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-N-[5-(2-{4-[(2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetamido)pentyl]acetamide
663.	6-[(2-{4-[(2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetyl)oxy]hexyl 2-{4-[(2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetate
664.	3-methoxy-4-({3-[4-({1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)benzene-1-sulfonamide
665.	2-{5-methanesulfonyl-2-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]phenoxy}acetamide
666.	2-(3-{[4-methanesulfonyl-2-(2-methoxyethoxy)phenyl]amino}prop-1-yn-1-yl)-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
667.	2-(4-{[2-(3-{[4-methanesulfonyl-2-(2-methoxyethoxy)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)ethan-1-ol

Mol #	IUPAC name
668.	3-methoxy-4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzoic acid
669.	2-{2-[(3-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-5-methanesulfonylphenoxy}acetamide
670.	4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidine-1-carboxamide
671.	2-{3-[(4-methoxypyridin-3-yl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
672.	4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidine-1-carbothioamide
673.	4-[(2-{3-[(6-methanesulfonyl-4-methoxypyridin-3-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ^6 -thiane-1,1-dione
674.	3-methoxy-4-{[3-(4-{[1-(2-methoxyethyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
675.	4-{[2-(3-{[4-(ethanesulfonyl)-2-methoxyphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1 λ^6 -thiane-1,1-dione
676.	2-(3-{[4-(ethanesulfonyl)-2-methoxyphenyl]amino}prop-1-yn-1-yl)-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
677.	4-{[3-(4-{[1-(2,3-dihydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
678.	methyl 4-{[3-(4-{[1-(2,3-dihydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoate
679.	methyl 3-methoxy-4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzoate
680.	3-methoxy-4-({3-[4-({1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)benzamide
681.	4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-N-methylpiperidine-1-carboximidamide
682.	2-{3-[(6-methanesulfonyl-4-methoxypyridin-3-yl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
683.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[1-(pyridin-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
684.	3-(4-{[2-(3-{[4-(ethanesulfonyl)-2-methoxyphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)propane-1,2-diol
685.	2-(3-{[4-(ethanesulfonyl)-2-methoxyphenyl]amino}prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
686.	2-hydroxy-S-{3-methoxy-4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]phenyl}ethane-1-sulfonamido
687.	2-(3-{[4-methanesulfonyl-2-(2,2,2-trifluoroethoxy)phenyl]amino}prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
688.	4-{[2-(3-{[4-methanesulfonyl-2-(2,2,2-trifluoroethoxy)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1λ ⁶ -thiane-1,1-dione
689.	2-hydroxy-S-(3-methoxy-4-{[3-(4-{[1-(oxan-4-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}phenyl)ethane-1-sulfonamido
690.	S-(4-{[3-(4-{[1-(2,3-dihydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxyphenyl)-2-hydroxyethane-1-sulfonamido
691.	2-{3-methoxy-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]phenyl}-2-methylpropanenitrile
692.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-[(3R,4R)-3,4-dihydroxypyrrolidin-1-yl]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}benzene-1-sulfonamide
693.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-[(3R,4R)-3,4-dihydroxypyrrolidin-1-yl]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}benzene-1-sulfonamide
694.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-(4-hydroxypiperidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}benzene-1-sulfonamide
695.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(4-hydroxypiperidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}benzene-1-sulfonamide
696.	2-{4-[(3-{4-[(1,1-dioxo-1λ ⁶ -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino]-3-methoxyphenyl}-2-methylpropanenitrile

Mol #	IUPAC name
697.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
698.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
699.	(3S,4S)-1-[(1S,4S)-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexyl]pyrrolidine-3,4-diol
700.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
701.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
702.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N,N-dimethyl-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
703.	3-methoxy-4-{[3-(4-{[(2-methoxyethyl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
704.	2-[(2-{3-[(2-methoxy-4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]acetamide
705.	4-[(3-{4-[(1,5-dihydroxypentan-3-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxybenzene-1-sulfonamide
706.	N-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)acetamide
707.	3-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-1-(1-methylpiperidin-4-yl)urea
708.	3-methoxy-4-{[3-(4-{[(1-methylpiperidin-4-yl)carbamoyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
709.	N-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-4-methylpiperazine-1-carboxamide
710.	N-(2-{3-[(4-carbamoyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-4-methylpiperazine-1-carboxamide
711.	3-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-1-[(1S,4S)-4-(dimethylamino)cyclohexyl]urea

Mol #	IUPAC name
712.	1-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-3-(pyridin-4-yl)urea
713.	3-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-1-[(1R,4R)-4-(dimethylamino)cyclohexyl]urea
714.	3-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-1-[1-(2-methoxyethyl)piperidin-4-yl]urea
715.	3-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-1-[1-(oxan-4-yl)piperidin-4-yl]urea
716.	1-[1-(2,3-dihydroxypropyl)piperidin-4-yl]-3-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)urea
717.	2-(4-{[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)carbamoyl]amino}piperidin-1-yl)acetamide
718.	3-methoxy-4-({3-[4-({2-oxaspiro[3.3]heptan-6-yl} amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl} amino)benzene-1-sulfonamide
719.	[1-(chloromethyl)-3-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclobutyl]methanol
720.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-{2-oxaspiro[3.3]heptan-6-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
721.	4-({3-[4-({2-azaspiro[3.3]heptan-6-yl} amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl} amino)-3-methoxybenzene-1-sulfonamide
722.	N-{2-azaspiro[3.3]heptan-6-yl}-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
723.	3-methoxy-N-methyl-4-{3-(4-{[(1R,4R)-4-(methylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
724.	3-methoxy-N-methyl-4-{3-(4-{[(1R,4R)-4-aminocyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
725.	3-methoxy-N-methyl-4-{3-(4-{[(1S,4S)-4-aminocyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
726.	rel-(1R,3R)-N ¹ -(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,3-diamine

Mol #	IUPAC name
727.	rac-(1R,3S)-N ¹ -(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,3-diamine
728.	(1R,2S)-N ¹ -(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,2-diamineQ
729.	rac-(1R,2S)-N ¹ -(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,2-diamine
730.	rel-(1R,3S)-3-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexan-1-ol
731.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-hydroxy-4-methylcyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
732.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-hydroxy-4-methylcyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
733.	4-[(3-{4-[(4-cyanocyclohexyl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxy-N-methylbenzamide
734.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-cyanocyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
735.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-cyanocyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
736.	3-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexane-1-carboxylic acid
737.	2-fluoro-N ¹ -(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,4-diamine
738.	(1R,2R,4S)-2-fluoro-N ¹ -(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,4-diamine
739.	2-fluoro-N ¹ -(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ⁴ -methylcyclohexane-1,4-diamine
740.	(1R,2R,4S)-2-fluoro-N ¹ -(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ⁴ -methylcyclohexane-1,4-diamine
741.	2-fluoro-N ¹ -(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ⁴ ,N ⁴ -dimethylcyclohexane-1,4-diamine

Mol #	IUPAC name
742.	(1R,2R,4S)-2-fluoro-N ¹ -(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ⁴ ,N ⁴ -dimethylcyclohexane-1,4-diamine
743.	(3S,4R)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexan-1-ol
744.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-[bis(2-hydroxyethyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
745.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-[bis(2-hydroxyethyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
746.	4-((3-(4-(((1R,4R)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
747.	4-((3-(4-(((1S,4S)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
748.	3-methoxy-N-(1,2-oxazol-3-yl)-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
749.	3-methoxy-N-(oxan-4-yl)-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
750.	3-methoxy-N-(1,2-oxazol-3-yl)-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
751.	3-methoxy-N-(oxan-4-yl)-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
752.	N-(3-(4-(((1S,4S)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)propionamide
753.	N-(3-(4-(((1R,4R)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)propionamide
754.	3-methoxy-N-(5-methyl-1,2-oxazol-3-yl)-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide

Mol #	IUPAC name
755.	3-methoxy-N-(5-methyl-1,2-oxazol-3-yl)-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
756.	(1S,4S)-N ⁴ -(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ¹ -(2-methoxyethyl)-N ¹ -methylcyclohexane-1,4-diamine
757.	(1R,4R)-N ⁴ -(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ¹ -(2-methoxyethyl)-N ¹ -methylcyclohexane-1,4-diamine
758.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-[(3S,4S)-3,4-dihydroxypyrrolidin-1-yl]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
759.	4-((3-(4-(((1R,4R)-4-((3R,4R)-3,4-dihydroxypyrrolidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
760.	4-((3-(4-(((1R,4S)-4-((3S,4S)-3,4-dihydroxypyrrolidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
761.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-[bis(2-methoxyethyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
762.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-[bis(2-methoxyethyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
763.	4-({3-[4-({1,4-dioxaspiro[4.5]decan-8-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)-3-methoxybenzene-1-sulfonamide
764.	N-{1,4-dioxaspiro[4.5]decan-8-yl}-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
765.	3-methoxy-4-[(3-{4-[(4-oxocyclohexyl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
766.	4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexan-1-one
767.	(1R,4R)-N ⁴ -[2-(3-{[2-methoxy-4-(morpholine-4-sulfonyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine

Mol #	IUPAC name
768.	(1S,4S)- N ⁴ -[2-(3-{[2-methoxy-4-(morpholine-4-sulfonyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
769.	N,N-bis(2-hydroxyethyl)-3-methoxy-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
770.	N,N-bis(2-hydroxyethyl)-3-methoxy-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
771.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
772.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
773.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
774.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
775.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
776.	(1R,4R)- N ⁴ -{2-[3-(2-methoxy-4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl]amino)prop-1-yn-1-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
777.	(1R,4R)- N ⁴ -(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-[(oxiran-2-yl)methyl]-1H-indol-4-yl)-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
778.	2-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1H-indol-1-yl)methyl]prop-2-enenitrile
779.	5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenol
780.	5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenol
781.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile

Mol #	IUPAC name
782.	2-(5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}phenoxy)acetonitrile
783.	N-(3-methoxy-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}benzenesulfonyl)acetamide
784.	N-(3-methoxy-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}benzenesulfonyl)acetamide
785.	N-(3-methoxy-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}benzenesulfonyl)propanamide
786.	N-(3-methoxy-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}benzenesulfonyl)propanamide
787.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}phenoxy)ethan-1-ol
788.	2-(5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}phenoxy)ethan-1-ol
789.	(1R,4R)- N ⁴ -[2-(3-{[4-methanesulfonyl-2-(2-methoxyethoxy)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
790.	N-(3-(4-(((1R,4R)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)isobutyramide
791.	N-(3-(4-(((1S,4S)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)isobutyramide
792.	(1R,4R)- N ⁴ -[2-(3-{[4-methanesulfonyl-2-(2,2,2-trifluoroethoxy)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
793.	(1S,4S)- N ⁴ -[2-(3-{[4-methanesulfonyl-2-(2,2,2-trifluoroethoxy)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
794.	(1S,4S)- N ⁴ -{2-[3-(2-amino-4-methanesulfonylphenoxy)prop-1-yn-1-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl}-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
795.	(1R,4R)- N ⁴ -(2-{3-[(2-ethoxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine

Mol #	IUPAC name
796.	(1S,4S)- N ⁴ -(2-{3-[(2-ethoxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
797.	3-hydroxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino} benzamide
798.	3-hydroxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino} benzamide
799.	3-(2-methoxyethoxy)-N-methyl-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino} benzamide
800.	(1R,4R)- N ⁴ -{2-[3-(2-amino-4-methanesulfonylphenoxy)prop-1-yn-1-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl}-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
801.	N-ethyl-3-methoxy-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino} benzamide
802.	N-ethyl-3-methoxy-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino} benzamide
803.	3-(2-methoxyethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino} benzamide
804.	3-(2-fluoroethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino} benzamide
805.	3-(2-fluoroethoxy)-N-methyl-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino} benzamide
806.	3-(fluoromethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino} benzamide
807.	3-(fluoromethoxy)-N-methyl-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino} benzamide
808.	(1S,4S)- N ⁴ -(2-{3-[4-methanesulfonyl-2-(methylamino)phenoxy]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine

Mol #	IUPAC name
809.	(1R,4R)-N ⁴ -(2-{3-[4-methanesulfonyl-2-(methylamino)phenoxy]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
810.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-(methylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
811.	(1S,4S)-N ⁴ -(2-{3-[2-(dimethylamino)-4-methanesulfonylphenoxy]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
812.	(1R,4R)-N ⁴ -(2-{3-[2-(dimethylamino)-4-methanesulfonylphenoxy]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
813.	3-(cyanomethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
814.	3-(2-cyanoethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
815.	N-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]oxy}phenyl)acetamide
816.	N-(2-((3-(4-(((1S,4S)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)oxy)-5-(methylsulfonyl)phenyl)acetamide
817.	(1R,4R)-N ¹ -(2-(3-((2-(fluoromethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ⁴ ,N ⁴ -dimethylcyclohexane-1,4-diamine
818.	(1S,4S)-N ¹ -(2-(3-((2-(fluoromethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ⁴ ,N ⁴ -dimethylcyclohexane-1,4-diamine
819.	(1R,4R)-N ⁴ -[2-(3-{[4-(ethanesulfonyl)-2-methoxyphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
820.	(1S,4S)-N ⁴ -[2-(3-{[4-(ethanesulfonyl)-2-methoxyphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
821.	2-(3-methoxy-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenyl)-2-methylpropanenitrile
822.	2-(4-((3-(4-(((1S,4S)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)-2-methylpropanenitrile
823.	3-(cyanomethoxy)-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide

Mol #	IUPAC name
824.	3-(cyanomethoxy)-4-((3-(4-(((1S,4S)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
825.	3-(3-(4-(((1R,4R)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-6-(methylsulfonyl)benzo[d]oxazol-2(3H)-one
826.	3-(3-(4-(((1S,4S)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-6-(methylsulfonyl)benzo[d]oxazol-2(3H)-one
827.	3-methoxy-N,N-dimethyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino} benzene-1-sulfonamide
828.	(1R,4R)-N ¹ -(2-(3-(((3S,4R)-3-methoxytetrahydro-2H-pyran-4-yl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ⁴ ,N ⁴ -dimethylcyclohexane-1,4-diamine
829.	(1S,4S)-N ¹ -(2-(3-(((3S,4R)-3-methoxytetrahydro-2H-pyran-4-yl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ⁴ ,N ⁴ -dimethylcyclohexane-1,4-diamine
830.	(1R,4R)-N ⁴ -(2-{3-[(4-chloro-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
831.	(1S,4S)-N ¹ -(2-(3-((4-chloro-2-methoxyphenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ⁴ ,N ⁴ -dimethylcyclohexane-1,4-diamine
832.	4-((3-(4-(((1R,4R)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-2-fluoro-5-methoxybenzamide
833.	4-((3-(4-(((1S,4S)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-2-fluoro-5-methoxybenzamide
834.	(1R,4R)-N ⁴ -[2-(3-{[2-methoxy-4-(trifluoromethyl)phenyl]amino} prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
835.	(1S,4S)-N ¹ -(2-(3-((2-methoxy-4-(trifluoromethyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ⁴ ,N ⁴ -dimethylcyclohexane-1,4-diamine
836.	2-fluoro-5-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino} benzamide
837.	4-((3-(4-(((1S,4S)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-2-fluoro-5-methoxy-N-methylbenzamide
838.	(1S,4S)-N ⁴ -[2-(3-{[4-methanesulfonyl-2-(trifluoromethyl)phenyl]amino} prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine

Mol #	IUPAC name
839.	(1R,4R)-N ⁴ -[2-(3-{[4-methanesulfonyl-2-(trifluoromethyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
840.	(1R,4R)-N ⁴ -(2-{3-[(4-methanesulfonyl-2-methylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
841.	(1S,4S)-N ¹ ,N ¹ -dimethyl-N ⁴ -(2-(3-((2-methyl-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,4-diamine
842.	(1R,4R)-N ⁴ -[2-(3-{[4-methanesulfonyl-2-(trifluoromethoxy)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
843.	(1S,4S)-N ¹ ,N ¹ -dimethyl-N ⁴ -(2-(3-((4-(methylsulfonyl)-2-(trifluoromethoxy)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,4-diamine
844.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(diethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
845.	4-((3-(4-(((1S,4S)-4-(diethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide
846.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(diethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
847.	4-((3-(4-(((1S,4S)-4-(diethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
848.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(diethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
849.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
850.	2-(5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
851.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide

Mol #	IUPAC name
852.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
853.	N-ethyl-3-methoxy-4-{[3-(4-{[(1R,4R)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
854.	N-ethyl-3-methoxy-4-((3-(4-(((1S,4S)-4-((2-methoxyethyl)(methyl)amino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
855.	(1R,4R)-N ¹ -(2-(3-((2-(fluoromethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ⁴ -(2-methoxyethyl)-N ⁴ -methylcyclohexane-1,4-diamine
856.	(1S,4S)-N ¹ -(2-(3-((2-(fluoromethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ⁴ -(2-methoxyethyl)-N ⁴ -methylcyclohexane-1,4-diamine
857.	3-(fluoromethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
858.	3-(fluoromethoxy)-N-methyl-4-{[3-(4-{[(1S,4S)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
859.	3-(fluoromethoxy)-4-((3-(4-(((1S,4S)-4-((2-methoxyethyl)(methyl)amino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-N-methylbenzamide
860.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
861.	3-methoxy-4-((3-(4-(((1S,4S)-4-((2-methoxyethyl)(methyl)amino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
862.	(1R,4R)-N ¹ ,N ¹ -diethyl-N ⁴ -(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,4-diamine

Mol #	IUPAC name
863.	(1S,4S)-N ¹ ,N ¹ -diethyl-N ⁴ -(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,4-diamine
864.	3-(cyanomethoxy)-4-{[3-(4-{[(1R,4R)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
865.	3-(cyanomethoxy)-4-{[3-(4-{[(1S,4S)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
866.	3-(fluoromethoxy)-4-{[3-(4-{[(1R,4R)-4-[bis(2-methoxyethyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
867.	3-(fluoromethoxy)-4-{[3-(4-{[(1S,4S)-4-[bis(2-methoxyethyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
868.	3-(fluoromethoxy)-4-{[3-(4-{[(1R,4R)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
869.	3-(fluoromethoxy)-4-{[3-(4-{[(1S,4S)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
870.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
871.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
872.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
873.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
874.	2-(2-{3-[4-methanesulfonyl-2-methoxyphenyl]amino}prop-1-yn-1-yl)-4-{[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino}-1H-indol-1-yl]acetonitrile
875.	4-({3-[1-(2-fluoroethyl)-4-{[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino}-1H-indol-2-yl]prop-2-yn-1-yl}amino)-3-methoxy-N-methylbenzamide

Mol #	IUPAC name
876.	1-(2-fluoroethyl)-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]-1H-indol-4-amine
877.	4-({3-[1-(cyanomethyl)-4-{{(1R,4R)-4-(morpholin-4-yl)cyclohexyl}amino}-1H-indol-2-yl]prop-2-yn-1-yl}amino)-3-methoxy-N-methylbenzamide
878.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-propyl-N-[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]-1H-indol-4-amine
879.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2-methylpropyl)-N-[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]-1H-indol-4-amine
880.	1-(2,2-difluoroethyl)-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]-1H-indol-4-amine
881.	3-methoxy-4-((3-(4-(((1R,4R)-4-morpholinocyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
882.	3-methoxy-4-((3-(4-(((1S,4S)-4-morpholinocyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
883.	N-ethyl-3-methoxy-4-{{3-(4-{{(1R,4R)-4-(morpholin-4-yl)cyclohexyl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}benzamide
884.	N-ethyl-3-methoxy-4-((3-(4-(((1S,4S)-4-morpholinocyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
885.	2-(5-methanesulfonyl-2-{{3-(4-{{(1R,4R)-4-(morpholin-4-yl)cyclohexyl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}phenoxy)acetonitrile
886.	2-(5-methanesulfonyl-2-{{3-(4-{{(1S,4S)-4-(morpholin-4-yl)cyclohexyl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}phenoxy)acetonitrile
887.	3-methoxy-N-methyl-4-{{3-(4-{{(1R,4R)-4-(morpholin-4-yl)cyclohexyl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}benzene-1-sulfonamide
888.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-(3-methanesulfonylazetidin-1-yl)cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
889.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1S,4S)-4-(3-(methylsulfonyl)azetidin-1-yl)cyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
890.	3-methoxy-4-{{3-(4-{{(1R,4R)-4-(3-methanesulfonylazetidin-1-yl)cyclohexyl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}benzene-1-sulfonamide

Mol #	IUPAC name
891.	3-methoxy-4-((3-(4-(((1S,4S)-4-(3-(methylsulfonyl)azetidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
892.	3-methoxy-N-methyl-4-{{3-(4-{{(1R,4R)-4-(3-methanesulfonylazetidin-1-yl)cyclohexyl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}benzamide
893.	3-methoxy-N-methyl-4-((3-(4-(((1S,4S)-4-(3-(methylsulfonyl)azetidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
894.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{2-azaspiro[3.3]heptan-2-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
895.	N-((1S,4S)-4-(2-azaspiro[3.3]heptan-2-yl)cyclohexyl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
896.	3-methoxy-N-methyl-4-{{3-(4-{{(1R,4R)-4-{2-azaspiro[3.3]heptan-2-yl}cyclohexyl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}benzamide
897.	4-((3-(4-(((1S,4S)-4-(2-azaspiro[3.3]heptan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide
898.	3-methoxy-4-{{3-(4-{{(1R,4R)-4-{2-azaspiro[3.3]heptan-2-yl}cyclohexyl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}benzene-1-sulfonamide
899.	4-((3-(4-(((1S,4S)-4-(2-azaspiro[3.3]heptan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
900.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-(2-azaspiro[3.3]heptan-6-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
901.	4-((3-(4-((2-azaspiro[3.3]heptan-6-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
902.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
903.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
904.	3-methoxy-4-{{3-(4-{{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
905.	3-methoxy-4-{{3-(4-{{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
906.	N-(3-methoxy-4-{{3-(4-{{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzenesulfonyl)propanamide
907.	N-(3-methoxy-4-{{3-(4-{{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzenesulfonyl)propanamide
908.	N-(3-methoxy-4-{{3-(4-{{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzenesulfonyl)acetamide
909.	N-(3-methoxy-4-{{3-(4-{{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzenesulfonyl)acetamide
910.	N-((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((2-(2-fluoroethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
911.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((2-(2-fluoroethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
912.	3-methoxy-4-{{3-(4-{{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
913.	3-methoxy-4-{{3-(4-{{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide

Mol #	IUPAC name
914.	5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenol
915.	5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenol
916.	N-(3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)propionamide
917.	N-(3-(4-(((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)propionamide
918.	N-(2-hydroxy-4-methanesulfonylphenyl)-2-methyl-N-[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]propanamide
919.	N-(3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)isobutyramide
920.	2-(3-{[4-methanesulfonyl-2-(2-methoxyethoxy)phenyl]amino}prop-1-yn-1-yl)-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
921.	2-(3-{[4-methanesulfonyl-2-(2-methoxyethoxy)phenyl]amino}prop-1-yn-1-yl)-N-[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
922.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
923.	2-(5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile

Mol #	IUPAC name
924.	5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenyl 2-methylpropanoate
925.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)ethan-1-ol
926.	2-(5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)ethan-1-ol
927.	N-(3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)acetamide
928.	5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenyl 2-methylpropanoate
929.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
930.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
931.	2-(3-{[4-methanesulfonyl-2-(2,2,2-trifluoroethoxy)phenyl]amino}prop-1-yn-1-yl)-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
932.	2-(3-{[4-methanesulfonyl-2-(2,2,2-trifluoroethoxy)phenyl]amino}prop-1-yn-1-yl)-N-[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
933.	2-[3-(2-amino-4-methanesulfonylphenoxy)prop-1-yn-1-yl]-N-[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
934.	2-{3-[(2-ethoxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
935.	2-{3-[(2-ethoxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
936.	3-(2-methoxyethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
937.	3-(2-methoxyethoxy)-N-methyl-4-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
938.	N-ethyl-3-methoxy-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
939.	N-ethyl-3-methoxy-4-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
940.	3-(2-fluoroethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
941.	3-(2-fluoroethoxy)-N-methyl-4-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
942.	3-(cyanomethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
943.	3-(cyanomethoxy)-N-methyl-4-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
944.	2-{3-[4-methanesulfonyl-2-(methylamino)phenoxy]prop-1-yn-1-yl}-N-[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
945.	2-{3-[4-methanesulfonyl-2-(methylamino)phenoxy]prop-1-yn-1-yl}-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
946.	2-[3-(2-amino-4-methanesulfonylphenoxy)prop-1-yn-1-yl]-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
947.	N-((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-(2-amino-4-(methylsulfonyl)phenoxy)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
948.	3-hydroxy-N-methyl-4-{{3-(4-{{(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}benzamide
949.	3-methoxy-4-[(3-{4-[(4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzonitrile
950.	3-methoxy-4-{{3-(4-{{(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}benzonitrile
951.	2-(3-methoxy-4-{{3-(4-{{(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}phenyl)-2-methylpropanenitrile
952.	2-(4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)-2-methylpropanenitrile
953.	3-(fluoromethoxy)-N-methyl-4-{{3-(4-{{(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}benzamide
954.	4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-(fluoromethoxy)-N-methylbenzamide
955.	3-(2-cyanoethoxy)-N-methyl-4-{{3-(4-{{(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}benzamide
956.	4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-(2-cyanoethoxy)-N-methylbenzamide
957.	2-(3-{{2-(fluoromethoxy)-4-methanesulfonylphenyl}amino}prop-1-yn-1-yl)-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
958.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((2-(fluoromethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
959.	3-(cyanomethoxy)-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
960.	4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-(cyanomethoxy)benzenesulfonamide
961.	3-(fluoromethoxy)-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
962.	3-(fluoromethoxy)-4-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
963.	4-((3-(4-(((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzenesulfonamide
964.	4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzenesulfonamide
965.	N-((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((4-chloro-2-methoxyphenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
966.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((4-chloro-2-methoxyphenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
967.	4-((3-(4-(((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N,N-dimethylbenzenesulfonamide
968.	4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N,N-dimethylbenzenesulfonamide

Mol #	IUPAC name
969.	N-((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((4-(ethylsulfonyl)-2-methoxyphenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
970.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((4-(ethylsulfonyl)-2-methoxyphenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
971.	N-((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-(((3S,4R)-3-methoxytetrahydro-2H-pyran-4-yl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
972.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-(((3S,4R)-3-methoxytetrahydro-2H-pyran-4-yl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
973.	2-fluoro-5-methoxy-4-{{3-(4-{{(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl}amino}benzamide
974.	4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-2-fluoro-5-methoxybenzamide
975.	2-fluoro-5-methoxy-N-methyl-4-{{3-(4-{{(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl}amino}benzamide
976.	4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-2-fluoro-5-methoxy-N-methylbenzamide
977.	2-(3-{{2-methoxy-4-(trifluoromethyl)phenyl}amino}prop-1-yn-1-yl)-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
978.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((2-methoxy-4-(trifluoromethyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
979.	4-((3-(4-(((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoic acid
980.	4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoic acid

Mol #	IUPAC name
981.	2-fluoro-5-methoxy-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzoic acid
982.	4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-2-fluoro-5-methoxybenzoic acid
983.	2-{3-[(4-methanesulfonyl-2-methylphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
984.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((2-methyl-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
985.	2-(3-{[4-methanesulfonyl-2-(trifluoromethoxy)phenyl]amino}prop-1-yn-1-yl)-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
986.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((4-(methylsulfonyl)-2-(trifluoromethoxy)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
987.	2-(3-{[4-methanesulfonyl-2-(trifluoromethyl)phenyl]amino}prop-1-yn-1-yl)-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
988.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((4-(methylsulfonyl)-2-(trifluoromethyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
989.	2-{3-[(2-chloro-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
990.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((2-chloro-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
991.	3-(3-(4-(((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-6-(methylsulfonyl)benzo[d]oxazol-2(3H)-one

Mol #	IUPAC name
992.	3-(3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-6-(methylsulfonyl)benzo[d]oxazol-2(3H)-one
993.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1S,4S)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
994.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
995.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
996.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
997.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
998.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
999.	3-(cyanomethoxy)-4-{[3-(4-{[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1000.	3-(cyanomethoxy)-4-{[3-(4-{[(1S,4S)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1001.	2-(3-methoxy-4-{[3-(4-{[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenyl)-2-methylpropanenitrile
1002.	2-(4-((3-(4-(((1S,4S)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)-2-methylpropanenitrile

Mol #	IUPAC name
1003.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
1004.	2-(5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
1005.	N-((4-((3-(4-(((1R,4R)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)sulfonyl)acetamide
1006.	N-((4-((3-(4-(((1S,4S)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)sulfonyl)acetamide
1007.	N-((4-((3-(4-(((1R,4R)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)sulfonyl)-2-aminoacetamide
1008.	N-((4-((3-(4-(((1S,4S)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)sulfonyl)-2-aminoacetamide
1009.	methyl 2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetate
1010.	methyl 2-(2-((3-(4-(((1S,4S)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-5-(methylsulfonyl)phenoxy)acetate
1011.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetic acid
1012.	2-(2-((3-(4-(((1S,4S)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-5-(methylsulfonyl)phenoxy)acetic acid
1013.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
1014.	2-(3-{[4-(ethanesulfonyl)-2-methoxyphenyl]amino}prop-1-yn-1-yl)-N-[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1015.	2-(3-{[4-(ethanesulfonyl)-2-methoxyphenyl]amino}prop-1-yn-1-yl)-N-[(1S,4S)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1016.	3-(fluoromethoxy)-4-{[3-(4-{[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1017.	3-(fluoromethoxy)-4-{[3-(4-{[(1S,4S)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1018.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{6-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1019.	4-((3-(4-(((1S,4S)-4-(6-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide
1020.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{6-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1021.	4-((3-(4-(((1S,4S)-4-(6-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1022.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{6-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1023.	N-((1S,4S)-4-(6-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1024.	N-((1R,4R)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)-2-(3-((2-(fluoromethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1025.	N-((1S,4S)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)-2-(3-((2-(fluoromethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
1026.	4-(3-(4-(((1R,4R)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-7-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one
1027.	4-(((3-(4-(((1R,4R)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzenesulfonamide
1028.	4-(((3-(4-(((1S,4S)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzenesulfonamide
1029.	N-(((1R,4R)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)-2-(3-((2-ethoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1030.	N-(((1S,4S)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)-2-(3-((2-ethoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1031.	3-methoxy-4-{{3-(4-{{(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}benzamide
1032.	4-(((3-(4-(((1S,4S)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzamide
1033.	3-methoxy-4-{{3-(4-{{(1R,4R)-4-{6-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}benzamide
1034.	4-(((3-(4-(((1S,4S)-4-(6-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzamide
1035.	2-fluoro-5-methoxy-N-methyl-4-{{3-(4-{{(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}benzamide
1036.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-(((1R,4R)-4-(3-methoxypyrrolidin-1-yl)cyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1037.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-(((1S,4S)-4-(3-methoxypyrrolidin-1-yl)cyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
1038.	3-methoxy-4-((3-(4-(((1R,4R)-4-(3-methoxypyrrolidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1039.	3-methoxy-4-((3-(4-(((1S,4S)-4-(3-methoxypyrrolidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1040.	2-(3-{[2-(fluoromethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-N-[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1041.	2-(3-{[2-(fluoromethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-N-[(1S,4S)-4-(morpholin-4-yl)cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1042.	3-(cyanomethoxy)-4-{[3-(4-{[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1043.	3-(cyanomethoxy)-4-{[3-(4-{[(1S,4S)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1044.	3-(fluoromethoxy)-4-{[3-(4-{[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1045.	3-(fluoromethoxy)-4-{[3-(4-{[(1S,4S)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1046.	2-(3-((2-ethoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1R,4R)-4-morpholinocyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1047.	2-(3-((2-ethoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1S,4S)-4-morpholinocyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1048.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-(3-methoxypiperidin-1-yl)cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1049.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1S,4S)-4-(3-methoxypiperidin-1-yl)cyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1050.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-(4-methoxypiperidin-1-yl)cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1051.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1S,4S)-4-(4-methoxypiperidin-1-yl)cyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1052.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(4-methoxypiperidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide

Mol #	IUPAC name
1053.	3-methoxy-4-((3-(4-(((1S,4S)-4-(4-methoxypiperidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-N-methylbenzamide
1054.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(4-methoxypiperidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1055.	3-methoxy-4-((3-(4-(((1S,4S)-4-(4-methoxypiperidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1056.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(3-methoxypiperidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1057.	3-methoxy-4-((3-(4-(((1S,4S)-4-(3-methoxypiperidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-N-methylbenzamide
1058.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(3-methoxypiperidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1059.	3-methoxy-4-((3-(4-(((1S,4S)-4-(3-methoxypiperidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1060.	3-methoxy-4-((3-(4-(((1R,4R)-4-morpholinocyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1061.	3-methoxy-4-((3-(4-(((1S,4S)-4-morpholinocyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1062.	4-[(1R,4R)-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexyl]-1λ ⁶ -thiomorpholine-1,1-dione
1063.	4-((1S,4S)-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)cyclohexyl)thiomorpholine 1,1-dioxide
1064.	4-[(1R,4R)-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexyl]-1λ ⁴ -thiomorpholin-1-one
1065.	4-[(1S,4S)-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexyl]-1λ ⁴ -thiomorpholin-1-one
1066.	4-((3-(4-(((1R,4R)-4-(1,1-dioxidothiomorpholino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide
1067.	4-((3-(4-(((1S,4S)-4-(1,1-dioxidothiomorpholino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide

Mol #	IUPAC name
1068.	4-((1S,4S)-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)cyclohexyl)thiomorpholine 1-oxide
1069.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(1-oxo-1λ ⁴ -thiomorpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1070.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(1-oxo-1λ ⁴ -thiomorpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1071.	3-methoxy-4-((3-(4-(((1S,4S)-4-(1-oxidothiomorpholino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1072.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(1,1-dioxo-1λ ⁶ -thiomorpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1073.	4-((3-(4-(((1S,4S)-4-(1,1-dioxidothiomorpholino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1074.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1S,4S)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1075.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1076.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1077.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1078.	4-((3-(4-(((1S,4S)-4-(2-oxa-7-azaspiro[3.5]nonan-7-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1079.	3-(cyanomethoxy)-4-{[3-(4-{[(1R,4R)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide

Mol #	IUPAC name
1080.	3-(cyanomethoxy)-4-{[3-(4-{[(1S,4S)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1081.	3-(fluoromethoxy)-4-{[3-(4-{[(1R,4R)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1082.	3-(fluoromethoxy)-4-{[3-(4-{[(1S,4S)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1083.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{1-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1084.	N-[(1S,4S)-4-(1-oxa-7-azaspiro[3.5]nonan-7-yl)cyclohexyl]-2-(3-[(2-methoxy-4-(methylsulfonyl)phenyl)amino]prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1085.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{1-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1086.	4-[(3-(4-(((1S,4S)-4-(1-oxa-7-azaspiro[3.5]nonan-7-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino]-3-methoxy-N-methylbenzamide
1087.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{1-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1088.	4-[(3-(4-(((1S,4S)-4-(1-oxa-7-azaspiro[3.5]nonan-7-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino]-3-methoxybenzenesulfonamide
1089.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
1090.	2-(5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile

Mol #	IUPAC name
1091.	2-(3-{[2-(fluoromethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-N-[(1R,4R)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1092.	2-(3-{[2-(fluoromethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-N-[(1S,4S)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1093.	N-((1R,4R)-4-(2-oxa-7-azaspiro[3.5]nonan-7-yl)cyclohexyl)-2-(3-((2-ethoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1094.	N-((1S,4S)-4-(2-oxa-7-azaspiro[3.5]nonan-7-yl)cyclohexyl)-2-(3-((2-ethoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1095.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1096.	N-((1R,4R)-4-(2-oxa-7-azaspiro[3.5]nonan-7-yl)cyclohexyl)-2-(3-((4-(ethylsulfonyl)-2-methoxyphenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1097.	N-((1S,4S)-4-(2-oxa-7-azaspiro[3.5]nonan-7-yl)cyclohexyl)-2-(3-((4-(ethylsulfonyl)-2-methoxyphenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1098.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1099.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1S,4S)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1100.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1101.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide

Mol #	IUPAC name
1102.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1103.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1104.	2-{3-[(2-ethoxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1105.	2-{3-[(2-ethoxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-[(1S,4S)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1106.	N-ethyl-3-methoxy-4-{[3-(4-{[(1R,4R)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1107.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
1108.	2-(2-((3-(4-(((1S,4S)-4-(6-oxa-3-azabicyclo[3.1.1]heptan-3-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-5-(methylsulfonyl)phenoxy)acetonitrile
1109.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-oxa-8-azaspiro[4.5]decan-8-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1110.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{2-oxa-8-azaspiro[4.5]decan-8-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1111.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{2-oxa-8-azaspiro[4.5]decan-8-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1112.	4-((3-(4-(((1R,4R)-4-(2-oxa-8-azaspiro[4.5]decan-8-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-benzo[d]imidazol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide

Mol #	IUPAC name
1113.	4-((3-(4-(((1S,4S)-4-(2-oxa-8-azaspiro[4.5]decan-8-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-benzo[d]imidazol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1114.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{3-oxa-9-azaspiro[5.5]undecan-9-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1115.	N-((1S,4S)-4-(3-oxa-9-azaspiro[5.5]undecan-9-yl)cyclohexyl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1116.	3-methoxy-N-methyl-4-{[3-(4-[(1R,4R)-4-{3-oxa-9-azaspiro[5.5]undecan-9-yl}cyclohexyl]amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1117.	4-((3-(4-(((1S,4S)-4-(3-oxa-9-azaspiro[5.5]undecan-9-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide
1118.	3-methoxy-4-{[3-(4-[(1R,4R)-4-{3-oxa-9-azaspiro[5.5]undecan-9-yl}cyclohexyl]amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1119.	4-((3-(4-(((1S,4S)-4-(3-oxa-9-azaspiro[5.5]undecan-9-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1120.	3-methoxy-N-methyl-4-{[3-(4-[(1R,4R)-4-(pyrrolidin-1-yl)cyclohexyl]amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1121.	3-methoxy-N-methyl-4-((3-(4-(((1S,4S)-4-(pyrrolidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
1122.	3-methoxy-4-{[3-(4-[(1R,4R)-4-(pyrrolidin-1-yl)cyclohexyl]amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1123.	3-methoxy-4-((3-(4-(((1S,4S)-4-(pyrrolidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1124.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-(pyrrolidin-1-yl)cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1125.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1S,4S)-4-(pyrrolidin-1-yl)cyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
1126.	-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-(3-methoxypyrrolidin-1-yl)cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1127.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(3-methoxypyrrolidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1128.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(3-methoxypyrrolidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1129.	3-methoxy-4-((3-(4-(((1S,4S)-4-(3-methoxypyrrolidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-N-methylbenzamide
1130.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{hexahydro-1H-furo[3,4-c]pyrrol-5-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1131.	3-methoxy-4-((3-(4-(((1S,4S)-4-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1132.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{hexahydro-1H-furo[3,4-c]pyrrol-5-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1133.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1R,4R)-4-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)cyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1134.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{hexahydro-1H-furo[3,4-c]pyrrol-5-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1135.	3-methoxy-N-methyl-4-((3-(4-(((1S,4S)-4-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
1136.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-[4-(trifluoromethyl)piperidin-1-yl]cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1137.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-N-((1S,4S)-4-(4-(trifluoromethyl)piperidin-1-yl)cyclohexyl)-1H-indol-4-amine

Mol #	IUPAC name
1138.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-[4-(trifluoromethyl)piperidin-1-yl]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1139.	3-methoxy-N-methyl-4-((3-(1-(2,2,2-trifluoroethyl)-4-(((1S,4S)-4-(4-(trifluoromethyl)piperidin-1-yl)cyclohexyl)amino)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
1140.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-[4-(trifluoromethyl)piperidin-1-yl]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1141.	3-methoxy-4-((3-(1-(2,2,2-trifluoroethyl)-4-(((1S,4S)-4-(4-(trifluoromethyl)piperidin-1-yl)cyclohexyl)amino)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1142.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-(4-methanesulfonylpiperidin-1-yl)cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1143.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1S,4S)-4-(4-(methylsulfonyl)piperidin-1-yl)cyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1144.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(4-methanesulfonylpiperidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1145.	3-methoxy-N-methyl-4-((3-(4-(((1S,4S)-4-(4-(methylsulfonyl)piperidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
1146.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(4-methanesulfonylpiperidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1147.	3-methoxy-4-((3-(4-(((1S,4S)-4-(4-(methylsulfonyl)piperidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1148.	1-[(1S,3R)-3-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexyl]-4,5-dihydro-1H-1,2,3,4-tetrazol-5-one
1149.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1R,4R)-4-morpholinocyclohexyl)-1-(oxiran-2-ylmethyl)-1H-indol-4-amine

Mol #	IUPAC name
1150.	2-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-4-(((1R,4R)-4-morpholinocyclohexyl)amino)-1H-indol-1-yl)methyl)acrylonitrile
1151.	N-((1R,4R)-4-(2-oxa-8-azaspiro[4.5]decan-8-yl)cyclohexyl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-benzo[d]imidazol-4-amine
1152.	N-((1S,4S)-4-(2-oxa-8-azaspiro[4.5]decan-8-yl)cyclohexyl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-benzo[d]imidazol-4-amine
1153.	4-((3-(4-(((1R,4R)-4-(2-oxa-8-azaspiro[4.5]decan-8-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-benzo[d]imidazol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide
1154.	4-((3-(4-(((1S,4S)-4-(2-oxa-8-azaspiro[4.5]decan-8-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-benzo[d]imidazol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide
1155.	1-[1-(2-hydroxyethyl)piperidin-4-yl]-3-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)urea
1156.	3-methoxy-4-({3-[4-({2-oxaspiro[3.3]heptan-6-yl} amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl} amino)benzene-1-sulfonamide
1157.	[1-(chloromethyl)-3-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclobutyl]methanol
1158.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-{2-oxaspiro[3.3]heptan-6-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1159.	4-({3-[4-({2-azaspiro[3.3]heptan-6-yl} amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl} amino)-3-methoxybenzene-1-sulfonamide
1160.	N-{2-azaspiro[3.3]heptan-6-yl}-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1161.	3-methoxy-N-methyl-4-{3-[4-({(1R,4R)-4-(methylamino)cyclohexyl} amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino} benzamide
1162.	3-methoxy-N-methyl-4-{3-[4-({(1R,4R)-4-aminocyclohexyl} amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino} benzamide
1163.	3-methoxy-N-methyl-4-{3-[4-({(1S,4S)-4-aminocyclohexyl} amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino} benzamide

Mol #	IUPAC name
1164.	rel-(1R,3R)-N ¹ -(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,3-diamine
1165.	rac-(1R,3S)-N ¹ -(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,3-diamine
1166.	(1R,2S)-N ¹ -(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,2-diamine
1167.	rac-(1R,2S)-N ¹ -(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,2-diamine
1168.	rel-(1R,3S)-3-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexan-1-ol
1169.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-hydroxy-4-methylcyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1170.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-hydroxy-4-methylcyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1171.	4-[(3-{4-[(4-cyanocyclohexyl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxy-N-methylbenzamide
1172.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-cyanocyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1173.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-cyanocyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1174.	3-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexane-1-carboxylic acid
1175.	2-fluoro-N ¹ -(2-{3-[(2-methoxy-4-(methylsulfonyl)phenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,4-diamine
1176.	(1R,2R,4S)-2-fluoro-N ¹ -(2-{3-[(2-methoxy-4-(methylsulfonyl)phenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,4-diamine
1177.	2-fluoro-N ¹ -(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ⁴ -methylcyclohexane-1,4-diamine
1178.	(1R,2R,4S)-2-fluoro-N ¹ -(2-{3-[(2-methoxy-4-(methylsulfonyl)phenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ⁴ -methylcyclohexane-1,4-diamine

Mol #	IUPAC name
1179.	2-fluoro-N ¹ -(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ⁴ ,N ⁴ -dimethylcyclohexane-1,4-diamine
1180.	(1R,2R,4S)-2-fluoro-N ¹ -(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ⁴ ,N ⁴ -dimethylcyclohexane-1,4-diamine
1181.	(3S,4R)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexan-1-ol
1182.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-[bis(2-hydroxyethyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1183.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-[bis(2-hydroxyethyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1184.	4-((3-(4-(((1R,4R)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1185.	4-((3-(4-(((1S,4S)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1186.	3-methoxy-N-(1,2-oxazol-3-yl)-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1187.	3-methoxy-N-(oxan-4-yl)-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1188.	3-methoxy-N-(1,2-oxazol-3-yl)-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1189.	3-methoxy-N-(oxan-4-yl)-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1190.	N-(3-(4-(((1S,4S)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)propionamide
1191.	N-(3-(4-(((1R,4R)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)propionamide
1192.	3-methoxy-N-(5-methyl-1,2-oxazol-3-yl)-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide

Mol #	IUPAC name
1193.	3-methoxy-N-(5-methyl-1,2-oxazol-3-yl)-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1194.	(1S,4S)-N ⁴ -(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ¹ -(2-methoxyethyl)-N ¹ -methylcyclohexane-1,4-diamine
1195.	(1R,4R)-N ⁴ -(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ¹ -(2-methoxyethyl)-N ¹ -methylcyclohexane-1,4-diamine
1196.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-[(3S,4S)-3,4-dihydroxypyrrolidin-1-yl]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1197.	4-((3-(4-(((1R,4R)-4-((3R,4R)-3,4-dihydroxypyrrolidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1198.	4-((3-(4-(((1R,4S)-4-((3S,4S)-3,4-dihydroxypyrrolidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1199.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-[bis(2-methoxyethyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1200.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-[bis(2-methoxyethyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1201.	4-({3-[4-({1,4-dioxaspiro[4.5]decan-8-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)-3-methoxybenzene-1-sulfonamide
1202.	N-{1,4-dioxaspiro[4.5]decan-8-yl}-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1203.	3-methoxy-4-[(3-{4-[(4-oxocyclohexyl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
1204.	4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexan-1-one
1205.	(1R,4R)-N ⁴ -[2-(3-{[2-methoxy-4-(morpholine-4-sulfonyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine

Mol #	IUPAC name
1206.	(1S,4S)-N ⁴ -[2-(3-{[2-methoxy-4-(morpholine-4-sulfonyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
1207.	N,N-bis(2-hydroxyethyl)-3-methoxy-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1208.	N,N-bis(2-hydroxyethyl)-3-methoxy-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1209.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1210.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1211.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1212.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1213.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1214.	(1R,4R)-N ⁴ -{2-[3-(2-methoxy-4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl]amino)prop-1-yn-1-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
1215.	(1R,4R)-N ⁴ -(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-[(oxiran-2-yl)methyl]-1H-indol-4-yl)-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
1216.	2-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1H-indol-1-yl)methyl]prop-2-enenitrile
1217.	5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenol
1218.	5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenol
1219.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile

Mol #	IUPAC name
1220.	2-(5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}phenoxy)acetonitrile
1221.	N-(3-methoxy-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}benzenesulfonyl)acetamide
1222.	N-(3-methoxy-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}benzenesulfonyl)acetamide
1223.	N-(3-methoxy-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}benzenesulfonyl)propanamide
1224.	N-(3-methoxy-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}benzenesulfonyl)propanamide
1225.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}phenoxy)ethan-1-ol
1226.	2-(5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}phenoxy)ethan-1-ol
1227.	(1R,4R)- N ⁴ -[2-(3-{[4-methanesulfonyl-2-(2-methoxyethoxy)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
1228.	N-(3-(4-(((1R,4R)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)isobutyramide
1229.	N-(3-(4-(((1S,4S)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)isobutyramide
1230.	(1R,4R)- N ⁴ -[2-(3-{[4-methanesulfonyl-2-(2,2,2-trifluoroethoxy)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
1231.	(1S,4S)- N ⁴ -[2-(3-{[4-methanesulfonyl-2-(2,2,2-trifluoroethoxy)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
1232.	(1S,4S)- N ⁴ -{2-[3-(2-amino-4-methanesulfonylphenoxy)prop-1-yn-1-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl}-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
1233.	(1R,4R)- N ⁴ -(2-{3-[(2-ethoxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine

Mol #	IUPAC name
1234.	(1S,4S)-N ⁴ -(2-{3-[(2-ethoxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
1235.	3-hydroxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1236.	3-hydroxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1237.	3-(2-methoxyethoxy)-N-methyl-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1238.	(1R,4R)-N ⁴ -{2-[3-(2-amino-4-methanesulfonylphenoxy)prop-1-yn-1-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl}-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
1239.	N-ethyl-3-methoxy-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1240.	N-ethyl-3-methoxy-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1241.	3-(2-methoxyethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1242.	3-(2-fluoroethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1243.	3-(2-fluoroethoxy)-N-methyl-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1244.	3-(fluoromethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1245.	3-(fluoromethoxy)-N-methyl-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1246.	(1S,4S)-N ⁴ -(2-{3-[4-methanesulfonyl-2-(methylamino)phenoxy]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine

Mol #	IUPAC name
1247.	(1R,4R)-N ⁴ -(2-{3-[4-methanesulfonyl-2-(methylamino)phenoxy]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
1248.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-(methylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1249.	(1S,4S)-N ⁴ -(2-{3-[2-(dimethylamino)-4-methanesulfonylphenoxy]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
1250.	(1R,4R)-N ⁴ -(2-{3-[2-(dimethylamino)-4-methanesulfonylphenoxy]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
1251.	3-(cyanomethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1252.	3-(2-cyanoethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1253.	N-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]oxy}phenyl)acetamide
1254.	N-(2-((3-(4-(((1S,4S)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)oxy)-5-(methylsulfonyl)phenyl)acetamide
1255.	(1R,4R)-N ¹ -(2-(3-((2-(fluoromethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ⁴ ,N ⁴ -dimethylcyclohexane-1,4-diamine
1256.	(1S,4S)-N ¹ -(2-(3-((2-(fluoromethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ⁴ ,N ⁴ -dimethylcyclohexane-1,4-diamine
1257.	(1R,4R)-N ⁴ -[2-(3-{[4-(ethanesulfonyl)-2-methoxyphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
1258.	(1S,4S)-N ⁴ -[2-(3-{[4-(ethanesulfonyl)-2-methoxyphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
1259.	2-(3-methoxy-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenyl)-2-methylpropanenitrile
1260.	2-(4-((3-(4-(((1S,4S)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)-2-methylpropanenitrile
1261.	3-(cyanomethoxy)-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide

Mol #	IUPAC name
1262.	3-(cyanomethoxy)-4-((3-(4-(((1S,4S)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1263.	3-(3-(4-(((1R,4R)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-6-(methylsulfonyl)benzo[d]oxazol-2(3H)-one
1264.	3-(3-(4-(((1S,4S)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-6-(methylsulfonyl)benzo[d]oxazol-2(3H)-one
1265.	3-methoxy-N,N-dimethyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino} benzene-1-sulfonamide
1266.	(1R,4R)-N ¹ -(2-(3-(((3S,4R)-3-methoxytetrahydro-2H-pyran-4-yl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ⁴ ,N ⁴ -dimethylcyclohexane-1,4-diamine
1267.	(1S,4S)-N ¹ -(2-(3-(((3S,4R)-3-methoxytetrahydro-2H-pyran-4-yl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ⁴ ,N ⁴ -dimethylcyclohexane-1,4-diamine
1268.	(1R,4R)-N ⁴ -(2-{3-[(4-chloro-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
1269.	(1S,4S)-N ¹ -(2-(3-((4-chloro-2-methoxyphenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ⁴ ,N ⁴ -dimethylcyclohexane-1,4-diamine
1270.	4-((3-(4-(((1R,4R)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-2-fluoro-5-methoxybenzamide
1271.	4-((3-(4-(((1S,4S)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-2-fluoro-5-methoxybenzamide
1272.	(1R,4R)-N ⁴ -[2-(3-{[2-methoxy-4-(trifluoromethyl)phenyl]amino} prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
1273.	(1S,4S)-N ¹ -(2-(3-((2-methoxy-4-(trifluoromethyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ⁴ ,N ⁴ -dimethylcyclohexane-1,4-diamine
1274.	2-fluoro-5-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino} benzamide
1275.	4-((3-(4-(((1S,4S)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-2-fluoro-5-methoxy-N-methylbenzamide
1276.	(1S,4S)-N ⁴ -[2-(3-{[4-methanesulfonyl-2-(trifluoromethyl)phenyl]amino} prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine

Mol #	IUPAC name
1277.	(1R,4R)-N ⁴ -[2-(3-{[4-methanesulfonyl-2-(trifluoromethyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
1278.	(1R,4R)-N ⁴ -(2-{3-[(4-methanesulfonyl-2-methylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
1279.	(1S,4S)-N ¹ ,N ¹ -dimethyl-N ⁴ -(2-(3-((2-methyl-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,4-diamine
1280.	(1R,4R)-N ⁴ -[2-(3-{[4-methanesulfonyl-2-(trifluoromethoxy)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
1281.	(1S,4S)-N ¹ ,N ¹ -dimethyl-N ⁴ -(2-(3-((4-(methylsulfonyl)-2-(trifluoromethoxy)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,4-diamine
1282.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(diethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1283.	4-((3-(4-(((1S,4S)-4-(diethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide
1284.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(diethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1285.	4-((3-(4-(((1S,4S)-4-(diethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1286.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(diethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1287.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
1288.	2-(5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
1289.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide

Mol #	IUPAC name
1290.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1291.	N-ethyl-3-methoxy-4-{[3-(4-{[(1R,4R)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1292.	N-ethyl-3-methoxy-4-((3-(4-(((1S,4S)-4-((2-methoxyethyl)(methyl)amino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
1293.	(1R,4R)-N ¹ -(2-(3-((2-(fluoromethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ⁴ -(2-methoxyethyl)-N ⁴ -methylcyclohexane-1,4-diamine
1294.	(1S,4S)-N ¹ -(2-(3-((2-(fluoromethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ⁴ -(2-methoxyethyl)-N ⁴ -methylcyclohexane-1,4-diamine
1295.	3-(fluoromethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1296.	3-(fluoromethoxy)-N-methyl-4-{[3-(4-{[(1S,4S)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1297.	3-(fluoromethoxy)-4-((3-(4-(((1S,4S)-4-((2-methoxyethyl)(methyl)amino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-N-methylbenzamide
1298.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1299.	3-methoxy-4-((3-(4-(((1S,4S)-4-((2-methoxyethyl)(methyl)amino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1300.	(1R,4R)-N ¹ ,N ¹ -diethyl-N ⁴ -(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,4-diamine

Mol #	IUPAC name
1301.	(1S,4S)-N ¹ ,N ¹ -diethyl-N ⁴ -(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,4-diamine
1302.	3-(cyanomethoxy)-4-{[3-(4-{[(1R,4R)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1303.	3-(cyanomethoxy)-4-{[3-(4-{[(1S,4S)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1304.	3-(fluoromethoxy)-4-{[3-(4-{[(1R,4R)-4-[bis(2-methoxyethyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1305.	3-(fluoromethoxy)-4-{[3-(4-{[(1S,4S)-4-[bis(2-methoxyethyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1306.	3-(fluoromethoxy)-4-{[3-(4-{[(1R,4R)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1307.	3-(fluoromethoxy)-4-{[3-(4-{[(1S,4S)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1308.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1309.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1310.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1311.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1312.	2-(2-{3-[4-methanesulfonyl-2-methoxyphenyl]amino}prop-1-yn-1-yl)-4-{[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino}-1H-indol-1-yl)acetonitrile
1313.	4-({3-[1-(2-fluoroethyl)-4-{[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino}-1H-indol-2-yl]prop-2-yn-1-yl}amino)-3-methoxy-N-methylbenzamide

Mol #	IUPAC name
1314.	1-(2-fluoroethyl)-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]-1H-indol-4-amine
1315.	4-({3-[1-(cyanomethyl)-4-[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino]-1H-indol-2-yl]prop-2-yn-1-yl}amino)-3-methoxy-N-methylbenzamide
1316.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-propyl-N-[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]-1H-indol-4-amine
1317.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2-methylpropyl)-N-[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]-1H-indol-4-amine
1318.	1-(2,2-difluoroethyl)-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]-1H-indol-4-amine
1319.	3-methoxy-4-((3-(4-(((1R,4R)-4-morpholinocyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1320.	3-methoxy-4-((3-(4-(((1S,4S)-4-morpholinocyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1321.	N-ethyl-3-methoxy-4-({3-(4-[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino} benzamide
1322.	N-ethyl-3-methoxy-4-((3-(4-(((1S,4S)-4-morpholinocyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
1323.	2-(5-methanesulfonyl-2-{3-(4-[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino} phenoxy)acetonitrile
1324.	2-(5-methanesulfonyl-2-{3-(4-[(1S,4S)-4-(morpholin-4-yl)cyclohexyl]amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino} phenoxy)acetonitrile
1325.	3-methoxy-N-methyl-4-({3-(4-[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino} benzene-1-sulfonamide
1326.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-(3-methanesulfonylazetidin-1-yl)cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1327.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1S,4S)-4-(3-(methylsulfonyl)azetidin-1-yl)cyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1328.	3-methoxy-4-({3-(4-[(1R,4R)-4-(3-methanesulfonylazetidin-1-yl)cyclohexyl]amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino} benzene-1-sulfonamide

Mol #	IUPAC name
1329.	3-methoxy-4-((3-(4-(((1S,4S)-4-(3-(methylsulfonyl)azetidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1330.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(3-methanesulfonylazetidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1331.	3-methoxy-N-methyl-4-((3-(4-(((1S,4S)-4-(3-(methylsulfonyl)azetidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
1332.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{2-azaspiro[3.3]heptan-2-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1333.	N-((1S,4S)-4-(2-azaspiro[3.3]heptan-2-yl)cyclohexyl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1334.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-azaspiro[3.3]heptan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1335.	4-((3-(4-(((1S,4S)-4-(2-azaspiro[3.3]heptan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide
1336.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{2-azaspiro[3.3]heptan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1337.	4-((3-(4-(((1S,4S)-4-(2-azaspiro[3.3]heptan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1338.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-(2-azaspiro[3.3]heptan-6-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1339.	4-((3-(4-((2-azaspiro[3.3]heptan-6-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1340.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1341.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
1342.	3-methoxy-4-{{3-(4-{{(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}benzene-1-sulfonamide
1343.	3-methoxy-4-{{3-(4-{{(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}benzene-1-sulfonamide
1344.	N-(3-methoxy-4-{{3-(4-{{(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}benzenesulfonyl)propanamide
1345.	N-(3-methoxy-4-{{3-(4-{{(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}benzenesulfonyl)propanamide
1346.	N-(3-methoxy-4-{{3-(4-{{(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}benzenesulfonyl)acetamide
1347.	N-(3-methoxy-4-{{3-(4-{{(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}benzenesulfonyl)acetamide
1348.	N-((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((2-(2-fluoroethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1349.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((2-(2-fluoroethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1350.	3-methoxy-4-{{3-(4-{{(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}benzamide
1351.	3-methoxy-4-{{3-(4-{{(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}benzamide

Mol #	IUPAC name
1352.	5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenol
1353.	5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenol
1354.	N-(3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)propionamide
1355.	N-(3-(4-(((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)propionamide
1356.	N-(2-hydroxy-4-methanesulfonylphenyl)-2-methyl-N-[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]propanamide
1357.	N-(3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)isobutyramide
1358.	2-(3-{[4-methanesulfonyl-2-(2-methoxyethoxy)phenyl]amino}prop-1-yn-1-yl)-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1359.	2-(3-{[4-methanesulfonyl-2-(2-methoxyethoxy)phenyl]amino}prop-1-yn-1-yl)-N-[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1360.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
1361.	2-(5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile

Mol #	IUPAC name
1362.	5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenyl 2-methylpropanoate
1363.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)ethan-1-ol
1364.	2-(5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)ethan-1-ol
1365.	N-(3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)acetamide
1366.	5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenyl 2-methylpropanoate
1367.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1368.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1369.	2-(3-{[4-methanesulfonyl-2-(2,2,2-trifluoroethoxy)phenyl]amino}prop-1-yn-1-yl)-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1370.	2-(3-{[4-methanesulfonyl-2-(2,2,2-trifluoroethoxy)phenyl]amino}prop-1-yn-1-yl)-N-[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1371.	2-[3-(2-amino-4-methanesulfonylphenoxy)prop-1-yn-1-yl]-N-[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1372.	2-[3-[(2-ethoxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl]-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
1373.	2-{3-[(2-ethoxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1374.	3-(2-methoxyethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1375.	3-(2-methoxyethoxy)-N-methyl-4-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1376.	N-ethyl-3-methoxy-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1377.	N-ethyl-3-methoxy-4-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1378.	3-(2-fluoroethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1379.	3-(2-fluoroethoxy)-N-methyl-4-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1380.	3-(cyanomethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1381.	3-(cyanomethoxy)-N-methyl-4-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1382.	2-{3-[4-methanesulfonyl-2-(methylamino)phenoxy]prop-1-yn-1-yl}-N-[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1383.	2-{3-[4-methanesulfonyl-2-(methylamino)phenoxy]prop-1-yn-1-yl}-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1384.	2-[3-(2-amino-4-methanesulfonylphenoxy)prop-1-yn-1-yl]-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
1385.	N-((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-(2-amino-4-(methylsulfonyl)phenoxy)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1386.	3-hydroxy-N-methyl-4-{{3-(4-{{(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}benzamide
1387.	3-methoxy-4-[(3-{4-[(4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzonitrile
1388.	3-methoxy-4-{{3-(4-{{(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}benzonitrile
1389.	2-(3-methoxy-4-{{3-(4-{{(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}phenyl)-2-methylpropanenitrile
1390.	2-(4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)-2-methylpropanenitrile
1391.	3-(fluoromethoxy)-N-methyl-4-{{3-(4-{{(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}benzamide
1392.	4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-(fluoromethoxy)-N-methylbenzamide
1393.	3-(2-cyanoethoxy)-N-methyl-4-{{3-(4-{{(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}benzamide
1394.	4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-(2-cyanoethoxy)-N-methylbenzamide
1395.	2-(3-{{2-(fluoromethoxy)-4-methanesulfonylphenyl}amino}prop-1-yn-1-yl)-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
1396.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((2-(fluoromethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1397.	3-(cyanomethoxy)-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1398.	4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-(cyanomethoxy)benzenesulfonamide
1399.	3-(fluoromethoxy)-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1400.	3-(fluoromethoxy)-4-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1401.	4-((3-(4-(((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzenesulfonamide
1402.	4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzenesulfonamide
1403.	N-((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((4-chloro-2-methoxyphenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1404.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((4-chloro-2-methoxyphenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1405.	4-((3-(4-(((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N,N-dimethylbenzenesulfonamide
1406.	4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N,N-dimethylbenzenesulfonamide

Mol #	IUPAC name
1407.	N-((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((4-(ethylsulfonyl)-2-methoxyphenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1408.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((4-(ethylsulfonyl)-2-methoxyphenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1409.	N-((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-(((3S,4R)-3-methoxytetrahydro-2H-pyran-4-yl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1410.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-(((3S,4R)-3-methoxytetrahydro-2H-pyran-4-yl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1411.	2-fluoro-5-methoxy-4-{{3-(4-{{(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}benzamide
1412.	4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-2-fluoro-5-methoxybenzamide
1413.	2-fluoro-5-methoxy-N-methyl-4-{{3-(4-{{(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}benzamide
1414.	4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-2-fluoro-5-methoxy-N-methylbenzamide
1415.	2-(3-{{2-methoxy-4-(trifluoromethyl)phenyl}amino}prop-1-yn-1-yl)-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1416.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((2-methoxy-4-(trifluoromethyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1417.	4-((3-(4-(((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoic acid
1418.	4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoic acid

Mol #	IUPAC name
1419.	2-fluoro-5-methoxy-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzoic acid
1420.	4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-2-fluoro-5-methoxybenzoic acid
1421.	2-{3-[(4-methanesulfonyl-2-methylphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1422.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((2-methyl-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1423.	2-(3-{[4-methanesulfonyl-2-(trifluoromethoxy)phenyl]amino}prop-1-yn-1-yl)-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1424.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((4-(methylsulfonyl)-2-(trifluoromethoxy)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1425.	2-(3-{[4-methanesulfonyl-2-(trifluoromethyl)phenyl]amino}prop-1-yn-1-yl)-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1426.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((4-(methylsulfonyl)-2-(trifluoromethyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1427.	2-{3-[(2-chloro-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1428.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((2-chloro-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1429.	3-(3-(4-(((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-6-(methylsulfonyl)benzo[d]oxazol-2(3H)-one

Mol #	IUPAC name
1430.	3-(3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-6-(methylsulfonyl)benzo[d]oxazol-2(3H)-one
1431.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1S,4S)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1432.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1433.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1434.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1435.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1436.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1437.	3-(cyanomethoxy)-4-{[3-(4-{[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1438.	3-(cyanomethoxy)-4-{[3-(4-{[(1S,4S)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1439.	2-(3-methoxy-4-{[3-(4-{[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenyl)-2-methylpropanenitrile
1440.	2-(4-((3-(4-(((1S,4S)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)-2-methylpropanenitrile

Mol #	IUPAC name
1441.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
1442.	2-(5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
1443.	N-((4-((3-(4-(((1R,4R)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)sulfonyl)acetamide
1444.	N-((4-((3-(4-(((1S,4S)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)sulfonyl)acetamide
1445.	N-((4-((3-(4-(((1R,4R)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)sulfonyl)-2-aminoacetamide
1446.	N-((4-((3-(4-(((1S,4S)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)sulfonyl)-2-aminoacetamide
1447.	methyl 2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetate
1448.	methyl 2-(2-((3-(4-(((1S,4S)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-5-(methylsulfonyl)phenoxy)acetate
1449.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetic acid
1450.	2-(2-((3-(4-(((1S,4S)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-5-(methylsulfonyl)phenoxy)acetic acid
1451.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
1452.	2-(3-{[4-(ethanesulfonyl)-2-methoxyphenyl]amino}prop-1-yn-1-yl)-N-[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1453.	2-(3-{[4-(ethanesulfonyl)-2-methoxyphenyl]amino}prop-1-yn-1-yl)-N-[(1S,4S)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1454.	3-(fluoromethoxy)-4-{[3-(4-{[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1455.	3-(fluoromethoxy)-4-{[3-(4-{[(1S,4S)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1456.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{6-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1457.	4-((3-(4-(((1S,4S)-4-(6-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide
1458.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{6-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1459.	4-((3-(4-(((1S,4S)-4-(6-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1460.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{6-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1461.	N-((1S,4S)-4-(6-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1462.	N-((1R,4R)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)-2-(3-((2-(fluoromethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1463.	N-((1S,4S)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)-2-(3-((2-(fluoromethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
1464.	4-(3-(4-(((1R,4R)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-7-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one
1465.	4-(((3-(4-(((1R,4R)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzenesulfonamide
1466.	4-(((3-(4-(((1S,4S)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzenesulfonamide
1467.	N-(((1R,4R)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)-2-(3-((2-ethoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1468.	N-(((1S,4S)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)-2-(3-((2-ethoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1469.	3-methoxy-4-{{3-(4-{{(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl}amino)}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}benzamide
1470.	4-(((3-(4-(((1S,4S)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzamide
1471.	3-methoxy-4-{{3-(4-{{(1R,4R)-4-{6-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl}amino)}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}benzamide
1472.	4-(((3-(4-(((1S,4S)-4-(6-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzamide
1473.	2-fluoro-5-methoxy-N-methyl-4-{{3-(4-{{(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl}amino)}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}benzamide
1474.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-(((1R,4R)-4-(3-methoxypyrrolidin-1-yl)cyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1475.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-(((1S,4S)-4-(3-methoxypyrrolidin-1-yl)cyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
1476.	3-methoxy-4-((3-(4-(((1R,4R)-4-(3-methoxypyrrolidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1477.	3-methoxy-4-((3-(4-(((1S,4S)-4-(3-methoxypyrrolidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1478.	2-(3-{[2-(fluoromethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-N-[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1479.	2-(3-{[2-(fluoromethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-N-[(1S,4S)-4-(morpholin-4-yl)cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1480.	3-(cyanomethoxy)-4-{[3-(4-{[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1481.	3-(cyanomethoxy)-4-{[3-(4-{[(1S,4S)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1482.	3-(fluoromethoxy)-4-{[3-(4-{[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1483.	3-(fluoromethoxy)-4-{[3-(4-{[(1S,4S)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1484.	2-(3-((2-ethoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1R,4R)-4-morpholinocyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1485.	2-(3-((2-ethoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1S,4S)-4-morpholinocyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1486.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-(3-methoxypiperidin-1-yl)cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1487.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1S,4S)-4-(3-methoxypiperidin-1-yl)cyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1488.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-(4-methoxypiperidin-1-yl)cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1489.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1S,4S)-4-(4-methoxypiperidin-1-yl)cyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1490.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(4-methoxypiperidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide

Mol #	IUPAC name
1491.	3-methoxy-4-((3-(4-(((1S,4S)-4-(4-methoxypiperidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-N-methylbenzamide
1492.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(4-methoxypiperidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1493.	3-methoxy-4-((3-(4-(((1S,4S)-4-(4-methoxypiperidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1494.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(3-methoxypiperidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1495.	3-methoxy-4-((3-(4-(((1S,4S)-4-(3-methoxypiperidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-N-methylbenzamide
1496.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(3-methoxypiperidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1497.	3-methoxy-4-((3-(4-(((1S,4S)-4-(3-methoxypiperidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1498.	3-methoxy-4-((3-(4-(((1R,4R)-4-morpholinocyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1499.	3-methoxy-4-((3-(4-(((1S,4S)-4-morpholinocyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1500.	4-[(1R,4R)-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexyl]-1λ ⁶ -thiomorpholine-1,1-dione
1501.	4-((1S,4S)-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)cyclohexyl)thiomorpholine 1,1-dioxide
1502.	4-[(1R,4R)-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexyl]-1λ ⁴ -thiomorpholin-1-one
1503.	4-[(1S,4S)-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexyl]-1λ ⁴ -thiomorpholin-1-one
1504.	4-((3-(4-(((1R,4R)-4-(1,1-dioxidothiomorpholino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide
1505.	4-((3-(4-(((1S,4S)-4-(1,1-dioxidothiomorpholino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide

Mol #	IUPAC name
1506.	4-((1S,4S)-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)cyclohexyl)thiomorpholine 1-oxide
1507.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(1-oxo-1λ ⁴ -thiomorpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1508.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(1-oxo-1λ ⁴ -thiomorpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1509.	3-methoxy-4-((3-(4-(((1S,4S)-4-(1-oxidothiomorpholino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1510.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(1,1-dioxo-1λ ⁶ -thiomorpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1511.	4-((3-(4-(((1S,4S)-4-(1,1-dioxidothiomorpholino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1512.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1S,4S)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1513.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1514.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1515.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1516.	4-((3-(4-(((1S,4S)-4-(2-oxa-7-azaspiro[3.5]nonan-7-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1517.	3-(cyanomethoxy)-4-{[3-(4-{[(1R,4R)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide

Mol #	IUPAC name
1518.	3-(cyanomethoxy)-4-{[3-(4-{[(1S,4S)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1519.	3-(fluoromethoxy)-4-{[3-(4-{[(1R,4R)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1520.	3-(fluoromethoxy)-4-{[3-(4-{[(1S,4S)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1521.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{1-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1522.	N-[(1S,4S)-4-(1-oxa-7-azaspiro[3.5]nonan-7-yl)cyclohexyl]-2-(3-[(2-methoxy-4-(methylsulfonyl)phenyl)amino]prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1523.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{1-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1524.	4-[(3-(4-(((1S,4S)-4-(1-oxa-7-azaspiro[3.5]nonan-7-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino]-3-methoxy-N-methylbenzamide
1525.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{1-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1526.	4-[(3-(4-(((1S,4S)-4-(1-oxa-7-azaspiro[3.5]nonan-7-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino]-3-methoxybenzenesulfonamide
1527.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
1528.	2-(5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile

Mol #	IUPAC name
1529.	2-(3-{[2-(fluoromethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-N-[(1R,4R)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1530.	2-(3-{[2-(fluoromethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-N-[(1S,4S)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1531.	N-((1R,4R)-4-(2-oxa-7-azaspiro[3.5]nonan-7-yl)cyclohexyl)-2-(3-((2-ethoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1532.	N-((1S,4S)-4-(2-oxa-7-azaspiro[3.5]nonan-7-yl)cyclohexyl)-2-(3-((2-ethoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1533.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1534.	N-((1R,4R)-4-(2-oxa-7-azaspiro[3.5]nonan-7-yl)cyclohexyl)-2-(3-((4-(ethylsulfonyl)-2-methoxyphenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1535.	N-((1S,4S)-4-(2-oxa-7-azaspiro[3.5]nonan-7-yl)cyclohexyl)-2-(3-((4-(ethylsulfonyl)-2-methoxyphenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1536.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1537.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1S,4S)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1538.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1539.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide

Mol #	IUPAC name
1540.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1541.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1542.	2-{3-[(2-ethoxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1543.	2-{3-[(2-ethoxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-[(1S,4S)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1544.	N-ethyl-3-methoxy-4-{[3-(4-{[(1R,4R)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1545.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
1546.	2-(2-((3-(4-(((1S,4S)-4-(6-oxa-3-azabicyclo[3.1.1]heptan-3-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-5-(methylsulfonyl)phenoxy)acetonitrile
1547.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-oxa-8-azaspiro[4.5]decan-8-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1548.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{2-oxa-8-azaspiro[4.5]decan-8-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1549.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{2-oxa-8-azaspiro[4.5]decan-8-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1550.	4-((3-(4-(((1R,4R)-4-(2-oxa-8-azaspiro[4.5]decan-8-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-benzo[d]imidazol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide

Mol #	IUPAC name
1551.	4-((3-(4-(((1S,4S)-4-(2-oxa-8-azaspiro[4.5]decan-8-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-benzo[d]imidazol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1552.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{3-oxa-9-azaspiro[5.5]undecan-9-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1553.	N-((1S,4S)-4-(3-oxa-9-azaspiro[5.5]undecan-9-yl)cyclohexyl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1554.	3-methoxy-N-methyl-4-{[3-(4-[(1R,4R)-4-{3-oxa-9-azaspiro[5.5]undecan-9-yl}cyclohexyl]amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1555.	4-((3-(4-(((1S,4S)-4-(3-oxa-9-azaspiro[5.5]undecan-9-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide
1556.	3-methoxy-4-{[3-(4-[(1R,4R)-4-{3-oxa-9-azaspiro[5.5]undecan-9-yl}cyclohexyl]amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1557.	4-((3-(4-(((1S,4S)-4-(3-oxa-9-azaspiro[5.5]undecan-9-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1558.	3-methoxy-N-methyl-4-{[3-(4-[(1R,4R)-4-(pyrrolidin-1-yl)cyclohexyl]amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1559.	3-methoxy-N-methyl-4-((3-(4-(((1S,4S)-4-(pyrrolidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
1560.	3-methoxy-4-{[3-(4-[(1R,4R)-4-(pyrrolidin-1-yl)cyclohexyl]amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1561.	3-methoxy-4-((3-(4-(((1S,4S)-4-(pyrrolidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1562.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-(pyrrolidin-1-yl)cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1563.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1S,4S)-4-(pyrrolidin-1-yl)cyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
1564.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-(3-methoxypyrrolidin-1-yl)cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1565.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(3-methoxypyrrolidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1566.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(3-methoxypyrrolidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1567.	3-methoxy-4-((3-(4-(((1S,4S)-4-(3-methoxypyrrolidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-N-methylbenzamide
1568.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{hexahydro-1H-furo[3,4-c]pyrrol-5-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1569.	3-methoxy-4-((3-(4-(((1S,4S)-4-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1570.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{hexahydro-1H-furo[3,4-c]pyrrol-5-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1571.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1R,4R)-4-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)cyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1572.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{hexahydro-1H-furo[3,4-c]pyrrol-5-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1573.	3-methoxy-N-methyl-4-((3-(4-(((1S,4S)-4-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
1574.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-[4-(trifluoromethyl)piperidin-1-yl]cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1575.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-N-((1S,4S)-4-(4-(trifluoromethyl)piperidin-1-yl)cyclohexyl)-1H-indol-4-amine

Mol #	IUPAC name
1576.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-[4-(trifluoromethyl)piperidin-1-yl]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1577.	3-methoxy-N-methyl-4-((3-(1-(2,2,2-trifluoroethyl)-4-(((1S,4S)-4-(4-(trifluoromethyl)piperidin-1-yl)cyclohexyl)amino)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
1578.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-[4-(trifluoromethyl)piperidin-1-yl]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1579.	3-methoxy-4-((3-(1-(2,2,2-trifluoroethyl)-4-(((1S,4S)-4-(4-(trifluoromethyl)piperidin-1-yl)cyclohexyl)amino)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1580.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-(4-methanesulfonylpiperidin-1-yl)cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1581.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1S,4S)-4-(4-(methylsulfonyl)piperidin-1-yl)cyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1582.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(4-methanesulfonylpiperidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1583.	3-methoxy-N-methyl-4-((3-(4-(((1S,4S)-4-(4-(methylsulfonyl)piperidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
1584.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(4-methanesulfonylpiperidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1585.	3-methoxy-4-((3-(4-(((1S,4S)-4-(4-(methylsulfonyl)piperidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1586.	1-[(1S,3R)-3-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexyl]-4,5-dihydro-1H-1,2,3,4-tetrazol-5-one
1587.	2-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-4-(((1R,4R)-4-morpholinocyclohexyl)amino)-1H-indol-1-yl)methyl)acrylonitrile

Mol #	IUPAC name
1588.	N-((1R,4R)-4-(2-oxa-8-azaspiro[4.5]decan-8-yl)cyclohexyl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-benzo[d]imidazol-4-amine
1589.	N-((1S,4S)-4-(2-oxa-8-azaspiro[4.5]decan-8-yl)cyclohexyl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-benzo[d]imidazol-4-amine
1590.	4-(((3-(4-(((1R,4R)-4-(2-oxa-8-azaspiro[4.5]decan-8-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-benzo[d]imidazol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide
1591.	4-(((3-(4-(((1S,4S)-4-(2-oxa-8-azaspiro[4.5]decan-8-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-benzo[d]imidazol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide
1592.	1-{3-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]pyrrolidin-1-yl}-3-methoxypropan-2-ol
1593.	N-[3-(4-{[1-(2-hydroxy-3-methoxypropyl)pyrrolidin-3-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]benzamide
1594.	1-{3-[(2-{3-[(4-methanesulfonyl)phenyl]amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]pyrrolidin-1-yl}-3-methoxypropan-2-ol
1595.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[1-(oxan-4-yl)pyrrolidin-3-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1596.	2-(3-{[2-methoxy-4-(morpholine-4-sulfonyl)phenyl]amino}prop-1-yn-1-yl)-N-(piperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1597.	3-methoxy-N,N-dimethyl-4-[(3-{4-[(piperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
1598.	2-{5-methanesulfonyl-2-[(3-{4-[(piperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]phenoxy}acetonitrile
1599.	3-methoxy-4-((3-(4-(piperidin-4-ylamino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
1600.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(3R)-piperidin-3-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1601.	3-methoxy-4-[[3-(4-{[(2S,4S)-2-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino]benzene-1-sulfonamide

Mol #	IUPAC name
1602.	3-methoxy-4-((3-(4-((1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1603.	2-(3-{[4-methanesulfonyl-2-(trifluoromethoxy)phenyl]amino}prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1604.	N-(1-methylpiperidin-4-yl)-2-(3-((4-(methylsulfonyl)-2-(2,2,2-trifluoroethoxy)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1605.	2-{4-methoxy-5-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
1606.	3-methoxy-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-N-(1,2-oxazol-3-yl)benzene-1-sulfonamide
1607.	3-methoxy-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-N-(oxan-4-yl)benzene-1-sulfonamide
1608.	3-methoxy-N-(5-methyl-1,2-oxazol-3-yl)-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
1609.	N-(2-hydroxyethyl)-3-methoxy-N-methyl-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
1610.	3-methoxy-N,N-dimethyl-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
1611.	4-[(3-{6-fluoro-4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxybenzene-1-sulfonamide
1612.	6-fluoro-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1613.	2-(3-((4-methoxy-6-(methylsulfonyl)pyridin-3-yl)amino)prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1614.	3-methoxy-N-(2-methoxyethyl)-N-methyl-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
1615.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)(methyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1616.	1-(4-{3-methoxy-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzenesulfonyl}piperazin-1-yl)ethan-1-one

Mol #	IUPAC name
1617.	2-(3-{[2-methoxy-4-(morpholine-4-sulfonyl)phenyl]amino}prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1618.	3-methoxy-4-((3-(4-((1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzoic acid
1619.	3-methoxy-N-methyl-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzamide
1620.	N,N-bis(2-hydroxyethyl)-3-methoxy-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
1621.	3-methoxy-N-methyl-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
1622.	2-[3-({2-methoxy-4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}amino)prop-1-yn-1-yl]-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1623.	5-methanesulfonyl-2-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]phenol
1624.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-6-methoxy-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1625.	2-{3-[2-(dimethylamino)-4-methanesulfonylphenoxy]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1626.	2-{5-methanesulfonyl-2-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]phenoxy}acetonitrile
1627.	2-(3-{[2-(fluoromethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1628.	2-(3-{[2-methoxy-4-(morpholine-4-carbonyl)phenyl]amino}prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1629.	1-{3-methoxy-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzoyl}piperidin-4-ol
1630.	3-(3-(4-((1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-6-(methylsulfonyl)benzo[d]oxazol-2(3H)-one
1631.	2-(3-{[2-methoxy-4-(5-methoxypyridin-3-yl)phenyl]amino}prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
1632.	2-{3-[(5-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1633.	N-(2-hydroxyethyl)-3-methoxy-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzamide
1634.	3-methoxy-N-(2-methoxyethyl)-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzamide
1635.	3-methoxy-N-(1-methylpiperidin-4-yl)-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzamide
1636.	2-[3-({4-[4-(dimethylamino)piperidine-1-carbonyl]-2-methoxyphenyl}amino)prop-1-yn-1-yl]-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1637.	3-methoxy-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-N-(oxan-4-yl)benzamide
1638.	2-(3-{[2-methoxy-4-(4-methylpiperazine-1-carbonyl)phenyl]amino}prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1639.	2-{3-[(2-methoxy-4-{2-oxa-6-azaspiro[3.3]heptane-6-carbonyl}phenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1640.	2-(3-{[2-methoxy-4-(pyridin-3-yl)phenyl]amino}prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1641.	2-(3-{[2-methoxy-4-(pyridin-4-yl)phenyl]amino}prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1642.	N-(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)pyridine-3-carboxamide
1643.	2-(3-{[2-methoxy-4-(1,3-oxazol-2-yl)phenyl]amino}prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1644.	2-{3-[(3-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1645.	N-(1-methylpiperidin-4-yl)-2-[3-({4-[(morpholin-4-yl)methyl]phenyl}amino)prop-1-yn-1-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1646.	2-(3-{[2-methoxy-4-(1,3-thiazol-2-yl)phenyl]amino}prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
1647.	2-[3-({2-methoxy-4-[1-(2-methoxyethyl)-1H-pyrazol-4-yl]phenyl}amino)prop-1-yn-1-yl]-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1648.	2-{3-[(2-methoxy-4-{7-oxa-2-azaspiro[3.5]nonane-2-carbonyl}phenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1649.	2-{3-[(4-chloro-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1650.	2-(3-(((3S,4R)-3-methoxytetrahydro-2H-pyran-4-yl)amino)prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1651.	2-fluoro-5-methoxy-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzamide
1652.	2-(3-{[2-methoxy-4-(trifluoromethyl)phenyl]amino}prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1653.	2-fluoro-5-methoxy-N-methyl-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzamide
1654.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-[(oxiran-2-yl)methyl]-1H-indol-4-amine
1655.	2-(3-((2-ethoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1656.	2-{3-[(2-fluoro-4-methanesulfonyl-6-methoxyphenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1657.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-3-methyl-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1658.	2-(3-(((3R,4R)-3-methoxytetrahydro-2H-pyran-4-yl)amino)prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1659.	2-{3-[(5-fluoro-4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1660.	2-{3-[(5-methanesulfonylthiophen-2-yl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1661.	N-methyl-5-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]thiophene-2-carboxamide

Mol #	IUPAC name
1662.	N,N-dimethyl-5-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]thiophene-2-carboxamide
1663.	5-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]thiophene-2-carboxylic acid
1664.	2-(3-((4-methoxypyridin-3-yl)amino)prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1665.	2-(2-((3-(4-((1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-5-(methylsulfonyl)phenoxy)acetamide
1666.	N-(2-hydroxyethyl)-3-methoxy-4-((3-(4-((1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1667.	4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)-1-methylpiperidin-2-one
1668.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(3R,4S)-3-methoxy-1-methylpiperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1669.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(3S,4R)-3-methoxy-1-methylpiperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1670.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(3S,4R)-3-methoxy-1-methylpiperidin-4-yl]-N-methyl-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1671.	N-(1-ethylpiperidin-4-yl)-2-(3-{[2-(fluoromethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1672.	4-[(3-{4-[(1-ethylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxy-N-methylbenzamide
1673.	2-{2-[(3-{4-[(1-ethylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-5-methanesulfonylphenoxy}acetonitrile
1674.	N-(1-ethylpiperidin-4-yl)-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1675.	4-[(3-{4-[(1-ethylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxybenzene-1-sulfonamide
1676.	3-methoxy-N-methyl-4-{[3-(4-{[1-(propan-2-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide

Mol #	IUPAC name
1677.	2-(5-methanesulfonyl-2-{[3-(4-{[1-(propan-2-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino} phenoxy)acetonitrile
1678.	2-(3-{[2-(fluoromethoxy)-4-methanesulfonylphenyl]amino} prop-1-yn-1-yl)-N-[1-(propan-2-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1679.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[1-(propan-2-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1680.	3-methoxy-4-{[3-(4-{[1-(propan-2-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino} benzene-1-sulfonamide
1681.	2-[2-(2-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino]piperidin-1-yl} ethoxy)ethoxy)ethan-1-ol
1682.	4-({4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino]piperidin-1-yl} methyl)-1,3-dioxolan-2-one
1683.	3-methoxy-4-({3-[4-({1-[(2-oxo-1,3-dioxolan-4-yl)methyl]piperidin-4-yl} amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl} amino)benzene-1-sulfonamide
1684.	4-{[3-(4-{[1-(2,3-dihydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxy-N-(1,2-oxazol-3-yl)benzene-1-sulfonamide
1685.	4-((3-(4-((1-(2,3-dihydroxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1686.	4-({3-[4-({1-[(2S)-2,3-dihydroxypropyl]piperidin-4-yl} amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl} amino)-3-methoxybenzene-1-sulfonamide
1687.	4-({3-[4-({1-[(2R)-2,3-dihydroxypropyl]piperidin-4-yl} amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl} amino)-3-methoxybenzene-1-sulfonamide
1688.	4-{[3-(4-{[1-(2,3-dihydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxy-N-(5-methyl-1,2-oxazol-3-yl)benzene-1-sulfonamide
1689.	4-{[3-(4-{[1-(2,3-dihydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxy-N-(oxan-4-yl)benzene-1-sulfonamide

Mol #	IUPAC name
1690.	4-{[3-(4-{[1-(2,3-dihydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-(2-hydroxyethyl)-3-methoxy-N-methylbenzene-1-sulfonamide
1691.	2-(5-{[3-(4-{[1-(2,3-dihydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-4-methoxypyridin-2-yl)-2-methylpropanenitrile
1692.	N-(2-hydroxyethyl)-3-methoxy-N-methyl-4-{[3-(4-{[1-(oxan-4-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1693.	3-(4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)propane-1,2-diol
1694.	(2R)-3-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propane-1,2-diol
1695.	(2S)-3-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propane-1,2-diol
1696.	3-[4-({2-[3-((2-methoxy-4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl)amino)prop-1-yn-1-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl]propane-1,2-diol
1697.	4-((3-(4-((1-(2,3-dihydroxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoic acid
1698.	methyl 4-((3-(4-((1-(2,3-dihydroxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoate
1699.	3-methoxy-4-[(3-{4-[(1-{[(4R)-2-oxo-1,3-dioxolan-4-yl]methyl}piperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
1700.	(4R)-4-({4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}methyl)-1,3-dioxolan-2-one
1701.	4-{[3-(4-{[1-(2,3-dihydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N,N-dimethylbenzene-1-sulfonamide
1702.	2-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}EtOAc
1703.	N-(1-{[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl}piperidin-4-yl)-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
1704.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propan-2-yl acetate
1705.	4-[(3-{4-[(1-{[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl}piperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxybenzene-1-sulfonamide
1706.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-ol
1707.	1-(4-((2-(3-((4-(ethylsulfonyl)-2-methoxyphenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)-3-methoxypropan-2-ol
1708.	1-ethoxy-3-(4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)propan-2-ol
1709.	4-{[3-(4-{[1-(2,3-dihydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-(2-methoxyethyl)-N-methylbenzene-1-sulfonamide
1710.	1-(acetyloxy)-3-{4-[(2-{3-[(2-methoxy-4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propan-2-yl acetate
1711.	4-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
1712.	3-methoxy-4-{[3-(4-{[1-(2-methoxyacetyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1713.	1-(4-(N-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)acetamido)piperidin-1-yl)propan-2-yl acetate
1714.	1-[4-(4-{[3-(4-{[1-(2,3-dihydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzenesulfonyl)piperazin-1-yl]ethan-1-one
1715.	(4S)-4-({4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}methyl)-1,3-dioxolan-2-one
1716.	1-(acetyloxy)-3-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propan-2-yl acetate
1717.	N-[1-(2,3-dimethoxypropyl)piperidin-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
1718.	4-{[3-(4-{[1-(2,3-dimethoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
1719.	3-(4-{[2-(3-{[2-methoxy-4-(morpholine-4-sulfonyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)propane-1,2-diol
1720.	4-({3-[4-({1-[(2R)-2,3-dihydroxypropyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)-3-methoxybenzamide
1721.	2-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethyl 2-methylpropanoate
1722.	2-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethyl propanoate
1723.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-(propanoyloxy)propan-2-yl propanoate
1724.	1-{4-[(2-{3-[(2-methoxy-4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-(propanoyloxy)propan-2-yl propanoate
1725.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-[(2-methylpropanoyl)oxy]propan-2-yl 2-methylpropanoate
1726.	1-{4-[(2-{3-[(2-methoxy-4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-[(2-methylpropanoyl)oxy]propan-2-yl 2-methylpropanoate
1727.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propan-2-yl propanoate
1728.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propan-2-yl 2-methylpropanoate
1729.	2-hydroxy-3-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propyl 2-methylpropanoate
1730.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-yl acetate

Mol #	IUPAC name
1731.	2-hydroxy-3-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propyl propanoate
1732.	N,N-bis(2-hydroxyethyl)-4-{[3-(4-{[1-(2-hydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
1733.	4-{[3-(4-{[1-(2-hydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-methylbenzamide
1734.	(S)-4-((3-(4-((1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide
1735.	1-{4-[(2-{3-[(2-methoxy-4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propan-2-yl 2-methylpropanoate
1736.	1-{4-[(2-{3-[(2-methoxy-4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propan-2-yl acetate
1737.	2-{4-[(2-{3-[(2-methoxy-4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethyl 2-methylpropanoate
1738.	4-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-methylbenzamide
1739.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-yl propanoate
1740.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-yl 2-methylpropanoate
1741.	1-methoxy-3-{4-[(2-{3-[(2-methoxy-4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propan-2-yl 2-methylpropanoate
1742.	1-{4-[(2-{3-[(2-methoxy-4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propan-2-yl propanoate
1743.	N-(4-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzenesulfonyl)acetamide

Mol #	IUPAC name
1744.	N-(4-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzenesulfonyl)propanamide
1745.	2-{4-[(2-{3-[(2-methoxy-4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethyl propanoate
1746.	4-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-methylbenzene-1-sulfonamide
1747.	1-methoxy-3-{4-[(2-{3-[(2-methoxy-4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propan-2-yl propanoate
1748.	(2R)-1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-ol
1749.	(2S)-1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-ol
1750.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1751.	3-methoxy-4-((3-(4-((1-(2-methoxyethyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1752.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-(1-(2-methoxyethyl)piperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1753.	3-methoxy-4-{[3-(4-{[1-(2-methoxyethyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-methylbenzamide
1754.	3-methoxy-4-{[3-(4-{[1-(2-methoxyethyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-methylbenzene-1-sulfonamide
1755.	2-{4-[(2-{3-[(2-methoxy-4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}EtOAc
1756.	1-methoxy-3-{4-[(2-{3-[(2-methoxy-4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propan-2-yl acetate
1757.	4-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzamide
1758.	2-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-5-methanesulfonylphenol

Mol #	IUPAC name
1759.	4-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxy-N,N-dimethylbenzene-1-sulfonamide
1760.	4-({3-[4-({1-[(2R)-3-hydroxy-2-methoxypropyl]piperidin-4-yl} amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl} amino)-3-methoxybenzene-1-sulfonamide
1761.	N-(4-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxybenzenesulfonyl)-N-methylpropanamide
1762.	1-(4-{[2-(3-{[2-(2-fluoroethoxy)-4-methanesulfonylphenyl]amino} prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino} piperidin-1-yl)-3-methoxypropan-2-ol
1763.	1-(4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)tetradecan-1-one
1764.	1-methoxy-3-(4-{[2-(3-{[2-methoxy-4-(propanamidulosulfonyl)phenyl]amino} prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino} piperidin-1-yl)propan-2-yl propanoate
1765.	1-(4-{[2-(3-{[2-methoxy-4-(propanamidulosulfonyl)phenyl]amino} prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino} piperidin-1-yl)-3-(propanoyloxy)propan-2-yl propanoate
1766.	(2R)-3-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-2-methoxypropan-1-ol
1767.	(2S)-3-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-2-methoxypropan-1-ol
1768.	1-{4-[(2-{3-[(2-ethoxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-ol
1769.	4-({3-[4-({1-[(2S)-3-hydroxy-2-methoxypropyl]piperidin-4-yl} amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl} amino)-3-methoxybenzene-1-sulfonamide
1770.	4-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxy-N-(propan-2-yl)benzamide

Mol #	IUPAC name
1771.	3-hydroxy-4-{{3-(4-{{1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}benzene-1-sulfonamide
1772.	(2R)-1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-yl 2-methylpropanoate
1773.	N-(3-(4-((1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(N-propionylsulfamoyl)phenyl)propionamide
1774.	1-(4-{{2-(3-{{4-methanesulfonyl-2-(2-methoxyethoxy)phenyl}amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl}amino}piperidin-1-yl)-3-methoxypropan-2-ol
1775.	(2S)-1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-yl 2-methylpropanoate
1776.	N-(3-(4-((1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)acetamide
1777.	N-(3-(4-((1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)propionamide
1778.	N-(3-(4-((1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)isobutyramide
1779.	2-(2-{{3-(4-{{1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}-5-methanesulfonylphenoxy)acetonitrile
1780.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-5-methoxy-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-ol
1781.	1-(4-{{2-(3-{{2-(2-hydroxyethoxy)-4-methanesulfonylphenyl}amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl}amino}piperidin-1-yl)-3-methoxypropan-2-ol

Mol #	IUPAC name
1782.	1-(4-{[2-(3-{[4-methanesulfonyl-2-(2,2,2-trifluoroethoxy)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)-3-methoxypropan-2-ol
1783.	1-[4-(2-[3-(2-amino-4-methanesulfonylphenoxy)prop-1-yn-1-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino)piperidin-1-yl]-3-methoxypropan-2-ol
1784.	4-({3-[4-({1-[(2R)-2-hydroxy-3-methoxypropyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)-3-methoxy-N-methylbenzamide
1785.	4-({3-[4-({1-[(2S)-2-hydroxy-3-methoxypropyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)-3-methoxy-N-methylbenzamide
1786.	4-({3-[4-({1-[(2R)-3-hydroxy-2-methoxypropyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)-3-methoxy-N-methylbenzamide
1787.	4-({3-[4-({1-[(2S)-3-hydroxy-2-methoxypropyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)-3-methoxy-N-methylbenzamide
1788.	1-{4-[(2-{3-[4-methanesulfonyl-2-(methylamino)phenoxy]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-ol
1789.	3-(2-fluoroethoxy)-4-{3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-methylbenzamide
1790.	4-{3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-(2-methoxyethoxy)-N-methylbenzamide
1791.	3-(cyanomethoxy)-4-{3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-methylbenzamide
1792.	N-ethyl-4-{3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzamide
1793.	1-(4-{[2-(3-{[2-methoxy-4-(methylcarbamoyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)-3-(propanoyloxy)propan-2-yl propanoate
1794.	1-methoxy-3-(4-{[2-(3-{[2-methoxy-4-(methylcarbamoyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)propan-2-yl propanoate
1795.	4-{3-(4-{[1-(2,3-dihydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-methylbenzamide

Mol #	IUPAC name
1796.	3-(2-cyanoethoxy)-4-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-methylbenzamide
1797.	1-ethoxy-3-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propan-2-ol
1798.	2-(2-{[3-(4-{[1-(2-hydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-5-methanesulfonylphenoxy)acetonitrile
1799.	1-(4-{[2-(3-{[4-(ethanesulfonyl)-2-methoxyphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)-3-methoxypropan-2-ol
1800.	3-(fluoromethoxy)-4-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-methylbenzamide
1801.	1-(4-{[2-(3-{[2-(fluoromethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)-3-methoxypropan-2-ol
1802.	2-(4-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxyphenyl)-2-methylpropanenitrile
1803.	(2S)-1-(4-{[2-(3-{[2-(fluoromethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)-3-methoxypropan-2-ol
1804.	(2R)-1-(4-{[2-(3-{[2-(fluoromethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)-3-methoxypropan-2-ol
1805.	1-(4-{[2-(3-{[2-(difluoromethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)-3-methoxypropan-2-ol
1806.	3-(2-hydroxy-3-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propoxy)propane-1,2-diol
1807.	1-{4-[(2-{3-[(5-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-ol
1808.	3-(3-(4-((1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-6-(methylsulfonyl)benzo[d]oxazol-2(3H)-one

Mol #	IUPAC name
1809.	1-{4-[(2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-ol
1810.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-(2,2,2-trifluoroethoxy)propan-2-ol
1811.	4-hydroxy-9-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-2-oxa-6 λ^5 -azaspiro[5.5]undecan-6-ylum
1812.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[1-(3-methoxypropyl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1813.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-3-methyl-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-ol
1814.	1-{4-[(2-{3-[(5-fluoro-4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-ol
1815.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[1-(oxetan-3-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1816.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-(1-(tetrahydrofuran-3-yl)piperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1817.	(R)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-(1-(tetrahydrofuran-3-yl)piperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1818.	(S)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-(1-(tetrahydrofuran-3-yl)piperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1819.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-(1-((tetrahydrofuran-2-yl)methyl)piperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1820.	2-fluoro-4-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-5-methoxybenzamide
1821.	1-methoxy-3-(4-((2-(3-(((3S,4R)-3-methoxytetrahydro-2H-pyran-4-yl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)propan-2-ol
1822.	1-(4-{[2-(3-{[4-(cyclopropanesulfonyl)-2-methoxyphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)-3-methoxypropan-2-ol
1823.	3-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propanenitrile

Mol #	IUPAC name
1824.	4-(4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)butanenitrile
1825.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-{1-[(oxolan-2-yl)methyl]piperidin-4-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1826.	1-methoxy-3-(4-{[2-(3-{[2-methoxy-4-(trifluoromethyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)propan-2-ol
1827.	2-fluoro-4-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-5-methoxy-N-methylbenzamide
1828.	1-(4-{[2-(3-{[4-(benzenesulfonyl)-2-methoxyphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)-3-methoxypropan-2-ol
1829.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[1-(2-methoxy-2-methylpropyl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1830.	2-(4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)ethan-1-ol
1831.	1-methoxy-3-(4-{[2-(3-{[2-methoxy-4-(propane-2-sulfonyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)propan-2-ol
1832.	1-{3-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-ol
1833.	1-methoxy-3-(4-((2-(3-(((3R,4R)-3-methoxytetrahydro-2H-pyran-4-yl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)propan-2-ol
1834.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-propyl)-1H-indol-4-yl]amino}piperidin-1-yl}-3-methoxypropan-2-ol
1835.	1-(4-{[1-(2-fluoroethyl)-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1H-indol-4-yl]amino}piperidin-1-yl)-3-methoxypropan-2-ol
1836.	2-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1H-indol-1-yl)acetonitrile
1837.	1-(4-{[1-(2-chloroethyl)-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1H-indol-4-yl]amino}piperidin-1-yl)-3-methoxypropan-2-ol
1838.	rac-1-[(3R,4S)-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-3-methylpiperidin-1-yl]-3-methoxypropan-2-ol

Mol #	IUPAC name
1839.	rac-1-[(3R,4R)-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-3-methylpiperidin-1-yl]-3-methoxypropan-2-ol
1840.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-ol
1841.	1-[4-(1-{[(2,2-difluorocyclopropyl)methyl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1H-indol-4-yl}amino)piperidin-1-yl]-3-methoxypropan-2-ol
1842.	4-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
1843.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[1-(3-methanesulfonylpropyl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1844.	4-{[3-(4-{[1-(3-methanesulfonylpropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
1845.	1-(4-{[2-(3-{[4-methanesulfonyl-2-(trifluoromethyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)-3-methoxypropan-2-ol
1846.	1-(4-{[1-(2,2-difluoroethyl)-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1H-indol-4-yl]amino}piperidin-1-yl)-3-methoxypropan-2-ol
1847.	1-(4-{[2-(3-{[4-methanesulfonyl-2-(trifluoromethoxy)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)-3-methoxypropan-2-ol
1848.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(3,3,3-trifluoropropyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-ol
1849.	1-(4-{[1-(2,2-difluoropropyl)-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1H-indol-4-yl]amino}piperidin-1-yl)-3-methoxypropan-2-ol
1850.	1-{4-[(2-{3-[(2-chloro-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-ol
1851.	1-{4-[(2-{3-[(2-fluoro-4-methanesulfonyl-6-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-ol
1852.	1-(4-((2-(3-((4-((6-oxa-3-azabicyclo[3.1.1]heptan-3-yl)sulfonyl)-2-methoxyphenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)-3-methoxypropan-2-ol

Mol #	IUPAC name
1853.	(2S)-1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-yl propanoate
1854.	1-{4-[(2-{3-[(4-chloro-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-ol
1855.	2-(2-(4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)ethoxy)ethan-1-ol
1856.	4-((3-(4-((1-(2,3-dihydroxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-N-(2-hydroxyethyl)-3-methoxybenzenesulfonamide
1857.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[1-(4-methyl-1,3-thiazol-2-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1858.	N-(1-cyclopropylpiperidin-4-yl)-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1859.	4-[(3-{4-[(1-cyclopropylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxybenzoic acid
1860.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-{1-[(3R)-oxolan-3-yl]piperidin-4-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1861.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-{1-[(3S)-oxolan-3-yl]piperidin-4-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1862.	3-methoxy-4-{[3-(4-{[1-(oxan-4-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzoic acid
1863.	3-methoxy-4-((3-(4-((1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
1864.	N-(2-hydroxyethyl)-3-methoxy-4-((3-(4-((1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1865.	3-methoxy-4-((3-(4-((1'-methyl-[1,4'-bipiperidin]-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
1866.	3-methoxy-4-((3-(4-((1-(2-(4-methylpiperazin-1-yl)-2-oxoethyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
1867.	2-{2-[(3-{4-[(1-acetyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-5-methanesulfonylphenoxy} acetonitrile

Mol #	IUPAC name
1868.	4-{[3-(4-{[1-(2-hydroxyacetyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N,N-dimethylbenzene-1-sulfonamide
1869.	2-hydroxy-1-{4-[(2-{3-[(2-hydroxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl} ethan-1-one
1870.	2-hydroxy-1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl} ethan-1-one
1871.	N-((3S,4S)-1,3-dimethylpiperidin-4-yl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1872.	N-((3R,4R)-1,3-dimethylpiperidin-4-yl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1873.	N-((3R,4R)-1,3-dimethylpiperidin-4-yl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1874.	N-((3R,4S)-1,3-dimethylpiperidin-4-yl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1875.	N-((3S,4R)-1,3-dimethylpiperidin-4-yl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1876.	1-(4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)-2-methylpiperidin-1-yl)ethan-1-one
1877.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-2-methylpiperidin-1-yl} ethan-1-one
1878.	4-{[3-(4-{[(2S,4S)-1-acetyl-2-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
1879.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-2-methoxyethan-1-one
1880.	2-hydroxy-1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl} propan-1-one

Mol #	IUPAC name
1881.	2-methoxy-1-(4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)ethan-1-one
1882.	3-methoxy-4-((3-(4-((1-(2-methoxyacetyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1883.	4-{[3-(4-{[1-(2-hydroxypropanoyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
1884.	3-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile
1885.	4-{[3-(4-{[1-(2-cyanoacetyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
1886.	4-{[3-(4-{[1-(2-hydroxyacetyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
1887.	4-[(3-{4-[(1-acetyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino]-3-methoxybenzene-1-sulfonamide
1888.	2-(dimethylamino)-1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethan-1-one
1889.	4-((3-(4-((1-(dimethylglycyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1890.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-2-methylpropan-1-one
1891.	3-methoxy-4-{[3-(4-{[1-(2-methylpropanoyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1892.	4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)-N,N-dimethylpiperidine-1-carboxamide
1893.	4-[(3-{4-[(1-acetyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino]-3-methoxy-N,N-dimethylbenzene-1-sulfonamide
1894.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propan-1-one
1895.	3-methoxy-4-[(3-{4-[(1-propanoyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino]benzene-1-sulfonamide

Mol #	IUPAC name
1896.	1-(4-{[2-(3-{[2-methoxy-4-(morpholine-4-sulfonyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)ethan-1-one
1897.	3-methoxy-4-[(3-{4-[(1-{[(4S)-2-oxo-1,3-dioxolan-4-yl]methyl}piperidin-4-yl]amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
1898.	N-((3-methoxy-4-((3-(4-((1-((2-oxo-1,3-dioxolan-4-yl)methyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)phenyl)sulfonyl)propionamide
1899.	N-[3-methoxy-4-({3-[4-({1-[(2-oxo-1,3-dioxolan-4-yl)methyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)benzenesulfonyl]acetamide
1900.	3-methoxy-N-methyl-4-({3-[4-({1-[(2-oxo-1,3-dioxolan-4-yl)methyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)benzamide
1901.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-(octahydroindolizin-7-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1902.	N-[(7R,8aS)-octahydroindolizin-7-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1903.	N-[(7R,8aR)-octahydroindolizin-7-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1904.	rac-(3R,4S)-3-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1-methylpiperidin-4-ol
1905.	rac-(3R,4R)-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1-methylpiperidin-3-ol
1906.	3-methoxy-4-((3-(4-((1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1907.	rac-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1908.	N-((3S,4S)-3-fluoro-1-methylpiperidin-4-yl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1909.	N-[(3S,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
1910.	N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1911.	N-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1912.	N-[(3R,4R)-3-fluoro-1-methylpiperidin-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1913.	rac-4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino})-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
1914.	rac-4-{[3-(4-{[(3R,4R)-3-fluoro-1-methylpiperidin-4-yl]amino})-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
1915.	rac-methyl 4-{[3-(4-{[(3R,4R)-3-fluoro-1-methylpiperidin-4-yl]amino})-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxybenzoate
1916.	rac-methyl 4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino})-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxybenzoate
1917.	rac-4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino})-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
1918.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino})-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
1919.	4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino})-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
1920.	rac-4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino})-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxybenzamide
1921.	rac-4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino})-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxy-N-methylbenzamide
1922.	4-(((3-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide
1923.	rac-4-{[3-(4-{[(3R,4R)-3-fluoro-1-methylpiperidin-4-yl]amino})-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxy-N-methylbenzamide
1924.	2-fluoro-4-(((3-(4-(((3R,4S)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-5-methoxy-N-methylbenzamide

Mol #	IUPAC name
1925.	2-fluoro-4-((3-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-5-methoxy-N-methylbenzamide
1926.	4-{[3-(4-{[(3R,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
1927.	4-{[3-(4-{[(3S,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
1928.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
1929.	4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
1930.	methyl 4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoate
1931.	rac-4-{[3-(4-{[(3R,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzamide
1932.	methyl 4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoate
1933.	rac-N-[(3R,4S)-3-fluoro-1-(propan-2-yl)piperidin-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1934.	rac-4-{[3-(4-{[(3R,4S)-3-fluoro-1-(propan-2-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
1935.	rac-ethyl 4-{[3-(4-{[(3R,4S)-3-fluoro-1-(propan-2-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoate
1936.	rac-ethyl 4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoate
1937.	(2R)-1-(acetyloxy)-3-[(3RS,4SR)-3-fluoro-4-[(2-{3-[(2-methoxy-4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]propan-2-yl acetate
1938.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzamide
1939.	4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzamide

Mol #	IUPAC name
1940.	N-[(3S,4R)-3-fluoro-1-(propan-2-yl)piperidin-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1941.	N-[(3R,4S)-3-fluoro-1-(propan-2-yl)piperidin-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1942.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino})-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxy-N-methylbenzamide
1943.	4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino})-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxy-N-methylbenzamide
1944.	rac-2-hydroxypropyl 4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino})-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxybenzoate
1945.	4-((3-(4-(((3R,4S)-3-fluoro-1-methylpiperidin-4-yl)amino))-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-N-isopropyl-3-methoxybenzamide
1946.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino})-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxy-N-(propan-2-yl)benzamide
1947.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-(propan-2-yl)piperidin-4-yl]amino})-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
1948.	4-{[3-(4-{[(3R,4S)-3-fluoro-1-(propan-2-yl)piperidin-4-yl]amino})-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
1949.	rac-2-[(3R,4S)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]acetamide
1950.	N-[(3S,4R)-1-ethyl-3-fluoropiperidin-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1951.	N-[(3R,4S)-1-ethyl-3-fluoropiperidin-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1952.	rac-4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino})-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxy-N-(2-methoxyethyl)benzamide
1953.	rac-4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino})-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxy-N,N-dimethylbenzamide

Mol #	IUPAC name
1954.	rac-4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-(2-hydroxy-3-methoxypropyl)-3-methoxybenzamide
1955.	rac-4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-(propan-2-yl)benzamide
1956.	rac-4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-(oxan-4-yl)benzamide
1957.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-(oxan-4-yl)benzamide
1958.	rac-N-[(3R,4S)-1-ethyl-3-fluoropiperidin-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1959.	ethyl 4-{[3-(4-{[(3S,4R)-3-fluoro-1-(propan-2-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoate
1960.	ethyl 4-((3-(4-(((3R,4S)-1-ethyl-3-fluoropiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoate
1961.	ethyl 4-{[3-(4-{[(3S,4R)-1-ethyl-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl] amino}-3-methoxybenzoate
1962.	ethyl 4-{[3-(4-{[(3R,4S)-1-ethyl-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl] amino}-3-methoxybenzoate
1963.	ethyl 4-{[3-(4-{[(3R,4S)-3-fluoro-1-(propan-2-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoate
1964.	2-fluoro-4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-5-methoxy-N-methylbenzamide
1965.	2-fluoro-4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-5-methoxy-N-methylbenzamide
1966.	4-{[3-(4-{[(3R,4S)-1-ethyl-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl] amino}-3-methoxybenzoic acid
1967.	4-{[3-(4-{[(3S,4R)-1-ethyl-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl] amino}-3-methoxybenzoic acid

Mol #	IUPAC name
1968.	rac-N-(2-{bis[(pyridin-2-yl)methyl]amino}ethyl)-4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzamide
1969.	rac-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-methyl-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1970.	rac-4-((3-(4-(((3R,4S)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoic acid
1971.	rac-4-{[3-(4-{[(3R,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
1972.	2-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl] amino}-5-methanesulfonylphenol
1973.	2-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl] amino}-5-methanesulfonylphenol
1974.	rac-6-fluoro-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1975.	N-(4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl] amino}-3-methoxybenzenesulfonyl)acetamide
1976.	N-(4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl] amino}-3-methoxybenzenesulfonyl)acetamide
1977.	ethyl 4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl] amino}-3-methoxybenzoate
1978.	ethyl 4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl] amino}-3-methoxybenzoate
1979.	N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(3-{[2-(fluoromethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1980.	N-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]-2-(3-{[2-(fluoromethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
1981.	2-{3-[(2-ethoxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1982.	2-{3-[(2-ethoxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1983.	4-{[3-(4-{[(3S,4R)-3-fluoropiperidin-4-yl]amino})-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
1984.	4-{[3-(4-{[(3R,4S)-3-fluoropiperidin-4-yl]amino})-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
1985.	N-((3S,4R)-3-fluoropiperidin-4-yl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1986.	N-((3R,4S)-3-fluoropiperidin-4-yl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1987.	4-{[3-(4-{[(3S,4R)-3-fluoropiperidin-4-yl]amino})-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxybenzamide
1988.	4-((3-(4-(((3R,4S)-3-fluoropiperidin-4-yl)amino))-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzamide
1989.	4-{[3-(4-{[(3R,4S)-3-fluoropiperidin-4-yl]amino})-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxy-N-methylbenzamide
1990.	4-{[3-(4-{[(3R,4S)-3-fluoropiperidin-4-yl]amino})-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
1991.	2-[(3S,4R)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]ethan-1-ol
1992.	2-[(3R,4S)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]ethan-1-ol
1993.	2-(dimethylamino)-1-[(3S,4R)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]ethan-1-one
1994.	2-(dimethylamino)-1-[(3R,4S)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]ethan-1-one

Mol #	IUPAC name
1995.	4-{[3-(4-{[(3S,4R)-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-methylbenzamide
1996.	4-{[3-(4-{[(3S,4R)-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
1997.	N-[(3S,4R)-3-fluoro-1-(2-methoxyethyl)piperidin-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1998.	N-[(3R,4S)-3-fluoro-1-(2-methoxyethyl)piperidin-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1999.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-[(2R)-2-hydroxy-3-methoxypropyl]piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
2000.	1-[(3S,4R)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]ethan-1-one
2001.	1-[(3R,4S)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]ethan-1-one
2002.	1-[(3S,4R)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]propan-1-one
2003.	1-[(3R,4S)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]propan-1-one
2004.	1-[(3S,4R)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]-2-methoxyethan-1-one
2005.	1-[(3R,4S)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]-2-methoxyethan-1-one
2006.	4-{[3-(4-{[(3R,4S)-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzamide
2007.	4-{[3-(4-{[(3R,4S)-3-fluoro-1-[(2R)-2-hydroxy-3-methoxypropyl]piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
2008.	N-[(7S,8R)-7-fluoro-1,4-dioxaspiro[4.5]decan-8-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
2009.	1-[(3S,4R)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]propan-2-ol
2010.	1-((3S,4S)-3-fluoro-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)-3-methoxypropan-2-ol
2011.	1-((3R,4S)-3-fluoro-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)-3-methoxypropan-2-ol
2012.	4-((3-(4-(((3S,4S)-3-fluoro-1-((R)-2-hydroxy-3-methoxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoic acid
2013.	4-((3-(4-(((3R,4S)-3-fluoro-1-((R)-2-hydroxy-3-methoxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoic acid
2014.	4-((3-(4-(((3R,4S)-3-fluoro-1-((R)-2-hydroxy-3-methoxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoic acid
2015.	4-((3-(4-(((3S,4R)-3-fluoro-1-((R)-2-hydroxy-3-methoxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoic acid
2016.	methyl 4-((3-(4-(((3S,4R)-3-fluoro-1-((R)-2-hydroxy-3-methoxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoate
2017.	methyl 4-((3-(4-(((3R,4S)-3-fluoro-1-((R)-2-hydroxy-3-methoxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoate
2018.	(R)-1-((3R,4S)-3-fluoro-4-((2-(3-((2-fluoro-6-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-propyl-1H-indol-4-yl)amino)piperidin-1-yl)-3-methoxypropan-2-ol
2019.	(R)-1-((3R,4S)-4-((1-allyl-2-(3-((2-fluoro-6-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1H-indol-4-yl)amino)-3-fluoropiperidin-1-yl)-3-methoxypropan-2-ol
2020.	4-{3-(4-{[(3S,4R)-1-[(2R)-2,3-dihydroxypropyl]-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide

Mol #	IUPAC name
2021.	4-{[3-(4-{[(3R,4S)-1-[(2R)-2,3-dihydroxypropyl]-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
2022.	(2R)-1-[(3RS,4SR)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-propyl-1H-indol-4-yl)amino]piperidin-1-yl]-3-methoxypropan-2-ol
2023.	4-((3-(4-(((3S,4S)-3-fluoro-1-((R)-2-hydroxy-3-methoxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoic acid
2024.	4-((3-(4-(((3S,4S)-3-fluoro-1-((R)-2-hydroxy-3-methoxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoic acid
2025.	4-((3-(4-(((3R,4R)-3-fluoro-1-((R)-2-hydroxy-3-methoxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoic acid
2026.	(2R)-1-(acetyloxy)-3-[(3R,4S)-3-fluoro-4-[(2-{3-[(2-methoxy-4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]propan-2-yl acetate
2027.	N-[(2R)-2,3-dihydroxypropyl]-4-{[3-(4-{[(3RS,4SR)-3-fluoro-1-[(2R)-2-hydroxy-3-methoxypropyl]piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
2028.	(2R)-1-(acetyloxy)-3-[(3S,4R)-3-fluoro-4-[(2-{3-[(2-methoxy-4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]propan-2-yl acetate
2029.	rac-N-(2-{bis[(pyridin-2-yl)methyl]amino}ethyl)-2-[(3R,4S)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]acetamide
2030.	2-amino-1-[(3R,4S)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]ethan-1-one
2031.	2-amino-1-[(3S,4R)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]ethan-1-one

Mol #	IUPAC name
2032.	1-[(3R,4S)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]propan-2-ol
2033.	3-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-ol
2034.	(4-((3-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoyl)glycine
2035.	methyl 4-{[3-(4-[[[(3S,4R)-3-fluoro-1-(2-methoxyethyl)piperidin-4-yl]amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxybenzoate
2036.	4-{[3-(4-[[[(3S,4R)-3-fluoro-1-(2-methoxyethyl)piperidin-4-yl]amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
2037.	methyl 4-{[3-(4-[[[(3S,4R)-3-fluoro-1-(2-hydroxyethyl)piperidin-4-yl]amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxybenzoate
2038.	methyl 4-{[3-(4-[[[(3S,4R)-3-fluoro-1-(2-hydroxypropyl)piperidin-4-yl]amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxybenzoate
2039.	methyl 4-{[3-(4-[[[(3S,4R)-1-(carbamoylmethyl)-3-fluoropiperidin-4-yl]amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxybenzoate
2040.	methyl 4-{[3-(4-[[[(3R,4S)-3-fluoro-1-(2-methoxyethyl)piperidin-4-yl]amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxybenzoate
2041.	methyl 4-{[3-(4-[[[(3R,4S)-3-fluoro-1-(2-hydroxyethyl)piperidin-4-yl]amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxybenzoate
2042.	4-{[3-(4-[[[(3R,4S)-3-fluoro-1-(2-methoxyethyl)piperidin-4-yl]amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
2043.	methyl 4-{[3-(4-[[[(3R,4S)-3-fluoro-1-(2-hydroxypropyl)piperidin-4-yl]amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxybenzoate
2044.	N-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]-2-{3-[(2-methoxy-4-{2-oxa-6-azaspiro[3.3]heptane-6-carbonyl}phenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2045.	N-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]-2-{3-[(2-methoxy-4-{7-oxa-2-azaspiro[3.5]nonane-2-carbonyl}phenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2046.	4-{[3-(4-[[[(3S,4R)-3-fluoro-1-(2-hydroxyethyl)piperidin-4-yl]amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxybenzoic acid

Mol #	IUPAC name
2047.	N-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]-2-(3-{[2-methoxy-4-(morpholine-4-carbonyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2048.	N-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]-2-(3-{[2-methoxy-4-(4-methylpiperazine-1-carbonyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2049.	4-{[3-(4-{[(3R,4S)-3-fluoro-1-(2-hydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
2050.	4-{[3-(4-{[(3R,4S)-3-fluoro-1-(2-hydroxyethyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
2051.	methyl 4-{[3-(4-{[(3S,4R)-1-[(dimethylcarbamoyl)methyl]-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoate
2052.	methyl 4-{[3-(4-{[(3R,4S)-1-[(dimethylcarbamoyl)methyl]-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoate
2053.	methyl 4-{[3-(4-{[(3R,4S)-1-(carbamoylmethyl)-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoate
2054.	2-((3R,4S)-3-fluoro-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)acetamide
2055.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-(1,3-thiazol-2-yl)benzamide
2056.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide
2057.	1-(4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoyl)piperidin-4-ol
2058.	4-{[3-(4-{[(3S,4R)-1-[(dimethylcarbamoyl)methyl]-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
2059.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-(2-hydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
2060.	tert-butyl (3S,4R)-4-{[2-(3-{[4-(ethanesulfonyl)-2-methoxyphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-3-fluoropiperidine-1-carboxylate

Mol #	IUPAC name
2061.	2-(3-((4-(ethylsulfonyl)-2-methoxyphenyl)amino)prop-1-yn-1-yl)-N-((3S,4R)-3-fluoropiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2062.	4-{[3-(4-{{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxy-N-[2-(morpholin-4-yl)ethyl]benzamide
2063.	4-{[3-(4-{{[(3R,4S)-1-(carbamoylmethyl)-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
2064.	4-{[3-(4-{{[(3S,4R)-1-(carbamoylmethyl)-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
2065.	4-{[3-(4-{{[(3R,4S)-1-[(dimethylcarbamoyl)methyl]-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
2066.	tert-butyl (3S,4R)-4-[(2-{3-[(2-ethoxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-3-fluoropiperidine-1-carboxylate
2067.	(2S)-2-[(4-{[3-(4-{{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxyphenyl)formamido]pentanedioic acid
2068.	(2S)-4-carbamoyl-2-[(4-{[3-(4-{{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxyphenyl)formamido]butanoic acid
2069.	4-{[3-(4-{{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonic acid
2070.	1,5-dimethyl (2S)-2-[(4-{[3-(4-{{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxyphenyl)formamido]pentanedioate
2071.	2-[3-(4-{[4-(dimethylamino)piperidine-1-carbonyl]-2-methoxyphenyl}amino)prop-1-yn-1-yl]-N-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2072.	4-{[3-(4-{{[(3S,4R)-1-(carboxymethyl)-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
2073.	2-(3-{[4-(ethanesulfonyl)-2-methoxyphenyl]amino}prop-1-yn-1-yl)-N-[(3S,4R)-3-fluoropiperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
2074.	(1R,2R,4S)-2-fluoro-N ¹ -(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,4-diamine
2075.	(1R,2R,4S)-2-fluoro-N ¹ -(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ⁴ -methylcyclohexane-1,4-diamine
2076.	(1S,3R,4R)-3-fluoro-N ⁴ -(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N ¹ ,N ¹ -dimethylcyclohexane-1,4-diamine
2077.	2-(4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzenesulfonyl)ethan-1-ol
2078.	N-ethyl-4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzamide
2079.	2-{3-[(2-ethoxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-[(3S,4R)-3-fluoropiperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2080.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N,N-dimethylbenzamide
2081.	N-ethyl-4-((3-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide
2082.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-methyl-N-(propan-2-yl)benzamide
2083.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-(2-methoxyethyl)benzamide
2084.	N-[2-(diethylamino)ethyl]-4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzamide
2085.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-(2-hydroxyethyl)-3-methoxybenzamide
2086.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-[(2R,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]benzamide

Mol #	IUPAC name
2087.	4-((3-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-N-(1-hydroxypropan-2-yl)-3-methoxybenzamide
2088.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-[(2R)-1-hydroxypropan-2-yl]-3-methoxybenzamide
2089.	N-[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]cyclopropanecarboxamide
2090.	(1R,2R)-N-[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]-2-phenylcyclopropane-1-carboxamide
2091.	N-[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]-1-methyl-1H-pyrrole-3-carboxamide
2092.	1-ethyl-N-[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]-1H-pyrrole-3-carboxamide
2093.	1-tert-butyl-N-[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]-1H-pyrrole-3-carboxamide
2094.	methyl (2S)-4-carbamoyl-2-[(4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxyphenyl)formamido]butanoate
2095.	4-((3-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-N-((R)-2-hydroxypropyl)-3-methoxybenzamide
2096.	rac-4-{[3-(4-{[(3R,4S)-1-ethyl-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl] amino}-3-methoxybenzoic acid
2097.	4-((3-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-N-((S)-2-hydroxypropyl)-3-methoxybenzamide
2098.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-(2-hydroxy-3-methoxypropyl)-3-methoxybenzamide
2099.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-[(2S)-2-hydroxypropyl]-3-methoxybenzamide
2100.	N-(2,3-dihydroxypropyl)-4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzamide

Mol #	IUPAC name
2101.	N-[(2R)-2,3-dihydroxypropyl]-4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzamide
2102.	N-[(2S)-2,3-dihydroxypropyl]-4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzamide
2103.	N-(1,5-dihydropentan-3-yl)-4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzamide
2104.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-(3-hydroxy-2-methoxypropyl)-3-methoxybenzamide
2105.	1-[(4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxyphenyl)formamido]-3-[(2-methylpropanoyl)oxy]propan-2-yl 2-methylpropanoate
2106.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-[(2-oxo-1,3-dioxolan-4-yl)methyl]benzamide
2107.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-(2-methanesulfonyl)ethyl)-3-methoxybenzamide
2108.	1-(acetyloxy)-3-[(4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxyphenyl)formamido]propan-2-yl acetate
2109.	1-[(4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxyphenyl)formamido]-3-(propanoyloxy)propan-2-yl propanoate
2110.	2-[(4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxyphenyl)formamido]propyl 2-methylpropanoate

Mol #	IUPAC name
2111.	(S)-5-ethoxy-2-(4-((3-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzamido)-5-oxopentanoic acid
2112.	(4-((3-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoyl)-L-glutamine
2113.	(S)-2-(4-((3-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzamido)-5-methoxy-5-oxopentanoic acid
2114.	(S)-1-((3S,4S)-3-fluoro-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)-3-methoxypropan-2-ol
2115.	(S)-1-((3R,4R)-3-fluoro-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)-3-methoxypropan-2-ol
2116.	(S)-1-((3R,4S)-3-fluoro-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)-3-methoxypropan-2-ol
2117.	(S)-1-((3S,4R)-3-fluoro-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)-3-methoxypropan-2-ol
2118.	1-((3S,4S)-3-fluoro-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)-3-methoxypropan-2-ol
2119.	1-((3R,4S)-3-fluoro-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)-3-methoxypropan-2-ol
2120.	(R)-1-((3S,4S)-3-fluoro-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)-3-methoxypropan-2-ol
2121.	(R)-1-((3R,4R)-3-fluoro-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)-3-methoxypropan-2-ol

Mol #	IUPAC name
2122.	(R)-1-((3R,4S)-3-fluoro-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)-3-methoxypropan-2-ol
2123.	(R)-1-((3S,4R)-3-fluoro-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)-3-methoxypropan-2-ol
2124.	4-((3-(4-(((3R,4S)-3-fluoro-1-((R)-2-hydroxy-3-methoxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
2125.	1-(3,3-difluoro-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)-3-methoxypropan-2-ol
2126.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-(1-methylazepan-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2127.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]azepan-1-yl}-3-methoxypropan-2-ol
2128.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-{8-methyl-8-azabicyclo[3.2.1]octan-3-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2129.	2-(3-{[4-methanesulfonyl-2-(trifluoromethoxy)phenyl]amino}prop-1-yn-1-yl)-N-(oxan-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2130.	3-methoxy-4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-N-(1,2-oxazol-3-yl)benzene-1-sulfonamide
2131.	3-methoxy-N-(oxan-4-yl)-4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
2132.	3-methoxy-N-(5-methyl-1,2-oxazol-3-yl)-4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
2133.	2-{4-methoxy-5-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
2134.	N-(2-hydroxyethyl)-3-methoxy-N-methyl-4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
2135.	6-fluoro-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-(oxan-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
2136.	4-[(3-{6-fluoro-4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxybenzene-1-sulfonamide
2137.	3-methoxy-N,N-dimethyl-4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
2138.	3-methoxy-N-(2-methoxyethyl)-N-methyl-4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
2139.	1-(4-{3-methoxy-4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzenesulfonyl}piperazin-1-yl)ethan-1-one
2140.	2-(3-{[2-methoxy-4-(morpholine-4-sulfonyl)phenyl]amino}prop-1-yn-1-yl)-N-(oxan-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2141.	3-methoxy-N-methyl-4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzamide
2142.	3-methoxy-4-((3-(4-((tetrahydro-2H-pyran-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzoic acid
2143.	methyl 3-methoxy-4-((3-(4-((tetrahydro-2H-pyran-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzoate
2144.	3-methoxy-4-((3-(4-((tetrahydro-2H-pyran-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
2145.	3-methoxy-N-(2-methoxyethyl)-N-methyl-4-((3-(4-((tetrahydro-2H-pyran-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
2146.	N,N-bis(2-hydroxyethyl)-3-methoxy-4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
2147.	3-methoxy-N-methyl-4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
2148.	5-methanesulfonyl-2-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]phenol
2149.	3-methoxy-4-[(3-{5-methoxy-4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
2150.	2-[3-({2-methoxy-4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}amino)prop-1-yn-1-yl]-N-(oxan-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
2151.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-5-methoxy-N-(oxan-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2152.	3-methoxy-4-{[3-{6-methoxy-4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl]amino}benzene-1-sulfonamide
2153.	5-methanesulfonyl-2-{[3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl]amino}phenyl propanoate
2154.	N-(2-hydroxyethyl)-3-methoxy-4-((3-(4-((tetrahydro-2H-pyran-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
2155.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(2S,4R)-2-methyloxan-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2156.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(2S,4S)-2-methyloxan-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2157.	3-methoxy-4-{[3-(4-{[(2S,4R)-2-methyloxan-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
2158.	3-methoxy-4-{[3-(4-{[(2S,4S)-2-methyloxan-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
2159.	3-methoxy-4-{[3-(4-{[(2S,4R)-2-methyloxan-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
2160.	3-methoxy-4-{[3-(4-{[(2S,4S)-2-methyloxan-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
2161.	rac-N-[(3R,4R)-3-fluorooxan-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2162.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((3R,4S)-3-methoxytetrahydro-2H-pyran-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2163.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((3S,4S)-3-methoxytetrahydro-2H-pyran-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2164.	N-[(3S,4S)-3-fluorooxan-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2165.	N-[(3R,4R)-3-fluorooxan-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
2166.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(2R,4R,6S)-2,6-dimethyloxan-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2167.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(2R,4S,6S)-2,6-dimethyloxan-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2168.	3-methoxy-4-{[3-(4-{[(2R,4R,6S)-2,6-dimethyloxan-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
2169.	3-methoxy-4-{[3-(4-{[(2R,4S,6S)-2,6-dimethyloxan-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
2170.	3-methoxy-4-{[3-(4-{[(2R,4S,6S)-2,6-dimethyloxan-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
2171.	3-methoxy-4-{[3-(4-{[(2R,4R,6S)-2,6-dimethyloxan-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
2172.	4-((2-(3-((4-methoxypyridin-3-yl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)tetrahydro-2H-thiopyran 1,1-dioxide
2173.	2-{5-[(3-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-4-methoxypyridin-2-yl}-2-methylpropanenitrile
2174.	4-{[2-(3-{[4-methanesulfonyl-2-(trifluoromethoxy)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1 λ^6 -thiane-1,1-dione
2175.	4-{[2-(3-{[2-methoxy-4-(morpholine-4-sulfonyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1 λ^6 -thiane-1,1-dione
2176.	4-({2-[3-({2-[2-(dimethylamino)ethoxy]-4-methanesulfonylphenyl]amino)prop-1-yn-1-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl}amino)-1 λ^6 -thiane-1,1-dione
2177.	4-[(3-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-N-(2-hydroxyethyl)-3-methoxy-N-methylbenzene-1-sulfonamide
2178.	4-[(3-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxy-N-(1,2-oxazol-3-yl)benzene-1-sulfonamide
2179.	4-[(3-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxy-N-(5-methyl-1,2-oxazol-3-yl)benzene-1-sulfonamide
2180.	4-[(3-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxy-N-(oxan-4-yl)benzene-1-sulfonamide

Mol #	IUPAC name
2181.	N-(2,3-dihydroxypropyl)-4-[(3-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxybenzene-1-sulfonamide
2182.	N-[2-(dimethylamino)ethyl]-4-[(3-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxy-N-methylbenzene-1-sulfonamide
2183.	4-[(3-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxy-N,N-dimethylbenzene-1-sulfonamide
2184.	4-({2-[3-({4-[(4-acetylpiperazin-1-yl)sulfonyl]-2-methoxyphenyl}amino)prop-1-yn-1-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl}amino)-1 λ^6 -thiane-1,1-dione
2185.	4-[(3-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxy-N-(2-methoxyethyl)-N-methylbenzene-1-sulfonamide
2186.	4-[(2-{3-[(2-methoxy-4-{2-oxa-6-azaspiro[3.3]heptane-6-sulfonyl}phenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ^6 -thiane-1,1-dione
2187.	4-({2-[3-({2-methoxy-4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}amino)prop-1-yn-1-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl}amino)-1 λ^6 -thiane-1,1-dione
2188.	4-[(3-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxy-N-methylbenzamide
2189.	4-((2-(3-((4-methoxy-6-(methylsulfonyl)pyridin-3-yl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)tetrahydro-2H-thiopyran 1,1-dioxide
2190.	4-((2-(3-((4-(methylsulfonyl)-2-(2,2,2-trifluoroethoxy)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)tetrahydro-2H-thiopyran 1,1-dioxide
2191.	2-(2-((3-(4-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-5-(methylsulfonyl)phenoxy)acetamide
2192.	2-(2-((3-(4-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-5-(methylsulfonyl)phenoxy)acetamide
2193.	N-(2,3-dihydroxypropyl)-4-((3-(4-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide

Mol #	IUPAC name
2194.	3-methoxy-4-((3-(4-(3-(1-methylpiperidin-4-yl)ureido)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide

TABLE 2. Aryl-linked indole compounds of the disclosure.

Mol #	Structure IUPAC name
2195.	4-{4- [(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}benzamide
2196.	4- ({2- [4-(aminomethyl)phenyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl} amino)-1 λ^6 -thiane-1,1-dione
2197.	4-[(2-{4-[(methylamino)methyl]phenyl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ^6 -thiane-1,1-dione
2198.	tert-butyl N- [(4-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl} phenyl)methyl]-N-methylcarbamate
2199.	4-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-N-methylbenzamide
2200.	tert-butyl N- [(4-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl} phenyl)methyl]carbamate
2201.	2-(5-{[(4-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl} phenyl)methyl]amino}pyridin-2-yl)-2-methylpropanenitrile
2202.	4-{[2-(4-{[(4-methanesulfonylphenyl)amino]methyl} phenyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1 λ^6 -thiane-1,1-dione
2203.	4-[(2-{4-[(phenylamino)methyl]phenyl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ^6 -thiane-1,1-dione
2204.	3-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl} benzonitrile
2205.	4-{[2-(2-fluoro-4-methylphenyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1 λ^6 -thiane-1,1-dione
2206.	4-{[2-(3-chlorophenyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1 λ^6 -thiane-1,1-dione
2207.	-{[2-(3-methoxyphenyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1 λ^6 -thiane-1,1-dione
2208.	4-{[2-(4-chlorophenyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1 λ^6 -thiane-1,1-dione
2209.	4-tert-butyl-N-[(4-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl} phenyl)methyl]benzamide

Mol #	Structure IUPAC name
2210.	4-cyano-N-[(4-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}phenyl)methyl]benzamide
2211.	4-chloro-N-[(4-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}phenyl)methyl]benzamide
2212.	3-[6-(1-cyano-1-methylethyl)pyridin-3-yl]-1-[(4-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}phenyl)methyl]urea
2213.	3-[(4-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}phenyl)methyl]-1-phenylurea
2214.	3-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}benzoic acid
2215.	4-({2-[3-(dimethylamino)phenyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl}amino)-1 λ^6 -thiane-1,1-dione
2216.	3-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-N-methylbenzamide
2217.	4-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}benzoic acid
2218.	4-[(2-{4-[(morpholin-4-yl)methyl]phenyl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ^6 -thiane-1,1-dione
2219.	methyl N-(3-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}phenyl)carbamate
2220.	1-(4-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}phenyl)cyclopropane-1-carbonitrile
2221.	4-({2-[4-(hydroxymethyl)phenyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl}amino)-1 λ^6 -thiane-1,1-dione
2222.	1-[(4-{4-[(1,1-dioxo-1 λ^6 -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}phenyl)methyl]-3-(4-methanesulfonylphenyl)urea
2223.	4-{2-[4-[(6-methanesulfonylpyridin-3-yl)amino]methyl]phenyl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1 λ^6 -thiane-1,1-dione
2224.	2-(4-{[(4-methanesulfonylphenyl)amino]methyl}phenyl)-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	Structure IUPAC name
2225.	2-(4-{{(6-methylpyridin-3-yl)amino}methyl}phenyl)-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2226.	2-(4-{{(4-chlorophenyl)amino}methyl}phenyl)-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2227.	2-(4-{{(4-methoxyphenyl)amino}methyl}phenyl)-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2228.	2-(4-{{(3-chlorophenyl)amino}methyl}phenyl)-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2229.	6-methyl-N-{{[4-(5-{{(1-methylpiperidin-4-yl)amino}methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)phenyl]methyl}pyridin-3-amine
2230.	N-{{[2-(4-{{(4-methanesulfonylphenyl)amino}methyl}phenyl)-1-(2,2,2-trifluoroethyl)-1H-indol-5-yl]methyl}-1-methylpiperidin-4-amine
2231.	2-(5-amino-[1,1'-biphenyl]-3-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2232.	2-{4-[amino(phenyl)methyl]phenyl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2233.	2-(4-(amino(cyclohexyl)methyl)phenyl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2234.	2-{4-[(cyclopentylamino)methyl]phenyl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2235.	2-(4-{1-[(4-methanesulfonylphenyl)amino]ethyl}phenyl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2236.	(+/-)-2-{4-[(cyclopropylamino)methyl]phenyl}-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2237.	(+/-)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(4-{{(4-methanesulfonyl-2-methoxyphenyl)amino}methyl}phenyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2238.	N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(4-{{(4-methanesulfonylphenyl)amino}methyl}phenyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	Structure IUPAC name
2239.	(+/-)-N- {[4-(4- {[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino }-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)phenyl]methyl} benzamide
2240.	(+/-)-N- {[4-(4- {[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino }-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)phenyl]methyl} cyclopropanecarboxamide
2241.	1-methoxy-3-(4- {[2-(3-methyl-2H-indazol-6-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino } piperidin-1-yl)propan-2-ol
2242.	1-(4- {[2-(2H-indazol-6-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino } piperidin-1-yl)-3-methoxypropan-2-ol
2243.	4- {[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino }-1-(2,2,2-trifluoroethyl)-2',3'-dihydro-1H,1'H-[2,6'-biindol]-2'-one
2244.	4-(4-((1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)isoindolin-1-one
2245.	N-[3-(4- {[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino }-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)phenyl]acetamide

TABLE 3. Heteroaryl-linked indole compounds of the disclosure.

Mol #	IUPAC name
2246.	4-((2-(6-methoxypyridin-3-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)tetrahydro-2H-thiopyran 1,1-dioxide -indol-4-amine
2247.	4-((2-(6-methylpyridin-3-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)tetrahydro-2H-thiopyran 1,1-dioxide
2248.	4-((2-(6-(dimethylamino)pyridin-3-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)tetrahydro-2H-thiopyran 1,1-dioxide
2249.	4-((2-(quinolin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)tetrahydro-2H-thiopyran 1,1-dioxide
2250.	4-((2-(2-fluoropyridin-3-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)tetrahydro-2H-thiopyran 1,1-dioxide
2251.	1-(4-((2-(5-aminopyridin-3-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)-3-methoxypropan-2-ol
2252.	2-(2-amino-6-phenylpyridin-4-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2253.	5-(4-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-N-methylpicolinamide
2254.	2-(2-amino-6-phenylpyrimidin-4-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2255.	2-(2-amino-6-(cyclohex-1-en-1-yl)pyrimidin-4-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2256.	2-(2-amino-6-cyclohexylpyrimidin-4-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2257.	2-(2-(methylamino)pyrimidin-4-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2258.	2-(2-aminopyrimidin-4-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2259.	4-{[2-(1-methyl-1H-pyrazol-3-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1λ ⁶ -thiane-1,1-dione
2260.	4-({2-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl}amino)-1λ ⁶ -thiane-1,1-dione
2261.	4-[(2-{1-[(pyridin-3-yl)methyl]-1H-pyrazol-4-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1λ ⁶ -thiane-1,1-dione
2262.	4-((2-(1-(2-methoxyethyl)-1H-pyrazol-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)tetrahydro-2H-thiopyran 1,1-dioxide

Mol #	IUPAC name
2263.	4-[(2-{1-[(pyridin-4-yl)methyl]-1H-pyrazol-4-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1 λ ⁶ -thiane-1,1-dione
2264.	2-(5-amino-1-phenyl-1H-pyrazol-3-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2265.	2-{5-[amino(phenyl)methyl]-1H-pyrazol-3-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2266.	2-(5-amino-1H-pyrazol-3-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2267.	2-(5-{[(4-methanesulfonylphenyl)amino]methyl}-1H-pyrazol-3-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2268.	2-[5-(methylamino)-1H-pyrazol-3-yl]-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2269.	2-(5-{[(4-methanesulfonylphenyl)amino]methyl}-1,3,4-thiadiazol-2-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2270.	N-{[5-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-thiadiazol-2-yl]methyl}cyclopropanecarboxamide
2271.	N-{[5-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-thiadiazol-2-yl]methyl}benzamide
2272.	(+/-)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(5-{[(4-methanesulfonyl-2-methoxyphenyl)amino]methyl}-1,3,4-thiadiazol-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2273.	(+/-)-N-[(3R,4R)-3-fluoro-1-methylpiperidin-4-yl]-2-(5-{[(4-methanesulfonyl-2-methoxyphenyl)amino]methyl}-1,3,4-thiadiazol-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2274.	(+/-)-N-{[5-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-thiadiazol-2-yl]methyl}cyclopentanecarboxamide
2275.	(+/-)-N-{[5-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-thiadiazol-2-yl]methyl}thiophene-2-carboxamide
2276.	1-fluoro-N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]cyclopropane-1-carboxamide

Mol #	IUPAC name
2277.	(+/-)-2,2-difluoro-N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]cyclopropane-1-carboxamide
2278.	(+/-)-(1R,2S)-2-methyl-N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]cyclopropane-1-carboxamide
2279.	(+/-)-(1R,2R)-2-methyl-N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]cyclopropane-1-carboxamide
2280.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]cyclopropanecarboxamide
2281.	(+/-)-N-{[5-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-thiadiazol-2-yl)methyl} oxetane-3-carboxamide
2282.	(+/-)-N-{[5-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-thiadiazol-2-yl)methyl} cyclobutanecarboxamide
2283.	(+/-)-methyl N-{[5-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-thiadiazol-2-yl)methyl} carbamate
2284.	methyl 4-{[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]carbonyl}benzoate
2285.	(+/-)-N-{[5-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-thiadiazol-2-yl)methyl}-1-methylpiperidine-4-carboxamide
2286.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]pyridine-2-carboxamide
2287.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]pyridine-3-carboxamide
2288.	(+/-)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-{5-[(methylamino)methyl]-1,3,4-thiadiazol-2-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2289.	(+/-)-benzyl N-{[5-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-thiadiazol-2-yl)methyl} carbamate
2290.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]-4-[(morpholin-4-yl)methyl]benzamide

Mol #	IUPAC name
2291.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]-3-[(morpholin-4-yl)methyl]benzamide
2292.	N-{[5-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-thiadiazol-2-yl)methyl}cyclopropanecarboxamide
2293.	N-{[5-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-thiadiazol-2-yl)methyl}cyclopropanecarboxamide
2294.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]pyridine-4-carboxamide
2295.	2-fluoro-N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]benzamide
2296.	3-fluoro-N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]benzamide
2297.	4-fluoro-N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]benzamide
2298.	(+/-)-(1S,2S)-N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]-2-phenylcyclopropane-1-carboxamide
2299.	4-{[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]carbonyl}benzoic acid
2300.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]-1H-indazole-5-carboxamide
2301.	3-methyl-1-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]urea
2302.	2-methyl-N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]propanamide
2303.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]acetamide
2304.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]-2-phenylacetamide
2305.	2-methoxy-N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]acetamide

Mol #	IUPAC name
2306.	N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(5-{[(4-methanesulfonyl-2-methoxyphenyl)amino]methyl}-1,3,4-thiadiazol-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2307.	N-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]-2-(5-{[(4-methanesulfonyl-2-methoxyphenyl)amino]methyl}-1,3,4-thiadiazol-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2308.	4-methoxy-N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]benzamide
2309.	3-methoxy-N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]benzamide
2310.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]butanamide
2311.	2-methoxy-N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]benzamide
2312.	2-[5-(aminomethyl)-1,3,4-thiadiazol-2-yl]-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2313.	3,3-dimethyl-1-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]urea
2314.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]-1H-indazole-6-carboxamide
2315.	benzyl N-{[5-(4-{[(3S,4R)-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-thiadiazol-2-yl]methyl} carbamate
2316.	1-methyl-N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]cyclopropane-1-carboxamide
2317.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]-1H-pyrazole-4-carboxamide
2318.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]-1H-pyrazole-5-carboxamide
2319.	1-ethyl-N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]cyclopropane-1-carboxamide
2320.	(+/-)-methyl (1R,2R)-2-{[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]carbonyl}cyclopropane-1-carboxylate

Mol #	IUPAC name
2321.	(+/-)-(1R,2R)-2-{{[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]carbamoyl} cyclopropane-1-carboxylic acid
2322.	1-methyl-N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]-1H-pyrrole-3-carboxamide
2323.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]-1H-pyrrole-3-carboxamide
2324.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]-2-(thiophen-2-yl)cyclopropane-1-carboxamide
2325.	N-(1-methylpiperidin-4-yl)-2-(5-{[(pyrrolidin-3-yl)amino]methyl}-1,3,4-thiadiazol-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2326.	(+/-)-(1R,2S)-2-{{[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]carbamoyl} cyclopropane-1-carboxylic acid
2327.	N-(1-methylpiperidin-4-yl)-2-(5-{[(1H-pyrazol-4-yl)amino]methyl}-1,3,4-thiadiazol-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2328.	N-((5-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-thiadiazol-2-yl)methyl)cyclopentanecarboxamide
2329.	N-((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)-2-(5-(((2-methoxy-4-(methylsulfonyl)phenyl)amino)methyl)-1,3,4-thiadiazol-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2330.	N-((5-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-thiadiazol-2-yl)methyl)benzamide
2331.	N-((5-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-thiadiazol-2-yl)methyl)cyclopropanecarboxamide
2332.	2-(5-(((dimethylamino)methyl)-1,3,4-thiadiazol-2-yl)-N-((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2333.	N-((3S,4S)-3-fluoro-1-methylpiperidin-4-yl)-2-(5-(((2-methoxy-4-(methylsulfonyl)phenyl)amino)methyl)-1,3,4-thiadiazol-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
2334.	N-{{2-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3-thiazol-4-yl)methyl} cyclopropanecarboxamide
2335.	N-{{2-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3-thiazol-4-yl)methyl} benzamide
2336.	(+/-)-N-{{2-(4-{{(3R,4S)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3-thiazol-5-yl)methyl} benzamide
2337.	N-[(2-{4-[(1-methylpiperidin-4-yl)amino]}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3-thiazol-5-yl)methyl]benzamide
2338.	(+/-)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(1,3-thiazol-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2339.	N-[(2-{4-[(1-methylpiperidin-4-yl)amino]}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3-thiazol-5-yl)methyl]cyclopropanecarboxamide
2340.	(+/-)-N-{{2-(4-{{(3R,4S)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3-thiazol-5-yl)methyl} cyclopropanecarboxamide
2341.	(+/-)-2-[5-(aminomethyl)-1,3-thiazol-2-yl]-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2342.	2-(4-(aminomethyl)thiazol-2-yl)-N-((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2343.	(+/-)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-{5-[(phenylamino)methyl]-1,3-thiazol-2-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2344.	N-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]-2-(5-{{(4-methanesulfonyl-2-methoxyphenyl)amino}methyl}}-1,3-thiazol-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2345.	2-(5-{{(4-methanesulfonylphenyl)amino}methyl}thiophen-2-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2346.	(+/-)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(5-{{(4-methanesulfonyl-2-methoxyphenyl)amino}methyl}thiophen-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2347.	(+/-)-N-{{5-(4-{{(3R,4S)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)thiophen-2-yl)methyl} benzamide
2348.	(+/-)-N-{{5-(4-{{(3R,4S)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)thiophen-2-yl)methyl} cyclopropanecarboxamide

Mol #	IUPAC name
2349.	N-(1-methylpiperidin-4-yl)-2-(5-(((4-(methylsulfonyl)phenyl)amino)methyl)thiophen-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2350.	N-((5-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)thiophen-2-yl)methyl)benzamide
2351.	N-((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)-2-(5-(((2-methoxy-4-(methylsulfonyl)phenyl)amino)methyl)thiophen-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2352.	2-(5-(amino(cyclohexyl)methyl)-1,3,4-oxadiazol-2-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2353.	N-(1-methylpiperidin-4-yl)-2-{5-[(phenylamino)methyl]-1,3,4-oxadiazol-2-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2354.	2-(5-(amino(tetrahydro-2H-pyran-4-yl)methyl)-1,3,4-oxadiazol-2-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2355.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-oxadiazol-2-yl)methyl]cyclopropanecarboxamide
2356.	2-(5-[[4-(methanesulfonyl)phenyl]amino]methyl)-1,3,4-oxadiazol-2-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2357.	N-(1-methylpiperidin-4-yl)-2-(5-[[1H-pyrazol-4-yl]amino]methyl)-1,3,4-oxadiazol-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2358.	2-(5-(aminomethyl)-1,3,4-oxadiazol-2-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2359.	(+/-)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(5-[[4-(methanesulfonyl-2-methoxyphenyl)amino]methyl]-1,3,4-oxadiazol-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2360.	(+/-)-N-{[5-(4-[[3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]-1,3,4-oxadiazol-2-yl]methyl}-2-methoxybenzamide
2361.	(+/-)-2-[5-(aminomethyl)-1,3,4-oxadiazol-2-yl]-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2362.	(+/-)-N-{[5-(4-[[3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]-1,3,4-oxadiazol-2-yl]methyl}-4-methoxybenzamide
2363.	(+/-)-N-{[5-(4-[[3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]-1,3,4-oxadiazol-2-yl]methyl}benzamide

Mol #	IUPAC name
2364.	(+/-)-N-{{5-(4-{{(3R,4S)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-oxadiazol-2-yl}methyl}-3-methoxybenzamide
2365.	(+/-)-N-{{5-(4-{{(3R,4S)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-oxadiazol-2-yl}methyl}thiophene-2-carboxamide
2366.	(+/-)-2-(5-{{(cyclopropylmethyl)amino}methyl}-1,3,4-oxadiazol-2-yl)-N-{{(3R,4S)-3-fluoro-1-methylpiperidin-4-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2367.	(+/-)-N-{{(3R,4S)-3-fluoro-1-methylpiperidin-4-yl}-2-(5-{{(3-methanesulfonylphenyl)amino}methyl}-1,3,4-oxadiazol-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2368.	(+/-)-N-{{(3R,4R)-3-fluoro-1-methylpiperidin-4-yl}-2-(5-{{(4-methanesulfonyl-2-methoxyphenyl)amino}methyl}-1,3,4-oxadiazol-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2369.	(+/-)-2-(5-((bis(cyclopropylmethyl)amino)methyl)-1,3,4-oxadiazol-2-yl)-N-((3R,4S)-3-fluoro-1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2370.	(+/-)-N-((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)-2-(5-(((3-methylsulfonyl)phenyl)amino)methyl)-1,3,4-oxadiazol-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2371.	(+/-)-N-((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)-2-(5-(((2-methoxy-4-methylsulfonyl)phenyl)amino)methyl)-1,3,4-oxadiazol-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2372.	(+/-)-2-(5-(aminomethyl)-1,3,4-oxadiazol-2-yl)-N-((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2373.	(+/-)-N-((3S,4S)-3-fluoro-1-methylpiperidin-4-yl)-2-(5-(((2-methoxy-4-methylsulfonyl)phenyl)amino)methyl)-1,3,4-oxadiazol-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2374.	N-((5-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino))-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-oxadiazol-2-yl)methyl)benzamide
2375.	(+/-)-N-((5-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino))-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-oxadiazol-2-yl)methyl)thiophene-2-carboxamide

Mol #	IUPAC name
2376.	(+/-)-N-((5-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-oxadiazol-2-yl)methyl)-2-methoxybenzamide
2377.	(+/-)-N-((5-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-oxadiazol-2-yl)methyl)-3-methoxybenzamide
2378.	(+/-)-N-((5-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-oxadiazol-2-yl)methyl)-4-methoxybenzamide
2379.	(+/-)-2-(5-(((cyclopropylmethyl)amino)methyl)-1,3,4-oxadiazol-2-yl)-N-((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2380.	(+/-)-N-((3R,4R)-3-fluoro-1-methylpiperidin-4-yl)-2-(5-(((2-methoxy-4-(methylsulfonyl)phenyl)amino)methyl)-1,3,4-oxadiazol-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2381.	2-(3-(((4-methanesulfonylphenyl)amino)methyl)-1,2,4-oxadiazol-5-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2382.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-3-yl)methyl]cyclopropanecarboxamide
2383.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-3-yl)methyl]benzamide
2384.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-3-yl)methyl]thiophene-2-carboxamide
2385.	1-methyl-N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-3-yl)methyl]-1H-pyrazole-4-carboxamide
2386.	1-methyl-N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-3-yl)methyl]-1H-pyrazole-3-carboxamide
2387.	N-(1-methylpiperidin-4-yl)-2-{5-[(phenylamino)methyl]-1,2,4-oxadiazol-3-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2388.	N-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]thiophene-2-carboxamide
2389.	N-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]benzamide
2390.	(+/-)-(1S,2R)-2-fluoro-N-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]cyclopropane-1-carboxamide

Mol #	IUPAC name
2391.	N-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]cyclopropanecarboxamide
2392.	(+/-)-(1S,2S)-2-fluoro-N-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]cyclopropane-1-carboxamide
2393.	4-chloro-N-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]benzamide
2394.	N-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]-1,3-thiazole-2-carboxamide
2395.	4-fluoro-N-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]benzamide
2396.	4-cyano-N-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]benzamide
2397.	1-methyl-N-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]-1H-pyrrole-3-carboxamide
2398.	3-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]-1-phenylurea
2399.	1-methyl-N-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]-1H-pyrazole-4-carboxamide
2400.	1-methyl-N-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]-1H-pyrazole-3-carboxamide
2401.	(+/-)-(1R,2R)-N-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]-2-phenylcyclopropane-1-carboxamide
2402.	(+/-)-(1R,2R)-2-methyl-N-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]cyclopropane-1-carboxamide
2403.	(+/-)-(1R,2S)-2-methyl-N-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]cyclopropane-1-carboxamide
2404.	N-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]cyclopropanecarboxamide
2405.	N-[(3-{4-(benzylamino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]cyclopropanecarboxamide

Mol #	IUPAC name
2406.	N-[(3-{4-[(1-acetylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]cyclopropanecarboxamide
2407.	N-[(3-{4-[(1,1-dioxo-1 λ ⁶ -thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]cyclopropanecarboxamide
2408.	N-[(3-{4-[(1-benzylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]cyclopropanecarboxamide
2409.	N-[(3-{4-[(1-cyclopropylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]cyclopropanecarboxamide
2410.	N-[(3-{4-[(cyclopropylmethyl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]cyclopropanecarboxamide
2411.	N-[(3-{4-[(cyclobutylmethyl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]cyclopropanecarboxamide
2412.	(+/-)-N-[(3-{4-[(pyrrolidin-3-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]cyclopropanecarboxamide
2413.	N-[(3-{4-[(1-ethylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]cyclopropanecarboxamide
2414.	(+/-)-N-[(3-{4-[(1-methylpyrrolidin-3-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]cyclopropanecarboxamide
2415.	N-{[3-(4-{[(3,4-zetidine-3-yl)methyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl]cyclopropanecarboxamide
2416.	(+/-)-N-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl]cyclopropanecarboxamide
2417.	(+/-)-N-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl]benzamide
2418.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl]cyclopropanecarboxamide
2419.	N-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl]cyclopropanecarboxamide

Mol #	IUPAC name
2420.	(+/-)-N-{{3-(4-{{(3R,4S)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl} thiophene-2-carboxamide
2421.	(+/-)-N-{{3-(4-{{(3R,4S)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl} thiophene-3-carboxamide
2422.	(+/-)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(5-{{(4-methanesulfonylphenyl)amino}methyl}-1,2,4-oxadiazol-3-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2423.	(+/-)-N-{{3-(4-{{(3R,4S)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}-1,3-thiazole-5-carboxamide
2424.	(+/-)-1-ethyl-N-{{3-(4-{{(3R,4S)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}-1H-pyrrole-3-carboxamide
2425.	(+/-)-(1R,2R)-N-{{3-(4-{{(3R,4S)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}-2-phenylcyclopropane-1-carboxamide
2426.	N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}-1-methyl-1H-pyrrole-3-carboxamide
2427.	N-{{3-(4-{{(3R,4S)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}-1-methyl-1H-pyrrole-3-carboxamide
2428.	(+/-)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(5-{{(4-methanesulfonyl-2-methoxyphenyl)amino}methyl}-1,2,4-oxadiazol-3-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2429.	(+/-)-1-tert-butyl-N-{{3-(4-{{(3R,4S)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}-1H-pyrrole-3-carboxamide
2430.	(+/-)-(1R,2R)-N-{{3-(4-{{(3RS,4SR)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}-2-phenylcyclopropane-1-carboxamide

Mol #	IUPAC name
2431.	1-ethyl-N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}-1H-pyrrole-3-carboxamide
2432.	1-ethyl-N-{{3-(4-{{(3R,4S)-3-fluoro-1-methylpiperidin-4-yl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}-1H-pyrrole-3-carboxamide
2433.	(+/-)-N-[(3R,4S)-3-fluoropiperidin-4-yl]-2-(5-{{(4-methanesulfonyl-2-methoxyphenyl)amino}methyl}-1,2,4-oxadiazol-3-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2434.	N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}thiophene-3-carboxamide
2435.	N-{{3-(4-{{(3R,4S)-3-fluoro-1-methylpiperidin-4-yl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}thiophene-3-carboxamide
2436.	(+/-)-N-[(3R,4S)-3-fluoropiperidin-4-yl]-2-(5-{{methyl(1H-pyrazol-4-yl)amino}methyl}-1,2,4-oxadiazol-3-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2437.	(+/-)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(5-{{methyl(1H-pyrazol-4-yl)amino}methyl}-1,2,4-oxadiazol-3-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2438.	(1RS,2RS)-2-cyano-N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}cyclopropane-1-carboxamide
2439.	1-tert-butyl-N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}-1H-pyrrole-3-carboxamide
2440.	(1RS,2SR)-2-cyano-N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}cyclopropane-1-carboxamide
2441.	N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}indolizine-2-carboxamide

Mol #	IUPAC name
2442.	N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}-1-phenyl-1H-imidazole-4-carboxamide
2443.	N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}-1-(2-methoxyethyl)-1H-pyrrole-3-carboxamide
2444.	N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}-1-(propan-2-yl)-1H-pyrrole-3-carboxamide
2445.	N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}pyridine-4-carboxamide
2446.	N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}pyridine-2-carboxamide
2447.	N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}pyridine-3-carboxamide
2448.	N-[(3S,4R)-3-fluoropiperidin-4-yl]-2-(5-{{(1H-pyrazol-4-yl)amino}methyl})-1,2,4-oxadiazol-3-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2449.	benzyl N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}carbamate
2450.	N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}-1-(2-fluoroethyl)-1H-pyrrole-3-carboxamide
2451.	(1S,2R)-N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}-2-phenylcyclopropane-1-carboxamide
2452.	(1R,2S)-N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}-2-phenylcyclopropane-1-carboxamide

Mol #	IUPAC name
2453.	N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}-5-methylthiophene-3-carboxamide
2454.	N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}-4-methylthiophene-3-carboxamide
2455.	(1R,2R)-N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}-2-(4-fluorophenyl)cyclopropane-1-carboxamide
2456.	N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}-2-methylthiophene-3-carboxamide
2457.	(1s,3r)-N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}-3-methylcyclobutane-1-carboxamide
2458.	5-chloro-N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}thiophene-3-carboxamide
2459.	N-[(3S,4R)-3-fluoropiperidin-4-yl]-2-(5-{{(1H-pyrazol-5-yl)amino}methyl})-1,2,4-oxadiazol-3-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2460.	2-chloro-N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}thiophene-3-carboxamide
2461.	N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}pyrazolo[1,5-a]pyridine-2-carboxamide
2462.	N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}imidazo[1,2-a]pyridine-2-carboxamide
2463.	1-cyclopropyl-N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}-1H-pyrrole-3-carboxamide

Mol #	IUPAC name
2464.	N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl}-1,5-dimethyl-1H-pyrrole-3-carboxamide
2465.	4-(dimethylamino)-N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl}benzamide
2466.	N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl}benzenesulfonamide
2467.	N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl}cyclobutanecarboxamide
2468.	(1r,3s)-N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl}-3-methylcyclobutane-1-carboxamide
2469.	(1R,2R)-N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl}-2-(2-fluorophenyl)cyclopropane-1-carboxamide
2470.	(1R,2R)-N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl}-2-(1-methyl-1H-pyrazol-4-yl)cyclopropane-1-carboxamide
2471.	(1R,2R)-N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl}-2-(pyridin-2-yl)cyclopropane-1-carboxamide
2472.	N-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]-2-(5-{{(1H-pyrazol-4-yl)amino}methyl}-1,2,4-oxadiazol-3-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2473.	N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl}acetamide
2474.	1-[2-(dimethylamino)ethyl]-N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl}-1H-pyrrole-3-carboxamide
2475.	N-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]-2-(5-{{(1H-pyrazol-5-yl)amino}methyl}-1,2,4-oxadiazol-3-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
2476.	1-tert-butyl-N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}-1H-pyrazole-4-carboxamide
2477.	N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}-1-(propan-2-yl)-1H-imidazole-4-carboxamide
2478.	(1S)-N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}-2,2-dimethylcyclopropane-1-carboxamide
2479.	(1R,2R)-N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}-2-[(4-methylpiperazin-1-yl)methyl]cyclopropane-1-carboxamide
2480.	(1R,2R)-N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}-2-(3-fluorophenyl)cyclopropane-1-carboxamide
2481.	N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}-1-methyl-1H-1,2,3-triazole-4-carboxamide
2482.	N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}-1-(1-hydroxypropan-2-yl)-1H-pyrrole-3-carboxamide
2483.	2-[3-({3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}carbonyl)-1H-pyrrol-1-yl]acetic acid
2484.	(1R)-N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}-2,2-dimethylcyclopropane-1-carboxamide
2485.	N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}-1-(2-methylpropyl)-1H-pyrrole-3-carboxamide
2486.	1-(cyclopropylmethyl)-N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl}methyl}-1H-pyrrole-3-carboxamide

Mol #	IUPAC name
2487.	3-(dimethylamino)-N-{{3-(4-{{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl}benzamide
2488.	N-{{3-(4-{{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl}-4-(pyrrolidin-1-yl)benzamide
2489.	N-{{3-(4-{{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl}-1-(2-hydroxypropyl)-1H-pyrrole-3-carboxamide
2490.	(1R,2R)-N-{{3-(4-{{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl}-2-[(morpholin-4-yl)methyl]cyclopropane-1-carboxamide
2491.	(1R,2R)-N-{{3-(4-{{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl}-2-[[propan-2-yl]amino]methyl}cyclopropane-1-carboxamide
2492.	(1R,2R)-N-{{3-(4-{{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl}-2-[(propylamino)methyl]cyclopropane-1-carboxamide
2493.	3-{3-({3-(4-{{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl}carbonyl)-1H-pyrrol-1-yl}propanoic acid
2494.	N-{{3-(4-{{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl}-1-(2-hydroxyethyl)-1H-pyrrole-3-carboxamide
2495.	1-(2,2-difluoroethyl)-N-{{3-(4-{{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl}-1H-pyrrole-3-carboxamide
2496.	N-{{3-(4-{{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl}-1-(2-methoxy-2-methylpropyl)-1H-pyrrole-3-carboxamide
2497.	N-{{3-(4-{{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl}-1-(2-hydroxy-2-methylpropyl)-1H-pyrrole-3-carboxamide

Mol #	IUPAC name
2498.	N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl}-1-(2-methoxypropyl)-1H-pyrrole-3-carboxamide
2499.	N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl}-1-methyl-1H-indole-6-carboxamide
2500.	N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl}-1-(propan-2-yl)-1H-pyrazole-4-carboxamide
2501.	4-(4,4-difluoropiperidin-1-yl)-N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl}benzamide
2502.	N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl}-1-(propan-2-yl)-1H-imidazole-5-carboxamide
2503.	N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl}-1H-indole-5-carboxamide
2504.	N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl}-1-methyl-1H-indole-5-carboxamide
2505.	N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl}-4-(morpholin-4-yl)benzamide
2506.	2-[5-(aminomethyl)-1,2,4-oxadiazol-3-yl]-N-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2507.	N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl}-3-(morpholin-4-yl)benzamide
2508.	N-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl}-3-(pyrrolidin-1-yl)benzamide

Mol #	IUPAC name
2509.	(1R,2R)-2-[(dimethylamino)methyl]-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}cyclopropane-1-carboxamide
2510.	(1R,2R)-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-2-[(pyrrolidin-1-yl)methyl]cyclopropane-1-carboxamide
2511.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-3-methyl-1H-indole-5-carboxamide
2512.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1H-indole-6-carboxamide
2513.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1-(2-methoxyethyl)-1H-imidazole-5-carboxamide
2514.	(1R,2R)-2-ethyl-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}cyclopropane-1-carboxamide
2515.	1-tert-butyl-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1H-imidazole-5-carboxamide
2516.	(1S,2S)-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-2-[(propan-2-yl)amino]methyl}cyclopropane-1-carboxamide
2517.	N-{[3-(4-{[(3S,4R)-1-ethyl-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1-(2-methoxyethyl)-1H-pyrrole-3-carboxamide
2518.	N-{[3-(4-{[(3R,4S)-1-ethyl-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1-(2-methoxyethyl)-1H-pyrrole-3-carboxamide
2519.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-3-methyl-1H-indole-6-carboxamide

Mol #	IUPAC name
2520.	(+/-)-N-{{5-(4-{{(3R,4S)-3-fluoro-1-methylpiperidin-4-yl}amino})-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-3-yl}methyl}cyclopropanecarboxamide
2521.	(+/-)-N-{{5-(4-{{(3R,4S)-3-fluoro-1-methylpiperidin-4-yl}amino})-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-3-yl}methyl}benzamide
2522.	(+/-)-N-{{5-(4-{{(3R,4S)-3-fluoro-1-methylpiperidin-4-yl}amino})-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-3-yl}methyl}thiophene-2-carboxamide
2523.	(+/-)-N-{{5-(4-{{(3R,4S)-3-fluoro-1-methylpiperidin-4-yl}amino})-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-3-yl}methyl}thiophene-3-carboxamide
2524.	(+/-)-N-{{5-(4-{{(3R,4S)-3-fluoro-1-methylpiperidin-4-yl}amino})-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-3-yl}methyl}-1,3-thiazole-5-carboxamide
2525.	N-((3-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino))-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1-(1-fluoropropan-2-yl)-1H-pyrrole-3-carboxamide
2526.	N-((3-(4-(((3S,4R)-1-ethyl-3-fluoropiperidin-4-yl)amino))-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1-(2-fluoroethyl)-1H-pyrrole-3-carboxamide
2527.	N-((3-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino))-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1-(1-methoxypropan-2-yl)-1H-pyrrole-3-carboxamide

EXAMPLE 2: *Combination of Compound 1 and Anti-PD-1 agent in mouse sarcoma model (MT373).*

[0412] Compound 1 is an indole compound substituted with a trifluoroethyl group at the 1-position; propynyl amino-methoxy-N-methylbenzamide group at the 2-position; and a heterocycle-substituted amino group at the 4-position.

[0413] The efficacy of Compound 1 was tested as a single agent and in combination with anti-PD-1 in a mouse syngeneic model of sarcoma (MT373). C57Bl/6 mice were implanted with MT373 cells, and tumors were grown to ~80 mm³. The mice were randomized on day 6 post-inoculation into one of six study groups. Mice were dosed orally (PO) with either vehicle control (0.2% HPC, 0.5%

Tween 80) twice per day once weekly (2Q7D); anti-PD-1 at 200 µg per mouse once every three days (Q3Dx35); Compound 1 at 75 mg/kg or 150 mg/kg twice per day, once weekly, for 6 weeks (2Q7Dx6); the combination of Compound 1 at 75 mg/kg + anti-PD-1 twice per day, once weekly (2Q7Dx15); or the combination of Compound 1 at 150 mg/kg + anti-PD-1 twice per day, once weekly (2Q7Dx15).

[0414] Animals: Female C57Bl/6 mice (120 total) were acclimatized for 1 week and were 8-10 weeks old at initiation of the study. Animals were group housed (N=5) in ventilated cages. Fluorescent lighting was provided on a 12-hour cycle (6:30 am-6:30 pm). Temperature and humidity were monitored and recorded daily and maintained between 68-72 °F (20-22.2 °C) and 30-70% humidity, respectively. 18% soy irradiated rodent feed and autoclaved acidified water was provided *ad libitum*.

[0415] Tumor Cell Culture: MT373 cells were cultured in DMEM medium with 10% fetal bovine serum. The cells were washed with PBS and counted at a total of 6.59x10⁸ cells with 92% viability. Cells were spun by centrifuge and resuspended in 50% PBS:50% Matrigel Matrix at a concentration of 5x10⁶ viable cells/200 µL.

[0416] Implantation of Mice: Cells were prepared for injections by drawing the cell suspension into a 1 mL tuberculin syringe fitted with a 25G 5/8" needle. Individual mice were manually restrained, the site of injection (right flank) was disinfected with a 70% ethanol swab, and 200 µL of cell suspension was injected subcutaneously.

[0417] Randomization and Study Setup: Implanted mice were monitored for palpable tumors. Five days post implant the mice with palpable tumors had their tumor sizes determined via digital caliper. Mice were selected and randomized into six treatment groups according to tumor size. Average tumor volume (mm³) and body weight (g) is reported in **TABLE 4A** and **4B**. Treatment began on the sixth day post-implant to facilitate twice daily dosing.

TABLE 4A

Group	N	Mean	St Dev	Min	Max
Group 1- Vehicle Control 2Q7Dx4	10	77.35	± 8.61	64.488	96.246
Group 2- Anti-PD-1 200µg Q3Dx35	10	84.08	± 18.43	53.95	116.30
Group 3- Compound 1 75 mg/kg 2Q7Dx6	10	82.46	± 16.79	58.42	114.05
Group 4- Compound 1 150 mg/kg 2Q7Dx15	10	79.04	± 23.07	53.11	117.04
Group 5- Compound 1 75 mg/kg 2Q7Dx15	10	80.96	± 15.78	51.69	106.31

+ Anti-PD-1 200µg Q3Dx35					
Group 6- Compound 1 150 mg/kg 2Q7Dx15 + Anti-PD-1 200µg Q3Dx35	10	79.54	± 11.10	63.56	103.10

TABLE 4B

Group	N	Mean	St Dev	Min	Max
Group 1- Vehicle Control 2Q7Dx4	10	18.48	± 0.81	17.40	19.50
Group 2- Anti-PD-1 200µg Q3Dx35	10	18.44	± 0.83	16.70	19.40
Group 3- Compound 1 75 mg/kg 2Q7Dx6	10	18.67	± 0.82	17.30	19.90
Group 4- Compound 1 150 mg/kg 2Q7Dx15	10	18.97	± 1.12	16.90	21.00
Group 5- Compound 1 75 mg/kg 2Q7Dx15 + Anti-PD-1 200µg Q3Dx35	10	18.48	± 0.92	16.50	20.10
Group 6- Compound 1 150 mg/kg 2Q7Dx15 + Anti-PD-1 200µg Q3Dx35	10	18.86	± 0.63	17.70	20.00

[0418] **Measurements and Calculation of Tumor Volume:** Tumor volume was calculated using the following equation: $(\text{longest diameter} \times \text{shortest diameter}^2)/2$. Individual tumor volumes and body weight measurements were taken twice weekly for all groups until the animals reached the humane endpoints. The calculation for percent tumor growth inhibition (TGI) was as follows: $[1 - ((T_t - T_0)/C_t - C_0))] \times 100$, where C_t is the mean tumor volume of the vehicle control group at time t , C_0 is the mean tumor volume of the vehicle control group at time 0, and T is the mean tumor volume of the treatment group. Tumor regression was determined with the equation $[(T_0 - T_t)/T_0] \times 100$ using the same definitions.

[0419] Group 1 animals were dosed PO with vehicle control (2% HPC, 0.5% Tween 80 in water (w/v/v)) twice a day (BID, 8 hours apart), once per week for four doses (2Q7Dx4). Group 2 animals were dosed interperitoneally (IP) with anti-PD-1 at 200 µg for 35 doses (Q3Dx35). Groups 3 and 4 animals were dosed PO twice a day (BID, 8 hours apart) with Compound 1 at 75 mg/kg for 6 doses (2Q7Dx6) or 150 mg/kg for 15 doses (2Q7Dx15), respectively. Groups 5 and 6 animals were dosed with Compound 1 at 75 and 150 mg/kg for 15 doses (2Q7Dx15) in combination with anti-PD-1 at 200 µg for 15 doses (Q3Dx15), respectively. **TABLE 5** shows the efficacy of the six study groups

and dosing regimens. All dosing was discontinued on day 102 and the remaining mice with no palatable tumors were monitored for survival. The time for each tumor to reach 2000 mm³ was determined and a median survival time for each dosed group could be calculated. At day 185, the study was terminated, and median survival was calculated across all groups. Some tumors that regressed but re-grew were collected 24 h post dose for subsequent genetic analysis.

TABLE 5

Group	Treatment	N	Route	Dosing Frequency & Duration	Dose (mg/kg)	Dose Volume (ml/kg)
1	Vehicle Control	10	PO	2Q7Dx4	-	10
2	Anti-PD-1	10	IP	Q3DX35	200 µg	10
3	Compound 1	10	PO	2Q7Dx6	75	10
4	Compound 1	10	PO	2Q7Dx15	150	10
5	Compound1+	10	PO	2Q7Dx15	75	10
	Anti-PD-1		IP	Q3DX35	200 µg	10
6	Compound1+	10	PO	2Q7Dx15	150	10
	Anti-PD-1		IP	Q3DX35	200 µg	10

[0420] MT373 mouse syngeneic sarcoma tumors implanted into female C57Bl/6 mice grew from an average of 77.4 mm³ to 2692 mm³ in 27 days with a median survival time of 20.9 days. Group 2 mice treated with anti-PD-1 (200 µg/mouse) Q3Dx35 resulted in 39% TGI by day 27 and a median survival time of 27.14 days. Mice in group 3 received Compound 1 at 75 mg/kg 2Q7Dx6 which resulted in 57% TGI by day 27 and median survival time of 32 days. Compound 1 administration at the higher dose of 150 mg/kg 2Q7Dx15 resulted in 95% TGI and a median survival of 42.9 days. Co-administration of Compound 1 with anti-PD-1 improved efficacy significantly for both dose levels of Compound 1. Mice in the 75 mg/kg Compound 1 + anti-PD-1 combination group demonstrated 91% TGI at day 27 with a median survival time of 43.7 days, while the 150 mg/kg Compound 1 + anti-PD-1 combination achieved 92% regression by day 27 and extended median survival time to >185 days.

[0421] At day 27, tumor growth inhibition (TGI) of 39.6%, 57.1%, 95.7%, and 91.2% was observed in animals treated with anti-PD-1, Compound 1 at 75 mg/kg, Compound 1 at 150 mg/kg, and the combination 75 mg/kg + 200µg anti-PD-1, respectively. Tumor regression of 92.3% was observed at day 27 in mice treated with Compound 1 at 150 mg/kg + anti-PD-1. **FIG. 1** shows changes in tumor volume (mm³) in a mouse syngeneic model of sarcoma (MT373) over 27 days upon receiving treatment with vehicle (2Q7Dx4); anti-PD-1 200 µg (Q3Dx35); Compound 1, 75 mg/kg (2Q7Dx6);

Compound 1, 150 mg/kg (2Q7Dx15); Compound 1, 75 mg/kg (2Q7Dx15) + anti-PD-1 (Q3Dx35); or Compound 1, 150 mg/kg (2Q7Dx15) + anti-PD-1 (Q3Dx35).

[0422] **FIG. 2** shows changes in tumor volume (mm³) in a mouse syngeneic model of sarcoma (MT373) over 185 days upon receiving treatment with vehicle (2Q7Dx4); anti-PD-1 200 µg (Q3Dx35); Compound 1, 75 mg/kg (2Q7Dx6); Compound 1, 150 mg/kg (2Q7Dx15); Compound 1, 75 mg/kg (2Q7Dx15) + anti-PD-1 (Q3Dx35); or Compound 1, 150 mg/kg (2Q7Dx15) + anti-PD-1 (Q3Dx35). The median survival time (defined as median time taken for tumors in a group to reach 2000 mm³) was significantly increased in mice receiving the high dose combination of Compound 1 at 150 mg/kg and anti-PD-1 to >185 days, when compared to vehicle control at 20.9 days. Compound 1 was well-tolerated by mice with no significant body weight loss across the course of the study. Mice were dosed on their various group regimens until day 102 after which dosing ceased and mice were monitored for clinical observations, tumor volume, and body weight measurements until day 185.

[0423] **TABLE 6** and **TABLE 7** show average percent tumor growth inhibition (%) across 27 days of study and 185 days of study, respectively. **TABLE 8** shows median survival time in days and increase in survival relative to the vehicle group for the 6 mouse groups.

TABLE 6

Day of Study	Group 1- Vehicle Control 2Q7Dx4	Group 2- Anti-PD-1 200µg Q3Dx35	Group 3- Compound 1 75 mg/kg 2Q7Dx6	Group 4- Compound 1 150 mg/kg 2Q7Dx15	Group 5- Compound 1 75 mg/kg 2Q7Dx15 + Anti-PD-1 200µg Q3Dx35	Group 6- Compound 1 150 mg/kg 2Q7Dx6 + Anti-PD-1 200µg Q3Dx35
2	0	13.5	83.0	69.9	92.8	37.6
6	0	47.3	87.1	95.5	>100	75.2
8	0	43.3	74.9	69.4	94.2	89.2
13	0	73.3	76.6	>100	>100	>100
16	0	75.3	77.9	97.4	99.0	>100
20	0	69.6	74.4	98.3	97.5	>100
23	0	62.0	69.0	95.8	65.4	>100
27	0	39.6	57.1	96.7	91.2	>100

TABLE 7 (n=10 unless noted)

Day of Study	Group 1- Vehicle Control 2Q7Dx4	Group 2- Anti-PD-1 200µg Q3Dx35	Group 3- Compound 1 75 mg/kg 2Q7Dx6	Group 4- Compound 1 150 mg/kg 2Q7Dx6	Group 5- Compound 1 75 mg/kg 2Q7Dx15 + Anti-PD-1 200µg Q3Dx35	Group 6- Compound 1 150 mg/kg 2Q7Dx6 + Anti-PD-1 200µg Q3Dx35
2	0	0	0	0	0	0
6	0	0	0	0	4.5	0
8	0	0	0	0	0	0
13	0	0	0	4.0	33.5	0.6
16	0	0	0	0	0	31.1
20	0	0	0	0	0	44.6
23	0 (n=6)	0	0	0	0	80
27	0 (n=2)	0 (n=9)	0	0	0	92.3
30	-NA-	0 (n=5)	0 (=7)	0	0	96.9
34	-NA-	0(n=3)	0 (n=7)	0	0	85.0
38	-NA-	0 (n=3)	0 (n=3)	0	0 (n=7)	82.9
41	-NA-	93.6 (n=2)	-NA-	0 (n=6)	0 (n=6)	77.8
44	-NA-	94.6 (n=2)	-NA-	0 (n=6)	0 (n=6)	71.8
48	-NA-	93.3 (n=2)	-NA-	0 (n=4)	0 (n=6)	48.3
51	-NA-	92.0 (n=2)	-NA-	0 (n=2)	100.00 (n=5)	23.0
55	-NA-	91.6 (n=2)	-NA-	100.00 (n=1)	100.00 (n=4)	0
58	-NA-	94.8 (n=2)	-NA-	100.00 (n=1)	100.00 (n=4)	0
63	-NA-	95.4 (n=2)	-NA-	100.00 (n=1)	100.00 (n=4)	0
66	-NA-	94.6 (n=2)	-NA-	100.00 (n=1)	99.3 (n=4)	0 (n=9)
70	-NA-	98.0 (n=2)	-NA-	100.00	95.8 (n=4)	0 (n=9)

Day of Study	Group 1- Vehicle Control 2Q7Dx4	Group 2- Anti-PD-1 200µg Q3Dx35	Group 3- Compound 1 75 mg/kg 2Q7Dx6	Group 4- Compound 1 150 mg/kg 2Q7Dx6	Group 5- Compound 1 75 mg/kg 2Q7Dx15 + Anti-PD-1 200µg Q3Dx35	Group 6- Compound 1 150 mg/kg 2Q7Dx6 + Anti-PD-1 200µg Q3Dx35
				(n=1)		
73	-NA-	97.6 (n=2)	-NA-	100.00 (n=1)	94.5 (n=4)	0 (n=8)
77	-NA-	96.7 (n=2)	-NA-	100.00 (n=1)	82.0 (n=4)	0 (n=8)
80	-NA-	96.9 (n=2)	-NA-	100.00 (n=1)	76.8 (n=4)	89.5 (n=8)
84	-NA-	98.0 (n=2)	-NA-	100.00 (n=1)	61.3 (n=4)	88.0 (n=7)
87	-NA-	97.2 (n=2)	-NA-	100.00 (n=1)	37.6 (n=4)	78.6 (n=7)
90	-NA-	98.5 (n=2)	-NA-	100.00 (n=1)	4.9 (n=4)	69.4 (n=7)
93	-NA-	97.3 (n=2)	-NA-	100.00 (n=1)	0 (n=4)	69.1 (n=7)
98	-NA-	97.6 (n=2)	-NA-	100.00 (n=1)	0 (n=4)	40.9 (n=7)
101	-NA-	96.3 (n=2)	-NA-	100.00 (n=1)	0 (n=4)	32.0 (n=7)
106	-NA-	97.4 (n=2)	-NA-	100.00 (n=1)	-NA-	-NA-
111	-NA-	96.8 (n=2)	-NA-	100.00 (n=1)	-NA-	-NA-
118	-NA-	97.3 (n=2)	-NA-	100.00 (n=1)	100.00 (n=3)	-NA-
125	-NA-	96.2 (n=2)	-NA-	100.00	100.00 (n=3)	97.7 (n=6)

Day of Study	Group 1- Vehicle Control 2Q7Dx4	Group 2- Anti-PD-1 200µg Q3Dx35	Group 3- Compound 1 75 mg/kg 2Q7Dx6	Group 4- Compound 1 150 mg/kg 2Q7Dx6	Group 5- Compound 1 75 mg/kg 2Q7Dx15 + Anti-PD-1 200µg Q3Dx35	Group 6- Compound 1 150 mg/kg 2Q7Dx6 + Anti-PD-1 200µg Q3Dx35
				(n=1)		
133	-NA-	96.8 (n=2)	-NA-	100.00 (n=1)	100.00 (n=3)	92.3 (n=6)
140	-NA-	96.8 (n=2)	-NA-	100.00 (n=1)	100.00 (n=3)	64.8 (n=6)
146	-NA-	98.9 (n=2)	-NA-	100.00 (n=1)	100.00 (n=3)	20.9 (n=6)
155	-NA-	98.1 (n=2)	-NA-	100.00 (n=1)	100.00 (n=3)	-NA-
161	-NA-	97.6 (n=2)	-NA-	100.00 (n=1)	100.00 (n=3)	-NA-
168	-NA-	95.5 (n=2)	-NA-	100.00 (n=1)	100.00 (n=3)	98.8 (n=5)
177	-NA-	98.2 (n=2)	-NA-	100.00 (n=1)	100.00 (n=3)	99.0 (n=5)
185	-NA-	97.1 (n=2)	-NA-	100.00 (n=1)	100.00 (n=3)	99.0 (n=5)
NA= no mice in the group.						

TABLE 8

Group	n	Range (Days)	Median Survival (Days)	Increase in Survival Relative to Vehicle (Days)
Group 1- Vehicle Control 2Q7Dx4	10	17.74 – 25.39	20.94	-

Group 2- Anti-PD-1 200µg Q3Dx35	10	22.68 – N/A	27.14	6.20
Group 3- Compound 1 75 mg/kg 2Q7Dx6	10	23.76 – 40.59	32.00	11.06
Group 4- Compound 1 150 mg/kg 2Q7Dx15	10	35.22 – N/A	42.90	21.96
Group 5- Compound 1 75 mg/kg 2Q7Dx15 + Anti-PD-1 200µg Q3Dx35	10	32.24 – N/A	43.78	22.84
Group 6- Compound 1 150 mg/kg 2Q7Dx15 + Anti-PD-1 200µg Q3Dx35	10	58.78 – N/A	>185.00	>164.06

[0424] FIG. 3 shows changes in tumor volume (mm³) in individual C57B1/6 mice implanted with MT373 mouse syngeneic sarcoma tumors upon receiving treatment with vehicle; anti-PD-1 200 µg; Compound 1, 75 mg/kg; Compound 1, 150 mg/kg; Compound 1, 75 mg/kg + anti-PD-1; or Compound 1, 150 mg/kg + anti-PD-1. MT373 tumors treated with vehicle control (0.2% HPC, 0.5% Tween 80) displayed consistent growth with all mice reaching ~2000 mm³ between days 20 and 27. Tumors on mice receiving anti-PD-1 Q3Dx35 demonstrated consistent growth inhibition through 13 days at which point 8 out of 10 tumors began to regrow at varied rates through day 38. Mice administered Compound 1 at 75 mg/kg 2Q7Dx6 displayed consistent tumor growth through 16 days, at which point two tumors (mouse 6 and mouse 10) trended much slower than the remaining mice until reaching 2000 mm³ at day 41. Mice administered Compound 1 at 150 mg/kg 2Q7Dx15; Compound 1 75 mg/kg 2Q7Dx15 + 200 µg anti-PD-1 Q3Dx35; and 150 mg/kg 2Q7Dx15 + 200 µg anti-PD-1 Q3Dx35 showed tumor stasis through day 20, at which point tumors began to escape or regrow at variable rates. At the conclusion of the study, two animals (Group 2 mouse 2, Group 6 mouse 10) had tumor stasis. Several animals (Group 2: n=1, Group 4: n=1, Group 5: n=3, Group 6: n=4) demonstrated complete tumor regression.

[0425] FIG. 4 shows changes in percentage survival of mice upon receiving treatment with vehicle; anti-PD-1; Compound 1, 75 mg/kg; Compound 1, 150 mg/kg; Compound 1, 75 mg/kg + anti-PD-1; or Compound 1, 150 mg/kg + anti-PD-1. TABLE 9 summarizes the median survival times (MST) of the six treatment groups. TABLE 10 and TABLE 11 show individual tumor volumes across study days 0-66 and days 70-185, respectively.

TABLE 9

Group	MST (Days)
Vehicle	21
Anti-PD-1 200 µg	27

Compound 1 75 mg/kg 2Q7D	32
Compound 1 150 mg/kg 2Q7D	43
PD-1 + Compound 1 75 mg/kg	44
PD-1 + Compound 1 150 mg/kg	>185

TABLE 10

Days	Mouse	0	1	6	8	13	16	20	23	27	30	34	38	41	44	48	51	55	58	63	66
Group 1 Vehicle Control 2Q7Dx4	1	70	144	172	164	450	977	221 9													
	2	78	143	139	144	314	506	110 9	229 9												
	3	76	80	112	99	245	465	908	158 3	285 4											
	4	64	107	170	178	451	830	157 5	243 4												
	5	79	92	122	183	462	928	167 1	347 3												
	6	70	93	89	131	256	475	826	121 1	252 9											
	7	85	91	137	190	516	125 3	297 3													
	8	83	104	113	146	319	608	135 0	281 4												
	9	72	100	167	172	541	821	210 2													
	10	96	129	152	190	471	110 1	227 7													
	Ave	77	108	137	160	403	727	170 1	230 2	282 2											
	SD	9	24	27	28	103	262	653	748	163											
Group 2 Anti-PD-1 200µg/mse Q3Dx35	1	54	118	145	153	243	448	104 1	211 3												
	2	77	95	124	140	76	38	16	7	0	5	18	7	11	9	11	14	14	9	8	9
	3	82	123	141	163	108	83	15	16	0	10	0	0	0	0	0	0	0	0	0	0
	4	70	105	117	120	120	79	99	200	439	752	171 4	365 5								

Days	Mouse	0	1	6	8	13	16	20	23	27	30	34	38	41	44	48	51	55	58	63	66
	5	116	144	132	150	228	490	945	1493	3815											
	6	107	117	83	108	255	430	889	1322	2321											
	7	93	93	89	118	288	449	919	1265	2064											
	8	86	100	102	110	117	204	505	840	1745	2989										
	9	94	123	133	140	169	334	831	1524	3432											
	10	61	91	90	106	107	61	510	520	1150	2165										
	Ave	84	111	118	181	171	262	577	180	1668	1188	577	1221	5	5	5	7	7	4	4	5
	SD	13	16	22	20	72	177	387	688	1319	1198	804	1721	5	5	6	7	7	4	4	5
Group 3 Compound 1 75 mg/kg 2Q7Dx6	1	80	93	108	105	204	322	687	962	873	986	3500									
	2	79	92	87	107	202	326	698	837	1270	1642	2824									
	3	58	81	89	103	152	227	385	711	783	1158	2566									
	4	114	103	109	133	249	394	844	1285	2077											
	5	78	96	91	130	173	295	854	1656	3460											
	6	88	66	77	63	106	86	71	92	118	164	593	1022	2114							
	7	69	89	so	95	193	297	650	1013	2045											
	8	94	86	85	92	108	170	330	497	574	743	1813	2750								
	9	62	74	83	107	112	199	355	532	649	982	2120									
	10	103	99	94	97	88	95	105	142	193	191	716	1563	3078							

Days	Mouse	0	1	6	8	13	16	20	23	27	30	34	38	41	44	48	51	55	58	63	66
	Ave	83	88	90	103	159	241	498	772	1204	888	2019	1778	2596							
	SD	17	11	10	19	51	98	273	463	988	489	995	722	482							
Group 4 Compound 1 150 Mg/kg 2Q7Dx15	1	68	54	43	73	65	135	128	261	379	653	1380	2406								
	2	53	75	63	97	53	113	92	192	231	568	1508	3114								
	3	87	143	97	159	207	133	176	337	269	506	1203	2162								
	4	113	128	85	134	83	34	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	5	85	86	77	129	93	136	106	136	58	86	328	609	990	1672	3099					
	6	60	73	101	101	44	53	63	74	93	143	302	595	843	1169	2418					
	7	57	76	92	71	40	43	91	103	187	306	615	1003	1652	2114						
	8	98	84	109	119	88	195	228	367	432	660	1067	2085								
	9	117	107	108	110	55	69	65	107	101	146	289	449	631	810	1730	2622				
	10	53	58	43	49	32	66	113	158	161	220	590	944	1566	2407						
	Ave	79	88	82	104	76	98	106	174	191	329	728	1337	947	1362	1312	1311	0	0	0	0
	SD	23	28	23	32	48	50	60	111	132	235	497	973	561	812	1153	1311	0	0	0	0
Group 5 Compound 1 75 Mg/kg 2Q7Dx15 + anti-PD-1 200µg/msec Q3Dx35	1	76	60	46	44	16	10	5	10	0	0	0	0	0	0	0	0	0	0	0	0
	2	106	100	78	144	59	156	166	294	594	888	2228									
	3	78	55	58	57	25	22	7	0	0	0	0	0	0	0	0	0	0	0	0	0
	4	88	136	91	104	50	93	129	128	295	407	922	1588	2068							
	5	88	91	92	83	25	42	17	18	13	39	137	440	696	1143	2286					
	6	101	91	94	95	36	42	14	0	0	0	0	0	0	0	0	0	0	0	0	0
	7	85	91	111	100	101	133	157	316	522	591	992	2274								

Days	Mouse	0	1	6	8	13	16	20	23	27	30	34	38	41	44	48	51	55	58	63	66
	8	52	58	58	47	20	19	0	0	0	0	0	0	0	0	0	0	0	0	0	2
	9	72	78	79	85	91	141	332	495	797	1285	2096									
	10	63	72	65	98	115	226	396	583	899	1489	2401									
	Ave	81	83	77	86	54	88	122	184	312	470	878	615	461	229	457	0	0	0	0	1
	SD	16	23	19	29	35	69	137	212	344	545	963	866	763	457	815	0	0	0	0	1
Group 6 Compound 1 150 ng/kg 2Q7Dx15 + anti-PD- 1 200 µg/mse Q3Dx35	1	87	134	89	82	40	30	29	0	0	0	0	0	0	0	0	0	0	0	0	0
	2	76	139	84	90	207	112	70	0	0	0	0	0	0	0	0	0	0	0	136	433
	3	70	86	140	129	108	64	78	0	0	0	0	0	0	0	0	0	0	0	0	0
	4	82	114	98	88	60	43	20	16	0	0	0	0	0	0	0	0	0	0	0	0
	5	77	52	46	67	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	6	85	71	119	122	79	65	55	24	9	9	31	76	111	150	343	517	853	1655	3853	
	7	103	101	84	68	72	65	42	18	0	0	0	0	0	0	0	0	0	0	0	0
	8	64	75	87	68	74	34	20	12	1	1	6	2	10	8	33	36	68	112	330	765
	9	85	132	121	118	110	100	100	81	52	15	76	47	45	86	29	36	63	76	43	35
	10	66	85	76	53	40	34	27	8	1	1	7	11	11	10	6	23	20	13	11	5
	Ave	80	99	94	89	79	55	44	16	6	3	12	14	18	23	41	61	100	186	437	1141
	SD	11	28	25	25	53	32	29	23	136	5	23	25	34	46	102	153	252	491	1143	2593

TABLE 11

Days	Mouse	70	73	77	80	84	87	90	93	98	101	106	111	118	125	133	140	146	155	161	168	177	185
Group 2 Anti-PD-1 200 µg/mse Q3Dx35	1																						
	2	3	4	6	5	3	5	2	5	4	6	4	5	4	6	5	5	2	3	4	7	3	5
	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	4																						
	5																						
	6																						
	7																						
	8																						
	9																						
	10																						

Days	Mouse	70	73	77	80	84	87	90	93	98	101	106	111	118	125	133	140	146	155	161	168	177	185
	Ave	2	2	3	3	2	2	1	2	2	3	2	3	2	3	3	3	1	2	2	3	1	2
	SD	2	2	3	3	2	2	1	2	2	3	2	3	2	3	3	3	1	2	2	3	1	2
Group 4 Compound 1 150 mg/kg 2Q7Dx15	1																						
	2																						
	3																						
	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	5																						
	6																						
	7																						
	8																						
	9																						
	10																						
	Ave	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	SD	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Group 5 Compound 1 75 mg/kg 2Q7Dx15 + anti-PD-1 200µg/mse Q3Dx35	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2																						
	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	4																						
	5																						
	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	7																						
	8	14	18	58	7	125	202	308	359	507	777	1538	3000										
	9																						
	10																						
	Ave	3	5	15	19	31	51	77	90	127	194	385	750	0	0	0	0	0	0	0	0	0	0
	SD	6	8	25	33	54	88	133	156	220	336	666	1299	0	0	0	0	0	0	0	0	0	0
Group 6 Compound 1 150 mg/kg 2Q7Dx15 + anti-PD- 1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2	893	1170	2553																			
	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	6																						
	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8	2002																					
	9	59	40	46	49	55	106	162	164	323	369	843	1643	6357									
	10	16	13	9	10	12	13	8	8	6	10	6	5	11	4	6	5	4	6	10	5	4	

Days	Mouse	70	73	77	80	84	87	90	93	98	101	106	111	118	125	133	140	146	155	161	168	177	185
200µg/mse	Ave	330	153	326	8	10	17	24	25	47	54	121	235	910	2	6	29	65	214	557	1	1	1
Q3Dx35	SD	652	385	842	17	19	37	56	57	113	129	295	575	2224	3	12	62	143	475	1240	2	2	2

[0426] **Body Weights:** Average mouse body weights were well-maintained over the course of the study. Mice dosed with vehicle control were an average of 22.9 g by the end of the study (day 27) with the percentage change varying between 1.36% early in the study to +27.74%. Mice administered anti-PD-1 lost 1.38% body weight early in the study but recovered and gained an average of 18.15% by Day 27. One mouse (6) lost 16.6% on Day 6 but recovered by day 13 with 1.1% body weight loss. Mice administered Compound 1 (Groups 3-6) also maintained body weight well throughout the study and no individual mouse lost more than 5% body weight. By day 27, Group 3 gained 12.96%, Group 4 gained 10.02%, Group 5 gained 11.65% and Group 6 gained 9.60%.

[0427] **TABLE 11** shows the average percent change in mouse body weight across the study (n=10 unless otherwise noted; n/a = no mice in the group). **TABLE 12** shows individual mouse body weights across the study from days 0-66. **TABLE 13** shows individual mouse body weights across the study from days 70-185. **FIG. 5** shows the changes in percent body weight change in female C57B1/6 mice implanted with MT373 mouse syngeneic sarcoma tumors upon receiving treatment with vehicle (2Q7Dx4); anti-PD-1 200 µg (Q3Dx35); Compound 1, 75 mg/kg (2Q7Dx6); Compound 1, 150 mg/kg (2Q7Dx15); Compound 1, 75 mg/kg (2Q7Dx15) + anti-PD-1 (Q3Dx35); or Compound 1, 150 mg/kg (2Q7Dx15) + anti-PD-1 (Q3Dx35).

TABLE 11

Day of study	Group 1 Vehicle control 2Q7Dx4	Group 2 Anti-PD-1 200µg Q3Dx35	Group 3 Compound 1 75 mg/kg 2Q7Dx6	Group 4 Compound 1 150 mg/kg 2Q7Dx6	Group 5 Compound 1 75 mg/kg 2Q7Dx15 + Anti-PD-1 200 µg Q3Dx35	Group 6 Compound 1 150 mg/kg 2Q7Dx6 + Anti-PD-1 200µg Q3Dx35
2	1.36±2.61	-1.38 ±3.28	2.05 ±1.40	3.47 ±2.49	3.29 ±2.67	2.28 ±2.32
6	3.11 ±3.28	2.48 ±7.18	2.90 ±2.56	4.67 ±4.56	4.53 ±2.60	5.62 ±2.89
8	5.91 ±3.53	5.00 ±6.47	4.29 ±4.05	2.69 ±4.48	6.20 ±3.41	0.94 ±2.49
13	8.28 ±2.30	7.56 ±4.24	4.88 ±2.70	7.86 ±5.56	6.28 ±3.51	7.74 ±4.13
16	12.10 ±3.67	9.36 ±5.45	7.06 ±2.34	8.02 ±3.80	10.43 ±4.02	8.00 ±3.47
20	15.81 ±7.19	10.50 ±4.51	8.75 ±2.85	8.06 ±4.79	8.07 ±5.72	9.05 ±3.43
23	16.91 ±1.44 (n=6)	11.69 ±5.38	12.43 ±4.12	8.47 ±5.21	10.39 ±4.54	8.04 ±3.30
27	27.74 ±2.22 (n=2)	18.15 ±6.10 (n=9)	12.96 ±5.24	10.02 ±7.27	11.65 ±3.45	9.60 ±3.19

30	n/a	18.00 $\pm$ 8.52 (n=5)	11.93 $\pm$ 6.80 (n=7)	12.48 $\pm$ 7.51	15.19 $\pm$ 4.93	11.46 $\pm$ 3.80
34	n/a	16.55 $\pm$ 6.43 (n=3)	18.26 $\pm$ 8.13 (n=7)	14.88 $\pm$ 6.40	16.91 $\pm$ 3.56	13.35 $\pm$ 4.23
38	n/a	23.70 $\pm$ 13.23 (n=3)	22.28 $\pm$ 4.13(n=3)	19.05 $\pm$ 7.92	18.13 $\pm$ 5.10 (n=7)	14.18 $\pm$ 3.30
41	n/a	15.55 $\pm$ 1.58 (n=2)	25.18 $\pm$ 5.26 (n=2)	17.97 $\pm$ 5.31(n=6)	17.52 $\pm$ 5.27 (n=6)	13.37 $\pm$ 4.43
44	n/a	15.03 $\pm$ 2.31 (n=2)	n/a	21.56 $\pm$ 8.64 (n=6)	18.10 $\pm$ 4.89 (n=5)	15.17 $\pm$ 4.59
48	n/a	18.21 $\pm$ 0.96 (n=2)	n/a	24.55 $\pm$ 7.11 (n=4)	19.40 $\pm$ 2.40 (n=5)	14.57 $\pm$ 3.66
51	n/a	17.91 $\pm$ 0.19 (n=2)	n/a	22.20 $\pm$ 8.23 (n=2)	23.21 $\pm$ 4.70 (n=5)	13.07 $\pm$ 4.28
55	n/a	18.19 $\pm$ 0.21 (n=2)	n/a	18.08 $\pm$ 0 (n=1)	22.07 $\pm$ 4.40 (n=4)	14.10 $\pm$ 4.53
58	n/a	19.54 $\pm$ 0.66(n=2)	n/a	19.77 $\pm$ 0 (n=1)	22.77 $\pm$ 4.81 (n=4)	15.77 $\pm$ 5.39
63	n/a	22.11 $\pm$ 2.99 (n=2)	n/a	20.90 $\pm$ 0 (n=1)	21.50 $\pm$ 4.48 (n=4)	20.06 $\pm$ 7.93
66	n/a	21.64 $\pm$ 0.75 (n=2)	n/a	22.60 $\pm$ 0 (n=1)	21.66 $\pm$ 3.16 (n=4)	20.18 $\pm$ 5.40 (n=9)
70	n/a	25.37 $\pm$ 1.30 (n=2)	n/a	23.16 $\pm$ 0 (n=1)	25.49 $\pm$ 4.64 (n=4)	20.82 $\pm$ 4.16 (n=9)
73	n/a	21.44 $\pm$ 1.89 (n=2)	n/a	18.08 $\pm$ 0 (n=1)	25.06 $\pm$ 4.50 (n=4)	20.20 $\pm$ 5.37 (n=8)
77	n/a	20.37 $\pm$ 1.83 (n=2)	n/a	20.34 $\pm$ 0 (n=1)	24.48 $\pm$ 4.48 (n=4)	19.86 $\pm$ 5.99 (n=8)
80	n/a	20.86 $\pm$ 0.35 (n=2)	n/a	23.73 $\pm$ 0 (n=1)	26.20 $\pm$ 4.69 (n=4)	20.18 $\pm$ 5.19 (n=7)
84	n/a	25.15 $\pm$ 0.58 (n=2)	n/a	26.55 $\pm$ 0 (n=1)	28.94 $\pm$ 6.62 (n=4)	21.82 $\pm$ 5.10 (n=7)
87	n/a	25.15 $\pm$ 0.58 (n=2)	n/a	21.47 $\pm$ 0 (n=1)	27.35 $\pm$ 5.85 (n=4))	22.82 $\pm$ 5.99 (n=7)

90	n/a	24.32 $\pm$ 0.60 (n=2)	n/a	24.29 $\pm$ 0 (n=1)	27.17 $\pm$ 4.70 (n=4)	21.94 $\pm$ 5.33 (n=7)
93	n/a	23.48 $\pm$ 1.78 (n=2)	n/a	21.47 $\pm$ 0 (n=1)	25.70 $\pm$ 3.59 (n=4)	19.00 $\pm$ 5.46 (n=7)
98	n/a	25.60 $\pm$ 2.43 (n=2)	n/a	23.73 $\pm$ 0 (n=1)	26.91 $\pm$ 5.28 (n=4)	21.86 $\pm$ 6.19 (n=7)
101	n/a	23.70 $\pm$ 3.66 (n=2)	n/a	22.60 $\pm$ 0 (n=1)	24.75 $\pm$ 3.99 (n=4)	19.90 $\pm$ 6.40 (n=7)
106	n/a	24.51 $\pm$ 3.24 (n=2)	n/a	22.03 $\pm$ 0 (n=1)	26.44 $\pm$ 4.25 (n=4)	20.47 $\pm$ 6.72 (n=7)
111	n/a	28.24 $\pm$ 3.80 (n=2)	n/a	26.55 $\pm$ 0 (n=1)	33.68 $\pm$ 4.22 (n=4)	26.06 $\pm$ 7.03 (n=7)
118	n/a	30.66 $\pm$ 3.29 (n=2)	n/a	33.33 $\pm$ 0 (n=1)	32.69 $\pm$ 7.76 (n=3)	29.52 $\pm$ 10.87 (n=7)
125	n/a	32.78 $\pm$ 3.94 (n=2)	n/a	28.25 $\pm$ 0 (n=1)	36.44 $\pm$ 8.93 (n=3)	29.89 $\pm$ 9.26 (n=6)
133	n/a	35.72 $\pm$ 4.16 (n=2)	n/a	38.42 $\pm$ 0 (n=1)	41.28 $\pm$ 6.86 (n=3)	29.70 $\pm$ 12.70 (n=6)
140	n/a	35.78 $\pm$ 1.89 (n=2)	n/a	41.24 $\pm$ 0 (n=1)	46.51 $\pm$ 4.41 (n=3)	37.02 $\pm$ 9.12 (n=6)
146	n/a	36.81 $\pm$ 3.35 (n=2)	n/a	34.46 $\pm$ 0 (n=1)	41.30 $\pm$ 7.73 (n=3)	35.09 $\pm$ 15.06 (n=6)
155	n/a	45.08 $\pm$ 4.04 (n=2)	n/a	42.37 $\pm$ 0 (n=1)	38.61 $\pm$ 10.37 (n=3)	38.99 $\pm$ 12.02 (n=6)
161	n/a	45.50 $\pm$ 8.56 (n=2)	n/a	47.46 $\pm$ 0 (n=1)	46.34 $\pm$ 1.29 (n=3)	42.41 $\pm$ 17.81 (n=6)
168	n/a	46.11 $\pm$ 5.50 (n=2)	n/a	46.33 $\pm$ 0 (n=1)	50.03 $\pm$ 2.60 (n=3)	41.43 $\pm$ 18.91 (n=5)
177	n/a	45.04 $\pm$ 5.56 (n=2)	n/a	44.63 $\pm$ 0 (n=1)	56.82 $\pm$ 5.25 (n=3)	43.87 $\pm$ 16.97 (n=5)
185	n/a	47.48 $\pm$ 4.29 (n=2)	n/a	47.46 $\pm$ 0 (n=1)	58.26 $\pm$ 6.54 (n=3)	46.83 $\pm$ 16.09 (n=5)

TABLE 12

Days	Mou	0	2	6	8	13	16	20	23	27	30	34	38	41	44	48	51	55	58	63	66
Group 1 Vehicle Control 2Q7Dx4	1	18.	19.	19.	19.	20.	21.	22.													
	2	17.	17.	17.	18.	18.	19.	20.	20.												
	3	17.	17.	18.	18.	19.	19.	20.	20.	22.											
	4	19.	19.	19.	20.	20.	21.	21.	22.												
	5	19.	19.	19.	19.	20.	20.	21.	22.												
	6	17.	18.	18.	19.	19.	19.	19.	20.	22.											
	7	17.	18.	19.	19.	19.	21.	23.													
	8	19.	19.	19.	20.	20.	21.	22.	23.												
	9	19.	19.	20.	21.	21.	22.	23.													
	10	18.	17.	18.	18.	19.	20.	19.													
	Ave	18.	18.	19.	19.	20.	20.	21.	21.	22.											
	SD	0.8	0.6	0.7	0.8	0.7	1.0	1.4	1.1	0.3											
Group 2 Anti-PD-1 200μg/mse Q3Dx35	1	19.	19.	19.	20.	20.	20.	21.	22.												
	1	19.	19.	20.	20.	21.	21.	21.	21.	20.	21.	22.	22.	22.	22.	22.	22.	22.	23.	24.	13.
	3	18.	18.	19.	18.	19.	19.	19.	20.	20.	20.	21.	21.	21.	21.	21.	21.	21.	21.	21.	21.
	4	16.	17.	18.	18.	19.	19.	18.	19.	20.	19.	20.	23.								
	5	19.	20.	21.	21.	21.	22.	22.	23.	23.											
	6	18.	17.	15.	15.	17.	17.	18.	18.	20.											
	7	18.	17.	19.	19.	19.	20.	21.	19.	22.											
	8	18.	17.	19.	20.	20.	20.	21.	11.	22.	24.										
	9	17.	17.	17.	18.	18.	19.	19.	20.	22.											
	10	18.	18.	19.	20.	20.	20.	20.	20.	22.	23.										
	Ave	18.	18.	18.	19.	19.	20.	20.	20.	21.	21.	20.	22.	21.	21.	22.	22.	22.	22.	22.	22.
	SD	0.8	0.9	1.6	1.4	1.1	1.2	1.4	1.4	1.3	1.8	0.7	1.0	0.8	0.7	0.9	1.2	1.1	1.0	1.7	1.3
Group 3 Compound 1 75 mg/kg 2Q7Dx6	1	18.	19.	19.	20.	19.	19.	20.	20.	20.	22.	23.									
	2	19.	19.	19.	20.	19.	20.	21.	21.	22.	22.	24.									
	3	19.	19.	20.	20.	20.	21.	21.	22.	21.	22.	23.									
	4	18.	18.	18.	18.	18.	19.	19.	19.	20.											
	5	17.	18.	18.	18.	18.	19.	19.	21.	21.											
	6	19.	19.	20.	20.	20.	20.	20.	21.	21.	20.	22.	22.	23.							

	7	17.	18.	18.	18.	18.	19.	19.	20.	21.											
	8	19.	19.	19.	19.	20.	20.	19.	21.	21.	21.	22.	24.								
	9	19.	20.	20.	21.	21.	21.	21.	21.	21.	21.	23.									
	10	17.	17.	17.	16.	18.	18.	18.	19.	18.	17.	1	21.	22.							
	Ave	18.	19.	19.	19.	19.	19.	20.	20.	21.	21.	22.	22.	22.							
	SD	0.8	0.8	0.9	1.3	1.0	1.0	1.0	0.9	1.0	1.9	2.2	1.6	0.6							
Group 4 Compound 1 150 mg/kg 2Q7Dx15	1	19.	20.	20.	20.	21.	21.	20.	21.	20.	21.	22.	22.								
	2	21.	21.	21.	21.	21.	21.	21.	22.	22.	23.	24.	25.								
	3	16.	18.	19.	18.	20.	19.	20.	20.	21.	22.	22.	23.								
	4	17.	18.	18.	18.	18.	19.	19.	19.	19.	19.	20.	21.	20.	20.	20.	20.	20.	21.	21.	21.
	5	19.	20.	21.	19.	21.	21.	21.	20.	21.	21.	22.	22.	22.	24.	26.					
	6	19.	19.	18.	18.	19.	19.	19.	19.	20.	20.	20.	21.	21.	22.	23.					
	7	19.	19.	19.	19.	20.	20.	20.	20.	20.	20.	21.	21.	22.	21.						
	8	18.	19.	19.	18.	20.	20.	20.	19.	19.	20.	21.	22.								
	9	18.	19.	19.	19.	20.	20.	20.	19.	20.	21.	21.	22.	22.	23.	23.	23.				
	10	18.	20.	20.	20.	21.	20.	20.	21.	22.	21.	21.	23.	23.	25.						
	Ave	18.	19.	19.	19.	20.	20.	20.	20.	20.	21.	21.	22.	22.	22.	288	21.	20.	21.	21.	21.
	SD	1.1	0.9	1.0	0.9	0.9	0.8	0.8	0.9	1.0	1.0	1.1	1.2	0.9	1.7	2.3	1.9	0.0	0.0	0.0	0.0
Group 5 Compound 1 75 mg/kg 2Q7Dx15 + Anti-PD-1 200μg/mse Q3Dx35	1	19.	20.	19.	20.	19.	20.	19.	20.	20.	21.	22.	21.	21.	21.	22.	23.	23.	23.	23.	22.
	2	18.	19.	19.	19.	19.	20.	19.	20.	20.	21.	21.									
	3	18.	19.	19.	20.	20.	21.	20.	21.	20.	20.	21.	21.	21.	21.	22.	22.	22.	22.	21.	22.
	4	19.	2a	20.	19.	20.	20.	20.	21.	21.	22.	22.	23.	23.							
	5	18.	18.	18.	18.	18.	19.	18.	19.	19.	19.	20.	20.	20.	20.	22.	23.				
	6	16.	17.	18.	18.	18.	19.	19.	19.	19.	20.	20.	20.	19.	20.	20.	21.	21.	21.	21.	20.
	7	20.	20.	20.	21.	20.	21.	19.	21.	22.	22.	23.	24.								
	8	17.	17.	18.	19.	19.	20.	20.	20.	20.	20.	21.	21.	21.	21.	20.	20.	20.	20.	20.	21.
	9	18.	19.	19.	19.	19.	20.	20.	20.	20.	21.	21.									
	10	18.	18.	19.	19.	19.	20.	21.	20.	2a	21.	22.									
	Ave	18.	19.	19	19.	19.	20.	19.	20.	20.	21.	21.	21.	21.	21.	21.	22.	21.	21.	21.	21.
	SD	0.9	0.9	0.7	0.8	0.7	0.6	0.6	0.7	0.8	1.0	1.0	1.4	1.2	0.5	1.0	1.2	1.1	1.1	1.1	0.9
Group 6	1	18.	19.	20.	18.	20.	20.	20.	20.	20.	20.	21.	22.	21.	22.	22.	21.	21.	21.	22.	22.

Compound 1 150 mg/kg 2Q7Dx15 + anti-PD- 1 200 µg/mse Q3Dx35	2	18.	18.	19.	19.	20.	20.	20.	20.	20.	21.	21.	21.	21.	21.	21.	21.	21.	22.	22.
	3	19.	20.	20.	20.	21.	21.	21.	21.	21.	22.	22.	22.	22.	23.	22.	23.	23.	22.	23.
	4	18.	18.	19.	18.	19.	18.	19.	19.	19.	19.	20.	20.	20.	20.	20.	20.	21.	21.	21.
	5	17.	17.	19.	18.	19.	19.	19.	19.	19.	20.	20.	21.	21.	21.	20.	20.	20.	21.	22.
	6	18.	19.	20.	18.	21.	20.	21.	20.	21.	21.	22.	21.	21.	21.	22.	22.	22.	23.	26.
	7	18.	19.	19.	18.	19.	20.	20.	19.	20.	20.	21.	20.	20.	20.	20.	20.	20.	20.	21.
	8	19.	19.	20.	19.	19.	20.	19.	19.	20.	70.	20.	21.	20.	20.	21.	20.	20.	21.	22.
	9	18.	19.	20.	18.	21.	19.	20.	20.	21.	20.	21.	20.	22.	22.	21.	20.	20.	21.	22.
	10	20.	20.	20.	19.	21.	21.	22.	21.	22.	22.	22.	23.	23.	22.	22.	22.	22.	22.	23.
	Ave	MU	19.	19.	19.	20.	20.	20.	20.	20.	21.	21.	21.	21.	21.	21.	21.	21.	22.	22.
	SD	0.6	0.8	0.5	0.6	0.8	0.9	0.7	0.1	0.8	0.1	0.9	0.8	0.8	0.8	0.8	1.0	0.9	0.9	1.4

TABLE 13

Days	Mous e	70	73	77	80	84	87	90	93	98	101	106	111	118	125	133	140	155	161	168	177	185
Group 2 anti-PD- 1 200µg/m se Q3Dx35	1																					
	2	24.5 0	23.3 0	23.1 0	23.4 0	24.2 0	24.2 0	24.2 0	24.2 0	24.7 0	24.5 0	24.6 0	25 40	25.8 0	26.3 0	26.9 0	26.6 0	27.0 0	28.7 0	29.1 0	28.9 0	29.2 0
	3	22.4 0	22.1 0	21.9 0	21.8 0	22.6 0	22.6 0	22.3 0	22.0 0	22.3 0	21.8 0	22.0 0	22.6 0	23.1 0	23.4 0	23.9 0	24.2 0	24.2 0	25.6 0	25.6 0	25.4 0	26.0 0
	4																					
	5																					
	6																					
	7																					
	8																					
	9																					
	10																					
	Ave	23.4 5	22.7 0	22.5 0	22.6 0	23.4 0	23.4 0	23.2 5	23.1 0	23.5 0	23.1 5	23.3 0	24.0 0	24.4 5	24.8 5	25.4 0	25.4 0	25.6 0	27.1 5	27.3 5	27.1 5	27.6 0
	SD	1.48	0.85	0.85	1.13	1.13	1.13	1.34	1.56	1.70	1.91	1.84	1.98	1.91	2.05	2.12	1.70	1.98	2.19	2.47	2.47	2.26
Group 4 Compou	1																					
	2																					
	3																					

nd 1 150 mg/kg 2Q7Dx1 5	4	21.80	20.90	21.30	21.90	22.40	21.50	22.00	21.50	21.90	21.70	21.60	21.40	23.60	2270	24.50	25.00	23.80	25.20	25.90	25.60	26.10
	5																					
	6																					
	7																					
	8																					
	9																					
	10																					
	Ave	21.80	20.90	21.30	21.90	22.40	21.50	22.00	21.50	21.90	21.70	21.60	22.40	23.60	22.70	24.50	25.00	23.80	25.20	25.90	25.60	26.10
	SD	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Group 5 Compound 1 75 mg/kg 2Q7Dx1 5 + anti-PD-1 200µg/mse Q3Dx35	1	23.50	23.50	23.60	23.50	23.80	23.90	23.90	23.90	23.60	23.70	25.50	24.20	25.00	26.60	27.20	27.80	27.60	29.10	30.20	30.90	
	2																					
	3	22.60	22.50	22.30	22.80	23.00	22.50	22.70	22.50	22.40	22.60	23.70	24.20	24.50	25.20	27.30	24.50	26.90	27.20	28.00	27.90	
	4																					
	5																					
	6	2180	21.70	21.60	21.90	22.80	22.30	22.00	21.60	2210	21.50	21.40	2270	23.30	24.20	24.60	24.80	24.20	20.90	25.00	26.70	26.90
	7																					
	8	2180	2170	21.50	22.00	22.50	22.30	22.30	21.70	22.20	21.70	22.70	2370									
	9																					
	10																					
Ave	22.43	22.35	22.25	22.55	23.03	22.75	22.73	22.48	22.68	22.30	22.60	23.90	23.90	24.57	25.47	26.43	25.50	25.13	27.10	28.30	28.57	
SD	0.81	0.85	0.97	0.75	0.56	0.77	0.83	1.07	0.83	0.95	0.94	1.17	0.52	0.40	1.03	1.42	2.00	3.68	2.05	1.77	2.08	
Group 6 Compound 1 150 mg/kg	1	23.10	22.30	22.50	22.40	22.70	23.00	22.60	22.20	22.40	22.30	23.40	24.10	24.50	24.80	26.60	27.40	26.50	27.70			
	2	23.40	23.60	22.10																		
	3	24.50	24/0	25.40	24.90	24.50	25.00	25.00	24.90	25.60	24.90	24.80	26.20	26.60	28.10	26.30	28.30	28.10	29.50	30.90	31.60	32.00

2Q7Dx1	4	21.8	21.1	21.2	21.4	21.3	21	21.3	20.6	20	20.9	21	22	21.2	21.9	22	24.5	22	22	24.0	23.9	24.3
5 +		0	0	0	0	0	60	0	0	90	0	00	30	0	0	60	0	00	90	0	0	0
anti-PD-	5	22.3	21.8	21.9	21.7	21.9	22.6	22.6	22.0	22.4	22.1	22.4	23.0	23.5	24.1	25.9	25.6	28.0	26.7	28.9	28.8	29.1
1		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
200pg/m	6																					
se																						
Q3Dx35	7	21.8	21.3	21.6	21.7	21.9	21.9	22.2	22.4	22.0	21.6	22.0	22.0	23.2	23.3	22.3	23.3	23.8	24.9	25.7	24.8	25.9
		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8	23.7																				
		0																				
	9	21.4	23.1	22.8	22.9	23.6	23.5	23.0	21.4	22.6	23.1	22.7	24.3	26.9								
		0	0	0	0	0	0	0	0	0	0	0	0	0								
	10	23.1	23.3	22.7	23.1	24	23.2	23.7	23.1	24.5	22.8	22.1	23.9	24.4	24.9	23.1	26.2	24.5	25.8	23.8	26.7	27.3
		0	0	0	0	40	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Ave	22.7	22.5	22.5	22.5	22.9	22.9	22.9	22.3	22.9	22.5	22.6	23.6	24.3	24.5	24.4	25.8	25.4	26.2	26.6	27.1	27.7
		9	9	3	9	0	7	1	7	1	3	3	9	3	5	7	8	8	5	6	6	2
	SD	1.03	1.13	1.28	1.21	1.28	1.13	1.18	1.36	1.59	1.28	1.20	1.42	1.98	2.05	2.00	1.84	2.46	2.29	3.13	3.11	2.98

[0428] **Clinical Observations:** Compound 1 was well tolerated throughout the study with no clinical observations made on the mice. One mouse (7) in group 2 mice administered anti-PD-1 at 200 µg Q3D displayed a necrotic tumor as well as one mouse (8) in group 5 administered Compound 1 75 mg/kg 2Q7D + anti-PD-1 200 µg Q3D. **TABLE 14** shows the date of death of individual mice in the treatment groups and relevant clinical observations.

TABLE 14

Group	Mouse Number	Date of Death (Study Day)	Method	Clinical Observations
Group 1 Vehicle 2Q7Dx4	1	20	Euthanasia	None; euthanized for tumor burden
	2	23	Euthanasia	None; euthanized for tumor burden
	3	27	Euthanasia	None; euthanized for tumor burden
	4	23	Euthanasia	None; euthanized for tumor burden
	5	23	Euthanasia	None; euthanized for tumor burden
	6	27	Euthanasia	None; euthanized for tumor burden
	7	20	Euthanasia	None; euthanized for tumor burden
	8	23	Euthanasia	None; euthanized for tumor burden
	9	20	Euthanasia	None; euthanized for tumor burden
	10	20	Euthanasia	None; euthanized for tumor burden
Group 2 Anti-PD-1 200µg Q3Dx35	1	23	Euthanasia	None; euthanized for tumor burden
	2	185	Re-enrolled in future study	None; study terminated
	3	185	Re-enrolled in future study	None; study terminated
	4	38	Euthanasia	None; euthanized for tumor burden
	5	27	Euthanasia	None; euthanized for tumor burden
	6	27	Euthanasia	None; euthanized for tumor burden
	7	27	Euthanasia	Tumor necrotic; euthanized for tumor burden
	8	30	Euthanasia	None; euthanized for tumor burden
	9	27	Euthanasia	None; euthanized for tumor burden
	10	30	Euthanasia	None; euthanized for tumor burden
Group 3 Compound 1	1	34	Euthanasia	None; euthanized for tumor burden
	2	34	Euthanasia	None; euthanized for tumor burden
	3	34	Euthanasia	None; euthanized for tumor burden

75 mg/kg 2Q7Dx6	4	27	Euthanasia	None; euthanized for tumor burden
	5	27	Euthanasia	None; euthanized for tumor burden
	6	41	Euthanasia	None; euthanized for tumor burden
	7	27	Euthanasia	None; euthanized for tumor burden
	8	38	Euthanasia	None; euthanized for tumor burden
	9	34	Euthanasia	None; euthanized for tumor burden
	10	41	Euthanasia	None; euthanized for tumor burden
Group 4 Compound 1 150 mg/kg 2Q7Dx15	1	34	Euthanasia	None; euthanized for tumor burden
	2	34	Euthanasia	None; euthanized for tumor burden
	3	34	Euthanasia	None; euthanized for tumor burden
	4	185	Re-enrolled in future study	None; study terminated
	5	48	Euthanasia	None; tumor Burden collected for 24H
	6	48	Euthanasia	None; tumor Burden collected for 24H
	7	44	Euthanasia	None; euthanized for tumor burden
	8	34	Euthanasia	None; euthanized for tumor burden
	9	51	Euthanasia	None; tumor Burden collected for 24H
	10	44	Euthanasia	None; euthanized for tumor burden
Group 5 Compound 1 75 mg/kg 2Q7Dx15 + Anti-PD-1 200 µg Q3Dx35	1	185	Euthanasia	None; study terminated
	2	34	Euthanasia	None; euthanized for tumor burden
	3	185	Euthanasia	None; study terminated
	4	41	Euthanasia	None; euthanized for tumor burden
	5	48	Euthanasia	None; euthanized for tumor burden
	6	185	Re-enrolled in future study	None; study terminated
	7	38	Euthanasia	None; euthanized for tumor burden
	8	111	Euthanasia	Tumor necrotic; euthanized for tumor burden
	9	34	Euthanasia	None; euthanized for tumor burden
	10	34	Euthanasia	None; euthanized for tumor burden
Group 6 Compound 1 150 mg/kg 2Q7Dx15 +	1	161	Euthanasia	None; tumor Burden collected for sequencing
	2	78	Euthanasia	None; tumor Burden collected for 24H
	3	185	Re-enrolled in future study	None; study terminated

Anti-PD-1 200 µg Q3Dx35	4	185	Re-enrolled in future study	None; study terminated
	5	185	Re-enrolled in future study	None; study terminated
	6	63	Euthanasia	None; euthanized for tumor burden
	7	185	Re-enrolled in future study	None; study terminated
	8	70	Euthanasia	None; tumor Burden collected for 24H
	9	118	Euthanasia	None; euthanized for tumor burden

[0429] The dose responsive anti-tumor effect was tested for Compound 1 in combination with anti-PD-1 in a mouse syngeneic model of sarcoma (MT373). Vehicle control treated animals had a median survival time of 20.94 days. Anti-PD-1 was dosed IP at 200 µg per mouse and resulted in 39.6% TGI and a median survival of 27.14 days. Compound 1 was dosed orally at 75 mg/kg or 150 mg/kg, resulting in 57.1% and 95.7% TGI, respectively by day 27 and median survival times of 32 and 42.9 days, respectively. Mice dosed with combination therapy; Compound 1 at 75 mg/kg + 200µg anti-PD-1, and Compound 1 at 150 mg/kg + 200 µg anti-PD-1, resulted in 91.2% TGI and 92.3% regression, respectively by day 27 of the study. Combination therapy similarly improved median survival times versus monotherapy with the low dose combination resulting in median survival of 43.78 days (a 22.84 day extension in survival compared to vehicle control). High-dose combination treatment delayed median survival time to >185 days, and a >164 day extension in survival compared to vehicle control. Following cessation of dosing on day 102, mice were continuously monitored until day 185. The anti-PD-1 group had one residual tumor in stasis and 10% cure; the 150 mg/kg Compound 1 2Q7Dx15 group had 10% cure; the Compound 1 75mg/kg 2Q7Dx15 + anti-PD-1 Q3Dx35 group had 30% cures with 1 mouse having a tumor that regrew and had to be euthanized at day 111; and the high dose combination group Compound 1 150 mg/kg 2Q7Dx15 + Anti-PD-1 (Q3Dx35) had 40% cures and 1 mouse with a residual tumor in stasis.

[0430] Administration of Compound 1 once weekly resulted in dose responsive anti-tumor effect with tumor grow delay. Combination therapy with anti-PD-1 significantly improved the anti-tumor effect demonstrating regression, cures, and a significant increase in median survival time at the highest dose level.

EXAMPLE 3: *Combination of Compound 1 and Anti-PD-1 agent in mouse sarcoma model (MT245).*

[0431] The efficacy of Compound 1 was tested as a single agent and in combination with anti-PD-1 in a mouse syngeneic model of sarcoma (MT245). C57Bl/6 mice were implanted with MT245 cells,

tumors were grown to $\sim 77 \text{ mm}^3$ and randomized on day 7 post-inoculation into one of seven study groups. Mice were dosed orally (PO) with either vehicle control (0.2% HPC, 0.5% Tween 80); dosed intraperitoneally (IP) with anti-PD-1 at 200 μg per mouse, once every three days, for 19 weeks (Q3Dx19); Compound 1 PO at 150 mg/kg, once weekly, for 5 weeks (Q7Dx5); Compound 1 at 300 mg/kg and 600 mg/kg, once weekly, for 9 weeks (Q7Dx9); and combinations of Compound 1 150 mg/kg (Q7Dx9) + anti-PD-1 200 μg (Q3Dx19); and Compound 1 300 mg/kg (Q7Dx9) + anti-PD-1 200 μg (Q3Dx19).

[0432] Animals: Female C57Bl/6 mice (90 total) were acclimatized for 1 week and were 8-10 weeks old at initiation of study. Animals were group housed (N=5) in ventilated cages. Fluorescent lighting was provided on a 12-hour cycle (6:30 am-6:30 pm). Temperature and humidity were monitored and recorded daily and maintained between 68-72°F (20-22.2°C) and 30-70% humidity, respectively. 18% soy irradiated rodent feed and autoclaved acidified water (pH 2.5-3) was provided ad libitum.

[0433] Tumor Cell Culture: MT245 cells were cultured according to the DMEM medium with 10% fetal bovine serum. The cells were washed with PBS and counted at a total of 2.33×10^8 cells with 85% viability. Cells were centrifuged and resuspended in 50% PBS:50% Matrigel Matrix at a concentration of 1×10^6 viable cells/100 μL .

[0434] Implantation of Mice: Cells were prepared for injections by drawing the cell suspension into a 1 mL tuberculin syringe fitted with a 25G 5/8" needle. Individual mice were manually restrained, the site of injection (right flank) was disinfected with a 70% ethanol swab, and 100 μL of cell suspension was injected subcutaneously.

[0435] Randomization and Study Setup: Implanted mice were monitored for palpable tumors. Six days post implant, the mice with palpable tumors had their tumor sizes determined via digital caliper. Mice were selected and randomized into six treatment groups according to tumor size. Average tumor volume (mm^3) and body weight (g) is reported in **TABLE 15A** and **TABLE 15B**, respectively. Treatment began on the seventh day post-implant to facilitate twice daily dosing.

TABLE 15**TABLE 15A**

Group	N	Mean	St Dev	Min	Max
Group 1- Vehicle Control Q7Dx3	10	77.01	± 10.33	60.03	96.80
Group 2- Anti-PD-1 200 μg Q3Dx19	10	76.88	± 9.74	61.85	95.65
Group 3- Compound 1 150 mg/kg Q7Dx5	10	77.11	± 9.70	62.43	95.29
Group 4- Compound 1 300 mg/kg Q7Dx9	10	76.82	± 9.19	62.42	92.60

Group 5- Compound 1 600 mg/kg Q7Dx9	10	77.00	± 9.33	62.50	92.51
Group 6- Compound 1 150 mg/kg + + Anti-PD-1 200 µg Q3Dx19	10	76.81	± 9.34	62.5	91.85
Group 7-Compound 1 300 mg/kg Q7Dx9 + Anti-PD-1 200 µg Q3Dx19	10	76.79	± 9.41	62.96	91.29

TABLE 15B

Group	N	Mean	St Dev	Min	Max
Group 1- Vehicle Control Q7Dx3	10	18.33	± 1.25	16.90	20.60
Group 2- Anti-PD1 200 µg Q3Dx19	10	18.57	± 0.91	17.42	19.90
Group 3- Compound 1 150 mg/kg Q7Dx5	10	18.14	± 0.63	17.27	18.96
Group 4- Compound 1 300 mg/kg Q7Dx9	10	17.96	± 1.20	15.60	19.80
Group 5- Compound 1 600 mg/kg Q7Dx9	10	18.34	± 0.52	17.60	19.22
Group 6- Compound 1 150 mg/kg Q7Dx9 + Anti-PD1 200 µg Q3Dx19	10	17.54	± 1.14	15.12	18.77
Group 7- Compound 1 300 mg/kg Q7Dx9 + Anti-PD1 200 µg Q3Dx19	10	18.72	± 1.32	16.28	20.84

[0436] Group 1 animals were dosed PO with vehicle control (2% HPC, 0.5% Tween 80 in water (w/v/v)) once per week for three doses (Q7Dx3). Group 2 animals were dosed IP with anti-PD-1 at 200 µg once every three days for 19 doses (Q3Dx19). Groups 3, 4 and 5 animals were dosed PO once a week with Compound 1 at 150 mg/kg for 5 doses (Q7Dx5), 300 mg/kg for 9 doses (Q7Dx9) and Compound 1 at 600 mg/kg for 9 doses (Q7Dx9), respectively. Groups 6 and 7 animals were dosed with Compound 1 at 150 and 300 mg/kg for 9 doses (Q7Dx9) in combination with anti-PD-1 at 200 µg for 19 doses (Q3Dx19), respectively. All dosing was terminated on day 55 and the remaining mice were monitored for survival. Mice were euthanized when individual tumors reached an endpoint of ~2000 mm³. At Day 157 the study was terminated, and median survival was calculated across all groups

[0437] **TABLE 16** show the seven efficacy study groups and dosing regimens of the study groups. **TABLE 17** shows the median survival time in days of the study groups and increases in survival time relative to mice in the vehicle control group. **TABLE 18** shows clinical observations of the mice of each study group and dates of death.

TABLE 16

Group	Treatment	N	Route	Dosing Frequency & Duration	Dose (mg/kg)	Dose Volume (mL/kg)
1	Vehicle Control	10	PO	Q7Dx3	NA	10
2	Anti-PD-1	10	IP	Q3Dx19	200 µg	10
3	Compound 1	10	PO	Q7Dx5	150	10
4	Compound 1	10	PO	07Dx9	300	10
5	Compound 1	10	PO	Q7Dx9	600	10
6	Compound 1	10	PO	Q7Dx9	150	10
	Anti-PD-1		IP	Q3Dx19	200 µg	10
7	Compound 1	10	PO	Q7Dx9	300	10
	Anti-PD-1		IP	Q3Dx19	200 µg	10

TABLE 17

Group	N	Range (Days)	Median (Days)	Increase in Survival Relative to Vehicle (Days)
Group 1- Vehicle Control Q7Dx3	10	15.96 to 20.00	19.30	-
Group 2- Anti-PD-1 200µg Q3Dx19	10	17.45 to >157.00	24.89	5.59
Group 3- Compound 1 150 mg/kg Q7Dx5	10	18.07 to 27.97	25.04	5.74
Group 4- Compound 1 300 mg/kg Q7Dx9	10	31.47 to N157.00	41.21	21.91
Group 5- Compound 1 600 mg/kg Q7Dx9	10	78.00 to >157.00	>157.00	>138.70
Group 6- Compound 1 150 mg/kg Q7Dx9 + Anti-PD-1 200 µg Q3Dx19	10	31.28 to >157.00	>157.00	>138.70
Group 7- Compound 1 300 mg/kg Q7Dx9 + Anti-PD-1 200 µg Q3Dx19	10	1-1/A	>157.00	>138.70

TABLE 18

Group	Mouse	Date of Death (Study Day)	Method	Clinical Observations
Group 1- Vehicle Control Q7Dx3	1	20	Euthanasia	None; euthanized for tumor burden
	2	20	Euthanasia	None; euthanized for tumor burden
	3	20	Euthanasia	Necrotic tumor; taken for humane endpoint
	4	20	Euthanasia	None; euthanized for tumor burden
	5	20	Euthanasia	None; euthanized for tumor burden
	6	17	Euthanasia	None; euthanized for tumor burden
	7	20	Euthanasia	None; euthanized for tumor burden
	8	20	Euthanasia	None; euthanized for tumor burden
	9	17	Euthanasia	None; euthanized for tumor burden
	10	20	Euthanasia	None; euthanized for tumor burden
Group 2- Anti-PD- 1 200 µg Q3Dx19	1	157	Re-enrolled in future study	None, study terminated
	2	25	Euthanasia	Necrotic tumor; taken for humane endpoint
	3	20	Euthanasia	None; euthanized for tumor burden
	4	25	Euthanasia	None; euthanized for tumor burden
	5	34	Euthanasia	None; euthanized for tumor burden
	6	19	Euthanasia	Necrotic tumor; taken for humane endpoint
	7	20	Euthanasia	None; euthanized for tumor burden
	8	25	Euthanasia	None; euthanized for tumor burden
	9	34	Euthanasia	None; euthanized for tumor burden
	10	25	Euthanasia	None; euthanized for tumor burden
Group 3- Compound 1 150 mg/kg Q7Dx5	11	20	Euthanasia	Necrotic tumor; animal cold to touch
	2	28	Euthanasia	None; euthanized for tumor burden
	3		Euthanasia	None; euthanized for tumor burden
	4	20	Euthanasia	None; euthanized for tumor burden
	5	25	Euthanasia	None; euthanized for tumor burden
	6	28	Euthanasia	None; euthanized for tumor burden
	7	28	Euthanasia	None; euthanized for tumor burden
	8	28	Euthanasia	None; euthanized for tumor burden
	9	20	Euthanasia	None; euthanized for tumor burden

Group	Mouse	Date of Death (Study Day)	Method	Clinical Observations
	10	20	Euthanasia	None; euthanized for tumor burden
Group 4- Compound 1 300 mg/kg Q7Dx9	1	42	Euthanasia	None; euthanized for tumor burden
	2	42	Euthanasia	None; euthanized for tumor burden
	3	157	Re-enrolled in future study	None, study terminated
	4	157	Re-enrolled in future study	None, study terminated
	5	38	Euthanasia	None; euthanized for tumor burden
	6	34	Euthanasia	None; euthanized for tumor burden
	7	157	Re-enrolled in future study	None, study terminated
	8	34	Euthanasia	None; euthanized for tumor burden
	9	157	Re-enrolled in future study	None, study terminated
	10	34	Euthanasia	None; euthanized for tumor burden
Group 5- Compound 1 600 mg/kg Q7Dx9	1	157	Re-enrolled in future study	None, study terminated
	2	157	Re-enrolled in future study	None, study terminated
	3	157	Re-enrolled in future study	None, study terminated
	4	157	Re-enrolled in future study	None, study terminated
	5	157	Re-enrolled in future study	None, study terminated
	6	78	Found Dead	Found dead
	7	157	Re-enrolled in future study	None, study terminated
	8	157	Re-enrolled in future study	None, study terminated

Group	Mouse	Date of Death (Study Day)	Method	Clinical Observations
	9	157	Re-enrolled in future study	None, study terminated
	10	157	Re-enrolled in future study	None, study terminated
Group 6- Compound 1 150 mg/kg Q7Dx9 + Anti-P13-1 200 µg Q3Dx19	1	42	Euthanasia	None; euthanized for tumor burden
	2	10	Found Dead	Found Dead, potential dosing error
	3	38	Euthanasia	None; euthanized for tumor burden
	4	34	Euthanasia	None; euthanized for tumor burden
	5	157	Re-enrolled in future study	None, study terminated
	6	157	Re-enrolled in future study	None, study terminated
	7	42	Euthanasia	Chest wound, taken for humane endpoint
	8	157	Re-enrolled in future study	None, study terminated
	9	157	Re-enrolled in future study	None, study terminated
	10	157	Re-enrolled in future study	None, study terminated
Group 7- Compound 1 300 mg/kg Q7Dx9 + Anti-PD-1 200 µg Q3Dx19	1	157	Re-enrolled in future study	None, study terminated
	2	157	Re-enrolled in future study	None, study terminated
	3	157	Re-enrolled in future study	None, study terminated
	4	157	Re-enrolled in future study	None, study terminated
	5	157	Re-enrolled in future study	None, study terminated

Group	Mouse	Date of Death (Study Day)	Method	Clinical Observations
	6	157	Re-enrolled in future study	None, study terminated
	7	157	Re-enrolled in future study	None, study terminated
	8	157	Re-enrolled in future study	None, study terminated
	9	157	Re-enrolled in future study	None, study terminated
	10	157	Re-enrolled in future study	None, study terminated

[0438] Measurements and Calculation of Tumor Volume: Tumor volume was calculated using the following equation: $(\text{longest diameter} \times \text{shortest diameter}^2)/2$. Individual tumor volumes and body weight measurements were taken twice weekly for all groups until the animals reached the humane endpoints. The calculation for percent tumor growth inhibition (TGI) is as follows: $[1 - ((T_t - T_0)/(C_t - C_0))] \times 100$, where C_t is the mean tumor volume of the vehicle control group at time t , C_0 is the mean tumor volume of the vehicle control group at time 0, and T is the mean tumor volume of the treatment group. Tumor regression was determined with the equation $[(T_0 - T_t)/T_0] \times 100$ using the same definitions.

[0439] At day 20, tumor growth inhibition (TGI) of 55.19%, 42.62%, 95.58% and 97.34% was observed in animals treated with 200 μg anti-PD-1 Q3Dx7; Compound 1 at 150 mg/kg Q7Dx3; Compound 1 at 300 mg/kg Q7Dx3; and Compound 1 at 150 mg/kg Q7Dx3 + 200 μg anti-PD-1 Q3Dx7, respectively. Tumor regression of 100% and 99.93% was observed at day 20 in mice treated with Compound 1 at 600 mg/kg Q7Dx3; and Compound 1 300 mg/kg Q7Dx3 + 200 μg Anti-PD-1 Q3Dx7, respectively. Median Survival Times (MST), defined as median time taken for tumors to reach 2000 mm^3 , were significantly increased in mice receiving the high dose of Compound 1 and both dose level combinations of Compound 1 and anti-PD-1 to >157 days, when compared to vehicle control at 19.3 days. Compound 1 and the combination with anti-PD-1 was well tolerated by mice with no significant body weight loss across the course of the study. Mice were dosed through day 55 of study and then monitored for clinical observations, tumor volume and body weight measurements.

[0440] MT245 mouse syngeneic sarcoma tumors implanted into female C57Bl/6 mice grew from an average of 77 mm³ to 2242 mm³ in 20 days with a median survival of 19.30 days. Tumors on mice administered anti-PD-1 200 µg Q3Dx19 showed 55.19 % TGI by day 20 with a median survival of 24.89 days. Mice in groups 3, 4 and 5 treated with Compound 1 at 150 mg/kg, 300 mg/kg and 600 mg/kg resulted in 42.62% TGI, 95.58% TGI and 100% regression by day 20, respectively. The median survival for those groups was observed to be 25.04, 41.21, and >157.00 days, respectively. Co-administration of Compound 1 with anti-PD-1 improved efficacy significantly for both dose levels of Compound 1. Mice in the 150 mg/kg combination group demonstrated 97.34 % TGI at day 20 with a median survival time of >157.00 days while the 300 mg/kg combination achieved 99.93 % regression and extended median survival time to >157.00 days.

[0441] **FIG. 6** shows changes in tumor volume (mm³) in female C57Bl/6 mice implanted with MT245 mouse syngeneic sarcoma tumors over 20 days upon receiving treatment with vehicle (Q7Dx3); anti-PD-1 200 µg (Q3Dx19); Compound 1, 150 mg/kg (Q7Dx5); Compound 1, 300 mg/kg (Q7Dx9); Compound 1, 600 mg/kg (Q7Dx9); Compound 1, 150 mg/kg (Q7Dx9) + anti-PD-1 200 µg (Q3Dx19); or Compound 1, 300 mg/kg (Q7Dx9) + anti-PD-1 200 µg (Q3Dx19). **TABLE 19** shows average percentage tumor growth inhibition (%) across 20 days of study (n=10 unless noted). **TABLE 20** shows average percentage tumor regression (%) across 157 days of study (n=10 unless noted).

TABLE 19

Day of Study	Group 1 Vehicle Control Q7Dx3	Group 2 Anti-PD-1 200µg Q3Dx19	Group 3 Comp 1 150 mg/kg Q7Dx5	Group 4 Comp 1 300 mg/kg Q7Dx9	Group 5 Comp 1 600 mg/kg Q7Dx9	Group 6 Comp 1 150 mg/kg Q7Dx9 + Anti-PD-1 200 µg Q3Dx19	Group 7 Comp 1 300 mg/kg Q7Dx9 + Anti-PD-1 200 µg Q3Dx19
0	0.00	0.00	0.00	0.00	0.00	0.00	0.00
3	0.00	0.00	96.72	>100	>100	77.22	>100
7	0.00	36.54	68.93	>100	>100	>100	>100
11	0.00	46.98	48.26	>100	>100	>100 (n=9)	>100
14	0.00	49.22	52.39	98.02	>100	99.43 (n=9)	>100
17	0.00	56.76	54.96	99.83	>100	99.05 (n=9)	>100
20	0.00 (n=8)	55.19 (n=9)	42.62	95.58	>100	97.34 (n=9)	>100

TABLE 20

Day of Study	Group 1 Vehicle Control Q7Dx3	Group 2 Anti-PD-1 200µg Q3Dx19	Group 3 Comp 1 150mg/kg Q7Dx5	Group 4 Comp 1 300mg/kg Q7Dx9	Group 5 Comp 1 600 mg/kg Q7Dx9	Group 6 Comp 1 150 mg/kg Q7Dx9 + Anti-PD-1 200 µg Q3Dx19	Group 7 Comp 1 300 mg/kg Q7Dx9 + Anti-PD-1 200 µg Q3Dx19
0	0.00	0.00	0.00	0.00	0.00	0.00	0.00
3	0.00	0.00	0.00	24.34	10.04	0.00	6.33
7	0.00	0.00	0.00	45.41	87.69	42.47	87.56
11	0.00	0.00	0.00	58.23	97.92	52.67 (n=9)	99.16
14	0.00	0.00	0.00	0.00	99.94	0.00 (n=9)	99.87
17	0.00	0.00	0.00	0.00	100.00	0.00 (n=9)	99.93
20	0.00 (n=8)	0.00 (n=9)	0.00	0.00	100.00	0.00 (n=9)	99.93
25	n/a	0.00 (n=7)	0.00 (n=6)	0.00	100.00	0.00 (n=9)	100.00
28	n/a	0.00 (n=3)	0.00 (n=5)	0.00	100.00	0.00 (n=9)	100.00
31	n/a	0.00 (n=3)	n/a	0.00	100.00	0.00 (n=9)	100.00
34	n/a	0.00 (n=3)	n/a	0.00	100.00	0.00 (n=9)	100.00
38	n/a	100.00 (n=1)	n/a	0.00 (n=7)	100.00	0.00 (n=8)	100.00
42	n/a	100.00 n=1	n/a	0.00 n=6	100.00	0.00 n=6	100.00
46	n/a	100.00 (n=1)	n/a	100.00 (n=4)	100.00	100.00 (n=5)	100.00
49	n/a	100.00 (n=1)	n/a	100.00 (n=4)	100.00	100.00 (n=5)	100.00
53	n/a	100.00 (n=1)	n/a	100.00 (n=4)	100.00	100.00 (n=5)	100.00

Day of Study	Group 1 Vehicle Control Q7Dx3	Group 2 Anti-PD-1 200µg Q3Dx19	Group 3 Comp 1 150mg/kg Q7Dx5	Group 4 Comp 1 300mg/kg Q7Dx9	Group 5 Comp 1 600 mg/kg Q7Dx9	Group 6 Comp 1 150 mg/kg Q7Dx9 + Anti-PD-1 200 µg Q3Dx19	Group 7 Comp 1 300 mg/kg Q7Dx9 + Anti-PD-1 200 µg Q3Dx19
56	n/a	100.00 (n=1)	n/a	100.00 (n=4)	100.00	100.00 (n=5)	100.00
59	n/a	100.00 (n=1)	n/a	100.00 (n=4)	100.00	100.00 (n=5)	100.00
63	n/a	100.00 (n=1)	n/a	100.00 (n=4)	100.00	100.00 (n=5)	100.00
67	n/a	100.00 (n=1)	n/a	100.00 (n=4)	100.00	100.00 (n=5)	100.00
73	n/a	100.00 n=1	n/a	100.00 n=4	100.00	100.00 n=5	100.00
80	n/a	100.00 (n=1)	n/a	100.00 (n=4)	100.00 (n=9)	100.00 (n=5)	100.00
87	n/a	100.00 (n=1)	n/a	100.00 (n=4)	100.00 (n=9)	100.00 (n=5)	100.00
94	n/a	100.00 (n=1)	n/a	100.00 (n=4)	100.00 (n=9)	100.00 (n=5)	100.00
102	n/a	100.00 (n=1)	n/a	100.00 (n=4)	100.00 (n=9)	100.00 (n=5)	100.00
109	n/a	100.00 (n=1)	n/a	100.00 (n=4)	100.00 (n=9)	100.00 (n=5)	100.00
116	n/a	100.00 (n=1)	n/a	100.00 (n=4)	100.00 (n=9)	100.00 (n=5)	100.00
123	n/a	100.00 (n=1)	n/a	100.00 (n=4)	100.00 (n=9)	100.00 (n=5)	100.00
157	n/a	100.00 (n=1)	n/a	100.00 (n=4)	100.00 (n=9)	100.00 (n=5)	100.00

[0442] MT245 tumors treated with vehicle control (2% HPC, 0.5% Tween 80) displayed consistent growth with animals reaching ~2000mm³ by Day 20 and were euthanized due to tumor burden. Tumors on mice receiving anti-PD-1 Q3Dx19 demonstrated consistent growth inhibition through 20 days, after which 9 out of 10 tumors began to regrow at varied rates through day 34. One tumor (1), remained a cure to the end of the study. Mice administered Compound 1 150 mg/kg Q7Dx5 displayed maximal TGI at day 3 with 96.72% but all tumors thereafter began to grow and mice were euthanized due to tumor burden between days 20 and 28. Mice administered with Compound 1 300 mg/kg Q7Dx9; Compound 1 600 mg/kg Q7Dx9; Compound 1 150 mg/kg Q7Dx9 + 200 µg anti-PD-1 Q3Dx19; and 300 mg/kg Q7Dx9 + 200 µg anti-PD-1 Q3Dx19 showed maximal tumor control early in the study. At the end of study, several mice had complete tumor regression (Group 4: n=4, Group 5: n=9, Group 6: n=5, Group 7: n=10).

[0443] **FIG. 7** shows changes in tumor volume (mm³) in female C57B1/6 mice implanted with MT245 mouse syngeneic sarcoma tumors over 157 days upon receiving treatment with vehicle (Q7Dx3); anti-PD-1 200 µg (Q3Dx19); Compound 1, 150 mg/kg (Q7Dx5); Compound 1, 300 mg/kg (Q7Dx9); Compound 1, 600 mg/kg (Q7Dx9); Compound 1, 150 mg/kg (Q7Dx9) + anti-PD-1 200 µg (Q3Dx19); or Compound 1, 300 mg/kg (Q7Dx9) + anti-PD-1 200 µg (Q3Dx19). **FIG. 8** shows changes in tumor volume (mm³) in individual C57B1/6 mice implanted with MT245 mouse syngeneic sarcoma tumors upon receiving treatment with vehicle (Q7Dx3); anti-PD-1 200 µg (Q3Dx19); Compound 1, 150 mg/kg (Q7Dx5); Compound 1, 300 mg/kg (Q7Dx9); Compound 1, 600 mg/kg (Q7Dx9); Compound 1, 150 mg/kg (Q7Dx9) + anti-PD-1 200 µg (Q3Dx19); or Compound 1, 300 mg/kg (Q7Dx9) + anti-PD-1 200 µg (Q3Dx19). **FIG. 9** provides a Kaplan-Meier survival curve of C57B1/6 mice implanted with MT245 mouse syngeneic sarcoma tumors upon receiving treatment with vehicle (Q7Dx3); anti-PD-1 200 µg (Q3Dx19); Compound 1, 150 mg/kg (Q7Dx5); Compound 1, 300 mg/kg (Q7Dx9); Compound 1, 600 mg/kg (Q7Dx9); Compound 1, 150 mg/kg (Q7Dx9) + anti-PD-1 200 µg (Q3Dx19); or Compound 1, 300 mg/kg (Q7Dx9) + anti-PD-1 200 µg (Q3Dx19). **TABLE 21** shows individual tumor volumes across the study for days 0-67. **TABLE 22** shows individual tumor volumes across the study for days 73-157.

TABLE 21

Days	Mouse	0	3	7	11	14	17	20	25	28	31	34	38	42	46	49	53	56	59	63	67
Group 1 Vehicle Control Q7Dx3	1	60	108	291	676	1096	1613	2635													
	2	67	113	272	542	1414	1872	3225													
	3	67	84	57	202	426	621	696													
	4	74	171	348	644	1311	1585	2013													
	5	74	81	187	462	874	1244	2112													
	6	80	180	317	653	982	2313														
	7	80	75	148	462	651	1418	2013													

	8	85	153	289	918	978	1504	3072												
	9	86	148	338	690	1499	2267													
	10	97	206	438	532	1064	1441	2171												
	Ave	77	132	268	578	1030	1588	2242												
	SD	11	46	110	188	332	492	786												
Group 2 Anti-PD-1 200 µg Q3Dx19	1	62	104	16	13	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2	66	155	55	71	167	293	429	1397											
	3	68	150	375	605	1140	1306	2450												
	4	74	172	188	394	522	857	1137	2079											
	5	74	129	128	130	252	633	671	1145	1252	1381	2075								
	6	79	176	387	809	1339	1913													
	7	79	147	212	416	613	580	2266												
	8	85	123	275	379	676	963	1210	2034											
	9	86	151	101	185	259	295	504	1051	1222	1887	2577								
	10	96	159	246	426	632	463	755	2005											
	Ave	77	147	198	343	561	730	1047	1387	825	1089	1550								
	SD	10	22	126	248	424	560	828	750	714	977	1366								
Group 3 Compound 1 150 mg/kg Q7Dx5	1	62	95	140	342	476	537	1154												
	2	66	48	36	131	222	415	699	1695	2644										
	3	68	82	176	499	861	1023	2020												
	4	73	100	158	405	714	995	1437	2782											
	5	75	97	110	260	343	502	872	1732	2084										
	6	79	51	61	161	233	362	649	982	2009										
	7	81	41	55	224	466	420	721	986	2078										
	8	85	96	122	529	379	634	915	1420	2455										
	9	86	95	311	591	686	984	2195												
	10	95	82	196	223	925	1704	2533												
	Ave	77	79	137	336	531	758	1319	1600	2254										
	SD	10	23	81	162	252	421	693	666	279										
Group 4 Compound 1 300 mg/kg Q7Dx9	1	62	57	23	19	19	35	76	261	475	388	757	917	2459						
	2	66	63	23	28	93	79	144	231	348	274	707	763	2137						
	3	68	70	9	0.5	0.5	0.5	0	0	0	0	0	0	0	0	0	0	0	0	0
	4	72	54	6	0.5	0.5	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	5	76	58	87	48	184	130	400	501	752	781	1371	2233							
	6	79	71	107	117	285	216	359	626	1161	1011	2093								
	7	81	57	8	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8	85	52	38	31	106	115	226	506	1168	936	2097								
	9	87	52	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10	93	50	113	68	269	218	520	1171	1266	1774	3221								
	Ave	77	58	42	32	96	79	173	330	517	516	1025	559	766	0	0	0	0	0	0
	SD	10	7	43	37	114	87	194	381	533	598	1136	839	1191	0	0	0	0	0	0
Group 5	1	63	39	10	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2	66	74	9	0.5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3	68	50	10	0.5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Compound 1 600 mg/kg Q7Dx9	4	72	73	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	5	76	62	7	5	0.5	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	6	7	103	12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	7	85	43	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8	83	91	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	9	87	96	28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10	93	61	0.5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Ave	77	69	9	2	0.05	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	SD	10	22	7	3	0.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Group 6 Compound 1 150 mg/kg Q7Dx9 + Anti-PD-1 200 µg Q3Dx19	1	63	95	68	75	133	173	287	318	491	499	910	1113	2260						
	2	66	79	83																
	3	69	56	63	107	255	247	425	528	778	691	1221	2314							
	4	71	90	86	121	350	399	497	879	1540	1807	3878								
	5	77	52	9	0.5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	6	77	121	46	9	0.5	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	7	8	130	19	0	0	0	0	0	0										
	8	83	55	6	0.5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	9	89	128	48	9	0.5	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10	92	87	14	6	0.5	0.5	0	0	0	0	0	0	0	0	0	0	0	0	0
	Ave	77	89	44	36	82	91	134	192	312	333	668	428	377	0	0	0	0	0	0
	SD	10	30	31	50	134	148	209	320	541	612	1292	856	922	0	0	0	0	0	0
Group 7 Compound 1 300 mg/kg Q7Dx9 + Anti-PD-1 200 µg Q3Dx19	1	63	102	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2	64	69	15	6	0.5	0.5	0	0	0	0	0	0	0	0	0	0	0	0	0
	3	70	51	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	4	71	75	11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	5	77	65	17	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	6	77	65	0.5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	7	83	104	15	0.5	0.5	0.5	0	0	0	0	0	0	0	0	0	0	0	0	0
	8	83	72	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	9	89	23	0.5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10	91	94	18	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Ave	77	72	10	0.6	0.1	0.1	0.1	0	0	0	0	0	0	0	0	0	0	0	0
	SD	10	24	7	2	0.2	0.2	0.2	0	0	0	0	0	0	0	0	0	0	0	0

TABLE 22. Individual tumor volumes across study (Days 73-157)

Days	Mouse	73	80	87	94	102	109	116	123	157
Group 2 Anti-PD-1 200 µg	1	0	0	0	0	0	0	0	0	0
	3									
	4									

Q3Dx19	5									
	6									
	7									
	S									
	9									
	10									
	Ave	0	0	0	0	0	0	0	0	0
	SD	0	0	0	0	0	0	0	0	0
Group 4 Compound 1 300 mg/kg Q7Dx9	1									
	2									
	3	0	0	0	0	0	0	0	0	0
	4	0	0	0	0	0	0	0	0	0
	5									
	6									
	7	0	0	0	0	0	0	0	0	0
	8									
	9	0	0	0	0	0	0	0	0	
	10									
	Ave	0	0	0	0	0	0	0	0	0
	SD	0	0	0	0	0	0	0	0	0
Group 5 Compound 1 600 mg/kg Q7Dx9	1	0	0	0	0	0	0	0	0	0
		0	0	0	0	0	0	0	0	0
	3	0	0	0	0	0	0	0	0	0
	4	0	0	0	0	0	0	0	0	0
	S	0	0	0	0	0	0	0	0	0
	6	0								
	7	0	0	0	0	0	0	0	0	0
	8	0	0	0	0	0	0	0	0	0
	9	0	0	0	0	0	0	0	0	0
	10	0	0	0	0	0	0	0	0	0
	Ave	0	0	0	0	0	0	0	0	0
	SD	0	0	0	0	0	0	0	0	0
Group 6	1									
	2									

Compound 1 150 mg/kg Q7Dx9 + Anti-PD-1 200 µg Q3Dx19	3									
	4									
	5	0	0	0	0	0	0	0	0	0
	6	0	0	0	0	0	0	0	0	0
	7									
	8	0	0	0	0	0	0	0	0	0
	9	0	0	0	0	0	0	0	0	0
	10	0	0	0	0	0	0	0	0	0
	Ave	0	0	0	0	0	0	0	0	0
	SD	0	0	0	0	0	0	0	0	0
Group 7 Compound 1 300 mg/kg Q7Dx9 + Anti-PD-1 200 µg Q3Dx19	1	0	0	0	0	0	0	0	0	0
	2	0	0	0	0	0	0	0	0	0
	3	0	0	0	0	0	0	0	0	0
	4	0	0	0	0	0	0	0	0	0
	5	0	0	0	0	0	0	0	0	0
	6	0	0	0	0	0	0	0	0	0
	7	0	0	0	0	0	0	0	0	0
	8	0	0	0	0	0	0	0	0	0
	9	0	0	0	0	0	0	0	0	0
	10	0	0	0	0	0	0	0	0	0
	Ave	0	0	0	0	0	0	0	0	0
	SD	0	0	0	0	0	0	0	0	0

[0444] **Body Weights:** Mouse body weights were well maintained over the course of the study (5). Mice dosed with vehicle control were an average of 20.33 g by the end of the study (day 20) with the percentage change varying between -0.28% early in the study to +11.69%. Mice administered anti-PD-1 consistently gained body weight through the study and by day 34 gained 16.65%. One mouse (7) began to lose weight at day 14 and by day 17 had a weight change of -9.5% and was euthanized for tumor burden on day 20. Two mice (1 and 9) that received Compound 1 150 mg/kg had a body weight change of -5.9% and -7.5% at day 20 when the mice were euthanized for tumor burden, all other mice in that group lost no more than 5% body weight. By day 123, Group 4 gained 26.82%, Group 5 gained 23.01%, Group 6 gained 24.82% and Group 7 gained 25.66%. In Group 5, one mouse (5) had body weight loss >5% early but recovered by day 17 and one mouse in Group 6 (10) had body weight loss >5% around day 31 but also recovered.

[0445] **FIG. 10** shows changes in percent body weight C57B1/6 mice implanted with MT245 mouse syngeneic sarcoma tumors upon receiving treatment with vehicle (Q7Dx3); anti-PD-1 200 μ g (Q3Dx19); Compound 1, 150 mg/kg (Q7Dx5); Compound 1, 300 mg/kg (Q7Dx9); Compound 1, 600 mg/kg (Q7Dx9); Compound 1, 150 mg/kg (Q7Dx9) + anti-PD-1 200 μ g (Q3Dx19); or Compound 1, 300 mg/kg (Q7Dx9) + anti-PD-1 200 μ g (Q3Dx19). **TABLE 23** shows average percentage changes in body weight of mice across the study (n=10 unless noted). **TABLE 24** shows individual body weights of mice across the study from days 0-67. **TABLE 25** shows individual body weights of mice across the study from days 73-157.

TABLE 23

Day of Study	Group 1 Vehicle Control Q713x3	Group 2 Anti-PD 1 200 μ g Q3Dx19	Group 3 Compound 1 300mg/kg Q7Dx5	Group 4 Compound 1 300 mg/kg Q7Dx9	Group 5 Compound 1 600 mg/kg Q7Dx9	Group 6 Compound 1 150mg/kg Q Dx9 +Anti-PD-1 200 μ g Q3Dx19	Group 7 Compound 1 300 mg/kg Q7Dx9 +Anti-PD-1 200 μ g Q3Dx19
0	0.00 $\pm$ 0.00	0.00 $\pm$ 0.00	0.00 $\pm$ 0.00	0.00 $\pm$ 0.00	0.00 $\pm$ 0.00	0.00 $\pm$ 0.00	0.00 $\pm$ 0.00
3	-0.28 $\pm$ 2.42	0.58 $\pm$ 2.10	0.38 $\pm$ 1.57	1.28 $\pm$ 3.05	-0.99 $\pm$ 3.49	1.23 $\pm$ 1.43	0.74 $\pm$ 4.93
7	2.60 $\pm$ 2.99	2.41 $\pm$ 2.18	1.47 $\pm$ 2.53	1.09 $\pm$ 2.31	0.18 $\pm$ 2.44	2.22 $\pm$ 1.92	2.46 $\pm$ 3.59
11	4.32 $\pm$ 2.30	1.50 $\pm$ 3.54	2.20 $\pm$ 4.34	3.75 $\pm$ 3.20	1.90 $\pm$ 1.99	3.00 $\pm$ 2.50	1.50 $\pm$ 3.62
14	3.33 $\pm$ 5.47	0.20 $\pm$ 3.88	0.60 $\pm$ 5.42	1.14 $\pm$ 3.00	-1.04 $\pm$ 2.34	2.31 $\pm$ 5.26 (n=9)	1.64 $\pm$ 3.47
17	7.81 $\pm$ 7.20	4.05 $\pm$ 9.80	4.10 $\pm$ 6.98	3.52 $\pm$ 3.85	2.40 $\pm$ 2.23	3.20 $\pm$ 2.43 (n=9)	2.09 $\pm$ 4.93
20	11.69 $\pm$ 9.95 (n=8)	4.43 $\pm$ 5.88 (n=9)	5.89 $\pm$ 7.37	4.59 $\pm$ 5.47	3.17 $\pm$ 2.17	4.17 $\pm$ 3.01 (n=9)	3.37 $\pm$ 2.92
25		6.84 $\pm$ 6.20 (n=7)	13.07 $\pm$ 9.84 (n=6)	6.84 $\pm$ 4.84	5.86 $\pm$ 3.36	6.35 $\pm$ 4.30 (n=9)	5.85 $\pm$ 4.37
28		11.64 $\pm$ 4.39 (n=3)	15.76 $\pm$ 8.25 (n=5)	4.57 $\pm$ 2.09	4.57 $\pm$ 2.09	8.87 $\pm$ 4.53 (n=9)	7.82 $\pm$ 3.77
31		13.74 $\pm$ 5.08 (n=3)		10.24 $\pm$ 7.54	6.75 $\pm$ 2.62	8.88 $\pm$ 8.61 (n=9)	9.88 $\pm$ 4.25
34		16.65 $\pm$ 7.79 (n=3)		13.27 $\pm$ 9.37	5.59 $\pm$ 2.70	11.69 $\pm$ 8.42 (n=9)	9.25 $\pm$ 4.28

38		11.98 ± 0.00 (n=1)		14.77 ± 8.41 (n=7)	9.99 ± 3.67	13.07 ± 7.25 (n=8)	11.17 ± 4.84
42		12.58 ± 0.00 (n=1)		15.13 ± 5.68 (n=6)	10.70 ± 3.70	14.06 ± 5.30 (n=7)	12.54 ± 6.54
46		18.54 ± 0.00 (n=1)		15.21 ± 5.27 (n=4)	13.47 ± 3.25	14.68 ± 2.68 (n=5)	10.82 ± 5.33
49		18.05 ± 0.00 (n=1)		14.89 ± 3.60 (n=4)	13.47 ± 3.25	14.68 ± 2.68 (n=5)	10.82 ± 5.33
53		20.03 ± 0.00		14.69 ± 4.37 (n=4)	13.38 ± 3.06	14.44 ± 4.49 (n=5)	14.91 ± 5.07
56		19.21 ± 0.00 (n=1)		14.83 ± 4.40 (n=4)	13.57 ± 3.48	15.04 ± 5.00 (n=5)	15.57 ± 5.64
59		20.42 ± 0.00 (n=1)		15.60 ± 4.59 (n=4)	13.51 ± 3.23	15.76 ± 5.60 (n=5)	15.26 ± 5.92
63		19.59 ± 0.00 (n=1)		17.01 ± 5.52 (n=4)	14.33 ± 2.85	16.89 ± 4.25 (n=5)	15.56 ± 5.31
67		19.37 ± 0.00 (n=1)		18.81 ± 7.85 (n=4)	14.15 ± 3.15	16.05 ± 4.81 (n=5)	20.30 ± 5.47
73		21.41 ± 0.00 (n=1)		20.86 ± 4.41 (n=4)	16.24 ± 3.31	19.80 ± 6.40 (n=5)	20.30 ± 5.47
80		22.52 ± 0.00 (n=1)		20.04 ± 4.95 (n=4)	16.41 ± 1.92 (n=9)	17.85 ± 6.51 (n=5)	19.36 ± 3.93
87		26.93 ± 0.00 (n=1)		21.66 ± 5.39 (n=4)	17.90 ± 3.37 (n=9)	18.06 ± 5.75 (n=5)	21.38 ± 4.39
94		25.50 ± 0.00 (n=1)		20.68 ± 4.41 (n=4)	18.17 ± 2.96 (n=9)	18.01 ± 6.67 (n=5)	21.00 ± 3.97
102		26.93 ± 0.00 (n=1)		24.86 ± 5.93 (n=4)	19.66 ± 3.78 (n=9)	25.79 ± 4.19 (n=5)	26.33 ± 4.18
109		25.28 ± 0.00 (n=1)		25.06 ± 6.31 (n=4)	22.72 ± 5.31 (n=9)	23.45 ± 4.10 (n=5)	25.33 ± 5.22
116		27.48 ± 0.00 (n=1)		27.02 ± 6.13 (n=4)	22.71 ± 5.56 (n=9)	24.84 ± 4.18 (n=5)	26.41 ± 5.16
123		28.59 ± 0.00 (n=1)		26.82 ± 5.88 (n=4)	23.01 ± 6.31 (n=9)	24.82 ± 4.17 (n=5)	25.66 ± 4.91

157		27.48 ± 0.00 (n=1)		32.14 ± 8.58 (n=4)	20.76 ± 3.23 (n=9)	29.44 ± 8.13 (n=5)	26.22 ± 4.19
-----	--	-----------------------	--	-----------------------	-----------------------	-----------------------	--------------

TABLE 24

Days	Mouse	0	3	7	11	14	17	20	25	28	31	34	38	42	46	49	53	56	59	63	67
Group 1 Vehicle Control Q7Dx3	1	20. 60	20. 20	21. 02	21. 09	20. 53	21. 07	20. 46													
	2	18. 10	17. 80	18. 60	18. 70	18. 58	19. 20	19. 70													
	3	19. 70	19. 38	20. 30	19. 95	18. 04	18. 56	19. 25													
	4	19. 20	18. 90	19. 05	19. 6	20. 05	20. 60	22. 57													
	5	17. 50	17. 78	18. 22	18. 40	18. 57	19. 45	19. 70													
	6	18. 03	17. 83	18. 50	19. 12	18. 57	19. 65														
	7	17. 09	17. 00	17. 40	18. 09	18. 20	18. 74	20. 05													
	8	17. 17	16. 62	16. 65	17. 26	17. 12	17. 82	19. 24													
	9	19. 00	19. 85	20. 33	20. 57	20. 83	21. 51														
	10	16. 90	17. 36	17. 98	18. 30	18. 60	20. 53	21. 65													
	Ave	18. 33	18. 27	18. 81	19. 11	18. 91	19. 71	20. 33													
	SD	1.2 5	1.2 3	1.3 9	1.1 9	1.1 8	1.1 9	1.2 0													
Group 2	1	18. 12	18. 3	18. 5	18. 14	18. 50	23. 00	19. 10	19. 65	19. 68	20. 45	20. 38	20. 29	20. 40	21. 48	21. 39	21. 75	21. 60	21. 82	21. 67	21. 63
	2	17. 42	17. 73	17. 87	17. 82	18. 48	18. 75	19. 25	18. 50												

Days	Mouse	0	3	7	11	14	17	20	25	28	31	34	38	42	46	49	53	56	59	63	67
Anti-PD-1 200µg Q3Dx19	3	17.80	17.84	18.12	17.16	16.54	17.18	18.62													
	4	19.90	19.54	20.05	20.63	19.96	19.90	19.15	18.81												
	5	18.60	19.09	19.18	19.76	19.20	20.35	20.70	21.20	21.70	22.17	23.37									
	6	17.59	17.90	17.85	16.90	17.08	17.34														
	7	18.13	18.80	19.40	19.00	17.42	16.40	16.98													
	8	19.26	19.06	19.50	19.76	19.85	19.86	20.50	21.09												
	9	19.00	19.14	19.91	19.80	19.13	20.19	20.07	21.00	20.83	20.74	21.25									
	10	19.88	19.24	19.73	19.60	19.96	20.20	21.10	20.82												
	Ave	18.57	18.66	19.01	18.86	18.61	19.32	19.50	20.15	20.74	21.12	21.67									
	SD	0.91	0.66	0.85	1.27	1.24	1.95	1.26	1.15	1.01	0.92	1.54									
Group 3 Compound 1 150 mg/kg Q7Dx5	1	18.33	18.40	18.70	18.5	17.44	17.56	17.25													
	2	18.69	18.30	18.70	18.70	18.52	18.35	19.50	20.00	20.83											
	3	18.23	18.20	18.46	19.20	19.00	18.93	19.84													
	4	17.56	17.50	17.20	18.26	18.78	19.70	20.25	22.75												
	5	17.40	17.40	17.50	18.20	18.16	18.95	19.20	20.47	21.29											
	6	17.60	18.00	18.00	17.90	17.73	18.75	19.00	18.90	20.54											

Days	Mouse	0	3	7	11	14	17	20	25	28	31	34	38	42	46	49	53	56	59	63	67
	7	18.80	18.77	18.40	19.45	18.35	19.57	19.81	19.20	19.56											
	8	18.96	18.90	19.40	19.62	18.93	20.27	20.45	21.75	23.56											
	9	18.60	18.70	19.50	17.00	16.81	17.05	17.20													
	10	17.27	17.9	18.22	18.50	18.60	19.50	19.40													
	Ave	18.14	18.20	18.41	18.53	18.23	18.86	19.19	20.51	21.16											
	SD	0.63	0.51	0.73	0.78	0.71	0.99	1.13	1.49	1.49											
Group 4 Compound 1 300 mg/kg Q7Dx9	1	19.80	19.20	20.20	20.45	20.41	20.85	20.97	21.57	20.92	20.77	21.00	21.16	23.02							
	2	17.76	18.20	18.22	17.84	17.89	18.26	18.53	18.81	19.16	19.80	19.90	20.88	21.72							
	3	15.60	16.07	16.00	16.50	16.37	16.92	17.50	17.55	17.82	18.12	18.20	18.90	18.53	18.70	18.32	18.76	18.80	19.00	19.52	20.36
	4	17.20	17.06	17.30	17.89	17.36	17.25	17.87	18.34	18.36	18.20	19.10	19.34	20.06	20.58	20.33	19.91	19.87	19.88	19.90	19.95
	5	17.34	17.66	18.02	18.60	17.87	18.97	19.50	18.60	19.85	20.20	21.82	22.39								
	6	17.75	18.46	17.60	18.32	17.98	17.24	16.94	17.88	16.90	17.30	18.58									
	7	19.15	18.96	18.60	19.06	18.40	19.40	19.30	19.47	19.96	20.37	20.40	21.20	21.00	21.08	21.16	21.58	21.68	21.87	21.85	21.80
	8	19.20	20.20	19.50	21.00	19.35	20.00	20.00	20.91	21.33	21.86	21.21									
	9	17.86	17.30	17.50	17.86	17.20	17.96	17.60	18.00	18.53	19.00	19.00	18.85	19.14	19.87	20.26	19.66	19.66	19.79	20.20	20.52
	10	17.9	18.65	18.5	18.73	18.66	18.94	19.36	20.6	21.87	22.11	23.8									

Days	Mouse	0	3	7	11	14	17	20	25	28	31	34	38	42	46	49	53	56	59	63	67
	Ave	17.96	18.18	18.14	18.63	18.15	18.58	18.76	19.17	19.47	19.77	20.30	20.39	20.58	20.06	20.02	19.98	20.00	20.14	20.37	20.66
	SD	1.20	1.19	1.18	1.31	1.14	1.29	1.28	1.40	1.61	1.61	1.72	1.37	1.67	1.03	1.20	1.18	1.21	1.22	1.03	0.80
Group 5 Compound 1 600 mg/kg 2Q7Dx9	1	17.90	18.50	18.70	18.30	18.10	18.36	18.56	19.20	18.20	19.20	18.80	19.30	19.78	19.49	18.96	19.87	19.90	19.91	20.00	20.50
	2	18.50	18.21	18.50	18.40	18.20	18.32	18.60	18.72	19.00	19.00	18.75	19.30	19.44	20.35	19.60	19.99	20.12	20.10	20.97	20.57
	3	18.80	18.71	18.80	19.21	18.76	19.51	19.16	20.15	19.65	19.96	20.00	20.69	21.41	21.65	20.37	20.85	20.85	21.00	21.20	21.20
	4	18.30	17.90	18.57	19.28	18.20	18.85	19.26	19.90	19.09	19.66	19.76	20.90	20.89	20.92	20.63	21.32	21.43	21.00	21.10	20.92
	5	18.60	17.50	18.40	18.62	18.00	18.41	18.70	18.80	19.08	19.50	19.00	19.90	20.15	20.67	19.78	21.08	21.11	21.00	21.07	20.93
	6	18.70	19.30	19.00	19.16	19.09	19.35	19.77	20.80	20.20	20.60	19.90	21.16	20.60	21.35	20.65	21.86	21.75	22.02	22.20	21.98
	7	17.98	18.17	18.50	18.77	18.28	18.42	18.86	19.35	19.15	19.80	19.90	20.81	21.21	21.52	20.26	20.96	20.89	20.80	20.90	21.51
	8	17.60	17.30	17.20	18.04	17.30	18.69	18.35	18.80	18.87	19.12	18.65	19.60	19.37	20.55	20.63	20.45	21.00	20.89	20.91	20.68
	9	19.22	19.16	18.60	19.40	18.70	19.92	19.52	20.18	20.10	20.60	20.00	21.10	20.90	21.56	20.90	21.68	21.20	21.20	21.23	21.23
	10	17.76	16.62	17.40	17.64	16.82	17.92	18.05	18.20	18.40	18.30	18.81	18.90	19.20	19.97	19.80	19.81	19.91	20.14	20.00	19.73
	Ave	18.34	18.16	18.37	18.68	18.15	18.78	18.91	19.41	19.17	19.57	19.36	20.17	20.30	20.80	20.16	20.79	20.82	20.81	20.96	20.93
	SD	0.52	0.87	0.59	0.59	0.67	0.62	0.51	0.82	0.65	0.71	0.59	0.86	0.81	0.73	0.61	0.74	0.64	0.62	0.63	0.62
Group 6	1	18.30	18.44	18.58	18.60	18.70	18.76	19.30	20.40	21.00	20.70	21.30	21.82	21.72							

Days	Mouse	0	3	7	11	14	17	20	25	28	31	34	38	42	46	49	53	56	59	63	67
Compound 1	2	15.12	15.36	15.65																	
150 mg/kg	3	16.52	16.44	17.10	17.60	17.40	17.18	17.40	18.75	18.86	19.56	20.23	20.60								
2Q7Dx9 + Anti-PD-1	4	18.50	18.91	18.80	19.10	18.85	19.04	19.00	19.90	20.40	21.30	22.96									
200 µg	5	18.30	18.40	18.50	18.40	18.11	18.22	18.30	18.80	18.50	19.28	19.26	19.80	20.52	21.06	19.67	20.08	20.00	20.10	21.00	20.19
Q3Dx19	6	17.50	17.48	17.65	17.96	18.20	18.26	18.47	18.50	19.46	19.52	19.50	19.87	20.30	20.33	19.80	20.24	20.25	20.40	20.76	21.02
	7	17.80	18.14	18.70	18.88	17.26	19.00	19.29	19.50	19.16	19.30	19.26	20.44	21.30							
	8	16.30	17.20	17.40	17.43	18.96	17.60	17.86	17.80	17.88	18.50	18.50	18.70	19.34	19.52	19.83	19.97	20.20	20.65	20.44	20.14
	9	18.00	17.90	18.20	18.40	17.86	18.50	18.40	18.94	19.74	19.45	19.60	20.00	19.98	20.53	20.86	20.95	21.15	20.90	20.89	20.94
	10	18.77	19.30	18.60	18.60	18.40	18.75	18.83	18.68	19.40	16.60	18.22	18.82	19.60	20.74	20.40	20.67	20.84	21.00	21.00	21.05
	Ave	17.54	17.76	17.92	18.33	18.19	18.37	18.54	19.03	19.38	19.36	19.87	20.01	20.39	20.44	20.11	20.38	20.49	20.61	20.82	20.67
	SD	1.14	1.18	0.99	0.56	0.61	0.63	0.64	0.78	0.95	1.32	1.47	1.00	0.87	0.58	0.50	0.41	0.48	0.37	0.23	0.46
Group 7	1	17.60	18.00	18.30	18.70	18.10	19.00	18.84	19.40	19.73	20.26	20.00	19.98	19.90	20.04	20.05	20.84	21.20	21.23	21.20	21.16
Compound 1	2	18.95	19.30	19.40	18.75	18.97	19.32	19.30	19.60	19.85	20.46	20.40	20.55	20.13	20.52	21.04	21.20	21.04	21.37	21.24	21.13
300 mg/kg	3	19.57	20.11	19.56	19.80	19.89	20.00	20.36	21.00	21.06	20.90	21.08	21.57	22.89	22.10	23.16	23.26	23.85	23.64	23.27	22.57
2Q7Dx9 + Anti-PD-1	4	16.28	16.80	17.46	16.95	17.06	14.75	17.27	18.60	18.40	19.30	19.00	19.70	19.47	19.56	20.06	20.20	20.02	20.17	20.30	20.57
	5	19.60	19.29	19.31	19.40	18.84	19.24	19.30	19.80	20.32	20.64	20.20	20.60	21.57	21.10	21.64	22.06	22.11	22.00	21.73	21.40

Days	Mouse	0	3	7	11	14	17	20	25	28	31	34	38	42	46	49	53	56	59	63	67
200 µg Q3Dx19	6	18.00	18.50	19.00	18.27	18.50	18.74	18.20	18.80	19.23	19.60	19.80	20.48	21.00	19.95	20.70	20.76	20.79	20.91	20.70	20.48
	7	20.84	18.30	19.90	19.60	20.09	20.90	20.76	20.80	21.30	21.95	21.44	21.68	20.51	20.70	21.09	21.85	21.70	21.37	22.00	22.42
	8	18.50	18.60	19.10	18.99	19.40	19.40	19.54	19.45	19.78	20.12	20.20	20.53	21.70	20.61	20.60	21.09	21.10	21.15	21.35	21.67
	9	19.85	21.03	20.97	21.00	21.14	21.00	20.82	21.60	22.34	22.00	21.91	22.05	21.85	21.92	22.45	22.56	22.63	22.57	23.12	23.38
	10	17.97	18.30	18.44	18.24	18.03	18.87	18.86	18.70	19.51	20.00	20.00	20.40	21.04	20.36	20.03	20.76	20.82	20.76	20.88	20.99
	Ave	18.72	18.82	19.14	18.97	19.00	19.12	19.33	19.78	20.15	20.52	20.40	20.75	21.01	20.69	21.16	21.46	21.58	21.52	21.58	21.58
	SD	1.32	1.18	0.96	1.09	1.18	1.73	1.12	1.04	1.14	0.90	0.85	0.76	1.04	0.82	1.02	0.95	1.06	0.99	0.98	0.94

TABLE 25

Days	Mouse	73	80	87	94	102	109	116	123	157
Anti-PD-1 200 µg Q3Dx19	1	22.00	22.20	23.00	22.74	23.00	22.70	23.10	23.30	23.10
	2									
	3									
	4									
	5									
	6									
	7									
	8									
	9									
	10									
	Ave	22.00	22.20	23.00	22.74	21.00	22.70	23.10	23.30	23.10
	SD	0	0	0	0	0	0	0	0	0
Group 4	1									
	2									
	3	19.66	19.78	20.01	19.65	20.85	20.96	21.20	21.12	20.85

Days	Mouse	73	80	87	94	102	109	116	123	157
Compound 1 300 mg/kg Q7Dx19	4	21.37	20.76	21.30	21.10	20.80	21.25	21.50	21.57	20.80
	5									
	6									
	7	22.18	22.30	22.50	22.45	23.32	23.30	24.00	23.83	25.32
	8									
	9	20.96	20.76	20.90	20.87	21.98	21.55	21.76	21.80	25.32
	10									
	Ave	21.04	20.90	21.18	21.02	21.7	21.8	22.1	22.08	23.07
	SD	1.05	1.04	1.03	1.15	1.19	1.05	1.28	1.20	2.60
Group 5 Compound 1 600 mg/kg Q7Dx9	1	20.62	20.80	20.80	21.20	20.78	22.13	22.18	22.20	20.79
	2	21.60	21.20	22.10	22.40	22.03	23.30	23.20	23.32	22.13
	3	22.50	21.45	21.75	21.63	22.36	24.60	24.65	25.12	22.36
	4	21.20	21.80	23	22.45	22.76	23.00	22.93	23.18	22.65
	5	21.30	22.02	21.89	22.20	21.34	21.62	21.54	21.39	22.34
	6	21.60								
	7	21.51	21.18	21.00	21.36	22.09	22.51	22.50	21.37	22.16
	8	21.40	20.75	21.03	21.00	22.11	21.88	22.11	22.08	22.05
	9	21.72	22.12	22.10	21.97	22.65	22.69	22.73	22.70	21.43
	10	19.65	20.34	20.44	20.34	20.85	20.34	20.21	20.20	21.85
	Ave	21.31	21.30	21.57	21.62	21.89	22.45	22.45	22.51	22.08
	SD	0.75	0.61	0.81	0.71	0.73	1.19	1.21	1.36	0.54
Group 6 Compound 1 150 mg/kg Q7Dx9 + Anti- PD-1 Q3Dx19	1									
	2									
	3									
	4									
	5	21.23	20.24	20.76	20.5	21.53	22.22	22.45	22.34	22.45
	6	21.16	21.32	21.17	21.22	23.13	22	21.98	21.87	23.91
	7									
	8	21.64	20.94	20.9	21.12	20.75	21.12	21.27	21.33	23.12
	9	20.56	21.33	21.3	21.3	22.91	22.62	21.22	23.25	22.91
	10	22.05	21.06	20.96	20.87	22.78	22	22.3	22.41	22.78
	Ave	21.33	20.98	21.02	21.00	22.42	21.99	22.24	22.24	23.03
	SD	0.56	0.45	0.22	0.32	0.96	0.55	0.71	0.71	0.55

Days	Mouse	73	80	87	94	102	109	116	123	157
Group 7 Compound 1 300 mg/kg Q7Dx9 + Anti-PD-1 Q3Dx19	1	22.40	22.00	22.37	21.93	21.65	23.12	23.21	23.23	22.76
	2	22.33	22.36	22.79	23.01	23.30	22.78	22.94	23.02	23.37
	3	24.00	23.80	24.32	24.22	24.45	23.67	24.55	24.43	24.54
	4	20.97	20.12	20.20	20.17	20.34	20.54	20.55	20.61	20.22
	5	22.05	21.82	21.90	21.89	23.48	22.76	22.90	22.83	23.34
	6	21.60	21.42	22.47	22.40	23.06	22.16	22.43	22.31	23.26
	7	23.40	24.50	25.00	24.87	25.58	26.74	26.43	25.87	25.54
	8	22.80	22.29	22.67	22.60	23.46	23.35	23.62	23.23	23.42
	9	23.57	24.00	24.13	23.99	25.15	26.37	26.87	26.52	25.60
	10	21.50	20.86	21.10	21.17	22.89	23.00	23.04	23.00	24.00
	Ave	22.46	22.32	21.70	22.63	23.44	23.45	23.65	21.51	23.61
	SO	0.98	1.41	1.47	1.45	1.46	1.85	1.87	1.71	1.53

[0446] The dose responsive anti-tumor effect of Compound 1 as a single agent and in combination with anti-PD-1 was tested in a mouse syngeneic model of sarcoma (MT245). Vehicle control treated animals had a median survival time of 19.30 days. Anti-PD-1 was dosed IP at 200 µg per mouse and resulted in 55.19% TGI at day 20 and a median survival of 24.89 days. Compound 1 was dosed PO as a single agent at 150 mg/kg Q7Dx5, 300 mg/kg Q7Dx9, and 600 mg/kg Q7Dx9, resulting in 42.62% TGI, 95.58% TGI and 100% regression respectively by day 20 of the study. Increase in median survival in the monotherapy groups compared to vehicle were 25.04, 41.21, and >157 days, respectively. Mice dosed with Compound 1 150 mg/kg Q7Dx9 + 200 µg Anti-PD-1 Q7Dx19, and Compound 1 600 mg/kg Q7Dx9 + 200 µg Anti-PD-1 Q7Dx19 resulted in 97.34% TGI and 99.93% regression, respectively by day 20 of the study and exhibited increases in median survival >157 days.

[0447] Following cessation of dosing on day 55 mice were continuously monitored until day 157. Mice with tumors that were not palatable or cured did not show signs of tumor re-growth during the 157 days. The anti-PD-1 Q3Dx9 group had one cure, the Compound 1 300 mg/kg group Q7Dx9 had 4 cures, the Compound 1 600 mg/kg group Q7Dx9 had 9 cures, the Compound 1 150 mg/kg Q7Dx9 + anti-PD-1 Q3Dx19 group had 5 cures, and the Compound 1 300 mg/kg Q7Dx9 + anti-PD-1 Q3Dx19 group had 10 cures.

[0448] Compound 1 was well tolerated throughout the dosing period and only minimal weight loss (<10%) in several mice across the groups were reported early in the study (up to day 25). Mice were euthanized when tumors reached ~2000 mm³ or if tumors were necrotic. One mouse in Group 5 (6) was found dead due to unknown reasons, one mouse in Group 6 (2) was found dead early in the study

most likely due to a dosing error, and one mouse in Group 6 (7) had an unrelated chest wound that required euthanasia. **TABLE 26** below provides the median survival time (MST).

TABLE 26

Group	MST (Days)
Vehicle	18
Anti-PD-1 200 µg	24
Compound 1 150 mg/kg Q7D	24
Compound 1 300 mg/kg Q7D	40
Compound 1 600 mg/kg Q7D	>108
PD1 + Compound 1 150 mg/kg	>108
PD1 + Compound 1 300 mg/kg	>108

[0449] Administration of Compound 1 once weekly resulted in dose responsive anti-tumor effect with tumor grow delay at lower doses and complete regression at the higher dose and a dose responsive increase in median survival time. Combination therapy with anti-PD-1 significantly improved the anti-tumor effect at lower doses of Compound 1 demonstrating regression, cures, and a significant increase in median survival time. **FIG. 11** shows changes in tumor volume (mm³) of C57Bl/6 mice implanted with MT245 mouse syngeneic sarcoma tumors upon receiving treatment with Vehicle; Compound 1, 150 mg/kg (Q7Dx2); Compound 1, 300 mg/kg (Q7Dx2); or Compound 1, 600 mg/kg (Q7Dx2).

EXAMPLE 4: *Combination of Compound 2 with an Anti-PD-1 Agent in Mouse Sarcoma (MT373) model*

[0450] Compound 2 is an indole compound substituted with a trifluoroethyl group at the 1-position; propynyl amino-methoxy-methylsulfonyl phenyl group at the 2-position; and a heterocycle-substituted amino group at the 4-position.

[0451] The efficacy of Compound 2 at various dose levels and regimens and in combination with one dose regimen of Anti-PD-1 in a subcutaneous mouse syngeneic model of sarcoma (MT373). Immunocompetent mice (C57Bl/6) were implanted subcutaneously with MT373 cells and randomized into study groups on day 6 post-implantation when tumors were ~75 mm³. Group 1 mice were dosed PO with vehicle control (0.2% HPC) twice a day (2Q7Dx4, 8 hours apart), once per week for four doses (2Q7Dx4). Group 2 mice were dosed interperitoneally (IP) with Anti-PD-1 at 200 µg every three days for 7 doses (Q3Dx7). Groups 3 and 4 mice were dosed PO daily (QD) with Compound 2 at 50 mg/kg for 44 doses (QDx44) or 100 mg/kg for 71 doses (QDx71), respectively. Groups 5 and 6 mice were dosed with Compound 2 at 150 and 300 mg/kg for 10 doses (2Q7Dx10) or 11 doses (2Q7Dx11), respectively. In Groups 7 and 8, mice were dosed with Compound 2 at 50

mg/kg for 71 doses (QDx71) and 150 mg/kg for 11 doses (2Q7Dx11) in combination with Anti-PD-1 at 200 µg for 24 doses (Q3Dx24), respectively.

[0452] Animals: Female C57Bl/6 mice (120 total) were acclimatized for 1 week and were 8-10 weeks at initiation of study. Animals were group housed (N=5) in ventilated cages. Fluorescent lighting was provided on a 12-hour cycle (6:30 am-6:30 pm). Temperature and humidity were monitored and recorded daily and maintained between 68-72°F (20-22.2°C) and 30-70 % humidity, respectively. 18 % soy irradiated rodent feed and autoclaved, acidified water (pH 2.5-3) was provided ad libitum.

[0453] Tumor Cell Culture: MT373 cells were cultured in DMEM medium with 10% fetal bovine serum. The cells were washed with PBS and counted at a total of 5.67×10^8 cells with 93.5% viability. Cells were centrifuged and resuspended in 50% PBS:50% Matrigel Matrix at a concentration of 5×10^6 viable cells/200 µL.

[0454] Implantation of Mice: Cells were prepared for injections by drawing the cell suspension into a 1 mL tuberculin syringe fitted with a 25G 5/8" needle. Individual mice were manually restrained, the site of injection (right flank) was disinfected with a 70% ethanol swab, and 200 µL of cell suspension was injected subcutaneously.

[0455] Randomization and Study Setup: Implanted mice were monitored for palpable tumors. Five days post implant the mice with palpable tumors had their tumor sizes determined via digital caliper. Mice were selected and randomized into six treatment groups according to tumor size. Average tumor volume (mm³) and body weight (g) is reported in **TABLE 27A** and **TABLE 27B**. Treatment began on the sixth day post-implant to facilitate twice daily dosing.

TABLE 27A

Group	N	Mean	St Dev	Min	Max
Group 1- Vehicle Control 2Q7Dx4	10	75.9	13.1	59.2	108.8
Group 2 – Anti-PD-1 200µg Q3Dx7	10	75.7	12.5	59.2	106.3
Group 3 – Compound 2 50 mg/kg QDx44	10	75.3	11.3	59.6	101.1
Group 4 - Compound 2 100 mg/kg QDx71	10	75.2	11.2	59.8	100.2
Group 5 - Compound 2 150 mg/kg 2Q7Dx44	10	74.8	10.3	60.7	96.1
Group 6 - Compound 2 300 mg/kg 2Q7Dx11	10	74.5	9.4	61.8	92.1
Group 7 - Compound 2 150 mg/kg QDx71 + Anti-PD-1 200µg Q3Dx24	10	74.2	9.1	61.9	89.8
Group 8- Compound 2 150 mg/kg 2Q7Dx11 + Anti-PD-1 200µg Q3Dx24	10	74.3	8.8	62.7	88.2

TABLE 27B

Group	N	Mean	St Dev	Min	Max
Group 1- Vehicle Control 2Q7Dx4	10	18.3	0.68	17.3	19.2
Group 2 – Anti-PD-1 200 μ Q3Dx7	10	18.0	0.82	16.8	19.3
Group 3 – Compound 2 50 mg/kg QDx44	10	17.3	1.4	15.8	19.6
Group 4 - Compound 2 100 mg/kg QDx71	10	18.1	0.80	17.0	19.3
Group 5 - Compound 2 150 mg/kg 2Q7Dx44	10	18.3	1.1	16.8	19.8
Group 6 - Compound 2 300 mg/kg 2Q7Dx11	10	17.7	0.97	16.1	19.1
Group 7 - Compound 2 150 mg/kg QDx71 + Anti-PD-1 200 μ g Q3Dx24	10	17.7	0.48	16.6	18.4
Group 8- Compound 2 150 mg/kg 2Q7Dx11 + Anti-PD-1 200 μ g Q3Dx24	10	17.0	1.1	15.6	18.6

[0456] Measurements and Calculation of Tumor Volume: Tumor volume was calculated using the following equation: $(\text{longest diameter} \times \text{shortest diameter}^2)/2$. Individual tumor volumes and body weight measurements were collected twice weekly for all groups until the animals reached the humane endpoints. The calculation for percent tumor growth inhibition (TGI) is as follows: $[1 - ((T_t - T_0)/(C_t - C_0))] \times 100$, where C_t is the mean tumor volume of the vehicle control group at time t , C_0 is the mean tumor volume of the vehicle control group at time 0, and T is the mean tumor volume of the treatment group. Tumor regression was determined with the equation $[(T_0 - T_t)/T_0] \times 100$ using the same definitions.

[0457] The study was continued until all actively growing tumors reached 2000 mm³ so that a median survival time could be calculated for all groups. All dosing was discontinued on day 70, after the last actively growing tumor reached 2000 mm³, and the remaining mice with no palatable tumors or small tumors (<100 mm³) that remained in stasis were monitored for survival. The time for each tumor to reach 2000 mm³ was determined and a median survival time for each study group was calculated. At day 182, the study was terminated, and median survival was calculated across all groups.

[0458] Mice that received the vehicle control survived 17.3 days, while mice dosed with Anti-PD-1 survived 24 days. Mice dosed with Compound 2 as a single agent at 50 or 100 mg/kg daily survived 28 and >182 days, respectively; while the twice daily once weekly regimens of 150 and 300 mg/kg resulted in 30.8 and 47.8 days median survival. For the 100 mg/kg daily group, 71 % of mice survived until termination of the study, while 20% survived in the 300 mg/kg 2Q7D group. A significant increase in median survival was measured when the sub-efficacious doses of Compound 2, 50 mg/kg QD and 150 mg/kg 2Q7D, were combined with Anti-PD-1 resulting in >182 median

survival for both groups. For the Compound 2 50 mg/kg QD + Anti-PD-1 group at 182 days, 89% of mice survived. 78% of the mice survived in the 150 mg/kg 2Q7D + Anti-PD-1 group.

[0459] By day 20 of the study, mice administered Compound 2 alone exhibited dose responsive single agent activity of 74% TGI (50 mg/kg QDx44), 40% regression (100 mg/kg QDx71), 92% TGI (150 mg/kg 2Q7Dx10), and 99% TGI (300 mg/kg 2Q7Dx11). Anti-PD-1 alone resulted in 72% TGI by day 20 of study. The combination of Anti-PD-1 with Compound 2 administered at either 50 mg/kg QDx71 or 150 mg/kg 2Q7Dx11 resulted in regression of 39% and 24%, respectively, at day 20 compared to vehicle control.

[0460] **TABLE 28** shows the 9 study groups that were treated with varying doses of vehicle, anti-PD-1, Compound 2, and Compound 2 in combination with Anti-PD-1. **TABLE 29** shows survival time of mice at the termination point (182 days).

TABLE 28

Group	Treatment	N	Route	Dosing Frequency & Duration	Dose (mg/Kg)	Dose Volume (mL/kg)
1	Vehicle Control	10	PO	2Q7Dx4	—	10
2	Anti-PD-1	10	IP	Q3DX7	200 µg	0.2*
3	Compound 2	10	PO	QDx44	50	10
4	Compound 2	10	PO	QDx71	100	10
5	Compound 2	10	PO	2Q7Dx10	150	10
6	Compound 2	10	PO	2Q7Dx11	300	10
7	Compound 2 +	10	PO	QDx71	50	10
	Anti-PD-1		IP	QD3X24	200 µg	0.2*
9	Compound 2 +	10	PO	2Q7Dx11	150	10
	Anti-PD-1		IP	Q3DX24	200 µg	0.2*
*mL/mouse						

TABLE 29

Group	N	Range (Days)	Median Survival (Days)	Increase in Survival Relative to Vehicle (Days)	% Survival of Mice at 182days
-------	---	--------------	------------------------	---	-------------------------------

Group 1 Vehicle Control 2Q7Dx4	10	15.53– 21.93	17.27	NA	NA
Group 2 Anti-PD-1 200µg Q3Dx7	10	20.85– 36.52	24.01	6.74	NA
Group 3 Compound 2 50 mg/kg QDx44	9	20.85– 42.63	28.00	10.73	NA
Group 4 Compound 2 100 mg/kg QDx71	7	48.74-NA	>182.00	>164.73	71 % (5/7)
Group 5 Compound 2 150 mg/kg 2QDx10	9	26.27– 64.45	30.81	14.54	NA
Group 6 Compound 2 300 mg/kg 2QDx11	10	33.01-NA	47.77	30.50	20 % (8/9)
Group 7 Compound 2 150 mg/kg QDx71 + Anti-PD-1 200 µg Q3Dx24	9	33.96-NA	>182.00	>164.73	89 % (8/9)
Group 8 Compound 2 150 mg/kg 2Q7Dx11 + Anti-PD-1 200 µg Q3Dx24	9	30.82-NA	>182.00	>164.73	78 % (7/9)

[0461] MT373 mouse sarcoma tumors implanted into female C57Bl/6 mice grew from an average of 75.9 mm³ to 2815.4 mm³ in 20 days. Day 20 was the last day with a significant number of vehicle controls remaining on study (N=8). Mice in groups 3-6 were administered Compound 2 as a single agent. In two daily dosing regimens, mice in group 3 received Compound 2 at 50 mg/kg QDx44 that resulted in 74.0 % TGI by day 20 and mice in group 4 received Compound 2 at 100 mg/kg QDx71 which exhibited 39.9 % regression by day 20. Compound 2 administration twice daily once per week of 150 mg/kg 2Q7Dx10 exhibited 92% TGI and 300 mg/kg 2Q7Dx11 exhibited 99. % TGI by Day 20 of study. Mice in group 2 were administered 200 µg Anti-PD-1 alone and in groups 7 and 8 in combination with Compound 2 at 50 mg/kg QDx71 and 150 mg/kg 2Q7Dx11. Mice administered Anti-PD-1 at 200 µg Q3Dx7 showed 72.3% TGI by day 20. Mice administered the combination of Compound 2 and Anti-PD-1 showed an increase in efficacy over either single agent in both dosing regimens tested. Mice in group 7 administered Compound 2 at 50 mg/kg QDx71 and 200 µg of Anti-

PD-1 Q3Dx24 exhibited 38.6% regression compared to single agents, 74% TGI and 72.3% TGI, respectively, by day 20. Mice in group 8 administered Compound 2 at 150 mg/kg 2Q7Dx11 and 200 µg of Anti-PD-1 Q3Dx24 exhibited 23.5% regression compared to single agents, 92% TGI and 72.3% TGI, respectively by day 20.

[0462] **FIG. 12** shows changes in tumor volume (mm³) for C57B1/6 mice implanted with MT373 mouse sarcoma tumors over 20 days upon receiving treatment with vehicle (2Q7Dx4); anti-PD-1 200 µg (Q3Dx7); Compound 2, 50 mg/kg (QDx44); Compound 2, 100 mg/kg (QDx71); Compound 2, 150 mg/kg (2Q7Dx10); Compound 2, 300 mg/kg (2Q7Dx11); Compound 2 50 mg/kg (QDx71) + anti-PD-1 200 µg (Q3Dx24); or Compound 2, 150 mg/kg (2Q7Dx11) + anti-PD-1 200 µg (Q3Dx24). **TABLE 30** shows individual tumor volumes across the study for days 0-69. **TABLE 31** shows individual tumor volumes across the study for days 72-182. Only mice left in the study are shown for groups 4 and 6-8. **TABLE 32** shows average percent growth inhibition (%) across 23 days of study (n=10 unless noted). **TABLE 33** shows average percentage tumor regression (%) across 182 days of study (n=10 unless noted).

TABLE 30

Days	Mouse	0	2	6	8	13	16	20	23	28	31	34	37	41	44	47	51	55	62	65	69
Group 1 Vehicle Control 2Q7Dx4	1	59.	95.	162	181	470	109	220													
		2	7	.6	.3	.6	6.4	0.5													
	2	65.	97.	141	153	301	589.	144	231												
		3	8	.0	.5	.5	0	2.8	0.4												
	3	65.	103	148	248	542	113	303													
		4	.8	.9	.6	.2	8.0	9.9													
	4	70.	97.	157	254	875	119	236													
		9	7	.2	.5	.3	8.1	3.0													
	5	71.	110	104	174	755	138	317													
		1	.5	.8	.4	.9	6.5	0.5													
	6	76.	100	168	317	846	169	364													
		9	.2	.9	.5	.8	9.0	7.5													
	7	82.	92.	104	258	570	140	343													
		6	7	.6	.8	.3	9.3	9.9													
	8	81.	116	181	339	954	219														
		8	.1	.4	.9	.1	3.0														
	9	77.	91.	157	280	825	215														
		1	2	.2	.0	.1	1.7														

Days	Mo use	0	2	6	8	13	16	20	23	28	31	34	37	41	44	47	51	55	62	65	69
	10	108.8	123.1	139.5	243.3	894.0	174.6	321.5													
	Ave	75.9	102.9	146.6	245.2	703.6	146.0	281.5	231.4												
	SD	13.8	10.5	25.4	60.7	217.6	497.3	745.4													
Group 2 Anti PD 1 200µg Q3Dx7	1	59.2	86.0	81.8	120.4	189.5	426.5	112.6	226.2												
	2	65.1	102.1	103.7	178.4	327.0	793.7	108.9	183.6	515.0											
	3	66.1	74.9	65.9	125.0	195.0	342.2	625.9	887.7	207.3											
	4	69.6	91.6	103.8	156.8	398.4	945.3	165.0	287.4												
	5	71.2	109.3	128.1	185.9	352.1	669.1	132.1	232.3												
	6	76.9	99.2	123.2	148.8	247.6	494.0	879.4	138.5	359.3											
	7	77.7	72.5	66.4	106.7	79.1	121.8	330.4	552.9	114.5	203.2										
	8	81.7	84.5	96.7	174.7	176.1	298.3	946.9	173.5	379.1											
	9	82.9	81.4	118.2	115.4	61.6	41.6	175.0	318.8	547.7	971.5	127.2	213.9								
	10	106.3	170.0	163.8	190.7	68.0	49.6	194.2	195.7	302.6	733.2	149.9	299.7								
Group 3	Ave	75.7	97.2	105.2	150.3	209.4	418.2	834.0	143.7	237.9	124.5	138.6	256.8								
	SD	13.2	28.2	30.0	31.6	121.1	311.5	495.6	923.1	184.6	691.9	160.4	608.3								
	1	59.6	71.4	65.9	126.8	92.7	202.9	441.1	812.8	157.3	220.5										

Days	Mo use	0	2	6	8	13	16	20	23	28	31	34	37	41	44	47	51	55	62	65	69
Compo und 2 50 mg/kg QDx44	2	64. 8	83. 9	80. 9	121. .0	74. 3	157. 4	483. 6	947. 9	214. 0.0											
	3	66. 2	76. 4	84. 5	74. 5	49. 4	46.2	23.7	38.5	175. 7	318. 5	791. 8	104. 8.6	153. 3.4	239. 1.1						
	4	69. 3	95. 4	80. 9	110. .4																
	5	71. 2	75. 2	79. 8	113. .2	73. 0	68.6	386. 0	690. 2	132. 2.0	236. 6.7										
	6	76. 8	108. .5	117. .2	145. .4	289. .2	939. 7	187. 2.5	232. 4.6												
	7	78. 2	78. 7	63. 1	81. 3	111. .3	149. 0	345. 8	509. 6	126. 5.9	231. 4.7										
	8	81. 5	92. 0	112. .1	171. .0	297. .8	742. 9	168. 1.2	312. 6.1												
	9	83. 9	84. 5	95. 0	102. .7	65. 5	108. 2	289. 3	502. 7	200. 0.5											
	10	101. .1	115. .0	119. .6	205. .1	402. .0	902. 4	157. 7.0	266. 4.7												
	Ave	75. 3	88. 1	89. 9	125. .1	161. .7	368. 6	788. 9	129. 0.8	141. 2.9	180. 2.1	791. 8	104. 8.6	153. 3.4	239. 1.1						
SD	11. 9	14. 6	20. 4	39. 8	131. .0	376. 4	707. 1	110. 8.5	701. 5	991. 3											
Group 4 Compo und 2 100 mg/kg QDx71	1	59. 8	97. 1	58. 3	78. 0	75. 2	38.2	74.2	57.3	105. 9	130. 6	160. 5	224. 7	425. 1	730. 2	152. 7.3	261. 3.7				
	2	64. 2	66. 7	45. 2																	
	3	66. 4	66. 7	41. 8	67. 8	23. 6	19.5	65.8	38.9	67.5	43.4	57.4	70.0	47.5	44.0	34.5	34.8	20. 6	45.4	25.3	21.2
	4	69. 1	66. 6	41. 8	56. 1	41. 7	32.4	42.4	24.7	30.6	32.5	23.4	23.0	8.3	22.2	16.1	9.7	0.5	0.5	0.0	0.0
	5	71. 4	62. 3	65. 0	60. 6	22. 0	17.6	14.5	15.1	16.1	19.8	13.0	20.5	6.3	0.5	0.5	0.5	0.5	0.5	0.5	7.1

Days	Mo use	0	2	6	8	13	16	20	23	28	31	34	37	41	44	47	51	55	62	65	69
	6	76. 3	108 .0	93. 2	78. 7	63. 2	24.4	0.5	8.3	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	7	78. 8	70. 2	65. 0	76. 2	52. 6	52.4	97.0	95.2	82.4	123. 0	105. 2	127. 6	123. 3	156. 7	126. 2	131. 1	105. .1	139. 4	98.4	123. 3
	8	81. 1	75. 3	62. 4	48. 7	17. 9	25.0	22.1	38.3	40.6	43.8	26.9	28.4	27.5	48.9	38.4	39.9	36. 5	33.5	29.3	35.5
	9	85. 0	84. 8																		
	10	100 .2	76. 2																		
	Ave	75. 2	77. 4	59. 1	66. 6	42. 3	29.9	45.2	39.7	49.1	56.1	55.2	70.6	91.1	143. 2	249. 0	404. 2	27. 2	36.6	25.6	31.2
	SD	11. 8	14. 9	17. 1	11. 8	22. 3	12.2	35.2	29.8	37.7	50.6	58.1	80.2	153. 2	264. 3	565. 3	975. 3	40. 9	54.0	38.1	47.2
Group 5 Compo und 2 150 mg/kg 2Q7Dx 10	1	60. 7	68. 9	93. 4	135 .1	129 .6	147. 6	408. 8	693. 7	154 9.6	202 9.9										
	2	63. 7	75. 4	84. 6	56. 5	112 .2	110. 2	209. 8	330. 5	835. 1	144 3.0	258 5.1									
	3	66. 5	75. 8	106 .1	111 .2	94. 9	86.0	160. 9	294. 5	809. 3	136 8.8	245 0.0									
	4	69. 0	77. 0	67. 9	94. 3	135 .7	171. 6	483. 7	694. 1	269 1.2											
	5	71. 5	67. 8	87. 1	114 .4	104 .1	127. 6	259. 1	306. 4	135 7.6	205 2.6										
	6	75. 2	76. 4	118 .6	105 .5	71. 8	83.8	185. 5	352. 6	123 8.5	154 9.6	291 1.5									
	7	79. 0	80. 5	136 .1	198 .3	248 .3															
	8	81. 0	75. 9	90. 4	146 .0	111 .4	266. 6	663. 2	122 6.9	237 8.7											
	9	85. 4	89. 8	105 .5	130 .9	94. 0	61.1	0.0	0.0	7.2	28.3	89.5	143. 5	199. 4	274. 2	359. 3	458. 6	655 .4	165 7.6	207 6.3	

Days	Mo use	0	2	6	8	13	16	20	23	28	31	34	37	41	44	47	51	55	62	65	69
	10	96.1	92.1	91.8	151.4	119.3	108.6	274.7	483.7	149.7	262.3										
	Ave	74.8	78.0	98.1	124.4	122.1	129.2	294.0	486.9	137.3	158.5	200.9	143.5	199.4	274.2	359.3	458.6	655.4	165.7	207.6	
	SD	10.8	7.8	19.2	38.0	48.0	61.6	196.9	350.4	812.9	815.1	129.4									
Group 6	1	61.8	68.6	70.5	94.7	73.5	110.5	143.1	212.2	521.4	651.0	118.1	162.6	240.9							
	2	63.3	52.0	60.7	98.3	75.8	127.1	337.2	446.8	107.7	144.9	227.3									
	3	67.5	62.0	88.1	98.8	71.2	56.8	81.3	133.9	313.5	396.3	779.7	110.4	200.8							
	4	68.5	63.2	57.6	48.9	35.5	42.3	44.2	64.7	228.0	275.8	444.3	648.0	114.5	135.3	188.5	332.2				
	5	71.7	99.3	106.7	113.1	89.9	41.0	51.5	36.6	0.5	0.5	38.0	38.7	59.6	62.9	125.6	189.2	332.1	123.5	177.9	303.4
	6	73.4	90.7	62.6	86.8	43.6	20.7	16.4	12.3	48.5	52.3	68.1	176.7	410.7	687.1	122.6	266.0	0	0	0	
	7	79.7	103.3	115.7	163.6	69.0	50.5	80.6	41.2	49.7	42.4	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	8	80.8	64.2	76.2	86.5	67.8	62.4	68.9	97.1	87.3	112.9	87.3	103.0	81.3	87.6	94.4	99.7	79.1	131.6	80.7	99.2
	9	86.0	81.4	77.5	83.5	48.2	34.5	0.5	8.9	38.3	43.0	71.7	116.8	359.3	721.4	149.4	315.8				
	10	92.1	105.8	94.1	121.1	76.7	73.3	140.4	162.3	585.8	633.8	109.4	153.0	282.0							
Compo und 2 300 mg/kg 2Q7Dx 11	Ave	74.5	79.1	81.0	99.5	65.1	61.9	96.4	121.6	295.0	365.7	603.8	593.9	103.1	485.4	804.3	157.9	137.1	455.7	620.0	104.4
	SD	9.9	19.6	19.8	29.7	17.0	33.6	96.4	132.5	344.7	452.2	740.7	662.4	110.6	533.3	828.7	163.2	173.5	678.4	100.4	172.4
	Group 7	1	61.9	69.9	50.2	49.9	19.0	12.2	0.5	0	0	0	0	0	0	0	0	0	0	0	0

Days	Mo use	0	2	6	8	13	16	20	23	28	31	34	37	41	44	47	51	55	62	65	69
Compo und 2 50 mg/kg QDx71 + Anti- PD-1 200 µg Q3Dx2 4	2	63. 0	78. 2	58. 3	41. 2	17. 8	13.8	16.5	9.1	11.1	10.0	13.8	15.9	9.5	0.5	0.5	0	0	0	0	0
	3	67. 7	85. 9	76. 6	70. 2	59. 6	31.8	235. 9	372. 7	877. 9	107. 7.2	201. 3.2	0	0	0	0	0	0	0	0	0
	4	68. 0	71. 9	68. 1	64. 1	71. 5	31.9	23.4	15.1	21.3	13.7	20.5	24.0	12.4	17.0	8.8	0.5	0.5	0.0	0.0	0.0
	5	72. 5	111. .1	49. 3	62. 5	39. 8	27.6	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	6	73. 0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	7	79. 8	87. 3	88. 3	80. 9	43. 9	46.5	53.7	33.3	0.5	0	0	0	0	0	0	0	0	0	0	0
	8	80. 6	92. 3	49. 8	40. 3	40. 6	8.5	10.7	12.4	0.0	0	0	0	0	0	0	0	0	0	0	0
	9	86. 1	67. 2	42. 9	48. 2	34. 2	29.3	37.6	35.6	34.4	35.0	26.1	28.9	26.9	22.7	16.6	11.9	16. 5	18.6	23.6	26.7
	10	89. 8	85. 6	125. .9	100. .3	88. 0	69.4	31.3	44.5	44.7	60.5	0.5	0.5	29.4	23.4	56.7	45.3	42. 5	40.5	25.1	30.5
	Ave	74. 2	83. 3	67. 7	62. 0	46. 0	30.1	45.6	58.1	110. 0	132. 9	230. 5	8.7	9.8	8.0	10.3	7.2	7.4	7.4	6.1	7.1
	SD	9.5	13. 6	26. 4	19. 8	23. 3	19.0	73.5	119. 0	288. 5	354. 7	668. 6	12.3	12.3	11.0	19.7	15.9	15. 3	14.9	11.3	13.3
Group 8 Compo und 2 150 mg/kg 2Q7Dx 11 200 µg	1	62. 7	69. 8	70. 2	53. 6	30. 8	12.4	21.2	21.8	8.3	12.3	0.5	0.5	0	0	0	0	0	0	0	0
	2	63. 0	52. 1	53. 7	29. 1	13. 5	0.5	0.0	0.5	0.5	0.5	0.5	0	0	0	0	0	0	0	0	0
	3	68. 0	73. 3	81. 8	78. 7	78. 9	65.5	274. 1	394. 8	128. 8.6	204. 4.6	0	0	0	0	0	0	0	0	0	0
	4	68. 0	61. 1	60. 9	47. 6	38. 1	38.6	20.7	26.4	0.5	0.5	0	0	0	0	0	0	0	0	0	0
	5	72. 9	78. 2	66. 3	100. .8	73. 6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Days	Mouse	0	2	6	8	13	16	20	23	28	31	34	37	41	44	47	51	55	62	65	69
Q3Dx2 4	6	73.0	74.8	88.5	87.9	57.7	47.7	85.0	136.3	345.0	544.4	824.3	132.4	207.8	0	0	0	0	0	0	0
	7	80.1	108.8	112.7	81.5	59.0	48.0	0.5	0.5	0.5	0.0	0.5	0	0	0	0	0	0.5	0.5	0	0
	8	80.3	70.2	53.1	59.9	34.8	20.9	27.3	30.1	30.8	45.6	59.1	55.1	38.5	39.4	33.4	26.7	25.7	14.6	13.4	16.0
	9	87.0	70.9	100.1	75.6	75.0	55.1	29.4	29.6	13.4	0.5	0	0	0	0	0	0	0	0	0	0
	10	88.2	76.4	88.0	108.5	70.3	53.1	53.5	42.6	26.1	15.8	19.9	16.3	0.5	0.5	0	0	0	0	0	0
	Ave	74.3	73.6	77.5	72.3	53.2	38.0	56.9	75.8	190.4	296.0	113.1	174.6	264.6	5.7	4.8	3.8	3.7	2.2	1.9	2.3
	SD	9.3	14.6	20.0	24.7	22.5	21.9	85.6	126.2	426.5	679.2	288.1	465.2	732.8	14.9	12.6	10.1	9.7	5.5	5.1	6.0

TABLE 31

Days	Mouse	72	76	84	93	100	107	115	121	129	135	143	149	156	164	170	182
Group 4 Compound 2 100 mg/kg QDx71	3	26.8	37.5	13.6	31.2	31.4	34.9	21.7	23.7	31.5	40.2	22.4	40.8	30.6	49.5	42.3	37.0
	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	5	8.3	20.1	0.5	8.8	7.2	8.7	6.2	9.6	14.4	11.8	7.4	4.7	12.4	10.0	13.9	6.3
	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	7	128.0	154.6	65.8	126.5	184.4	430.2	1172.0	1534.9	3168.5							
	8	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.0
	Ave	27.3	35.5	13.4	27.8	37.2	79.1	200.1	261.4	535.8	10.5	6.1	9.2	8.7	12.0	11.3	8.7
	SD	50.4	60.3	26.2	49.8	73.1	172.6	476.2	623.9	1289.8	17.4	9.6	17.8	13.3	21.4	18.3	16.1
Group 6 Compound 2 300 mg/kg	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8	83.1	66.4	53.9	56.0	51.6	61.8	42.8	31.5	27.7	19.8	14.9	28.4	37.0	41.6	33.8	18.8
	Ave	41.6	33.2	26.9	28.0	25.8	30.9	21.4	15.7	13.9	9.9	7.5	14.2	18.5	20.8	16.9	9.4
	SD	58.8	47.0	38.1	39.6	36.5	43.7	30.3	22.2	19.6	14.0	10.5	20.1	26.2	29.4	23.9	13.3

2Q7Dx11																	
Group 7 Compound 2 50 mg/kg QDx71 + Anti-PD-1 200µg Q3Dx24	1	e	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	9	21.9	15.4	8.2	13.7	21.1	21.4	27.9	11.4	13.6	10.4	6.7	13.3	9.5	14.6	14.7	18.0
	10	57.0	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
	Ave	9.9	2.0	1.1	1.8	2.7	2.7	3.6	1.5	1.8	1.4	0.9	1.7	1.2	1.9	1.9	2.3
	SD	20.5	5.4	2.9	4.8	7.4	7.5	9.9	4.0	4.8	3.6	2.4	4.7	3.3	5.1	5.2	6.3
Group 8 Compound 2 150 mg/kg 2Q7Dx11 + Anti-PD-1 200µg Q3Dx24	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2	0	0	0	0	0	0	0	0	0	0	0	0	39.3	34.4	60.6	53.3
	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8	20.9	24.5	0.5	12.5	8.3	15.5	10.3	9.6	9.8	4.4	8.6	9.4	10.3	16.5	21.8	11.9
	9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Ave	3.0	3.5	0.1	1.8	1.2	2.2	1.5	1.4	1.4	0.6	0.6	1.2	1.3	7.1	7.3	11.8
	SD	0	0	0	0	0	0	0	0	0	0	1.7	3.3	3.5	14.7	13.4	23.0

TABLE 32

Day of Study	Group 1- Vehicle Control 2Q7Dx4	Group 2- Anti-PD-1 200µg Q3Dx7	Group 3- Compound 2 50 mg/kg QDx44	Group 4- Compound 2 100 mg/kg QDx71	Group 5- Compound 2 150 mg/kg 2Q7Dx10	Group 6- Compound 2 300 mg/kg 2Q7Dx11	Group 7- Compound 2 50 mg/kg QDx71 + Anti-PD-1 200µg Q3Dx24	Group 8- Compound 2 150 mg/kg 2QDx11 + Anti-PD-1 200µg Q3Dx24
2	0	20.2	52.4	92.0	88.3	83.0	66.5 (N=9)	>100

6	0	58.3	79.3	>100 (N=8)	67.0	90.8	>100 (N=9)	95.4
8	0	55.9	70.5	>100 (N=7)	70.7	85.2	>100 (N=9)	>100
13	0	78.7	86.2 (N=9)	>100 (N=7)	92.5	>100	>100 (N=9)	>100
16	0	75.3	78.8 (N=9)	>100 (N=7)	96.1 (N=9)	>100	>100 (N=9)	>100 (N=9)
20	0 (N=8)	72.3	74.0 (N=9)	>100 (N=7)	92.0 (N=9)	99.2	>100 (N=9)	>100 (N=9)
23	0 (N=1)	39.0	45.6 (N=9)	>100 (N=7)	81.6 (N=9)	97.9	>100 (N=9)	99.9 (N=9)

TABLE 33

Day of Study	Group 1- Vehicle Control 2Q7Dx4	Group 2- Anti-PD-1 200µg Q3Dx7	Group 3- Compound 2 50 mg/kg QDx44	Group 4- Compound 2 100 mg/kg QDx71	Group 5- Compound 2 150 mg/kg 2Q7Dx10	Group 6- Compound 2 300 mg/kg 2Q7Dx11	Group 7- Compound 2 50 mg/kg QDx71 + Anti-PD-1 200µg Q3Dx24	Group 8- Compound 2 150 mg/kg 2QDx11 + Anti-PD-1 200µg Q3Dx24
2	0	0	0	0	0	0	0	1.0
6	0	0	0	21.4	0	0	8.8 (N=9)	0
8	0	0	0	11.5 (N=8)	0	0	16.5 (N=9)	2.7
13	0	0	0 (N=9)	43.7 (N=7)	0	12.6	38.0 (N=9)	28.5
16	0	0	0 (N=9)	60.2 (N=7)	0 (N=9)	16.9	59.4 (N=9)	48.9 (N=9)
20	0	0	0 (N=9)	39.9 (N=7)	0 (N=9)	0	38.6 (N=9)	23.5 (N=9)
23	0	0	0 (N=9)	47.2 (N=7)	0 (N=9)	0	21.8 (N=9)	0 (N=9)
28	0 (NA)	0 (N=7)	0 (N=6)	34.7 (N=7)	0 (N=9)	0	0 (N=9)	0 (N=9)
31	0 (NA)	0 (N=3)	0 (N=4)	25.4 (N=7)	0 (N=7)	0	0 (N=9)	0 (N=9)
34	0 (NA)	0 (N=2)	0 (N=1)	26.6 (N=7)	0 (N=4)	0	0 (N=9)	0 (N=8)
37	0 (NA)	0 (N=2)	0 (N=1)	6.1 (N=7)	0 (N=1)	0 (N=9)	88.3 (N=8)	0 (N=8)
41	0 (NA)	0 (NA)	0 (N=1)	0 (N=7)	0 (N=1)	0 (N=9)	86.8 (N=8)	0 (N=8)
44	0 (NA)	0 (NA)	0 (N=1)	0 (N=7)	0 (N=1)	0 (N=6)	89.3 (N=8)	92.3 (N=7)

47	0 (NA)	0 (NA)	0 (NA)	0 (N=7)	0 (N=1)	0 (N=6)	86.1 (N=8)	93.6 (N=7)
51	0 (NA)	0 (NA)	0 (NA)	0 (N=7)	0 (N=1)	0 (N=6)	90.3 (N=8)	94.9 (N=7)
55	0 (NA)	0 (NA)	0 (NA)	63.8 (N=6)	0 (N=1)	0 (N=3)	90.0 (N=8)	95.0 (N=7)
62	0 (NA)	0 (NA)	0 (NA)	51.4 (N=6)	0 (N=1)	0 (N=3)	90.0 (N=8)	97.1 (N=7)
65	0 (NA)	0 (NA)	0 (NA)	66.0 (N=6)	0 (N=1)	0 (N=3)	91.8 (N=8)	97.4 (N=7)
69	0 (NA)	0 (NA)	0 (NA)	58.5 (N=6)	0 (NA)	0 (N=3)	90.4 (N=8)	96.9 (N=7)
72	0 (NA)	0 (NA)	0 (NA)	63.8 (N=6)	0 (NA)	44.2 (N=2)	86.7 (N=8)	96.0 (N=7)
76	0 (NA)	0 (NA)	0 (NA)	52.9 (N=6)	0 (NA)	55.4 (N=2)	97.3 (N=8)	95.3 (N=7)
84	0 (NA)	0 (NA)	0 (NA)	82.2 (N=6)	0 (NA)	63.8 (N=2)	98.5 (N=8)	99.9 (N=7)
93	0 (NA)	0 (NA)	0 (NA)	63.0 (N=6)	0 (NA)	62.4 (N=2)	97.6 (N=8)	97.6 (N=7)
100	0 (NA)	0 (NA)	0 (NA)	50.5 (N=6)	0 (NA)	65.4 (N=2)	96.4 (N=8)	98.4 (N=7)
107	0 (NA)	0 (NA)	0 (NA)	0 (N=6)	0 (NA)	58.5 (N=2)	96.3 (N=8)	97.0 (N=7)
115	0 (NA)	0 (NA)	0 (NA)	0 (N=6)	0 (NA)	71.3 (N=2)	95.2 (N=8)	98.0 (N=7)
121	0 (NA)	0 (NA)	0 (NA)	0 (N=6)	0 (NA)	78.9 (N=2)	98.0 (N=8)	98.2 (N=7)
129	0 (NA)	0 (NA)	0 (NA)	0 (N=6)	0 (NA)	81.4 (N=2)	97.6 (N=8)	98.1 (N=7)
135	0 (NA)	0 (NA)	0 (NA)	86.0 (N=5)	0 (NA)	86.7 (N=2)	98.2 (N=8)	99.1 (N=7)
143	0 (NA)	0 (NA)	0 (NA)	91.9 (N=5)	0 (NA)	90.0 (N=2)	98.8 (N=8)	98.3 (N=7)
149	0 (NA)	0 (NA)	0 (NA)	87.8 (N=5)	0 (NA)	81.0 (N=2)	97.7 (N=8)	98.2 (N=7)
156	0 (NA)	0 (NA)	0 (NA)	88.4 (N=5)	0 (NA)	75.1 (N=2)	98.3 (N=8)	90.5 (N=7)
160	0 (NA)	0 (NA)	0 (NA)	84.0 (N=5)	0 (NA)	72.0 (N=2)	97.5 (N=8)	90.2 (N=7)
170	0 (NA)	0 (NA)	0 (NA)	84.9 (N=5)	0 (NA)	77.3 (N=2)	97.4 (N=8)	84.2 (N=7)
182	0 (NA)	0 (NA)	0 (NA)	88.5 (N=5)	0 (NA)	87.4 (N=2)	96.9 (N=8)	87.5 (N=7)
NA= no mice in the group								

[0463] The study was continued after the vehicle control mice succumbed and were euthanized due to tumor burden (2000 mm³). Individual mice in treatment groups were dosed and monitored until the tumor burden achieved the endpoint. **FIG. 13** shows changes in tumor volume (mm³) for C57B1/6 mice implanted with MT373 mouse sarcoma tumors over 182 days upon receiving treatment with vehicle (2Q7Dx4); anti-PD-1 200 µg (Q3Dx7); Compound 2, 50 mg/kg (QDx44); Compound 2, 100 mg/kg (QDx71); Compound 2, 150 mg/kg (2Q7Dx10); Compound 2, 300 mg/kg (2Q7Dx11); Compound 2 50 mg/kg (QDx71) + anti-PD-1 200 µg (Q3Dx24); or Compound 2, 150 mg/kg (2Q7Dx11) + anti-PD-1 200 µg (Q3Dx24). **FIG. 14** shows changes in tumor volume (mm³) of individual C57B1/6 mice implanted with MT373 mouse sarcoma tumors upon receiving treatment with vehicle (2Q7Dx4); anti-PD-1 200 µg (Q3Dx7); Compound 2, 50 mg/kg (QDx44); Compound 2, 100 mg/kg (QDx71); Compound 2, 150 mg/kg (2Q7Dx10); Compound 2, 300 mg/kg (2Q7Dx11);

Compound 2 50 mg/kg (QDx71) + anti-PD-1 200 µg (Q3Dx24); or Compound 2, 150 mg/kg (2Q7Dx11) + anti-PD-1 200 µg (Q3Dx24). MT373 tumors administered vehicle control (0.2% HPC) displayed consistent growth with all mice reaching ~2000 mm³ between days 16 and 23. Mice administered Compound 2 at 50 mg/kg QDx44 displayed consistent tumor growth and reached ~2000 mm³ between 23 and 44 days. Mice administered Compound 2 at 100 mg/kg QDx71 had an extended survival time with Mouse #1 reaching ~2000 mm³ at 51 days and Mouse #7 at 129 days. Five other mice in this group had tumor regression that persisted until the study ended at day 182.

[0464] Median survival was calculated for the single agents dosing groups, where the vehicle control group had a median survival of 17.3 days. For mice administered Compound 2 on the daily dosing regimen at 50 mg/kg QDx44 and 100 mg/kg QDx71, the median survival was 28 days and >182.0 days, respectively. The 100 mg/kg QDx71 group had 71% mice (2 tumor stasis and 3 cures, i.e., no palpable tumors under the skin) surviving by termination of the study. Administration of Compound 2 at 100 mg/kg QDx71 also showed a >164-day extension in survival compared to vehicle control. For mice administered Compound 2 on the twice daily, once a week dosing regimen at 150 mg/kg 2Q7Dx10 and 300 mg/kg 2Q7Dx11, the median survival was 30.8 days and 47.8 days, respectively. The 300 mg/kg 2Q7Dx11 group had 20% mice surviving by termination of the study (1 tumor stasis and 1 cure).

[0465] Median survival was also calculated for both combination groups compared to single agent. Mice in group 2 were administered Anti-PD-1 alone and had only a slight increase in median survival time of 24 days compared to 17.3 days in the vehicle control group. For both the combination groups, co-administration of Compound 2 and Anti-PD-1 exhibited an increase in survival compared to either single agent. Mice in group 7 administered Compound 2 at 50 mg/kg QDx71 and 200 µg of Anti-PD-1 Q3Dx24 showed a median survival of >182 days as compared to single agents, 28 days and 24 days, respectively. Mice in group 8 administered Compound 2 at 150 mg/kg 2Q7Dx11 and 200 µg of Anti-PD-1 Q3Dx24 showed a median survival of >182 days compared to single agents, 30.8 and 24 days, respectively. In both combination groups a >164-day extension in survival compared to vehicle control was observed. The group that received Compound 2 at 50 mg/kg QDx71 and 200 µg of Anti-PD-1 Q3Dx24 group had 89% of mice (2 tumor stasis and 6 cures) surviving at the termination of study. The group that received Compound 2 at 150 mg/kg 2Q7Dx11 and 200 µg of Anti-PD-1 Q3Dx24 group had 78% surviving (2 tumor stasis and 5 cures) mice at the end of the study.

[0466] **FIG. 15** shows changes in percent survival of C57B1/6 mice implanted with MT373 mouse sarcoma tumors upon receiving treatment with vehicle (2Q7Dx4); anti-PD-1 200 µg (Q3Dx7); Compound 2, 50 mg/kg (QDx44); Compound 2, 100 mg/kg (QDx71); Compound 2, 150 mg/kg (2Q7Dx10); Compound 2, 300 mg/kg (2Q7Dx11); Compound 2 50 mg/kg (QDx71) + anti-PD-1 200 µg (Q3Dx24); or Compound 2, 150 mg/kg (2Q7Dx11) + anti-PD-1 200 µg (Q3Dx24). **TABLE 34**

shows clinical observations of the mice of each study group and dates of death. TABLE 35 shows the MST for the animals.

TABLE 34

Group	Mouse Number	Date of Death (Study Day)	Method	Clinical Observations
Group 1 Vehicle Control 2Q7Dx4	1	20	Euthanasia	None; euthanized for tumor burden
	2	23	Euthanasia	None; euthanized for tumor burden
	3	20	Euthanasia	None; euthanized for tumor burden
	4	20	Euthanasia	None; euthanized for tumor burden
	5	20	Euthanasia	None; euthanized for tumor burden
	6	20	Euthanasia	None; euthanized for tumor burden
	7	20	Euthanasia	None; euthanized for tumor burden
	8	16	Euthanasia	None; euthanized for tumor burden
	9	16	Euthanasia	None; euthanized for tumor burden
	10	20	Euthanasia	None; euthanized for tumor burden
Group 2 Anti-PD-1 200µg Q3Dx7	1	23	Euthanasia	None; euthanized for tumor burden
	2	28	Euthanasia	None; euthanized for tumor burden
	3	28	Euthanasia	None; euthanized for tumor burden
	4	23	Euthanasia	None; euthanized for tumor burden
	5	23	Euthanasia	None; euthanized for tumor burden

Group	Mouse Number	Date of Death (Study Day)	Method	Clinical Observations
	6	28	Euthanasia	None; euthanized for tumor burden
	7	31	Euthanasia	None; euthanized for tumor burden
	8	28	Euthanasia	None; euthanized for tumor burden
	9	37	Euthanasia	None; euthanized for tumor burden
	10	37	Euthanasia	None; euthanized for tumor burden
Group 3 Compound 2 50 mg/kg QDx44	1	31	Euthanasia	None; euthanized for tumor burden
	2	28	Euthanasia	None; euthanized for tumor burden
	3	44	Euthanasia	None; euthanized for tumor burden
	4	8	Euthanasia	Animal found moribund 10/9/19
	5	31	Euthanasia	None; euthanized for tumor burden
	6	23	Euthanasia	None; euthanized for tumor burden
	7	31	Euthanasia	None; euthanized for tumor burden
	8	23	Euthanasia	None; euthanized for tumor burden
	9	28	Euthanasia	None; euthanized for tumor burden
	10	23	Euthanasia	None; euthanized for tumor burden
Group 4	1	51	Euthanasia	None; euthanized for tumor burden
Compound 2	2	8	Found Dead	Lab accident

Group	Mouse Number	Date of Death (Study Day)	Method	Clinical Observations
100 mg/kg QDx71	3	182	Re-enrolled in future study	None; study termination
	4	182	Re-enrolled in future study	None; study termination
	5	182	Re-enrolled in future study	None; study termination
	6	182	Re-enrolled in future study	None; study termination
	7	129	Euthanasia	None; euthanized for tumor burden
	8	182	Re-enrolled in future study	None; study termination
	9	3	Found Dead	Found Dead- 9% body weight loss 10/3/19, likely lab accident
	10	3	Found Dead	Found Dead- 9% body weight loss 10/3/19, likely lab accident
Group 5 Compound 2 150 mg/kg 2Q7Dx10	1	31	Euthanasia	None; euthanized for tumor burden
	2	34	Euthanasia	None; euthanized for tumor burden
	3	34	Euthanasia	None; euthanized for tumor burden
	4	28	Euthanasia	None; euthanized for tumor burden
	5	31	Euthanasia	None; euthanized for tumor burden
	6	34	Euthanasia	None; euthanized for tumor burden
	7	15	Found Dead	Lab accident
	8	28	Euthanasia	None; euthanized for tumor burden
	9	65	Euthanasia	None; euthanized for tumor burden

Group	Mouse Number	Date of Death (Study Day)	Method	Clinical Observations
	10	31	Euthanasia	None; euthanized for tumor burden
Group 6 Compound 2 300 mg/kg 2Q7Dx11	1	41	Euthanasia	None; euthanized for tumor burden
	2	34	Euthanasia	None; euthanized for tumor burden
	3	41	Euthanasia	None; euthanized for tumor burden
	4	51	Euthanasia	None; euthanized for tumor burden
	5	69	Euthanasia	None; euthanized for tumor burden
	6	51	Euthanasia	None; euthanized for tumor burden
	7	182	Re-enrolled in future study	None; study termination
	8	182	Re-enrolled in future study	None; study termination
	9	51	Euthanasia	None; euthanized for tumor burden
	10	41	Euthanasia	None; euthanized for tumor burden
Group 7 Compound 2 50 mg/kg QDx71 + Anti-PD-1 200µg Q3Dx24	1	182	Re-enrolled in future study	None; study termination
	2	182	Re-enrolled in future study	None; study termination
	3	34	Euthanasia	None; euthanized for tumor burden
	4	182	Re-enrolled in future study	None; study termination
	5	182	Re-enrolled in future study	None; study termination
	6	2	Found Dead	Lab accident

Group	Mouse Number	Date of Death (Study Day)	Method	Clinical Observations
	7	182	Re-enrolled in future study	None; study termination
	8	182	Re-enrolled in future study	None; study termination
	9	182	Re-enrolled in future study	None; study termination
	10	182	Re-enrolled in future study	None; study termination
Group 8 Compound 2 150 mg/kg 2Q7Dx11 + Anti-PD-1 200µg Q3Dx24	1	182	Re-enrolled in future study	None; study termination
	2	182	Re-enrolled in future study	None; study termination
	3	31	Euthanasia	None; euthanized for tumor burden
	4	182	Re-enrolled in future study	None; study termination
	5	16	Found Dead	Lab Accident
	6	41	Euthanasia	None; euthanized for tumor burden
	7	182	Re-enrolled in future study	None; study termination
	8	182	Re-enrolled in future study	None; study termination
	9	182	Re-enrolled in future study	None; study termination
	10	182	Re-enrolled in future study	None; study termination

TABLE 35

Group	MST (Days)
Vehicle	17
Anti-PD-1 200 µg	24
Compound 2 50 mg/kg QD	28

Compound 2 100 mg/kg QD	>156
PD-1 + Compound 2 50 mg/kg	>156

[0467] **Body Weights:** Average mouse body weights were well maintained over the course of the study. Mice dosed with vehicle control were an average of 21.9-22.4 g by the end of the study, day 20-23, with the percentage change varying between 0.33 % early in the study to +18.13-22.4% by the study end. One mouse (#10) lost >10 % on day 2 but recovered by day 16. Mice administered Anti-PD-1 gained an average of 11.8% by day 20. Mice in Group 4, 5, and 8 did not experience any body weight loss over 10% and gained an average of 4.6%, 3.9% and 5.6% at day 20, respectively. While in Group 3, one mouse (#10) lost >10% body weight on day 2 but recovered on day 13, in Group 6, one mouse (#1) lost >10% body weight on day 2 and recovered by day 6 and in Group 7, one mouse (#9) lost >10% body weight on day 6 and recovered by day 23. By day 23 on average, Group 3 gained 9.7 %, Group 6 gained 7.5 %, and Group 7 gained 5.5%.

[0468] **FIG. 16** shows changes in percent survival of C57B1/6 mice implanted with MT373 mouse sarcoma tumors upon receiving treatment with vehicle; anti-PD-1; Compound 2, 50 mg/kg (QD); Compound 2, 100 mg/kg (QD); or Compound 2, 50 mg/kg (QD) + anti-PD-1. **FIG. 17** shows changes in percentage body weight of C57B1/6 mice implanted with MT373 mouse sarcoma tumors upon receiving treatment with vehicle (2Q7Dx4); anti-PD-1 200 µg (Q3Dx7); Compound 2, 50 mg/kg (QDx44); Compound 2, 100 mg/kg (QDx71); Compound 2, 150 mg/kg (2Q7Dx10); Compound 2, 300 mg/kg (2Q7Dx11); Compound 2 50 mg/kg (QDx71) + anti-PD-1 200 µg (Q3Dx24); or Compound 2, 150 mg/kg (2Q7Dx11) + anti-PD-1 200 µg (Q3Dx24). **TABLE 36** shows individual mouse body weights across the study from days 0-69. **TABLE 37** shows individual mouse body weights across the study from days 72-182. Only mice left in the study are shown in groups 4 and 6-8. **TABLE 38** shows the average percent change in body weight across the study (n=10 unless noted).

TABLE 36

Days	Mouse	0	2	6	8	13	16	20	23	28	31	34	37	41	44	47	51	55	62	65	69
Group 1 Vehicle Control 2Q7Dx4	1	18.70	19.10	20.40	19.60	20.80	21.30	23.10													
	2	18.30	19.20	19.20	19.80	19.70	20.30	21.10	22.40												
	3	18.40	18.60	18.00	19.00	19.80	20.30	22.20													

Days	Mouse	0	2	6	8	13	16	20	23	28	31	34	37	41	44	47	51	55	62	65	69
	4	17.60	18.00	18.10	18.40	18.90	16.50	19.50													
	5	18.00	18.30	18.70	18.70	19.30	20.60	21.30													
	6	19.20	19.00	18.70	19.10	19.50	20.80	23.10													
	7	19.20	19.70	20.20	20.00	20.90	21.60	23.30													
	8	17.30	17.70	17.80	18.10	19.40	19.80														
	9	17.70	17.60	18.10	17.80	19.20	20.10														
	10	19.00	16.70	17.10	16.90	18.10	19.40	21.80													
	Ave	18.34	18.39	18.72	18.76	19.56	20.07	21.93	22.40												
	SD	0.68	0.91	1.03	1.00	0.83	1.42	1.29													
Group 2 Anti-PD-1 200 µg Q3Dx7	1	17.00	17.50	17.90	17.60	17.80	18.20	18.60	18.50												
	2	17.30	18.10	18.30	18.20	19.10	19.40	20.40	20.50	23.20											
	3	18.30	18.20	19.00	18.60	20.00	20.30	20.40	21.60	23.50											
	4	17.90	17.60	18.50	19.30	19.90	20.60	21.00	22.60												
	5	17.70	18.30	18.10	18.00	18.60	19.40	19.40	20.40												
	6	18.80	19.10	19.10	19.60	19.90	20.30	21.00	22.00	24.10											
	7	17.70	17.50	18.20	18.10	18.40	19.40	20.20	20.10	21.40	21.50										

Days	Mou se	0	2	6	8	13	16	20	23	28	31	34	37	41	44	47	51	55	62	65	69
	8	18. 70	18. 60	19. 00	19. 20	19. 40	19. 70	20. 10	20. 40	21. 60											
	9	19. 30	18. 60	19. 20	19. 30	20. 10	19. 30	20. 30	20. 50	20. 90	20. 50	20. 80	21. 30								
	10	16. 80	17. 50	17. 50	17. 60	18. 70	18. 60	19. 10	19. 10	19. 80	20. 40	21. 70	23. 10								
	Ave	17. 95	18. 16	18. 53	18. 55	19. 19	19. 54	20. 05	20. 57	22. 07	20. 20	21. 25	22. 20								
	SD	0.8 2	0.6 1	0.6 4	0.7 5	0.8 0	0.7 5	0.7 9	1.2 5	1.6 8	0.6 1	0.6 4	1.2 7								
Group 3 Compound 1 50 mg/kg QDx44	1	16. 30	16. 10	16. 40	16. 60	16. 30	16. 80	17. 30	17. 90	19. 00	19. 80										
	2	17. 40	17. 30	18. 10	18. 30	18. 40	18. 90	19. 30	19. 40	20. 20											
	3	16. 60	16. 90	17. 00	17. 10	17. 00	18. 00	17. 30	17. 00	17. 60	18. 00	18. 20	19. 50	MO)	21. 00						
	4	15. 80	15. 80	16. 10	16. 20																
	5	19. 00	19. 00	18. 90	19. 30	20. 30	20. 60	20. 60	22. 00	22. 70	23. 30										
	6	19. 60	19. 90	20. 40	20. 90	21. 90	22. 30	23. 60	24. 00												
	7	15. 80	15. 60	16. 40	17. 10	18. 30	18. 70	19. 70	20. 50	21. 20	21. 70										
	8	17. 90	16. 60	16. 60	16. 90	17. 30	17. 30	17. 80	19. 30												
	9	18. 70	18. 10	18. 10	18. 50	19. 10	18. 60	19. 20	20. 00	21. 60											
	10	16. 10	14. 10	14. 30	15. 40	16. 00	16. 80	17. 80	19. 00												
	Pose	17. 32	16. 94	17. 23	17. 63	18. 31	18. 67	19. 18	19. 99	20. 38	20. 70	18. 80	19. 50	20. 00	21. 00						

Days	Mou se	0	2	6	8	13	16	20	23	28	31	34	37	41	44	47	51	55	62	65	69
	SD	1.4 1	1.7 1	1.7 0	1.6 3	1.9 2	1.8 1	2.0 2	1.9 8	1.8 6	2.3 0										
Group 4 Compound 1 100 mg/kg QDx71	1	17. 30	16. 50	17. 70	17. 40	17. 10	17. 30	17. 60	17. 40	18. 10	18. 30	18. 50	18. 80	19. 00	19. 80	20. 00	20. 50				
	2	17. 50	17. 50	17. 00																	
	3	19. 10	19. 00	18. 80	19. 10	19. 00	19. 50	19. 70	19. 80	20. 80	20. 00	20. 30	20. 30	20. 50	21. 90	21. 30	21. 10	22. 00	21. 90	21. 80	22. 30
	4	17. 00	17. 40	17. 30	17. 40	17. 60	17. 70	18. 10	18. 10	18. 20	18. 20	18. 40	18. 60	19. 10	19. 10	19. 10	19. 10	19. 70	19. 60	19. 50	20. 10
	5	18. 40	18. 00	18. 40	18. 80	18. 80	19. 70	19. 40	20. 10	19. 60	19. 90	20. 10	20. 40	20. 00	21. 00	21. 40	21. 10	22. 00	21. 30	22. 00	22. 30
	6	17. 60	18. 30	18. 60	18. 30	18. 10	18. 50	18. 40	19. 00	18. 00	18. 20	17. 70	18. 00	18. 20	18. 10	18. 40	18. 20	18. 70	19. 30	19. 40	19. 80
	7	19. 00	19. 90	19. 80	19. 80	20. 40	20. 80	20. 20	21. 00	20. 80	20. 20	20. 80	21. 10	21. 00	21. 80	22. 40	22. 60	22. 60	22. 60	22. 50	23. 20
	8	18. 20	18. 20	18. 10	18. 30	18. 60	19. 00	19. 00	18. 90	19. 10	19. 10	19. 30	19. 70	19. 60	19. 60	20. 20	20. 00	20. 60	21. 30	21. 30	21. 60
	9	18. 00	16. 30																		
	10	19. 30	17. 40																		
	Ave	18. 14	17. 92	18. 21	18. 44	18. 44	18. 93	18. 91	19. 19	19. 23	19. 13	19. 30	19. 56	19. 63	20. 26	20. 40	20. 37	20. 93	21. 00	21. 08	21. 55
	SD	0.8 0	1.1 2	0.3 0	0.8 8	1.0 9	1.2 1	0.9 3	1.2 2	1.2 2	0.9 8	1.1 5	1.1 2	0.9 6	1.4 9	1.4 0	1.4 4	1.5 3	1.3 0	1.3 2	1.3 4
Group 5	1	18. 70	18. 90	18. 80	17. 70	18. 80	18. 90	19. 50	19. 90	21. 10	21. 60										
Compound 2	2	17. 40	17. 80	17. 90	16. 40	18. 30	16. 50	18. 00	17. 30	19. 50	18. 30	19. 60									
150 mg/kg	3	19. 60	19. 10	19. 50	18. 40	19. 90	18. 90	19. 20	19. 40	20. 70	20. 50	20. 40									

Days	Mou se	0	2	6	8	13	16	20	23	28	31	34	37	41	44	47	51	55	62	65	69
2Q7Dx1 0	4	16. 80	16. 70	16. 70	16. 10	16. 80	17. 10	17. 10	17. 50	19. 10											
	5	18. 40	18. 30	18. 40	17. 80	19. 00	19. 20	19. 50	19. 80	20. 50	21. 30										
	6	18. 20	17. 90	18. 90	18. 70	19. 90	19. 70	19. 80	19. 90	21. 50	22. 20	23. 60									
	7	162 0	16. 70	16. 80	16. 70	16. 90															
	8	19. 80	20. 00	20. 30	19. 90	20. 60	20. 70	21. 00	21. 80	23. 10											
	9	17. 20	17. 90	18. 40	17. 70	18. 50	17. 90	18. 30	19. 20	19. 40	19. 20	19. 70	19. 90	20. 00	20. 10	20. 10	19. 90	20. 70	21. 70	21. 80	
	10	19. 60	19. 70	20. 10	19. 70	20. 30	20. 00	20. 30	20. 60	22. 20	23. 00										
	Ave	18. 31	18. 30	18. 58	17. 91	18. 90	18. 77	19. 20	19. 19	20. 79	20. 87	20. 83	19. 90	20. 00	20. 10	20. 10	19. 90	20. 70	21. 70	21. 20	
	SD	1.1 2	1.1 3	1.2 2	1.3 0	1.3 2	1.3 7	1.1 9	1.4 1	1.3 4	1.6 6	1.8 8									
Group 6 Compound 2 300 mg/kg 2Q7Dx1 1	1	17. 30	15. 40	18. 00	16. 60	17. 40	18. 40	18. 30	18. 10	19. 00	19. 30	19. 90	20. 40	21. 40							
	2	17. 00	17. 70	17. 80	16. 80	18. 40	18. 40	19. 00	19. 60	20. 60	21. 20	22. 70									
	3	17. 20	17. 60	17. 40	16. 20	18. 10	115 0	19. 30	19. 20	20. 20	20. 90	20. 60	19. 80	21. 60							
	4	18. 80	17. 60	18. 30	17. 70	18. 50	18. 50	19. 50	18. 30	19. 90	19. 60	20. 10	20. 30	21. 30	21. 40	22. 70	22. 90				
	5	16. 10	15. 80	16. 40	15. 90	17. 10	16. 30	17. 70	16. 60	18. 00	18. 00	18. 70	18. 60	19. 30	18. 10	18. 80	18. 00	19. 10	20. 90	20. 80	23. 5
	6	17. 20	17. 30	18. 20	17. 70	18. 90	19. 60	19. 30	19. 30	19. 70	20. 00	20. 30	20. 00	20. 60	19. 80	21. 90	22. 20				
	7	19. 10	18. 70	18. 90	18. 30	18. 70	19. 10	19. 50	19. 80	19. 70	20. 10	19. 90	19. 40	20. 20	20. 30	20. 40	20. 30	20. 90	21. 20	20. 90	21. 8

Days	Mou se	0	2	6	8	13	16	20	23	28	31	34	37	41	44	47	51	55	62	65	69
	8	18. 70	19. 10	19. 30	18. 70	19. 80	19. 80	19. 80	200 0	20. 30	20. 70	20. 90	200 0	20. 60	19. 80	20. 70	20. 40	21. 90	22. 10	21. 90	22. 2
	9	18. 10	17. 70	18. 60	17. 70	18. 90	18. 70	19. 40	18. 90	19. 30	19. 60	19. 40	19. 00	19. 60	19. 50	21. 30	21. 90				
	10	17. 00	16. 30	17. 90	16. 60	17. 80	17. 50	17. 70	17. 70	18. 60	18. 90	19. 50	19. 30	20. 70							
	Ave	17. 65	17. 32	18. 08	17. 22	18. 36	18. 48	18. 95	18. 75	19. 53	19. 83	20. 20	19. 64	20. 59	19. 82	20. 97	20. 95	20. 63	21. 40	21. 0	22. 5
	SD	0.9 7	1.1 8	0.8 1	0.9 3	0.7 9	1.0 1	0.7 7	1.0 7	0.8 1	0.9 7	1.0 8	0.6 1	0.7 9	1.0 8	1.3 5	1.7 7	1.4 2	0.6 2	0.6 1	0.8 9
Group 7 Compound 2 50 mg/kg QDx71 + Anti- PD-1 200 µg Q3Dx24	1	17. 70	18. 30	17. 90	18. 00	18. 50	18. 70	18. 60	19. 10	19. 10	19. 00	19. 30	19. 50	19. 80	20. 40	20. 50	19. 80	20. 60	20. 00	20. 0	20. 7
	2	17. 70	17. 90	18. 40	18. 60	18. 40	18. 70	19. 00	18. 90	19. 10	19. 40	19. 4	20. 00	20. 00	20. 90	21. 00	20. 20	21. 30	21. 50	21. 50	21. 7
	3	17. 70	18. 60	18. 80	18. 80	18. 90	19. 30	19. 20	19. 60	20. 50	20. 60	21. 40									
	4	18. 10	16. 70	18. 20	18. 50	18. 60	19. 40	19. 20	19. 70	20. 10	20. 10	19. 30	19. 80	20. 10	20. 20	20. 60	20. 00	20. 50	20. 00	20. 00	21. 0
	5	17. 70	17. 60	18. 20	17. 90	18. 30	18. 80	18. 70	18. 20	18. 0	19. 10	19. 10	19. 60	20. 00	20. 20	20. 60	19. 60	20. 20	19. 00	19. 40	20. 0
	6	18. 40																			
	7	17. 60	17. 90	18. 00	18. 40	18. 90	19. 30	19. 30	19. 40	19. 00	19. 3	19. 20	19. 90	20. 30	20. 40	20. 50	18. 90	20. 10	21. 10	20. 50	20. 9
	8	16. 60	17. 00	16. 90	16. 60	17. 10	17. 40	17. 40	18. 0	17. 70	18. 20	17. 70	18. 40	18. 50	18. 50	18. 90	18. 60	19. 00	18. 80	18. 80	18. 8
	9	17. 80	16. 80	14. 50	15. 30	16. 50	16. 80	17. 60	17. 90	18. 10	18. 50	18. 80	19. 60	19. 30	19. 90	20. 00	19. 60	19. 90	20. 10	20. 0	21. 3
	10	17. 20	17. 20	17. 50	17. 80	17. 80	18. 40	17. 80	18. 50	18. 50	19. 10	19. 00	19. 30	19. 40	19. 60	20. 10	18. 20	20. 40	20. 00	19. 70	20. 1
	Ave	17. 65	17. 56	17. 60	17. 77	18. 11	18. 53	18. 53	18. 81	18. 99	19. 26	19. 24	19. 51	19. 68	20. 01	20. 28	19. 36	20. 5	20. 06	20. 08	20. 56

Days	Mouse	0	2	6	8	13	16	20	23	28	31	34	37	41	44	47	51	55	62	65	69
	SD	0.48	0.67	1.28	1.13	0.83	0.89	0.74	0.69	0.89	0.74	0.96	0.50	0.58	0.72	0.64	0.71	0.66	0.92	0.81	0.91
Group 8 Compound 2 150 mg/kg 2Q7Dx1 1 + Anti-PD-1 200 µg Q3Dx24	1	15.60	15.40	15.30	14.80	15.50	15.80	15.70	15.70	16.30	16.70	16.70	16.40	16.90	17.00	17.10	16.70	17.00	16.60	17.10	17.20
	2	16.10	16.50	17.20	17.10	18.00	17.70	17.70	17.10	18.00	18.40	18.60	18.50	19.50	19.40	19.80	20.00	19.70	19.50	20.60	20.10
	3	18.00	18.00	18.70	18.20	18.90	19.20	18.80	18.70	20.10	20.60										
	4	16.60	17.00	17.20	16.30	17.50	18.20	17.60	17.80	18.00	19.40	19.10	20.00	20.30	20.00	18.90	19.50	19.40	19.60	20.70	20.40
	5	15.90	15.50	16.10	15.80	16.60															
	6	18.60	18.40	18.70	18.60	19.90	19.80	20.20	20.00	21.20	20.60	21.40	21.40	23.70							
	7	16.20	16.70	17.20	17.00	17.30	18.30	17.90	18.00	18.30	17.80	18.30	18.40	19.20	20.00	19.70	19.00	19.40	19.30	19.20	18.90
	8	17.40	17.80	17.50	17.10	18.10	18.10	18.00	17.90	18.30	18.70	18.70	19.60	19.60	19.10	19.20	18.00	19.60	19.40	19.90	19.60
	9	18.20	18.40	18.40	17.80	18.60	18.50	18.00	18.40	18.20	18.40	18.80	19.00	19.20	20.00	19.30	19.10	19.60	19.80	19.70	20.20
	10	17.50	18.10	18.20	17.90	19.30	19.10	18.80	18.90	20.10	20.10	20.20	20.50	20.90	20.40	20.20	20.20	20.70	21.20	21.50	22.10
	Ave	17.01	17.18	17.45	17.06	17.97	18.30	18.08	18.06	18.72	18.97	18.98	19.23	19.91	19.41	19.17	18.93	19.34	19.34	19.81	19.90
	SD	1.06	1.14	1.12	1.16	1.31	1.14	1.20	1.20	1.48	1.32	1.38	1.53	1.92	1.15	1.01	1.22	1.13	1.37	1.41	1.50

TABLE 37

Days	Mouse	72	76	84	93	100	107	115	121	129	135	143	149	156	164	170	182
Group 4	3	22.40	22.50	24.36	23.60	23.30	24.80	24.50	24.90	24.87	25.50	26.30	26.45	27.30	27.50	27.10	28.50

Compound 2 100 mg/kg QDx71	4	19.9 0	19.9 0	20.2 7	21.4 0	21.5 0	21.4 0	20.9 0	21.2 0	21.4 0	21.5 0	21.4 0	22.5 0	22.5 0	22.8 0	22.5 0	23.3 0
	5	21.7 0	21.9 0	22.8 0	22.2 0	22.7 0	22.9 0	22.3 0	22.7 0	23.2 7	22.9 0	23.9 0	23.8 8	24.0 0	24.4 0	24.1 0	24.8 0
	6	19.1 0	19.4 0	19.4 1	19.7 0	19.9 0	19.4 0	20.4 0	20.6 0	20.3 5	20.7 0	20.9 0	20.7 6	21.1 0	20.9 0	21.2 0	21.2 0
	7	23.7 0	23.6 0	24.0 0	25.2 0	24.7 0	24.1 0	24.6 0	26.7 0	28.9 9							
	8	21.9 0	22.1 0	23.2 0	22.6 0	22 40	22.9 0	23.3 0	24.4 0	24.3 5	24.0 0	25.4 0	24.9 9	25.2 0	250 0	25.5 0	27.1 0
	Ave	21.4 5	21.5 7	22.3 4	22.4 5	22.4 2	22.5 8	22.6 7	23.4 2	23.8 7	22.9 2	23.5 8	23.7 2	24.0 2	24.1 2	24. 08	24. 98
	SD	1.68	1.60	2.03	1.88	1.63	1.95	1.78	2.34	3.04	1.92	2.38	2.20	2.4 0	2.47	2.34	2.92
Group 6 Compound 2 300 mg/kg 2Q7Dx11	7	21.2 0	22.2 0	23.1 5	22.3 0	22.5 0	23.5 0	22.7 0	23.2 0	23.5 5	22.4 0	24.0 0	243 0	24.3 0	23.4 0	23.3 0	23.1 0
	8	21.5 0	22.9 0	23.4 3	23.8 0	23.3 0	23.5 0	232 0	24.4 0	23.3 0	23.8 0	24.3 0	24.9 2	25.3 0	25.1 0	25.4 0	25.4 0
	Ave	21.3 5	22.5 5	23.2 9	23.0 5	22.9 0	23.5 0	22.9 5	23.8 0	23.43 0	23.1 0	24.1 5	24.6 1	24.8 0	24.2 5	24.2 0	24.2 5
	SD	0.21	0.49	0.20	1.06	0.57	0.00	0.35	0.85	0.18	0.99	0.21	0.44	0.71	1.20	1.48	1.63
Group 7 Compound 2 50 mg/kg QDx71 + Anti-PD-1 200 µg Q3Dx24	1	20.7 0	20. 80	21.6 0	21.9 0	22.0 0	22.4 0	23.3 0	23.5 0	22.6 9	23.4 0	22.8 0	22.7 6	23.1 0	22.9 0	23.0 0	24.4 0
	2	21.6 0	21.3 0	22.2 7	22.1 0	22.2 0	21.6 0	21.9 0	22.2 0	23.0 8	22.4 0	22.6 0	22.6 5	23.4 0	23.2 0	23.1 0	24.6 0
	4	20.0 0	21.0 0	21.9 9	21.9 0	22.0 0	22.0 0	22.2 0	22.1 0	22.0 0	22.4 0	22.0 0	22.1 2	22.9 0	2350 0	22.9 0	24.2 0
	5	20.1 0	20.2 0	21.5 1	21.1 0	20.4 0	21.4 0	21.9 0	21.6 0	21.4 6	21.9 0	22.0 0	22.0 4	23.2 0	23.3 0	23.8 0	23.7 0
	7	21.0 0	22.0 0	22.6 6	22.9 0	22.8 0	24.4 0	22.0 0	23.1 0	23.2 3	23.6 0	24.1 0	24.1 5	24.3 0	25.0 0	24.6 0	24.8 0
	8	19.4 0	19.6 0	19.7 8	21.3 0	19.8 0	20.3 0	20.1 0	21.1 0	21.4 0	21.1 0	21.6 0	21.5 6	21.8 0	21.8 0	22.0 0	21.9 0
	9	21.2 0	21.2 0	21.6 8	22.2 0	22.2 0	22. 30	20.8 0	22.2 0	21 22	22.1 0	22.3 0	22.7 0	23. 80	22.3 0	23.0 0	22. 30

	10	19.6 0	20.8 0	21.8 5	21.4 0	21.6 0	22.7 0	20.5 0	22.2 0	22.3 3	23.7 0	22.1 0	22.2 2	22.8 0	23.2 0	23.1 0	24.9 0
	Ave	20.4 5	20. 46	21.6 7	21.8 5	21.6 3	22.1 4	21.5 9	22.2 5	22.3 0	22.5 8	22.4 4	22.5 3	23.1 6	23.1 5	23.1 9	23.2 8
	SD	0.79	0.72	0.85	0.58	1.01	1.18	1.05	0.76	0.68	0.92	0.77	0.77	0.74	0.94	0.75	1.11
Group 8 Compound 2 150 mg/kg 2Q7Dx11 + Anti-PD-1 200 µg Q3Dx24	1	17.6 0	17.6 0	18.4 0	18.7 0	18.9 0	19.0 0	18.2 0	18.8 0	18.9 0	18. 80	19.4 0	19.5 4	19.2 0	19.0 0	19.3 0	20. 20
	2	20.7 0	20.4 0	21.1 5	21.7 0	22.8 0	22.0 0	23.2 0	22.9 0	23.2 0	22.5 0	23.6 0	23.4 3	23.7 0	24.5 0	23.8 0	24.7 0
	4	20.3 0	20.6 0	20.2 0	20.9 0	20.7 0	26. 90	20.4 0	21.6 0	21.7 8	21.0 0	21.7 0	21.7 7	21.3 0	21.4 0	21.0 0	21.9 0
	7	19.2 0	18.6 0	19.7 5	20.2 0	20.2 0	20.7 0	21.0 0	20.9 0	20.9 9	20.9 0	21.2 0	21.2 2	20.8 0	21.7 0	21.9 0	21.7 0
	8	19.2 0	19.6 0	20.4 2	21.0 0	20.6 0	20.4 0	21.2 0	21.3 0	21. 43	21.2 0	21.3 0	21.2 7	22.2 0	21.8 0	21.9 0	23.1 0
	9	20.6 0	19.9 0	20.9 0	21.4 0	20.6 0	20.7 0	21.2 0	21.4 0	21.5 6	22.0 0	22.0 0	22.1 5	22.7 0	21.7 0	21.3 0	22.9 0
	10	22.5 0	23.1 0	22.0 0	23.7 0	22.5 0	23.3 0	24.1 0	23.5 0	24.1 0	25.4 0	24.4 0	24.5 6	24.4 0	25.5 0	24.7 0	25.9 0
	Ave	20.1 0	19.9 7	20.4 0	21.0 9	20.9 0	21.0 0	21.1 3	21.4 9	21.7 1	21.6 9	21.9 4	21.9 9	22.0 4	22.2 3	21.9 9	23.0 0
	SD	1.50	1.73	1.14	1.52	1.35	1.34	1.91	1.51	1.66	2.01	1.65	1.63	1.78	2.15	1.79	1.78

TABLE 38

Day of Study	Group 1- Vehicle Control 2Q7D44	Group 2- Anti PD-1 200 µg Q3Dx7	Group 3- Compound d 2 50 mg/kg QDx44	Group 4- Compound d 2 100 mg/kg QDx71	Group 5- Compound d 2 150 mg/kg 2Q7Dx10	Group 6- Compound d 2 300 mg/kg 2Q7Dx11	Group 7- Compound d 2 50 mg/kg QDx71+ Anti-PD-1 200µg Q3Dx24	Group 8 Compound d 2 150 mg/kg 2QDx11+ Anti- PD-1 200µg Q3Dx24
2	0.33 ± 4.68	1.25 ± 2.81	-2.26±4.41	-1.17±5.17	-0.05 ± 1.42	-1.85±4.52	-0.02 14.17 (N=9)	0.99±2.08

Day of Study	Group 1- Vehicle Control 2Q7D44	Group 2- Anti PD-1 200 µg Q3Dx7	Group 3- Compound 2 50 mg/kg QDx44	Group 4- Compound 2 100 mg/kg QDx71	Group 5- Compound 2 150 mg/kg 2Q7Dx10	Group 6- Compound 2 300 mg/kg 2Q7Dx11	Group 7- Compound 2 50 mg/kg QDx71+ Anti-PD-1 200µg Q3Dx24	Group 8 Compound 2 150 mg/kg 2QDx11+ Anti- PD-1 200µg Q3Dx24
6	2.12 ± 5.16	3.28 ± 1.69	-0.54 ± 5.19	1.12 ± 2.91 (N=8)	1.46 ± 1.73	2.52 ± 2.75	0.22 ± 7.23 (N=9)	2.61 ± 2.75
8	2.35 ± 5.30	3.38 ± 2.23	1.80 ± 4.46	1.98 ± 1.69 (N=7)	-2.20 ± 3.11	-2.40 ± 2.71	1.15 ± 6.04 (N=9)	0.31 ± 3.44
13	6.74 ± 4.92	6.97 ± 3.18	4.67 ± 6.48 (N=9)	2.50 ± 2.66 (N=7)	3.20 ± 2.79	4.15 ± 3.99	3.11 ± 4.23 (N=9)	5.63 ± 3.63
16	9.43 ± 6.67	8.95 ± 3.88	6.79 ± 6.78 (N=9)	4.61 ± 3.10 (N=7)	1.54 ± 4.10 (N=9)	4.79 ± 4.58	5.51 ± 4.46 (N=9)	6.86 ± 3.97 (N=9)
20	18.13 ± 4.21 (N=8)	11.79 ± 4.08	9.72 ± 8.22 (N=9)	4.58 ± 1.71 (N=7)	3.92 ± 3.04 (N=9)	7.49 ± 3.79	5.50 ± 3.13 (N=9)	5.55 ± 4.04 (N=9)
23	22.40 ± 0.00 (N=1)	14.64 ± 5.82	14.37 ± 7.87 (N=9)	6.04 ± 3.52 (N=7)	5.45 ± 4.00 (N=9)	6.34 ± 5.30	7.10 ± 3.35 (N=9)	5.40 ± 3.49 (N=9)
28	(NA)	21.85 ± 8.92 (N=7)	17.97 ± 9.16 (N=7)	6.26 ± 2.53 (N=7)	12.52 ± 3.75 (N=9)	10.84 ± 5.53	8.08 ± 3.80 (N=9)	9.26 ± 5.07 (N=9)
31	(NA)	16.37 ± 8.79 (N=3)	22.47 ± 11.82 (N=4)	6.07 ± 1.55 (N=7)	12.60 ± 6.72	12.55 ± 6.58	9.62 ± 3.36 (N=9)	10.75 ± 4.98 (N=9)
34	(NA)	18.47 ± 15.13 (N=2)	13 ± 25 ± 0.00 (N=1)	6.68 ± 3.02 (N=7)	14.27 ± 10.90 (N=4)	14.73 ± 8.36	9.54 ± 4.55 (N=9)	11.48 ± 4.82 (N=8)
37	(NA)	23.93 ± 19.19 (N=2)	17.47 ± 0.00 (N=1)	8.11 ± 3.05 (N=7)	11.80 ± 0.00 (N=1)	11.09 ± 5.81	11.19 ± 1.39 (N=8)	12.92 ± 5.57 (N=8)

Day of Study	Group 1- Vehicle Control 2Q7D44	Group 2- Anti PD-1 200 µg Q3Dx7	Group 3- Compound 2 50 mg/kg QDx44	Group 4- Compound 2 100 mg/kg QDx71	Group 5- Compound 2 150 mg/kg 2Q7Dx10	Group 6- Compound 2 300 mg/kg 2Q7Dx11	Group 7- Compound 2 50 mg/kg QDx71+ Anti-PD-1 200µg Q3Dx24	Group 8 Compound 2 150 mg/kg 2QDx11+ Anti- PD-1 200µg Q3Dx24
41	(NA)	(NA)	20.48 ± 0.00 (N=1)	8.55 ± 2.85 (N=7)	12.36 ± 0.00 (N=1)	16.47 ± 7.22 (N=9)	12.11 ± 1.99 (N=8)	16.91 ± 7.45 (N=8)
44	(NA)	(NA)	26.51 ± 0.00 (N=1)	11.94 ± 4.94 (N=7)	12.92 ± 0.00 (N=1)	10.21 ± 4.06 (N=6)	14.02 ± 2.36 (N=8)	15.66 ± 6.07 (N=7)
47	(NA)	(NA)	(NA)	12.74 ± 4.46 (N=7)	12.92 ± 0.00 (N=1)	16.67 ± 7.27 (N=6)	15.53 ± 2.03 (N=8)	14.27 ± 6.27 (N=7)
51	(NA)	(NA)	(NA)	12.61 ± 5.41 (N=7)	11.80 ± 0.00 (N=1)	16.51 ± 8.81 (N=6)	10.32 ± 2.65 (N=8)	12.84 ± 7.76 (N=7)
55	(NA)	(NA)	(NA)	14.84 ± 4.84 (N=6)	16.29 ± 0.00 (N=1)	15.06 ± 4.94 (N=3)	15.40 ± 2.86 (N=8)	15.23 ± 5.57 (N=7)
62	(NA)	(NA)	(NA)	15.23 ± 3.12 (N=6)	21.91 ± 0.00 (N=1)	19.66 ± 9.50 (N=3)	14.33 ± 4.69 (N=8)	15.17 ± 6.14 (N=7)
65	(NA)	(NA)	(NA)	15.68 ± 3.39 (N=6)	22.47 ± 0.00 (N=1)	18.58 ± 9.97 (N=3)	14.39 ± 3.67 (N=13)	18.04 ± 7.60 (N=7)
69	(NA)	(NA)	(NA)	18.25 ± 3.44 (N=6)	(NA)	26.27 ± 17.21 (N=3)	17.14 ± 3.22 (N=8)	17.80 ± 6.82 (N=7)
72	(NA)	(NA)	(NA)	17.64 ± 5.32 (N=6)	(NA)	12.98 ± 2.81 (N=2)	16.53 ± 3.72 (N=8)	19.68 ± 6.95 (N=7)

Day of Study	Group 1- Vehicle Control 2Q7D44	Group 2- Anti PD-1 200 µg Q3Dx7	Group 3- Compound 2 50 mg/kg QDx44	Group 4- Compound 2 100 mg/kg QDx71	Group 5- Compound 2 150 mg/kg 2Q7Dx10	Group 6- Compound 2 300 mg/kg 2Q7Dx11	Group 7- Compound 2 50 mg/kg QDx71+ Anti-PD-1 200µg Q3Dx24	Group 8 Compound 2 150 mg/kg 2QDx11+ Anti- PD-1 200µg Q3Dx24
76	(NA)	(NA)	(NA)	18.29 ± 4.74 (N=6)	(NA)	19.35 ± 4.40 (N=2)	18.89± 3.32 (N=8)	18.92 ± 8.60 (N=7)
84	(NA)	(NA)	(NA)	22.46 ± 6.73 (N=6)	(NA)	23.25 ± 2.89 (N=2)	23.46± 3.32 (N=8)	21.55 ± 5.62 (N=7)
93	(NA)	(NA)	(NA)	23.14 ± 6.79 (N=6)	(NA)	22.01 ± 7.44 (N=2)	24.54 ± 3.53 (N=8)	25.56 ± 7.11 (N=7)
100	(NA)	(NA)	(NA)	23.00. ± 5.67 (N=6)	(NA)	21.20 ± 4.81 (N=2)	23.21 ± 4.40 (N=8)	24.62 ± 9.00(N=7)
107	(NA)	(NA)	(NA)	23.85 ± 6.91 (N=6)	(NA)	24.35 ± 1.86 (N=2)	26.15 ± 6.26 (N=8)	25.18 ± 8.24 (N=7)
115	(NA)	(NA)	(NA)	24.30 ± 5 26 (N=6)	(NA)	21.46 ± 3 69 (N=2)	22.98 ± 4.40 (N=8)	27.05 ± 10.61 (N=7)
121	(NA)	(NA)	(NA)	28.35 ± 8.38 (N=6)	(NA)	25.97 ± 6.37 (N=2)	26.81 ± 3.99 (N=4)	28.02 ± 8.60 (N=7)
129	(NA)	(NA)	(NA)	30.76±12.3 0 (N=6)	(NA)	23.95 ± 0 92 (N=2)	27.12 ± 409 (N=8)	29.34 ± 9 26 (N=7)
135	(NA)	(NA)	(NA)	26.78 ± 6.34 (N=5)	(NA)	22.28 ± 7.07 (N=2)	28.67 ± 5.36 (N=8)	29.09±9.76 (N=7)

Day of Study	Group 1- Vehicle Control 2Q7D44	Group 2- Anti PD-1 200 µg Q3Dx7	Group 3- Compound 2 50 mg/kg QDx44	Group 4- Compound 2 100 mg/kg QDx71	Group 5- Compound 2 150 mg/kg 2Q7Dx10	Group 6- Compound 2 300 mg/kg 2Q7Dx11	Group 7- Compound 2 50 mg/kg QDx71+ Anti-PD-1 200µg Q3Dx24	Group 8 Compound 2 150 mg/kg 2QDx11+ Anti- PD-1 200µg Q3Dx24
143	(NA)	(NA)	(NA)	30.36 ± 8.57 (N=5)	(NA)	27.80±3.03 (N=2)	27.89 ± 4.60 (N=8)	30.75 ± 9.43 (N=7)
149	(NA)	(NA)	(NA)	31.18 ± 8.20 (N=5)	(NA)	30.24 ± 4.27 (N=2)	28.39 ± 4.39 (N=8)	31.03 ± 9.08 (N=7)
156	(NA)	(NA)	(NA)	32.81 ± 8.76 (N=5)	(NA)	31.26 ± 5.71 (N=2)	32.00 ± 3.24 (N=8)	31.25 ± 8.77 (N=7)
164	(NA)	(NA)	(NA)	33.36 ± 9.27 (N=5)	(NA)	28.37 ± 8.28 (N=2)	31.93 ± 4.89 (N=8)	32.44 ± 12.3 (N=7)
170	(NA)	(NA)	(NA)	33.16 ± 8.53 (N=5)	(NA)	28.91 ± 9.79 (N=2)	32.16 ± 4.07 (N=8)	31.04 ± 10.79 (N=7)
182	(NA)	(NA)	(NA)	38.08±11.87 (N=5)	(NA)	28.39 ±10.53 (N=2)	36.06±5.75 (N=8)	37.03±9.85 (N=7)
N/A. no mice in the group								

[0469] **Clinical Observations:** In general, Compound 2 was well tolerated throughout the study. Some lab accidents and moribund mice were recorded in **TABLE 38**. These included one mouse (#4) in Group 3, mice administered Compound 2 50 mg/kg QDx44, 3 mice (#2, #9, #10) in Group 4 administered Compound 2 100 mg/kg QDx71, one mouse (#7) in group 5 administered Compound 2 150 mg/kg 2Q7Dx10, one mouse (#6) in group 7 administered Compound 2 50 mg/kg QDx71 + Anti-PD-1 200 µg Q3Dx24 and one mouse (#5) in group 8 administered Compound 2 150 mg/kg 2Q7Dx11 + Anti-PD-1 200 µg Q3Dx24.

[0470] This study was designed to test the dose responsive anti-tumor effect of Compound 2 alone and in combination with Anti-PD-1 in a mouse syngeneic model of sarcoma (MT373). Single agent activity was evaluated with two dosing regimens, daily and twice daily once per week. Compound 2 was dosed PO daily at 50 mg/kg or 100 mg/kg, and exhibited 74% TGI and 39.9 % regression, respectively by day 20. Compound 2 was also dosed PO twice daily once a week at 150 mg/kg or 300 mg/kg and exhibited 92% and 99.2% TGI, respectively. To evaluate the combination of Anti-PD-1 and Compound 2, Anti-PD-1 as a single agent was dosed IP at 200 µg per mouse and exhibited 72.3% TGI at day 20. Mice dosed with the combination of Compound 2 and Anti-PD-1 exhibited 38.6% regression for the 50 mg/kg daily dose of Compound 2 + Anti-PD-1 and 23.5% regression for the 150 mg/kg twice daily once a week dose of Compound 2 + Anti-PD-1, respectively. Compound 2 alone and in combination with Anti-PD-1 was well tolerated throughout the dosing period.

[0471] The study was terminated at Day 182, median survival was calculated for all groups as a measure of time for tumors to reach 2000 mm³. Mice administered vehicle control had a median survival time of 17.3 days whereas mice administered Anti-PD-1 only had a slightly improved median survival of 24 days. Compound 2 dosed PO daily at 50 mg/kg or 100 mg/kg exhibited median survival times of 28 and >182 days, respectively. Compound 2 dosed PO twice daily once a week at 150 mg/kg or 300 mg/kg exhibited median survival times of 30.8 and 47.7 days, respectively. The combination of Compound 2 + Anti-PD-1 improved median survival times versus either single agents with both dosing groups, 50 mg/kg QD + Anti-PD-1 and 150 mg/kg 2Q7D + Anti-PD-1, exhibiting a median survival of >182 days, a >164 day extension in survival compared to vehicle control.

[0472] Following cessation of dosing on day 70, mice were continuously monitored for tumor growth until day 182. Two of the single agent groups had some residual tumors or cures. The Compound 2 100 mg/kg group had 71 % of mice surviving and the Compound 2 300 mg/kg group had 20% of mice surviving at the termination of the study. However, an increase in the number of tumors in stasis or cures in both combination groups as compared to single agent was observed. The Compound 2 50 mg/kg + Anti-PD-1 group had 89% of mice surviving, and the Compound 2 150 mg/kg + Anti-PD-1 group had 78% of mice surviving at termination of the study.

[0473] Overall, administration of Compound 2 either daily or twice daily once per week resulted in a dose responsive anti-tumor effect with tumor grow delay and tumor regression at higher doses. Combining sub-efficacious dose levels of Compound 2 with Anti-PD-1 significantly improved the anti-tumor effect demonstrating regression, cures, and a significant increase in median survival time.

EMBODIMENTS

[0474] The following non-limiting embodiments provide illustrative examples of the invention, but do not limit the scope of the invention.

[0475] Embodiment 1. A method of treating cancer in a subject in need thereof, the method comprising: (i) administering to the subject a therapeutically-effective amount of a compound,

wherein the compound binds to a mutant p53 protein and reconforms the mutant p53 protein to a conformation of p53 that exhibits anti-cancer activity; and (ii) administering to the subject a therapeutically-effective amount of an anti-cancer agent that functions through a pathway other than p53-induced apoptosis.

[0476] Embodiment 2. The method of embodiment 1, wherein the compound increases a stability of the mutant p53 protein.

[0477] Embodiment 3. The method of embodiment 1 or 2, wherein the cancer expresses the mutant p53 protein.

[0478] Embodiment 4. The method of any one of embodiments 1-3, wherein the mutant p53 protein has a mutation at amino acid 220.

[0479] Embodiment 5. The method of any one of embodiments 1-4, wherein the mutant p53 protein is p53 Y220C.

[0480] Embodiment 6. The method of any one of embodiments 1-5, wherein the compound selectively binds the mutant p53 protein as compared to a wild type p53.

[0481] Embodiment 7. The method of any one of embodiments 1-6, wherein the cancer is ovarian cancer.

[0482] Embodiment 8. The method of any one of embodiments 1-6, wherein the cancer is breast cancer.

[0483] Embodiment 9. The method of any one of embodiments 1-6, wherein the cancer is lung cancer.

[0484] Embodiment 10. The method of any one of embodiments 1-9, wherein the administering of the compound is oral.

[0485] Embodiment 11. The method of any one of embodiments 1-9, wherein the administering of the compound is subcutaneous.

[0486] Embodiment 12. The method of any one of embodiments 1-9, wherein the administering of the compound is topical.

[0487] Embodiment 13. The method of any one of embodiments 1-12, wherein the therapeutically-effective amount of the compound is from about 500 mg to about 1200 mg.

[0488] Embodiment 14. The method of any one of embodiments 1-13, wherein the therapeutically-effective amount of the compound is about 500 mg.

[0489] Embodiment 15. The method of any one of embodiments 1-13, wherein the therapeutically-effective amount of the compound is about 1200 mg.

[0490] Embodiment 16. The method of any one of embodiments 1-13, wherein the therapeutically-effective amount of the compound is about 2000 mg/kg.

[0491] Embodiment 17. The method of any one of embodiments 1-16, wherein the subject is human.

[0492] Embodiment 18. The method of any one of embodiments 1-17, wherein the anti-cancer agent

is a small molecule.

[0493] Embodiment 19. The method of any one of embodiments 1-17, wherein the anti-cancer agent is an antibody.

[0494] Embodiment 20. The method of any one of embodiments 1-17, wherein the anti-cancer agent is an immune checkpoint inhibitor.

[0495] Embodiment 21. The method of any one of embodiments 1-17 or 20, wherein the immune checkpoint inhibitor is an anti-PD-1 agent.

[0496] Embodiment 22. The method of any one of embodiments 1-17, 20, or 21, wherein the anti-PD-1 agent is nivolumab.

[0497] Embodiment 23. The method of any one of embodiments 1-17, 20, or 21, wherein the anti-PD-1 agent is pembrolizumab.

[0498] Embodiment 24. The method of any one of embodiments 1-17, 20, or 21, wherein the anti-PD-1 agent is cemiplimab.

[0499] Embodiment 25. The method of any one of embodiments 1-17 or 20, wherein the immune checkpoint inhibitor is an anti-PD-L1 agent.

[0500] Embodiment 26. The method of any one of embodiments 1-17, 20, or 25, wherein the anti-PD-L1 agent is atezolizumab.

[0501] Embodiment 27. The method of any one of embodiments 1-17, 20, or 25, wherein the anti-PD-L1 agent is avelumab.

[0502] Embodiment 28. The method of any one of embodiments 1-17, 20, or 25, wherein the anti-PD-L1 agent is durvalumab.

[0503] Embodiment 29. The method of any one of embodiments 1-28, wherein the administering of the anti-cancer agent is oral.

[0504] Embodiment 30. The method of any one of embodiments 1-28, wherein the administering of the anti-cancer agent is subcutaneous.


[0505] Embodiment 31. The method of any one of embodiments 1-28, wherein the administering of the anti-cancer agent is topical.

[0506] Embodiment 32. The method of any one of embodiments 1-31, wherein the therapeutically-effective amount of the anti-cancer agent is from about 5 mg/kg to about 500 mg/kg.

[0507] Embodiment 33. The method of any one of embodiments 1-31, wherein the therapeutically-effective amount of the anti-cancer agent is from about 10 µg to about 500 µg.

[0508] Embodiment 34. The method of any one of embodiments 1-31 or 33, wherein the therapeutically-effective amount of the anti-cancer agent is about 200 µg.

[0509] Embodiment 35. The method of any one of embodiments 1-34, wherein the compound is of the formula:



wherein:

- each ----- is independently a single bond or a double bond;
- X^1 is CR^5 , CR^5R^6 , N, NR^5 , O, S, C=O, C=S, or a carbon atom connected to Q^1 ;
- X^2 is CR^7 , CR^7R^8 , N, NR^7 , O, S, C=O, C=S, or a carbon atom connected to Q^1 ;
- X^3 is CR^9 , CR^9R^{10} , N, NR^9 , O, S, C=O, C=S, or a carbon atom connected to Q^1 ;
- X^4 is CR^{11} , $\text{CR}^{11}\text{R}^{12}$, N, NR^{11} , O, S, C=O, C=S, or a carbon atom connected to Q^1 ;
- X^5 is CR^{13} , N, or NR^{13} ;

wherein at least one of X^1 , X^2 , X^3 , and X^4 is a carbon atom connected to Q^1 ;

- A is a linking group;
- Q^1 is C=O, C=S, C=CR¹⁴R¹⁵, C=NR¹⁴, alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond;
- m is 1, 2, 3, or 4;
- Y is N, O, or absent;
- R^1 is -C(O)R¹⁶, -C(O)OR¹⁶, -C(O)NR¹⁶R¹⁷, -OR¹⁶, -SR¹⁶, -NR¹⁶R¹⁷, -NR¹⁶C(O)R¹⁶, -OC(O)R¹⁶, -SiR¹⁶R¹⁷R¹⁸, alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, heterocyclyl, or halo, each of which is independently substituted or unsubstituted, or hydrogen;
- each R³ and R⁴ is independently -C(O)R¹⁹, -C(O)OR¹⁹, -C(O)NR¹⁹R²⁰, -SOR¹⁹, -SO₂R¹⁹, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen, or R³ and R⁴ together with the nitrogen atom to which R³ and R⁴ are bound form a ring, wherein the ring is substituted or unsubstituted, or R³ is absent;
- each R², R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, and R¹⁸ is independently -C(O)R²¹, -C(O)OR²¹, -C(O)NR²¹R²², -OR²¹, -SR²¹, -NR²¹R²², -NR²¹C(O)R²², -OC(O)R²¹, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R¹⁹ and R²⁰ is independently -C(O)R²³, -C(O)OR²³, -C(O)NR²³R²⁴, -OR²³, -SR²³, -NR²³R²⁴, -NR²³C(O)R²⁴, -OC(O)R²³, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R²¹ and R²² is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and


- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,

or a pharmaceutically-acceptable salt thereof.

[0510] Embodiment 36. The method of embodiment 35, wherein A is alkylene, alkenylene, or alkynylene, each of which is substituted or unsubstituted.

[0511] Embodiment 37. The method of embodiment 35, wherein A is aryl, heteroaryl, or heterocyclyl, each of which is substituted or unsubstituted.

[0512] Embodiment 38. The method of embodiment 35 or 36, wherein the compound is of the formula:



[0513] Embodiment 39. The method of any one of embodiments 35-38, wherein Q^1 is C_1 -alkylene.

[0514] Embodiment 40. The method of any one of embodiments 35-38, wherein Q^1 is a bond.

[0515] Embodiment 41. The method of any one of embodiments 35-40, wherein m is 1.

[0516] Embodiment 42. The method of any one of embodiments 35-40, wherein m is 2.

[0517] Embodiment 43. The method of any one of embodiments 35-42, wherein Y is N.

[0518] Embodiment 44. The method of any one of embodiments 35-42, wherein Y is O.


[0519] Embodiment 45. The method of any one of embodiments 35-44, wherein each R^3 and R^4 is independently alkyl, alkylene, alkenyl, alkenylene, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; or hydrogen.

[0520] Embodiment 46. The method of any one of embodiments 35-45, wherein R^3 is alkyl, alkylene, alkenyl, alkenylene, alkynyl, each of which is independently substituted or unsubstituted; and R^4 is aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted.

[0521] Embodiment 47. The method of any one of embodiments 35-45, wherein R^3 is H; and R^4 is aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted.

[0522] Embodiment 48. The method of any one of embodiments 35-47, wherein R^{13} is hydrogen.

[0523] Embodiment 49. The method of any one of embodiments 35, 36, 38, 40, 41, 43, 45-48, wherein the compound is of the formula:



wherein ring A is a cyclic group that is substituted or unsubstituted.


[0524] Embodiment 50. The method of any one of embodiments 35-49, wherein R^2 is substituted or unsubstituted alkyl.

[0525] Embodiment 51. The method of any one of embodiments 35-50, wherein R^2 is methyl, ethyl, propyl, iso-propyl, butyl, or tert-butyl, each of which is substituted or unsubstituted.

[0526] Embodiment 52. The method of any one of embodiments 35-51, wherein R^2 is substituted ethyl.

[0527] Embodiment 53. The method of any one of embodiments 35-52, wherein R^2 is trifluoroethyl.

[0528] Embodiment 54. The method of any one of embodiments 35, 36, 38, 40, 41, 43, or 45-53, wherein the compound is of the formula:



[0529] Embodiment 55. The method of any one of embodiments 35, 36, 38, 40, 41, 43, or 45-54, wherein ring A is aryl, heteroaryl, or heterocyclyl, each of which is substituted or unsubstituted.

[0530] Embodiment 56. The method of any one of embodiments 35, 36, 38, 40, 41, 43, or 45-55, wherein ring A is substituted aryl.

[0531] Embodiment 57. The method of any one of embodiments 35, 36, 38, 40, 41, 43, or 45-55, wherein ring A is substituted heteroaryl.


[0532] Embodiment 58. The method of any one of embodiments 35, 36, 38, 40, 41, 43, or 45-55, wherein ring A is substituted heterocyclyl.

[0533] Embodiment 59. The method of any one of embodiments 35-58, wherein R^1 is alkyl, alkenyl, $-C(O)R^{16}$, $-C(O)OR^{16}$, or $-C(O)NR^{16}R^{17}$, each of which is unsubstituted or substituted.

[0534] Embodiment 60. The method of any one of embodiments 35-59, wherein R^1 is substituted alkyl.

[0535] Embodiment 61. The method of any one of embodiments 35-60, wherein R^1 is alkyl substituted with $NR^{16}R^{17}$.

[0536] Embodiment 62. The method of any one of embodiments 35, 36, 38, 40, 41, 43, or 45-61, wherein the compound is of the formula:



[0537] Embodiment 63. The method of any one of embodiments 35-62, wherein each R^{16} and R^{17} is

independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, each of which is independently substituted or unsubstituted; or hydrogen.

[0538] Embodiment 64. The method of any one of embodiments 35-63, wherein R¹⁶ is hydrogen or alkyl.

[0539] Embodiment 65. The method of any one of embodiments 35-64, wherein R¹⁷ is aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted.

[0540] Embodiment 66. The method of any one of embodiments 35-65, wherein R¹⁷ is substituted aryl.

[0541] Embodiment 67. The method of any one of embodiments 35-66, wherein R¹⁷ is substituted phenyl.

[0542] Embodiment 68. The method of any one of embodiments 35-67, wherein R¹⁷ is phenyl substituted with a sulfoxide group, carboxyl group, amide group, amino group, alkyl, alkoxy, hydroxy, halo, cyano, or heterocyclyl, each of which is independently substituted or unsubstituted.

[0543] Embodiment 69. The method of any one of embodiments 35-68, wherein R¹⁷ is phenyl substituted with methoxy.

[0544] Embodiment 70. The method of any one of embodiments 35-69, wherein R¹⁷ is phenyl substituted with a substituted sulfoxide group.

[0545] Embodiment 71. The method of any one of embodiments 35-70, wherein R¹⁷ is phenyl substituted with a carboxyl group.

[0546] Embodiment 72. The method of any one of embodiments 35-71, wherein R¹⁷ is phenyl substituted with an amide group.

[0547] Embodiment 73. The method of embodiment 35, wherein the compound is 4-[(3-{4-[(1,5-dihydroxypentan-3-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxybenzene-1-sulfonamide.

[0548] Embodiment 74. The method of any one of embodiments 35, wherein the compound is 2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1r,4r)-4-morpholinocyclohexyl)-1-(oxiran-2-ylmethyl)-1H-indol-4-amine.

[0549] Embodiment 75. The method of any one of embodiments 35, wherein the compound is 3-methoxy-4-({3-[4-({2-oxaspiro[3.3]heptan-6-yl} amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl} amino)benzene-1-sulfonamide.

[0550] Embodiment 76. The method of any one of embodiments 35, wherein the compound is 4-((3-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide.

[0551] Embodiment 77. The method of any one of embodiments 35, wherein the compound is N-(2,3-dihydroxypropyl)-4-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl}amino}-3-methoxybenzamide.

[0552] Embodiment 78. The method of any one of embodiments 35, wherein the compound is 3-methoxy-N-(2-methoxyethyl)-N-methyl-4-((3-(4-((tetrahydro-2H-pyran-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide.

[0553] Embodiment 79. The method of any one of embodiments 35, wherein the compound is N-(2,3-dihydroxypropyl)-4-((3-(4-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide.

[0554] Embodiment 80. The method of any one of embodiments 35, wherein the compound is 3-methoxy-4-((3-(4-(3-(1-methylpiperidin-4-yl)ureido)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide.

[0555] Embodiment 81. The method of any one of embodiments 35, wherein the compound is N-((3S,4R)-3-fluoropiperidin-4-yl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine.

[0556] Embodiment 82. A method of treating a cancer in a subject in need thereof, the method comprising: (i) administering to the subject a therapeutically-effective amount of a compound that increases anti-cancer activity of a mutant p53 protein in the subject; and (ii) administering to the subject a therapeutically-effective amount of an anti-cancer agent that functions through a pathway other than p53-induced apoptosis.

[0557] Embodiment 83. The method of embodiment 82, wherein the compound binds to the mutant p53 protein and reconfirms the mutant p53 protein to a conformation of p53 that exhibits anti-cancer activity.

[0558] Embodiment 84. The method of embodiment 82 or 83, wherein the compound increases a stability of the mutant p53 protein.

[0559] Embodiment 85. The method of any one of embodiments 82-84, wherein the cancer expresses the mutant p53 protein.

[0560] Embodiment 86. The method of any one of embodiments 82-85, wherein the mutant p53 protein has a mutation at amino acid 220.

[0561] Embodiment 87. The method of any one of embodiments 82-86, wherein the mutant p53 protein is p53 Y220C.

[0562] Embodiment 88. The method of any one of embodiments 82-87, wherein the compound selectively binds the mutant p53 protein as compared to a wild type p53.

[0563] Embodiment 89. The method of any one of embodiments 82-88, wherein the cancer is ovarian cancer.

[0564] Embodiment 90. The method of any one of embodiments 82-88, wherein the cancer is breast cancer.

[0565] Embodiment 91. The method of any one of embodiments 82-88, wherein the cancer is lung cancer.

- [0566] Embodiment 92. The method of any one of embodiments 82-91, wherein the administering of the compound is oral.
- [0567] Embodiment 93. The method of any one of embodiments 82-91, wherein the administering of the compound is subcutaneous.
- [0568] Embodiment 94. The method of any one of embodiments 82-93, wherein the administering of the compound is topical.
- [0569] Embodiment 95. The method of any one of embodiments 82-94, wherein the therapeutically-effective amount of the compound is from about 500 mg to about 2000 mg.
- [0570] Embodiment 96. The method of any one of embodiments 82-95, wherein the therapeutically-effective amount of the compound is about 500 mg.
- [0571] Embodiment 97. The method of any one of embodiments 82-95, wherein the therapeutically-effective amount of the compound is about 1200 mg.
- [0572] Embodiment 98. The method of any one of embodiments 82-95, wherein the therapeutically-effective amount of the compound is about 2000 mg.
- [0573] Embodiment 99. The method of any one of embodiments 82-98, wherein the subject is human.
- [0574] Embodiment 100. The method of any one of embodiments 82-99, wherein the anti-cancer agent is a small molecule.
- [0575] Embodiment 101. The method of any one of embodiments 82-99, wherein the anti-cancer agent is an antibody.
- [0576] Embodiment 102. The method of any one of embodiments 82-99, wherein the anti-cancer agent is an immune checkpoint inhibitor.
- [0577] Embodiment 103. The method of any one of embodiments 82-99 or 102, wherein the immune checkpoint inhibitor is an anti-PD-1 agent.
- [0578] Embodiment 104. The method of any one of embodiments 82-99, 102, or 103, wherein the anti-PD-1 agent is nivolumab.
- [0579] Embodiment 105. The method of any one of embodiments 82-99, 102, or 103, wherein the anti-PD-1 agent is pembrolizumab.
- [0580] Embodiment 106. The method of any one of embodiments 82-99, 102, or 103, wherein the anti-PD-1 agent is cemiplimab.
- [0581] Embodiment 107. The method of any one of embodiments 82-99 or 102, wherein the immune checkpoint inhibitor is an anti-PD-L1 agent.
- [0582] Embodiment 108. The method of any one of embodiments 82-99, 102, or 107, wherein the anti-PD-L1 agent is atezolizumab.
- [0583] Embodiment 109. The method of any one of embodiments 82-99, 102, or 107, wherein the anti-PD-L1 agent is avelumab.

[0584] Embodiment 110. The method of any one of embodiments 82-99, 102, or 107, wherein the anti-PD-L1 agent is durvalumab.

[0585] Embodiment 111. The method of any one of embodiments 82-110, wherein the administering of the anti-cancer agent is oral.

[0586] Embodiment 112. The method of any one of embodiments 82-110, wherein the administering of the anti-cancer agent is subcutaneous.


[0587] Embodiment 113. The method of any one of embodiments 82-110, wherein the administering of the anti-cancer agent is topical.

[0588] Embodiment 114. The method of any one of embodiments 82-113, wherein the therapeutically-effective amount of the anti-cancer agent is from about 5 mg/kg to about 500 mg/kg.

[0589] Embodiment 115. The method of any one of embodiments 82-114, wherein the therapeutically-effective amount of the anti-cancer agent is from about 10 µg to about 500 µg.

[0590] Embodiment 116. The method of any one of embodiments 82-115, wherein the therapeutically-effective amount of the anti-cancer agent is about 200 µg.

[0591] Embodiment 117. The method of any one of embodiments 82-116, wherein the compound is of the formula:



wherein:

- each ----- is independently a single bond or a double bond;
- X^1 is CR^5 , CR^5R^6 , N, NR^5 , O, S, C=O, C=S, or a carbon atom connected to Q^1 ;
- X^2 is CR^7 , CR^7R^8 , N, NR^7 , O, S, C=O, C=S, or a carbon atom connected to Q^1 ;
- X^3 is CR^9 , CR^9R^{10} , N, NR^9 , O, S, C=O, C=S, or a carbon atom connected to Q^1 ;
- X^4 is CR^{11} , $CR^{11}R^{12}$, N, NR^{11} , O, S, C=O, C=S, or a carbon atom connected to Q^1 ;
- X^5 is CR^{13} , N, or NR^{13} ;

wherein at least one of X^1 , X^2 , X^3 , and X^4 is a carbon atom connected to Q^1 ;

- A is a linking group;
- Q^1 is C=O, C=S, C=CR¹⁴R¹⁵, C=NR¹⁴, alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond;
- m is 1, 2, 3, or 4;
- Y is N, O, or absent;
- R^1 is -C(O)R¹⁶, -C(O)OR¹⁶, -C(O)NR¹⁶R¹⁷, -OR¹⁶, -SR¹⁶, -NR¹⁶R¹⁷, -NR¹⁶C(O)R¹⁶, -OC(O)R¹⁶, -SiR¹⁶R¹⁷R¹⁸, alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, heterocyclyl, or halo, each of which is independently substituted or unsubstituted, or hydrogen;


- each R^3 and R^4 is independently $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen, or R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a ring, wherein the ring is substituted or unsubstituted, or R^3 is absent;
- each R^2 , R^5 , R^6 , R^7 , R^8 , R^9 , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , and R^{18} is independently $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R^{19} and R^{20} is independently $-C(O)R^{23}$, $-C(O)OR^{23}$, $-C(O)NR^{23}R^{24}$, $-OR^{23}$, $-SR^{23}$, $-NR^{23}R^{24}$, $-NR^{23}C(O)R^{24}$, $-OC(O)R^{23}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,

or a pharmaceutically-acceptable salt thereof.

[0592] Embodiment 118. The method of embodiment 117, wherein A is alkylene, alkenylene, or alkynylene, each of which is substituted or unsubstituted.

[0593] Embodiment 119. The method of embodiment 117, wherein A is aryl, heteroaryl, or heterocyclyl, each of which is substituted or unsubstituted.

[0594] Embodiment 120. The method of embodiment 117 or 118, wherein the compound is of the formula:



[0595] Embodiment 121. The method of any one of embodiments 117-120, wherein Q^1 is C_1 -alkylene.

[0596] Embodiment 122. The method of any one of embodiments 117-120, wherein Q^1 is a bond.

[0597] Embodiment 123. The method of any one of embodiments 117-122, wherein m is 1.

[0598] Embodiment 124. The method of any one of embodiments 117-122, wherein m is 2.

[0599] Embodiment 125. The method of any one of embodiments 117-124, wherein Y is N.

[0600] Embodiment 126. The method of any one of embodiments 117-124, wherein Y is O.


[0601] Embodiment 127. The method of any one of embodiments 117-126, wherein each R^3 and R^4 is independently alkyl, alkylene, alkenyl, alkenylene, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; or hydrogen.

[0602] Embodiment 128. The method of any one of embodiments 117-127, wherein R^3 is alkyl, alkylene, alkenyl, alkenylene, alkynyl, each of which is independently substituted or unsubstituted; and R^4 is aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted.

[0603] Embodiment 129. The method of any one of embodiments 117-128, wherein R^3 is H; and R^4 is aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted.

[0604] Embodiment 130. The method of any one of embodiments 117-129, wherein R^{13} is hydrogen.

[0605] Embodiment 131. The method of any one of embodiments 117, 118, 122, 125, or 127-130, wherein the compound is of the formula:



wherein ring A is a cyclic group that is substituted or unsubstituted.


[0606] Embodiment 132. The method of any one of embodiments 117-131, wherein R^2 is substituted or unsubstituted alkyl.

[0607] Embodiment 133. The method of any one of embodiments 117-132, wherein R^2 is methyl, ethyl, propyl, iso-propyl, butyl, or tert-butyl, each of which is substituted or unsubstituted.

[0608] Embodiment 134. The method of any one of embodiments 117-133, wherein R^2 is substituted ethyl.

[0609] Embodiment 135. The method of any one of embodiments 117-134, wherein R^2 is trifluoroethyl.

[0610] Embodiment 136. The method of any one of embodiments 117, 118, 122, 125, or 127-135, wherein the compound is of the formula:



[0611] Embodiment 137. The method of any one of embodiments 117, 118, 122, 125, or 127-136, wherein ring A is aryl, heteroaryl, or heterocyclyl, each of which is substituted or unsubstituted.

[0612] Embodiment 138. The method of any one of embodiments 117, 118, 122, 125, or 127-137,

wherein ring A is substituted aryl.

[0613] Embodiment 139. The method of any one of embodiments 117, 118, 122, 125, or 127-137, wherein ring A is substituted heteroaryl.


[0614] Embodiment 140. The method of any one of embodiments 117, 118, 122, 125, or 127-137, wherein ring A is substituted heterocyclyl.

[0615] Embodiment 141. The method of any one of embodiments 117-140, wherein R^1 is alkyl, alkenyl, $-C(O)R^{16}$, $-C(O)OR^{16}$, or $-C(O)NR^{16}R^{17}$, each of which is unsubstituted or substituted.

[0616] Embodiment 142. The method of any one of embodiments 117-141, wherein R^1 is substituted alkyl.

[0617] Embodiment 143. The method of any one of embodiments 117-142, wherein R^1 is alkyl substituted with $NR^{16}R^{17}$.

[0618] Embodiment 144. The method of any one of embodiments 117, 118, 122, 125, or 127-143, wherein the compound is of the formula:



[0619] Embodiment 145. The method of any one of embodiments 117, 118, 122, 125, or 127-144, wherein each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, each of which is independently substituted or unsubstituted; or hydrogen.

[0620] Embodiment 146. The method of any one of embodiments 117, 118, 122, 125, or 127-145, wherein R^{16} is hydrogen or alkyl.

[0621] Embodiment 147. The method of any one of embodiments 117, 118, 122, 125, or 127-146, wherein R^{17} is aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted.

[0622] Embodiment 148. The method of any one of embodiments 117, 118, 122, 125, or 127-147, wherein R^{17} is substituted aryl.

[0623] Embodiment 149. The method of any one of embodiments 117, 118, 122, 125, or 127-148, wherein R^{17} is substituted phenyl.

[0624] Embodiment 150. The method of any one of embodiments 117, 118, 122, 125, or 127-149, wherein R^{17} is phenyl substituted with a sulfoxide group, carboxyl group, amide group, amino group, alkyl, alkoxy, hydroxy, halo, cyano, or heterocyclyl, each of which is independently substituted or unsubstituted.

[0625] Embodiment 151. The method of any one of embodiments 117, 118, 122, 125, or 127-150, wherein R^{17} is phenyl substituted with methoxy.

[0626] Embodiment 152. The method of any one of embodiments 117, 118, 122, 125, or 127-151,

wherein R¹⁷ is phenyl substituted with a substituted sulfoxide group.

[0627] Embodiment 153. The method of any one of embodiments 117, 118, 122, 125, or 127-152, wherein R¹⁷ is phenyl substituted with a carboxyl group.

[0628] Embodiment 154. The method of any one of embodiments 117, 118, 122, 125, or 127-153, wherein R¹⁷ is phenyl substituted with an amide group.

[0629] Embodiment 155. The method of any one of embodiments 117, wherein the compound is 4-[(3-{4-[(1,5-dihydroxypentan-3-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxybenzene-1-sulfonamide.

[0630] Embodiment 156. The method of any one of embodiments 117, wherein the compound is 2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1r,4r)-4-morpholinocyclohexyl)-1-(oxiran-2-ylmethyl)-1H-indol-4-amine.

[0631] Embodiment 157. The method of any one of embodiments 117, wherein the compound is 3-methoxy-4-({3-[4-({2-oxaspiro[3.3]heptan-6-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)benzene-1-sulfonamide.

[0632] Embodiment 158. The method of any one of embodiments 117, wherein the compound is 4-((3-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide.

[0633] Embodiment 159. The method of any one of embodiments 117, wherein the compound is N-(2,3-dihydroxypropyl)-4-{{3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino})-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl}amino}-3-methoxybenzamide.

[0634] Embodiment 160. The method of any one of embodiments 117, wherein the compound is 3-methoxy-N-(2-methoxyethyl)-N-methyl-4-((3-(4-((tetrahydro-2H-pyran-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide.

[0635] Embodiment 161. The method of any one of embodiments 117, wherein the compound is N-(2,3-dihydroxypropyl)-4-((3-(4-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide.

[0636] Embodiment 162. The method of any one of embodiments 117, wherein the compound is 3-methoxy-4-((3-(4-(3-(1-methylpiperidin-4-yl)ureido)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide.

[0637] Embodiment 163. The method of any one of embodiments 117, wherein the compound is N-((3S,4R)-3-fluoropiperidin-4-yl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine.

[0638] Embodiment 164. A method of treating cancer, the method comprising: (i) administering to a subject in need thereof a therapeutically-effective amount of a compound that binds to a mutant p53 protein and reconfirms the mutant p53 protein to a conformation of p53 that exhibits anti-cancer activity; and (ii) administering to the subject a therapeutically-effective amount of an additional anti-

cancer agent that functions through a pathway other than p53-induced apoptosis, wherein if in a controlled study of treatment of the cancer in a first patient population and a second patient population: (a) a first median survival time of the first patient population is determined, wherein the first patient population is treated with the therapeutically-effective amount of the compound that binds to a mutant p53 protein and reconfirms the mutant p53 protein to a conformation of p53 that exhibits anti-cancer activity; and (b) a second median survival time of the second patient population is determined, wherein the second patient population is treated with the therapeutically-effective amount of the compound that binds to a mutant p53 protein and reconfirms the mutant p53 protein to a conformation of p53 that exhibits anti-cancer activity and the therapeutically-effective amount of the additional therapeutic agent; then the second median survival time is at least about 50% greater than is the first median survival time.

[0639] Embodiment 165. The method of embodiment 164, wherein the second median survival time is at least about 100% greater than the first median survival time.

[0640] Embodiment 166. The method of embodiment 164 or 165, wherein the second median survival time is at least about 200% greater than the first median survival time.

[0641] Embodiment 167. The method of any one of embodiments 164-166, wherein the compound increases a stability of the mutant p53 protein.

[0642] Embodiment 168. The method of any one of embodiments 164-167, wherein the cancer expresses the mutant p53 protein.

[0643] Embodiment 169. The method of any one of embodiments 164-168, wherein the mutant p53 protein has a mutation at amino acid 220.

[0644] Embodiment 170. The method of any one of embodiments 164-169, wherein the mutant p53 protein is p53 Y220C.

[0645] Embodiment 171. The method of any one of embodiments 164-170, wherein the compound selectively binds the mutant p53 protein as compared to a wild type p53.

[0646] Embodiment 172. The method of any one of embodiments 164-171, wherein the cancer is ovarian cancer.

[0647] Embodiment 173. The method of any one of embodiments 164-171, wherein the cancer is breast cancer.

[0648] Embodiment 174. The method of any one of embodiments 164-171, wherein the cancer is lung cancer.

[0649] Embodiment 175. The method of any one of embodiments 164-174, wherein the administering of the compound is oral.

[0650] Embodiment 176. The method of any one of embodiments 164-174, wherein the administering of the compound is subcutaneous.

[0651] Embodiment 177. The method of any one of embodiments 164-174, wherein the

administering of the compound is topical.

[0652] Embodiment 178. The method of any one of embodiments 164-177, wherein the therapeutically-effective amount of the compound is from about 500 mg to about 2000 mg.

[0653] Embodiment 179. The method of any one of embodiments 164-178, wherein the therapeutically-effective amount of the compound is about 500 mg.

[0654] Embodiment 180. The method of any one of embodiments 164-178, wherein the therapeutically-effective amount of the compound is about 1200 mg.

[0655] Embodiment 181. The method of any one of embodiments 164-178, wherein the therapeutically-effective amount of the compound is about 2000 mg.

[0656] Embodiment 182. The method of any one of embodiments 164-181, wherein the subject is human.

[0657] Embodiment 183. The method of any one of embodiments 164-182, wherein the anti-cancer agent is a small molecule.

[0658] Embodiment 184. The method of any one of embodiments 164-182, wherein the anti-cancer agent is an antibody.

[0659] Embodiment 185. The method of any one of embodiments 164-182, wherein the anti-cancer agent is an immune checkpoint inhibitor.

[0660] Embodiment 186. The method of any one of embodiments 164-182 or 185, wherein the immune checkpoint inhibitor is an anti-PD-1 agent.

[0661] Embodiment 187. The method of any one of embodiments 164-182, 185, or 186, wherein the anti-PD-1 agent is nivolumab.

[0662] Embodiment 188. The method of any one of embodiments 164-182, 185, or 186, wherein the anti-PD-1 agent is pembrolizumab.

[0663] Embodiment 189. The method of any one of embodiments 164-182, 185, or 186, wherein the anti-PD-1 agent is cemiplimab.

[0664] Embodiment 190. The method of any one of embodiments 164-182, or 185, wherein the immune checkpoint inhibitor is an anti-PD-L1 agent.

[0665] Embodiment 191. The method of any one of embodiments 164-182, 185, or 190, wherein the anti-PD-L1 agent is atezolizumab.

[0666] Embodiment 192. The method of any one of embodiments 164-182, 185, or 190, wherein the anti-PD-L1 agent is avelumab.

[0667] Embodiment 193. The method of any one of embodiments 164-182, 185, or 190, wherein the anti-PD-L1 agent is durvalumab.

[0668] Embodiment 194. The method of any one of embodiments 164-193, wherein the administering of the anti-cancer agent is oral.

[0669] Embodiment 195. The method of any one of embodiments 164-193, wherein the

administering of the anti-cancer agent is subcutaneous.


[0670] Embodiment 196. The method of any one of embodiments 164-193, wherein the administering of the anti-cancer agent is topical.

[0671] Embodiment 197. The method of any one of embodiments 164-196, wherein the therapeutically-effective amount of the anti-cancer agent is from about 5 mg/kg to about 500 mg/kg.

[0672] Embodiment 198. The method of any one of embodiments 164-197, wherein the therapeutically-effective amount of the anti-cancer agent is from about 10 µg to about 500 µg.

[0673] Embodiment 199. The method of any one of embodiments 164-198, wherein the therapeutically-effective amount of the anti-cancer agent is about 200 µg.

[0674] Embodiment 200. The method of any one of embodiments 164-199, wherein the compound is of the formula:



wherein:

- each --- is independently a single bond or a double bond;
- X^1 is CR^5 , CR^5R^6 , N, NR^5 , O, S, C=O, C=S, or a carbon atom connected to Q^1 ;
- X^2 is CR^7 , CR^7R^8 , N, NR^7 , O, S, C=O, C=S, or a carbon atom connected to Q^1 ;
- X^3 is CR^9 , CR^9R^{10} , N, NR^9 , O, S, C=O, C=S, or a carbon atom connected to Q^1 ;
- X^4 is CR^{11} , $CR^{11}R^{12}$, N, NR^{11} , O, S, C=O, C=S, or a carbon atom connected to Q^1 ;
- X^5 is CR^{13} , N, or NR^{13} ;

wherein at least one of X^1 , X^2 , X^3 , and X^4 is a carbon atom connected to Q^1 ;

- A is a linking group;
- Q^1 is C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond;
- *m* is 1, 2, 3, or 4;
- Y is N, O, or absent;
- R^1 is $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, $-SiR^{16}R^{17}R^{18}$, alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, heterocyclyl, or halo, each of which is independently substituted or unsubstituted, or hydrogen;
- each R^3 and R^4 is independently $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen, or R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a ring, wherein the ring is substituted or unsubstituted, or R^3 is absent;


- each R^2 , R^5 , R^6 , R^7 , R^8 , R^9 , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , and R^{18} is independently $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R^{19} and R^{20} is independently $-C(O)R^{23}$, $-C(O)OR^{23}$, $-C(O)NR^{23}R^{24}$, $-OR^{23}$, $-SR^{23}$, $-NR^{23}R^{24}$, $-NR^{23}C(O)R^{24}$, $-OC(O)R^{23}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,

or a pharmaceutically-acceptable salt thereof.

[0675] Embodiment 201. The method of embodiment 200, wherein A is alkylene, alkenylene, or alkynylene, each of which is substituted or unsubstituted.

[0676] Embodiment 202. The method of embodiment 200, wherein A is aryl, heteroaryl, or heterocyclyl, each of which is substituted or unsubstituted.

[0677] Embodiment 203. The method of embodiment 200 or 201, wherein the compound is of the formula:



[0678] Embodiment 204. The method of any one of embodiments 200-203, wherein Q^1 is C_1 -alkylene.

[0679] Embodiment 205. The method of any one of embodiments 200-203, wherein Q^1 is a bond.

[0680] Embodiment 206. The method of any one of embodiments 200-205, wherein m is 1.

[0681] Embodiment 207. The method of any one of embodiments 200-205, wherein m is 2.

[0682] Embodiment 208. The method of any one of embodiments 200-207, wherein Y is N.

[0683] Embodiment 209. The method of any one of embodiments 200-207, wherein Y is O.

[0684] Embodiment 210. The method of any one of embodiments 200-209, wherein each R^3 and R^4 is independently alkyl, alkylene, alkenyl, alkenylene, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; or hydrogen.


[0685] Embodiment 211. The method of any one of embodiments 200-210, wherein R^3 is alkyl,

alkylene, alkenyl, alkenylene, alkynyl, each of which is independently substituted or unsubstituted; and R^4 is aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted.

[0686] Embodiment 212. The method of any one of embodiments 200-211, wherein R^3 is H; and R^4 is aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted.

[0687] Embodiment 213. The method of any one of embodiments 200-212, wherein R^{13} is hydrogen.

[0688] Embodiment 214. The method of any one of embodiments 200, 201, 203, 205, 206, 208, or 210-213, wherein the compound is of the formula:



wherein ring A is a cyclic group that is substituted or unsubstituted.


[0689] Embodiment 215. The method of any one of embodiments 200, 201, 203, 205, 206, 208, or 210-214, wherein R^2 is substituted or unsubstituted alkyl.

[0690] Embodiment 216. The method of any one of embodiments 200, 201, 203, 205, 206, 208, or 210-215, wherein R^2 is methyl, ethyl, propyl, iso-propyl, butyl, or tert-butyl, each of which is substituted or unsubstituted.

[0691] Embodiment 217. The method of any one of embodiments 200, 201, 203, 205, 206, 208, or 210-216, wherein R^2 is substituted ethyl.

[0692] Embodiment 218. The method of any one of embodiments 200, 201, 203, 205, 206, 208, or 210-217, wherein R^2 is trifluoroethyl.

[0693] Embodiment 219. The method of any one of embodiments 200, 201, 203, 205, 206, 208, or 210-218, wherein the compound is of the formula:



[0694] Embodiment 220. The method of any one of embodiments 200, 201, 203, 205, 206, 208, or 210-219, wherein ring A is aryl, heteroaryl, or heterocyclyl, each of which is substituted or unsubstituted.

[0695] Embodiment 221. The method of any one of embodiments 200, 201, 203, 205, 206, 208, or 210-220, wherein ring A is substituted aryl.

[0696] Embodiment 222. The method of any one of embodiments 200, 201, 203, 205, 206, 208, or 210-220, wherein ring A is substituted heteroaryl.


[0697] Embodiment 223. The method of any one of embodiments 200, 201, 203, 205, 206, 208, or 210-220, wherein ring A is substituted heterocyclyl.

[0698] Embodiment 224. The method of any one of embodiments 200-223, wherein R^1 is alkyl, alkenyl, $-C(O)R^{16}$, $-C(O)OR^{16}$, or $-C(O)NR^{16}R^{17}$, each of which is unsubstituted or substituted.

[0699] Embodiment 225. The method of any one of embodiments 200-224, wherein R^1 is substituted alkyl.

[0700] Embodiment 226. The method of any one of embodiments 200-225, wherein R^1 is alkyl substituted with $NR^{16}R^{17}$.

[0701] Embodiment 227. The method of any one of embodiments 200, 201, 203, 205, 206, 208, or 210-226, wherein the compound is of the formula:



[0702] Embodiment 228. The method of any one of embodiments 200, 201, 203, 205, 206, 208, or 210-227, wherein each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, each of which is independently substituted or unsubstituted; or hydrogen.

[0703] Embodiment 229. The method of any one of embodiments 200, 201, 203, 205, 206, 208, or 210-228, wherein R^{16} is hydrogen or alkyl.

[0704] Embodiment 230. The method of any one of embodiments 200, 201, 203, 205, 206, 208, or 210-229, wherein R^{17} is aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted.

[0705] Embodiment 231. The method of any one of embodiments 200, 201, 203, 205, 206, 208, or 210-230, wherein R^{17} is substituted aryl.

[0706] Embodiment 232. The method of any one of embodiments 200, 201, 203, 205, 206, 208, or 210-231, wherein R^{17} is substituted phenyl.

[0707] Embodiment 233. The method of any one of embodiments 200, 201, 203, 205, 206, 208, or 210-232, wherein R^{17} is phenyl substituted with a sulfoxide group, carboxyl group, amide group, amino group, alkyl, alkoxy, hydroxy, halo, cyano, or heterocyclyl, each of which is independently substituted or unsubstituted.

[0708] Embodiment 234. The method of any one of embodiments 200, 201, 203, 205, 206, 208, or 210-233, wherein R^{17} is phenyl substituted with methoxy.

[0709] Embodiment 235. The method of any one of embodiments 200, 201, 203, 205, 206, 208, or 210-234, wherein R^{17} is phenyl substituted with a substituted sulfoxide group.

[0710] Embodiment 236. The method of any one of embodiments 200, 201, 203, 205, 206, 208, or 210-235, wherein R^{17} is phenyl substituted with a carboxyl group.

[0711] Embodiment 237. The method of any one of embodiments 200, 201, 203, 205, 206, 208, or 210-236, wherein R¹⁷ is phenyl substituted with an amide group.

[0712] Embodiment 238. The method of embodiment 200, wherein the compound is 4-[(3-{4-[(1,5-dihydroxypentan-3-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxybenzene-1-sulfonamide.

[0713] Embodiment 239. The method of any one of embodiments 200, wherein the compound is 2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1r,4r)-4-morpholinocyclohexyl)-1-(oxiran-2-ylmethyl)-1H-indol-4-amine.

[0714] Embodiment 240. The method of any one of embodiments 200, wherein the compound is 3-methoxy-4-({3-[4-({2-oxaspiro[3.3]heptan-6-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)benzene-1-sulfonamide.

[0715] Embodiment 241. The method of any one of embodiments 200, wherein the compound is 4-((3-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide.

[0716] Embodiment 242. The method of any one of embodiments 200, wherein the compound is N-(2,3-dihydroxypropyl)-4-{[3-(4-{{(3S,4R)-3-fluoro-1-methylpiperidin-4-yl}amino})-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl]amino}-3-methoxybenzamide.

[0717] Embodiment 243. The method of any one of embodiments 200, wherein the compound is 3-methoxy-N-(2-methoxyethyl)-N-methyl-4-((3-(4-((tetrahydro-2H-pyran-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide.

[0718] Embodiment 244. The method of any one of embodiments 200, wherein the compound is N-(2,3-dihydroxypropyl)-4-((3-(4-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide.

[0719] Embodiment 245. The method of any one of embodiments 200, wherein the compound is 3-methoxy-4-((3-(4-(3-(1-methylpiperidin-4-yl)ureido)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide.


[0720] Embodiment 246. The method of any one of embodiments 200, wherein the compound is N-((3S,4R)-3-fluoropiperidin-4-yl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine.

CLAIMS

WHAT IS CLAIMED IS:

1. A method of treating a cancer in a subject in need thereof, the method comprising:
 - (i) administering to the subject a therapeutically-effective amount of a compound that increases anti-cancer activity of a mutant p53 protein in the subject; and
 - (ii) administering to the subject a therapeutically-effective amount of an anti-cancer agent that functions through a pathway other than p53-induced apoptosis.
2. The method of claim 1, wherein the compound binds to the mutant p53 protein and reconfirms the mutant p53 protein to a conformation of p53 that exhibits anti-cancer activity.
3. The method of claim 1, wherein the compound increases a stability of the mutant p53 protein.
4. The method of claim 1, wherein the cancer expresses the mutant p53 protein.
5. The method of claim 1, wherein the mutant p53 protein has a mutation at amino acid 220.
6. The method of claim 1, wherein the mutant p53 protein is p53 Y220C.
7. The method of claim 1, wherein the compound selectively binds the mutant p53 protein as compared to a wild type p53.
8. The method of claim 1, wherein the cancer is ovarian cancer.
9. The method of claim 1, wherein the cancer is breast cancer.
10. The method of claim 1, wherein the cancer is lung cancer.
11. The method of claim 1, wherein the administering of the compound is oral.
12. The method of claim 1, wherein the therapeutically-effective amount of the compound is from about 500 mg to about 2000 mg.
13. The method of claim 1, wherein the subject is human.
14. The method of claim 1, wherein the anti-cancer agent is an immune checkpoint inhibitor.

15. The method of claim 14, wherein the immune checkpoint inhibitor is an anti-PD-1 agent.
16. The method of claim 14, wherein the immune checkpoint inhibitor is an anti-PD-L1 agent.
17. The method of claim 1, wherein the administering of the anti-cancer agent is oral.
18. The method of claim 1, wherein the therapeutically-effective amount of the anti-cancer agent is from about 5 mg/kg to about 500 mg/kg.
19. The method of claim 1, wherein the therapeutically-effective amount of the anti-cancer agent is from about 10 µg to about 500 µg.
20. The method of claim 1, wherein the compound is of the formula:



wherein:

- each ----- is independently a single bond or a double bond;
- X¹ is CR⁵, CR⁵R⁶, N, NR⁵, O, S, C=O, C=S, or a carbon atom connected to Q¹;
- X² is CR⁷, CR⁷R⁸, N, NR⁷, O, S, C=O, C=S, or a carbon atom connected to Q¹;
- X³ is CR⁹, CR⁹R¹⁰, N, NR⁹, O, S, C=O, C=S, or a carbon atom connected to Q¹;
- X⁴ is CR¹¹, CR¹¹R¹², N, NR¹¹, O, S, C=O, C=S, or a carbon atom connected to Q¹;
- X⁵ is CR¹³, N, or NR¹³;

wherein at least one of X¹, X², X³, and X⁴ is a carbon atom connected to Q¹;

- A is a linking group;
- Q¹ is C=O, C=S, C=CR¹⁴R¹⁵, C=NR¹⁴, alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond;
- m is 1, 2, 3, or 4;
- Y is N, O, or absent;
- R¹ is -C(O)R¹⁶, -C(O)OR¹⁶, -C(O)NR¹⁶R¹⁷, -OR¹⁶, -SR¹⁶, -NR¹⁶R¹⁷, -NR¹⁶C(O)R¹⁶, -OC(O)R¹⁶, -SiR¹⁶R¹⁷R¹⁸, alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, heterocyclyl, or halo, each of which is independently substituted or unsubstituted, or hydrogen;
- each R³ and R⁴ is independently -C(O)R¹⁹, -C(O)OR¹⁹, -C(O)NR¹⁹R²⁰, -SOR¹⁹, -SO₂R¹⁹, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen, or R³ and R⁴ together with


the nitrogen atom to which R^3 and R^4 are bound form a ring, wherein the ring is substituted or unsubstituted, or R^3 is absent;

- each R^2 , R^5 , R^6 , R^7 , R^8 , R^9 , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , and R^{18} is independently $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R^{19} and R^{20} is independently $-C(O)R^{23}$, $-C(O)OR^{23}$, $-C(O)NR^{23}R^{24}$, $-OR^{23}$, $-SR^{23}$, $-NR^{23}R^{24}$, $-NR^{23}C(O)R^{24}$, $-OC(O)R^{23}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,

or a pharmaceutically-acceptable salt thereof.

21. The method of claim 20, wherein A is alkylene, alkenylene, or alkynylene, each of which is substituted or unsubstituted.

22. The method of claim 20, wherein the compound is of the formula:



23. The method of claim 22, wherein Q^1 is C_1 -alkylene.

24. The method of claim 22, wherein Q^1 is a bond.

25. The method of claim 22, wherein m is 1.

26. The method of claim 22, wherein Y is N.


27. The method of claim 22, wherein each R^3 and R^4 is independently alkyl, alkylene, alkenyl,

alkenylene, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; or hydrogen.

28. The method of claim 27, wherein R^3 is H; and R^4 is aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted.

29. The method of claim 20, wherein R^{13} is hydrogen.

30. The method of claim 20, wherein the compound is of the formula:



wherein ring A is a cyclic group that is substituted or unsubstituted.

31. The method of claim 30, wherein R^2 is substituted or unsubstituted alkyl.

32. The method of claim 30, wherein R^2 is substituted ethyl.

33. The method of claim 32, wherein R^2 is trifluoroethyl.

34. The method of claim 30, wherein ring A is aryl, heteroaryl, or heterocyclyl, each of which is substituted or unsubstituted.


35. The method of claim 34, wherein ring A is substituted heteroaryl.

36. The method of claim 34, wherein ring A is substituted heterocyclyl.

37. The method of claim 30, wherein R^1 is alkyl, alkenyl, $-C(O)R^{16}$, $-C(O)OR^{16}$, or $-C(O)NR^{16}R^{17}$, each of which is unsubstituted or substituted.

38. The method of claim 37, wherein R^1 is alkyl substituted with $NR^{16}R^{17}$.

39. The method of claim 38, wherein the compound is of the formula:



40. The method of claim 39, wherein each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, each of which is independently substituted or unsubstituted; or hydrogen.
41. The method of claim 40, wherein R^{16} is hydrogen or alkyl.
42. The method of claim 40, wherein R^{17} is aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted.
43. The method of claim 42, wherein R^{17} is phenyl substituted with a sulfoxide group, carboxyl group, amide group, amino group, alkyl, alkoxy, hydroxy, halo, cyano, or heterocyclyl, each of which is independently substituted or unsubstituted.